

ALIXPARTNERS, LLP

Exhibit A

Detailed Description of Fees, Hours and Descriptions by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/01/20	JD	Call with R. Aleali (Purdue) re: catch up on outstanding issues	0.20
06/01/20	JD	Call with R. Aleali (Purdue) re: catch up after ad hoc committee call and catch up on open items and timeline.	0.30
06/02/20	LJD	Call with PJT RE: case status update.	0.30
06/04/20	LJD	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	LJD	Review UCC letter to the court.	0.50
06/04/20	GJK	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	JD	Review Purdue staffing needs.	0.30
06/04/20	JD	Weekly planning meeting with L. Donahue, J. DelConte, G. Koch (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. Turner, J. O'Connell, T. Melvin (all PJT) J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: go forward planning and progress update.	0.80
06/04/20	JD	Review agenda and status updates prior to weekly update call.	0.20
06/05/20	JDH	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	JD	Review status of ongoing work streams in advance of weekly call.	0.20
06/05/20	JD	Correspondence with R. Brown (Purdue) re: professional	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		fee accruals for April.	
06/05/20	JD	Review latest updated compensation summary from I. Arana (AlixPartners) for Willis Towers Watson.	0.60
06/05/20	JD	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	RDS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	MFR	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	LJD	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	LJD	Call with PJT RE: case status.	0.30
06/05/20	LJD	Review latest Purdue staffing needs.	0.40
06/05/20	GJK	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	FOS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	SKL	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/05/20	NAS	Call with J. DelConte, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon, R. Sublett (all AlixPartners) re: Weekly update call	0.80
06/08/20	GJK	Update to draft email to Mundipharma including calls with	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		C Oluwole (DPW).	
06/08/20	GJK	Call with I. McClatchey (Norton Rose) re: overall diligence.	0.30
06/08/20	GJK	Finalize and send email to Mundipharma executives re: outstanding diligence items and need for company responsiveness.	2.50
06/08/20	JD	Correspondence with C. Oluwole, C. Robertson (Davis Polk), J. Turner (PJT), J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.70
06/08/20	JD	Review PII lists for firms to work for the Monitor.	0.40
06/09/20	JD	Call with R. Aleali (Purdue) re: case catch up and go forward planning.	0.50
06/09/20	JD	Provide SAP access list to J. Lowne (Purdue).	0.20
06/09/20	GJK	Walkthrough of recent PJT valuation slide updates.	1.30
06/09/20	GJK	Review of third part debt obligations including review of original settlement framework, email exchanges with N. Simon (AlixPartners) on topic.	1.60
06/09/20	GJK	Walkthrough and provide feedback for updated Mundipharma interim diligence report with new valuation slides.	2.20
06/09/20	LJD	Call with K. Buckfire (Purdue Board Member) RE: case status.	0.40
06/09/20	LJD	Review and discuss Rhodes org doc for presentation to management.	0.60
06/10/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: Purdue staffing.	0.60
06/10/20	GJK	Review and planning re: B. Lea email and Mundipharma diligence next steps.	1.50
06/10/20	GJK	Review of potential changes to interim report finalization based on further diligence per B. Lea (Mundipharma)	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		email.	
06/10/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: Purdue staffing.	0.60
06/10/20	JD	Conversation with C. Robertson (Davis Polk) re: open work streams.	0.30
06/11/20	JD	Draft staffing and work stream plan for Purdue.	0.70
06/11/20	JD	Review various materials to be uploaded to the data room in response to AHC diligence questions.	0.50
06/11/20	JD	Call with E. Vonnegut (Davis Polk) re: Mundipharma diligence.	0.20
06/11/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: data room.	0.20
06/11/20	JD	Weekly update call with J. O'Connell, J. Turner (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, L. Donahue (both AlixPartners) and C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue).	0.80
06/11/20	JD	Call with R. Aleali (Purdue) re: follow up to weekly call.	0.20
06/11/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: data room.	0.20
06/11/20	GJK	Draft response to B. Lea (Mundipharma) and seek feedback from advisor group.	2.50
06/11/20	GJK	Review and comment on Analgesic slides for Mundipharma interim report appendix.	0.40
06/11/20	GJK	Update diligence planning based on recent IAC events and potential for management discussions.	3.00
06/11/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: updates to deck and diligence process.	0.20
06/11/20	LJD	Prepare for and attend weekly update call with J. O'Connell, J. Turner (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, L. Donahue	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		(both AlixPartners) and C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue).	
06/11/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: updates to deck and diligence process.	0.20
06/12/20	RC	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	NAS	Call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.60
06/12/20	NAS	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	LJD	Review and discuss revised workstream analysis from team.	0.60
06/12/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	GJK	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	GJK	Review follow up email and documents from C. Tam (Huron).	2.20
06/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to review latest draft of KPMG tax analysis.	1.00
06/12/20	GJK	Finalize draft email to B. Lea (Mundipharma) based on inputs/edits from advisors.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/12/20	GJK	Prepare for and attend call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.90
06/12/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	FOS	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	JD	Call with J. Turner (PJT), A. Lutchen, E. Vonnegut, C. Robertson (all Davis Polk), G. Koch, J. DelConte, N. Simon (all AlixPartners) re: Mundipharma diligence.	0.60
06/12/20	JD	Prepare agenda for weekly AlixPartners update call.	0.40
06/12/20	JD	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/12/20	JD	Correspondence with Purdue re: IQVIA data.	0.30
06/12/20	JD	Review Davis Polk workstreams chart.	0.50
06/12/20	JD	Correspondence with N. Simon (AlixPartners) and C. Robertson (Davis Polk) re: claims inquiries.	0.20
06/12/20	JDH	Call with S. Canniff, R. Collura, J. DelConte, L. Donahue, J. Hecht, G. Koch, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.70
06/15/20	JD	Call with R. Aleali (Purdue) re: work stream updates.	0.60
06/15/20	JD	Correspondence with AlixPartners team and with Purdue IT re: Purdue IT migration and system issues.	0.40
06/15/20	JD	Correspondence with Skadden re: Project Catalyst timeline.	0.20
06/16/20	JD	Call with C. Robertson (Davis Polk) re: Project Catalyst.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/16/20	JD	Call with C. Robertson (Davis Polk), J. Doyle, R. Aleali (both Purdue), R. Schnitzler (PJT) re: business development deal.	0.30
06/16/20	JD	Correspondence with Purdue IT and AlixPartners team re: system access.	0.30
06/16/20	JD	Correspondence with L. Donahue (AlixPartners) re: updated work streams.	0.30
06/16/20	JD	Correspondence with AlixPartners legal re: Project Catalyst.	0.50
06/17/20	JD	Review and provide comments on draft agenda for the professional's update call tomorrow.	0.30
06/17/20	JD	Review details re: air service charge schedule from first interim fee app.	0.30
06/17/20	NAS	Purdue IT account migration.	0.40
06/18/20	LJD	Prepare for and attend call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	1.20
06/18/20	JD	Call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	1.00
06/19/20	JDH	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/19/20	HSB	Call with H. Bhattal and J. DelConte (both AlixPartners) re: update on current status of case and ongoing work streams.	1.20
06/19/20	KM	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	ADD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	LJD	Prepare for and attend call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.60
06/19/20	MFR	Prepare for and attend call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.60
06/19/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	SKL	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	SKL	Call with S. Lemack and J. DelConte (both AlixPartners) re: open items.	0.30
06/19/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50
06/19/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/19/20	JD	Call with H. Bhattal and J. DelConte (both AlixPartners) re: update on current status of case and ongoing work streams.	1.20
06/19/20	JD	Call with S. Lemack and J. DelConte (both AlixPartners) re: open items.	0.30
06/22/20	LJD	Review and comment on cost of continuing in chapter 11 presentation for UCC.	0.80
06/22/20	HSB	Review Opioid Downside Sensitivity analysis.	0.50
06/22/20	HSB	Review Purdue Business Plan Outline PowerPoint document.	3.00
06/22/20	HSB	Review Purdue Pharma presentation prepared by PJT Partners with side-by-side comparison of possible total value from reorganization versus sale scenarios.	3.20
06/22/20	JD	Correspondence with J. Lowne (Purdue) re: UCC discussion and presentation next steps.	0.30
06/23/20	JD	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/23/20	JD	Review final 1st interim payment amounts in draft order from Davis Polk.	0.20
06/23/20	HSB	Complete review of Purdue Pharma presentation prepared by PJT Partners (with side-by-side comparison of possible total value from reorganization versus sale scenarios).	1.00
06/23/20	HSB	Review draft of Mundipharma Interim Report.	3.00
06/23/20	HSB	Complete review of Purdue Business Plan Outline PowerPoint document.	1.00
06/23/20	HSB	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/23/20	HSB	Review UCC Stipulation and due diligence letter.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/23/20	ADD	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/23/20	LJD	Review comments on UCC deck.	0.30
06/23/20	SKL	Call with H. Bhattal, S. Lemack, J. DelConte and A. DePalma (all AlixPartners) re: case status update and go forward planning.	0.70
06/24/20	HSB	Finish review of draft of Mundipharma Interim Report.	0.50
06/24/20	JD	Review and provide comments on latest Nalmafene court reporting.	0.50
06/24/20	JD	Correspondence with management, Davis Polk, PJT, Province, Akin and Jefferies re: scheduling management meetings and delayed emergence presentation and diligence questions.	1.20
06/25/20	JD	Correspondence with FA and IB advisors to set up a call on a potential BD deals.	0.40
06/25/20	HSB	Review document with PJT prepared presentation to the UCC from online data room.	1.20
06/25/20	HSB	Review Company document with Overview of Settlement Proposal dated 6/15/2020 from online data room.	1.20
06/25/20	LJD	Prepare for and attend board call.	4.30
06/26/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	FOS	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
06/26/20	RC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	HSB	Review audited financial statements for Purdue from online data room.	1.20
06/26/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/26/20	JD	Prepare agenda for weekly AlixPartners update call.	0.40
06/26/20	JD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.60
06/29/20	HSB	Conduct research and review examples of pharmaceutical b/k liquidation analysis.	1.50
06/29/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.30
06/29/20	JD	Call with C. Robertson (Davis Polk) re: delayed emergence follow up questions.	0.20
06/29/20	JD	Review correspondence re: IQVIA consent letter.	0.20
06/30/20	HSB	Conduct research and review examples of pharmaceutical b/k liquidation analysis.	1.00
07/01/20	HSB	Review supporting excel worksheets prepared by S. Lemack (AlixPartners) for cash forecast reports.	2.00
07/01/20	HSB	Review relevant first day motions with relevant background on customer programs and vendors.	0.70
07/01/20	JD	Review and provide comments on tomorrow's draft weekly call agenda.	0.20
07/01/20	JD	Create draft decision tree for go forward case strategy to	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		be used for board discussion.	
07/01/20	JD	Review and comment on updated case timeline from Davis Polk.	0.30
07/01/20	JD	Correspondence with Davis Polk re: sharing certain materials with various creditor constituencies.	0.40
07/01/20	LJD	Update call with K. Buckfire (Board Member).	0.50
07/01/20	LJD	Update call with J. Dubel (Board Member)	0.50
07/01/20	LJD	Update call with R. Aleali (Purdue).	0.50
07/02/20	LJD	Prepare for and attend call with DP and PJT re: board meeting on Friday	0.30
07/02/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	1.10
07/02/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	GJK	Call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	1.00
07/02/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re:	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Weekly update call.	
07/02/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	JD	Call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	1.00
07/02/20	JD	Call with R. Aleali (Purdue) re: follow up from all hands call.	0.30
07/02/20	JD	Call with J. Doyle, R. Aleali (both Purdue), C. Robertson (Davis Polk) re: business development deal.	0.30
07/02/20	JD	Review updated draft pacing calendar and exec summary slide.	0.20
07/02/20	JD	Review draft business development agreement motion.	0.30
07/02/20	JD	Prepare agenda for internal AlixPartners weekly update call.	0.30
07/02/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/02/20	JD	Correspondence with J. McClammy (Davis Polk) re: giving LTS access to certain materials.	0.10
07/02/20	KM	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/02/20	HSB	Review cash report (for week ending 6/26) prepared by S. Lemack (AlixPartners).	0.70
07/02/20	HSB	Review disclosure statements and liquidation analysis for recent pharmaceutical bankruptcies for purpose of preparing Purdue's liquidation analysis.	2.00
07/02/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/02/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/03/20	JD	Review correspondence re: special committee meetings and scheduling.	0.20
07/03/20	LJD	Strategy call with DP to discuss POR and next steps.	0.80
07/03/20	LJD	Update call with PJT.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/03/20	LJD	Update call with K. Buckfire (Board Member).	0.80
07/06/20	LJD	Update call with K. Buckfire (Board Member).	0.30
07/06/20	LJD	Update call with J. Dubel (Board Member)	0.40
07/06/20	LJD	Prepare for and attend call with L. Donahue, J. DelConte (both AlixPartners), J. O'Connell, T. Coleman, J. Turner (all PJT) re: case progress and go forward planning.	0.60
07/06/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning.	0.20
07/06/20	LJD	Review communication in advance of special committee call on Tuesday.	0.40
07/06/20	JD	Call with C. Oluwole (Davis Polk) re: diligence uploads.	0.10
07/06/20	JD	Call with L. Donahue, J. DelConte (both AlixPartners), J. O'Connell, T. Coleman, J. Turner (all PJT) re: case progress and go forward planning.	0.40
07/06/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning.	0.20
07/06/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.90
07/06/20	HSB	Prepare excel summary of disclosure statements and liquidation analysis for recent pharmaceutical bankruptcies for comparative purpose of preparing Purdue's liquidation analysis.	2.80
07/06/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.90
07/07/20	HSB	Review minimum cash analysis prepared by S. Lemack (AlixPartners) and evaluated minimum cash balance needed (in response to the AHC question on min cash.)	0.60
07/07/20	HSB	Review AHC diligence question list and the related info on the April Business Plan document.	1.50
07/07/20	HSB	Conduct a search for recent pharma bankruptcies and	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		reviewed underlying liquidation analysis.	
07/07/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence question discussion.	0.20
07/07/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	2.00
07/07/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	2.00
07/07/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence question discussion.	0.20
07/07/20	JD	Correspondence with Davis Polk and PJT re: weekly professionals update call.	0.40
07/07/20	JD	Review and provide comments on ad hoc committee tracker sheet from Davis Polk.	0.50
07/07/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning discussions.	0.30
07/07/20	LJD	Review AP and PJT comments for special committee meeting.	0.40
07/07/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning discussions.	0.30
07/07/20	LJD	Call with DP re: special committee issues.	0.40
07/08/20	LJD	Review and comment on IAC report.	1.50
07/08/20	LJD	Update call with PJT.	0.40
07/08/20	LJD	Update call with J. Dubel (Board Member).	0.60
07/08/20	JD	Prepare agenda for weekly update call with management, Davis Polk and PJT tomorrow morning.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/08/20	JD	Review proposed go forward process from Davis Polk.	0.30
07/08/20	JD	Call with E. Vonnegut (Davis Polk) re: case status and go forward planning.	0.20
07/08/20	JD	Call with R. Aleali (Purdue) re: open diligence item approvals and case planning.	0.50
07/08/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation for diligence call.	0.80
07/08/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance due diligence Questions.	2.00
07/08/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance due diligence Questions.	2.00
07/08/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation for diligence call.	0.80
07/08/20	HSB	Review weekly sales report prepared by S. Lemack (AlixPartners).	0.30
07/08/20	HSB	Review monthly Finance Update report for May 2020 prepared by S. Lemack (AlixPartners).	1.30
07/08/20	HSB	Review monthly Finance Update report (full deck) for May 2020.	0.50
07/09/20	HSB	Review Intralinks data room files (Hypothetical Scenario) while preparing for AHC diligence meeting.	1.10
07/09/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.70
07/09/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst discussion of outstanding diligence items.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/09/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst discussion of outstanding diligence items.	1.40
07/09/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) re: Project Catalyst VDR and diligence tracker.	0.70
07/09/20	LJD	Review and discuss board memo re: governance meeting and strategy.	0.60
07/09/20	LJD	Prepare for and attend update call with M. Kesselman (Purdue).	0.50
07/09/20	LJD	Review governance comparison decks and discuss.	1.50
07/10/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/10/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	NAS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	KM	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence and data room management.	2.40
07/10/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence and data room management.	2.40
07/10/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	ADD	Prepare for AlixPartners internal team update call.	0.50
07/10/20	HSB	Review excel file with May cash forecasts for Purdue.	0.50
07/10/20	HSB	Review month of April MOR for Purdue.	0.40
07/10/20	HSB	Review April business plan and compared amounts to actual today for Purdue.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/10/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	HSB	Review updated draft of monthly Finance report for May 2020 prepared by S. Lemack (AlixPartners).	0.40
07/13/20	HSB	Review excel file with annual consolidated financial statement forecasts while evaluating minimum cash needs.	0.70
07/14/20	HSB	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	1.80
07/14/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue), and K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.80
07/14/20	JD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	JD	Call with C. Robertson (Davis Polk) re: post-call catch up.	0.20
07/14/20	GJK	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	LJD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	
07/14/20	LJD	Review and comment on deck discussing confirmation.	0.70
07/14/20	LJD	Review and comment on quarterly fee app.	0.80
07/15/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.30
07/15/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.30
07/16/20	HSB	Compare outline of August business plan draft to April version and evaluated additional descriptions based on ytd financial performance.	0.40
07/16/20	HSB	Review draft of document with K. Buckfire's (Board Member) questions list and corresponding answers.	0.50
07/16/20	HSB	Review framework of August business plan document draft prepared by J.Lowne (Purdue).	1.00
07/16/20	HSB	Review Adhansia forecasts and reported results	0.60
07/16/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	1.00
07/16/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence process.	0.50
07/16/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract diligence process.	0.50
07/16/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue), and K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	
07/16/20	JD	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/16/20	JD	Call with R. Aleali (Purdue) re: group call follow-ups.	0.20
07/16/20	LJD	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/16/20	LJD	Review and comment on UCC deck.	1.10
07/16/20	LJD	Debrief call with PJT.	0.50
07/16/20	GJK	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/17/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	LJD	Review UCC / AHC deck and comment.	1.50
07/17/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/17/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	NAS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	JD	Create agenda for the Purdue weekly update call.	0.30
07/17/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	HSB	Review list of answers to K. Buckfire's (Board Member) questions.	0.30
07/17/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	HSB	Review sections of the April business plan document for info related to K. Buckfire's (Board Member) questions.	0.30
07/17/20	ADD	Prepare for AlixPartners engagement team update call.	0.50
07/17/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/20/20	HSB	Review Customer Program Reports prepared by S. Lemack (AlixPartners).	0.30
07/20/20	JD	Review LEK non-reliance letter.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/20/20	JD	Correspondence with PJT and management re: process for sharing the distributable value presentation with the individual creditors.	0.40
07/21/20	JD	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60
07/21/20	JD	Call with C. Robertson (Davis Polk) re: open issues.	0.10
07/21/20	JD	Review and comment on chart detailing the positions of the various committees in the case.	0.70
07/21/20	LJD	Prepare for and attend call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.70
07/21/20	HSB	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60
07/21/20	HSB	Review draft of Management's UCC presentation.	1.40
07/22/20	HSB	Review updated draft of responses to K. Buckfire (Board Member) questions.	0.30
07/22/20	HSB	Review weekly sales report (week ending 07/17) prepared by S. Lemack (AlixPartners).	0.30
07/22/20	JD	Call with M. Kesselman (Purdue), J. O'Connell, J. Turner (both PJT) re: case update.	0.60
07/24/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30
07/24/20	JD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/24/20	NAS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	LJD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	MFR	Prepare for and attend call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.60
07/24/20	GJK	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	FOS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	SKL	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	HSB	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	HSB	Review updated draft of responses to Purdue Board's strategic questions.	0.30
07/24/20	HSB	Continue to review disclosure statements & liquidation analysis for recent pharma bankruptcies.	0.40
07/24/20	HSB	Review disclosure statements and related liquidation analysis for recent pharma bankruptcies.	1.00
07/24/20	ADD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/24/20	ADD	Prepare for AlixPartners internal Purdue engagement team update meeting.	0.30
07/26/20	LJD	Prepare for and attend preparation call for UCC meeting tomorrow with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut (both Davis Polk), J. DelConte, and L. Donahue (both AlixPartners).	1.80
07/26/20	JD	Prep call for UCC call tomorrow with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut (both Davis Polk), J. DelConte, and L. Donahue (both AlixPartners).	1.60
07/27/20	HSB	Review final draft of document with responses to strategic questions raised by the Purdue Board.	0.30
07/28/20	HSB	Review weekly cash flow model file prepared by S. Lemack (AlixPartners).	0.80
07/28/20	HSB	Review investments file prepared by S. Lemack (AlixPartners).	0.50
07/28/20	NAS	Diligence call with D. Jefferies (Mundipharma Treasurer), G. Koch (AlixPartners), and other Mundipharma diligence advisors.	1.10
07/28/20	GJK	Diligence call with D. Jefferies (Mundipharma Treasurer), N. Simon (AlixPartners), and other Mundipharma diligence advisors.	1.10
07/29/20	HSB	Review OCP report prepared by S. Lemack (AlixPartners).	0.30
07/29/20	HSB	Review disclosure statements for recent pharma bankruptcies.	0.60
07/30/20	GJK	Mundipharma diligence call with S. Jamieson (Management Revisions), N. Simon (AlixPartners), and other Mundipharma diligence advisors.	1.80
07/30/20	GJK	Discussion with N. Simon (AlixPartners), FTI, and Province re: current status of Mundipharma diligence	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		process and post-call debrief with N. Simon (AlixPartners).	
07/30/20	NAS	Mundipharma diligence call with S. Jamieson (Management Revisions), G. Koch (AlixPartners), and other Mundipharma diligence advisors.	1.80
07/30/20	NAS	Discussion with G. Koch (AlixPartners), FTI, and Province re: current status of Mundipharma diligence process and post-call debrief with G. Koch (AlixPartners).	0.80
07/31/20	NAS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	GJK	Provide Mundipharma update on weekly AlixPartners team coordinating call.	0.50
07/31/20	MFR	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	MFR	Calls with F. Silva (AlixPartners) re: UCC Information requests.	0.30
07/31/20	LJD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	GJK	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	SKL	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		call.	
07/31/20	FOS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	FOS	Calls with M. Rule (AlixPartners) re: UCC Information requests.	0.30
07/31/20	HSB	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	ADD	Prepare for AlixPartners internal Purdue engagement team update meeting.	0.40
07/31/20	ADD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	ADD	Call with R. Schnitzler (PJT), K. McCafferty (AlixPartners) and J. Lieberman (SK Capital) re: Interested party diligence update.	0.60
07/31/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30
07/31/20	JD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	KM	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	KM	Call with R. Schnitzler (PJT), A. DePalma (AlixPartners) and J. Lieberman (SK Capital) re: interested party	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		diligence update.	
08/03/20	JD	Review and provide comments on draft KEIP / KERP motion.	0.60
08/04/20	GJK	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/04/20	LJD	Prepare for and attend weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.70
08/04/20	JD	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/04/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: post weekly professionals call planning.	0.50
08/04/20	HSB	Weekly catch up call with M. Huebner, C. Robertson (both Davis Polk), L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	0.60
08/06/20	HSB	Call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.70
08/06/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman,	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/06/20	JD	J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.70
08/06/20	JD	Call with J. DelConte, L. Donahue, H. Bhattal (all AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue) re: case update and go forward planning.	0.90
08/07/20	NAS	Calls with D. Consla (Davis Polk) re: KEIP/KERP motion.	0.50
08/07/20	SJC	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	LJD	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	MFR	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	GJK	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	FOS	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	SKL	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	HSB	Review agreed order among the UCC, the non-consenting	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		states group and the debtors re: discovery in the Ch 11 Cases.	
08/07/20	HSB	Weekly team update with H. Bhattal, S. Canniff, L. Donahue, G. Koch, S. Lemack, M. Rule, F. Silva, N. Simon (all AlixPartners).	0.50
08/07/20	JD	Call with D. Consola, E. Vonnegut and S. Brecher (all Davis Polk) re: KEIP/KERP motion.	0.20
08/07/20	JD	Call with S. Brecher, D. Consola (both Davis Polk), S. Hinden, D. Sims, J. Gartrell (all Willis Towers Watson), C. DiStefano, R. Aleali, K. Laurel (all Purdue) re: KEIP/KERP motion drafting.	3.20
08/10/20	JD	Correspondence with C. Oluwole (Davis Polk), R. Collura and G. Koch (AlixPartners) re: Sackler transfers call.	0.40
08/11/20	JD	Weekly catch up call with L. Donahue, J. DelConte, H. Bhattal, G. Koch (all AlixPartners), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler, T. Melvin (all PJT) re: weekly catch up on case progress.	0.80
08/11/20	JD	Review latest transfer trust checklist prior to call.	0.70
08/11/20	HSB	Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners).	0.80
08/11/20	GJK	Update Debtor professionals on weekly advisor coordinating call re: IACs.	0.80
08/11/20	LJD	Prepare for and attend weekly advisors call	0.90
08/12/20	JD	Review comments to draft Mundipharma email from the UCC and AHC. Provide comments re: same.	0.30
08/12/20	JD	Review and provide comments on agenda for tomorrow's call.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/13/20	JD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	0.90
08/13/20	JD	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	JD	Review Sackler cash and non-cash activity report shared on the conference call.	1.20
08/13/20	RC	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	LJD	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/13/20	GJK	Attend Sackler distribution history meeting with AHC professionals, UCC professionals, L. Donahue, G. Koch, R. Collura, J. DelConte (all AlixPartners), PJT, Davis Polk and Dechert.	0.70
08/14/20	GJK	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	LJD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack,	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		N. Simon (all AlixPartners)	
08/14/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	JD	Create agenda for weekly AlixPartners update call.	0.40
08/14/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	JD	Correspondence with Davis Polk and PJT re: distributable value and insurance proceeds.	0.40
08/14/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	ADD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.60
08/14/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.50
08/17/20	HSB	Review sale scenario valuation summary prepared by PJT Partners.	0.30
08/17/20	HSB	Review Avrio section of the April financial statement presentation with financial results	0.60
08/17/20	JD	Call with C. Robertson (Davis Polk) re: case progress.	0.20
08/18/20	JD	Review letter from the Debtors to the mediators re: go forward process.	0.30
08/18/20	HSB	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT),	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	
08/18/20	HSB	Review Purdue's recent audited financial statements and related disclosures around intangible assets related to the Purdue tax discussion with Davis Polk.	0.50
08/19/20	HSB	Distributable value call with H. Bhattal, J. DelConte (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT Partners), M. Atkinson (Province), K. Sheridan (Jefferies), L. Szlezinger (Jefferies).	0.30
08/19/20	HSB	Compared UCC distributable value analysis to financial results and reviewed for reasonableness.	0.50
08/19/20	JD	Distributable value call with H. Bhattal, J. DelConte (both AlixPartners), J. Turner, R. Schnitzler, T. Melvin (all PJT Partners), M. Atkinson (Province), K. Sheridan (Jefferies), L. Szlezinger (Jefferies).	0.30
08/20/20	JD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20
08/20/20	JD	Call with R. Aleali (Purdue) re: pos call follow ups.	0.20
08/20/20	HSB	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20
08/20/20	HSB	Review Adhansia information in preparation for related team discussion.	0.60
08/20/20	NAS	Review press coverage related to Purdue settlement negotiations.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/20/20	LJD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: case update and go forward planning.	1.20
08/21/20	GJK	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.50
08/21/20	ADD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/21/20	JD	Prepare agenda for weekly team update call.	0.40
08/21/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, N. Simon (all AlixPartners)	0.50
08/25/20	JD	Prepare agenda for internal call with DPW, AlixPartners and PJT.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/25/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	JD	Review proposed revised fee order re: 2nd interim fee applications. Correspondence re: fee order and hearing with E. Kardos (AlixPartners).	0.30
08/25/20	HSB	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	GJK	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/25/20	LJD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.90
08/26/20	JD	Prepare analysis of professional fee billings. Correspondence with E. Kardos (AlixPartners) re: same.	0.60
08/28/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30
08/28/20	JD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	HSB	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	LJD	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
08/28/20	MFR	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	SKL	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	SJC	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/28/20	NAS	Weekly team update call with H. Bhattal, S. Canniff, J. DelConte, L. Donahue, S. Lemack, M. Rule, N. Simon (all AlixPartners)	0.50
08/31/20	JD	Call with M. Huebner (Davis Polk) and M. Kesselman (Purdue) re: initial UCC feedback on KEIP/KERP motion.	0.30
08/31/20	JD	Call with R. Aleali (Purdue) re: KEIP/KERP motion.	0.40
08/31/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP motion.	0.30
08/31/20	JD	Review and provide comments on current draft KEIP/KERP motion. Correspondence with Davis Polk re: same.	1.30
09/01/20	JD	Prepare for and attend update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M. Huebner, J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners).	1.00
09/01/20	HSB	Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M.Huebner, J.McClammy, E.Vonnegut, B.Kaminetzky, T.Graulich, C.Robertson (all Davis Polk), J.O'Connell, T.Coleman, J.Turner (all PJT Partners).	0.60
09/01/20	LJD	Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M.Huebner, J.McClammy, E.Vonnegut, B.Kaminetzky, T.Graulich, C.Robertson (all Davis Polk),	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/01/20	GJK	J.O'Connell, T.Coleman, J.Turner (all PJT Partners). Update call with L. Donahue, J. DelConte, G. Koch, (all AlixPartners), M. Huebner, J. McClammy, E. Vonnegut, B. Kaminetzky, T. Graulich, C. Robertson (all Davis Polk), J. O'Connell, T. Coleman, J. Turner (all PJT Partners).	0.60
09/02/20	JD	Prepare agenda for meeting tomorrow with management, AlixPartners, PJT and Davis Polk.	0.40
09/03/20	JD	Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors.	1.10
09/03/20	HSB	Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors.	1.10
09/03/20	LJD	Call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (both Davis Polk), T. Coleman, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, H. Bhattal (all AlixPartners) re: weekly catch up call with management and advisors.	1.10
09/04/20	MFR	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/04/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/04/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/04/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/04/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/04/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/04/20	KM	Call with H. Bhattal, S. Canniff, J. DelConte, G. Koch, K. McCafferty, M. Rule (all AlixPartners) re: Weekly update.	0.50
09/08/20	HSB	Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward.	0.60
09/08/20	JD	Compose agenda for weekly professionals call.	0.30
09/08/20	JD	Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward.	0.60
09/08/20	GJK	Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward.	0.60
09/08/20	LJD	Call with M. Huebner, C. Robertson, B. Kamenetsky (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and planning go-forward.	0.60
09/09/20	JD	Review draft agenda for tomorrow's call with the company and the professionals.	0.20
09/10/20	JD	Call with J. Lowne (Purdue) re: post-call catch up.	0.20
09/10/20	JD	Review final wages motion and declarations.	1.50
09/10/20	JD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/10/20	LJD	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update.	0.50
09/10/20	GJK	Call with M. Kesselman, R. Aleali (both Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte and G. Koch (all AlixPartners) re: weekly update.	0.50
09/11/20	GJK	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	LJD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	MFR	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	SKL	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	FOS	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	JD	Prepare agenda for weekly AlixPartners call.	0.40
09/11/20	JD	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners) re: Weekly update:	0.40
09/11/20	NAS	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners)	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		re: Weekly update:	
09/11/20	HSB	Call with H. Bhattal, J. DelConte, L. Donahue, G. Koch, S. Lemack, M. Rule, S. Fernando, N. Simon (all AlixPartners)	0.40
		re: Weekly update:	
09/16/20	JD	Create agenda for all hands call tomorrow morning.	0.40
09/17/20	JD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.80
09/17/20	HSB	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.80
09/17/20	LJD	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.80
09/17/20	GJK	Call with C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: case update and go forward planning.	0.80
09/18/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	MFR	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/18/20	FOS	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	SKL	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	NAS	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	ADD	Prepare for Purdue internal team update call.	0.50
09/18/20	ADD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	KM	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/18/20	JD	Prepare agenda for weekly AlixPartners call.	0.30
09/18/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.60
09/21/20	HSB	Review PBGC claims related issues and requested information from Fidelity.	1.10
09/22/20	HSB	Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call.	0.60
09/22/20	JD	Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/22/20	LJD	Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call.	0.60
09/22/20	GJK	Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call.	0.60
09/24/20	GJK	Call with M. Huebner, B. Kamenetsky, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly advisors catch up call.	0.60
09/24/20	LJD	Prepare for and attend weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both PJT) re: go forward planning.	0.60
09/24/20	JD	Prepare for and attend weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both PJT) re: go forward planning.	0.50
09/24/20	HSB	Weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (both AlixPartners), M. Huebner, C. Robertson (all Davis Polk), J. O'Connell, T. Melvin (both PJT) re: go forward planning.	1.10
09/24/20	HSB	Review C. Landau (Purdue) UCC presentation dated July 2020.	0.90
09/25/20	HSB	Review C. Landau (Purdue) UCC presentation dated Feb 2020 ahead of meeting re: C. Landau (Purdue) deposition.	0.70
09/25/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners)	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		re: Weekly update.	
09/25/20	LTN	Intro to case call with L. Nguyen and J. DelConte (both AlixPartners).	0.60
09/25/20	ADD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	ADD	Prepare for Purdue AlixPartners engagement team update call.	0.40
09/25/20	JD	Prepare agenda for weekly AlixPartners call.	0.30
09/25/20	JD	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	JD	Intro to case call with L. Nguyen and J. DelConte (both AlixPartners).	0.60
09/25/20	GJK	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	FOS	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	SKL	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	SJC	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/25/20	NAS	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.70
09/28/20	JD	Correspondence with A. DePalma and S. Lemack (both	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: workplan and staffing.	
09/28/20	HSB	Conduct online research related to request from Davis Polk.	0.40
09/29/20	HSB	Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call.	0.30
09/29/20	HSB	Review KERP motion prepared by Davis Polk.	0.80
09/29/20	HSB	Review PBGC claim and prepare response to latest inquiry re: PBGC claim calculation.	0.80
09/29/20	JD	Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call.	0.30
09/29/20	NAS	Review motions related to extension of preliminary injunction posted to docket.	0.70
09/29/20	LJD	Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call.	0.30
09/29/20	GJK	Call with M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), L. Donahue, J. DelConte, G. Koch and H. Bhattal (all AlixPartners) re: weekly professionals planning call.	0.30
09/30/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: workplan and go forward staffing needs.	0.40
09/30/20	JD	Review motions filed by the UCC re: discovery and privileged documents.	1.10
09/30/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: workplan and go forward staffing needs.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
09/30/20	JD	Prepare agenda for tomorrow's call with all of the professionals and management.	0.30
09/30/20	HSB	Review recently court filings re: OCP cap raise and new addition.	0.20
Total			351.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	26.30	515.00	13,544.50
Sam K Lemack	9.00	515.00	4,635.00
Lan T Nguyen	0.60	515.00	309.00
Nate A Simon	13.50	515.00	6,952.50
Fernando O Silva	7.50	645.00	4,837.50
Sam J Canniff	7.50	645.00	4,837.50
Jon D Hecht	2.00	690.00	1,380.00
Ryan D Sublett	0.80	735.00	588.00
Gabe J Koch	49.30	840.00	41,412.00
HS Bhattal	74.60	840.00	62,664.00
Mark F Rule	8.40	910.00	7,644.00
Jesse DelConte	78.40	950.00	74,480.00
Kevin M McCafferty	18.80	950.00	17,860.00
Richard Collura	2.00	1,090.00	2,180.00
Lisa Donahue	52.80	1,195.00	63,096.00
Total Hours & Fees	351.50		306,420.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/01/20	SKL	Create accounts payable release file.	1.30
06/01/20	SKL	Review and reconcile list of indemnitee vendors approved for pre and postpetition payment from C. MacDonald (Purdue) and updated the AP tracker accordingly.	1.10
06/01/20	SKL	Finalize updates to the week ended 05/15 cash report based on feedback provided by E. Nowakowski (Purdue) and circulate for final sign-off and production.	1.60
06/01/20	SKL	Finalize updates to the Purdue and Rhodes forecast-to-actuals re: week ended 05/15 cash report.	1.20
06/02/20	SKL	Finalize review of a vendor's executed vendor agreement and updated the AP tracker accordingly so their invoices are released in today's payment run.	1.30
06/02/20	SKL	Finalize review of the docket for the latest restructuring professional fee applications and updated the restructuring fee tracker accordingly.	2.30
06/02/20	SKL	Finalize review of the docket for the latest retained professional fee applications and updated the retained fee tracker accordingly.	1.90
06/02/20	SKL	Prepare updated retained restructuring professional tracker that details the fee applications filed in the second interim fee period and circulate per DPW request.	2.70
06/02/20	SKL	Prepare updated retained professional fee summary and implemented into the latest tracker for DPW review.	1.50
06/02/20	SKL	Create accounts payable release file.	0.80
06/03/20	SKL	Create accounts payable release file.	0.70
06/03/20	SKL	Review the March flash report and prepared a new version that is non-PEO.	2.00
06/03/20	SKL	Review the latest weekly cash report for outstanding inquiries and prepared list of questions/items for E. Nowakowski (Purdue) and J. Liceaga (TXP) to provide	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		additional insight on.	
06/03/20	SKL	Review the latest PrimeClerk claims summary report and began creating the claims database accordingly.	2.60
06/04/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.90
06/04/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30
06/04/20	SKL	Prepare the updated IAC and Investment summaries for the latest weekly cash report and circulate open cash inquiries for E. Nowakowski (Purdue) and J. Liceaga (TXP) to provide additional detail on.	2.00
06/05/20	SKL	Update the Purdue cash summary of the latest weekly cash report and prepared the relevant slides for the cash report accordingly.	1.60
06/05/20	SKL	Update the Rhodes cash summary of the latest weekly cash report and prepared the relevant slides for the cash report accordingly.	1.30
06/05/20	SKL	Continue preparing the final slides of the weekly cash report.	1.40
06/05/20	SKL	Finalize updates to the 05/22 weekly cash report and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.80
06/05/20	SKL	Prepare updated reconciliation and summary of the rebate payments made in the last month and followed-up on open rebate related inquiries.	0.80
06/05/20	SKL	Create accounts payable release file.	0.90
06/08/20	SKL	Review the latest list of reporting inquiries provided by Province and provided update accordingly.	0.80
06/08/20	SKL	Finalize updates to the restructuring professional fee	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		tracker based on the latest fee applications filed on the docket.	
06/08/20	SKL	Finalize updates to the retained professional fee tracker based on the latest fee applications filed on the docket.	1.50
06/08/20	SKL	Begin preparing the next Purdue cash forecast by refreshing the latest summaries and preparing the source files for implementation into the model.	1.30
06/09/20	SKL	Prepare the latest open AP report and updated the OpEx section of the Purdue forecast accordingly.	2.40
06/09/20	SKL	Prepare the latest open AR report and updated the Customer Receipt section of the Purdue forecast accordingly.	2.20
06/09/20	SKL	Review the latest IAC transactions re: weekly cash actuals and updated the latest Purdue 13-week forecast accordingly.	2.10
06/09/20	SKL	Review the March flash report and prepared and non-PEO version of the report accordingly.	2.20
06/10/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.20
06/10/20	SKL	Review and reconcile the latest Paysource transactions report, reconciled against the EastWest transaction report, and updated the categorization accordingly.	1.70
06/10/20	SKL	Review and reconcile the latest IAC and investment related transactions and prepared list of open cash inquiries for E. Nowakowski (Purdue) accordingly.	2.10
06/10/20	SKL	Finalize updates to the Purdue and Rhodes summaries re: weekly cash actuals.	1.00
06/10/20	SKL	Review latest updates to the SAP and AP release processes and prepared accounts payable release files.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/11/20	SKL	Create accounts payable release file.	0.80
06/11/20	SKL	Prepare for and participate in meeting with C. MacDonald (Purdue) re: indemnitee firms and payment process.	1.10
06/11/20	SKL	Review and reconcile the full April 2020 financial presentation and began preparing the April flash report accordingly.	2.40
06/11/20	SKL	Finalize reconciliation of the full April 2020 financial presentation and finalized and circulate the April flash report accordingly.	2.70
06/11/20	SKL	Continue to make updates to the sales forecast and implement into the latest Purdue cash forecast.	2.30
06/12/20	SKL	Continue to work through and update the Customer Receipts and AR roll-forward section of the latest Purdue forecast.	1.80
06/12/20	SKL	Finalize updates to the Op. Ex. and AP roll-forward section of the latest Purdue cash forecast.	1.40
06/12/20	SKL	Finalize updates to the Retained professional, Restructuring professional, and Legal fee section of the latest Purdue forecast.	1.90
06/12/20	SKL	Create accounts payable release file.	0.90
06/12/20	SKL	Review latest feedback provided by C. Hobbick (Purdue) and updated the rebate section of the latest weekly cash report accordingly.	1.30
06/12/20	SKL	Review and reconcile the latest information provided by P. Phouthasone (Purdue) re: Rhodes sales, and prepared and circulate the latest Rhodes weekly sales report.	0.90
06/12/20	SKL	Review and reconcile the latest information provided by E. Nowakowski (Purdue) re: Purdue sales, and prepared and circulate the latest Purdue weekly sales report.	1.30
06/15/20	SKL	Create accounts payable release file.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/15/20	SKL	Prepare for and participate in call with I. Arana, S. Lemack (both AlixPartners) re: PPLP rebates in forecast.	0.80
06/15/20	SKL	Continue to finalize review of the latest IAC cash items and followed up with J. Liceaga (TXP) accordingly.	1.30
06/15/20	SKL	Finalize updates to the weekly cash report and circulate the deck for final sign-off.	2.20
06/15/20	SKL	Review and reconcile the latest Purdue rebate tracker and finalized updates to the customer rebate section of the latest cash forecast accordingly.	2.40
06/15/20	SKL	Finalize updates to the Purdue and Rhodes weekly sales reports and circulate to the company for final sign-off.	1.90
06/15/20	JD	Correspondence with J. Lowne (Purdue) and S. Lemack (AlixPartners) re: cash forecast to actual report.	0.30
06/15/20	JD	Review documents uploaded to the Project Catalyst dataroom.	0.70
06/15/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.40
06/16/20	SKL	Review the docket for the latest restructuring professional fee application and updated the Purdue cash forecast accordingly.	1.80
06/16/20	SKL	Review the docket for the latest retained professional fee application and updated the Purdue cash forecast accordingly.	1.70
06/16/20	SKL	Begin to finalize updates to the Op. Ex. portion of the latest 13 week Purdue forecast.	2.10
06/16/20	SKL	Continue to finalize updates to the Op. Ex. portion of the latest 13 week Rhodes forecast.	1.50
06/16/20	SKL	Continue to finalize updates to the customer rebate portion of the latest 13 week Purdue forecast.	1.70
06/16/20	SKL	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/17/20	SKL	Create accounts payable release file.	0.80
06/17/20	SKL	Continue to finalize updates to the customer rebate portion of the latest 13 week Rhodes forecast.	1.50
06/17/20	SKL	Prepare updated weekly sales report for Rhodes and circulate for final sign-off.	1.10
06/17/20	SKL	Finalize updates to the latest Purdue weekly sales report and circulate for final sign-off.	1.20
06/17/20	SKL	Prepare updated critical vendor analysis and circulate vendor breakdown accordingly.	1.50
06/17/20	SKL	Finalize updates to the Purdue cash forecast and updated the deck accordingly.	1.60
06/17/20	SKL	Finalize updates to the Rhodes cash forecast and updated and circulate the deck accordingly.	1.80
06/18/20	SKL	Create accounts payable release file.	0.90
06/18/20	SKL	Prepare and circulate the latest cash activity report for the May MOR.	2.30
06/18/20	SKL	Prepare and circulate the latest investment activity report for the May MOR.	2.10
06/18/20	SKL	Prepare and circulate the latest retained professional payment activity report for the May MOR.	2.00
06/18/20	SKL	Review and reconcile the latest Paysource transactions report, reconciled against the EastWest transaction report, and updated the categorization accordingly.	1.60
06/19/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.10
06/19/20	SKL	Review and reconcile the latest IAC and investment related transactions and prepared list of open cash inquiries.	1.70
06/19/20	SKL	Prepare for and participate in call with C. MacDonald	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		(Purdue) to finalize updates and answer questions re: the professional payment piece of the May MOR.	
06/19/20	SKL	Finalize updates to the professional payment piece of the May MOR following today's call with C. MacDonald (Purdue).	0.50
06/19/20	SKL	Update the customer rebate and restructuring professional piece of the latest cash forecast and recirculated accordingly.	1.80
06/19/20	SKL	Create accounts payable release file.	0.90
06/19/20	JD	Call with B. Soper (Stretto) re: cash management options.	0.30
06/19/20	JD	Review and provide comments on the latest cash flow forecast.	0.70
06/22/20	SKL	Finalize updates to the week ended 06/05 weekly cash report and circulated for final sign-off.	2.10
06/22/20	SKL	Create accounts payable release file.	0.80
06/22/20	SKL	Pulled the latest A/P information from SAP and began updating the Op. Ex. section of the Purdue forecast accordingly.	2.70
06/22/20	SKL	Update the Op. Ex. piece of the Rhodes forecast using the latest A/P information pulled from SAP.	1.90
06/22/20	SKL	Review and reconciled the latest rebate tracker and began updating the rebate section of the Purdue forecast accordingly.	2.10
06/22/20	JD	Review and comment on latest cash forecast to actual report.	0.70
06/22/20	HSB	Review cash forecast prepared by S. Lemack (AlixPartners).	0.30
06/23/20	JD	Call with B. Soper (Stretto) re: cash management options.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/23/20	SKL	Review latest feedback provided on a particular critical vendor's payment inquiry and prepared payment to the vendor accordingly.	1.60
06/23/20	SKL	Pulled the latest A/R information from SAP and began updating the Customer Receipt section of the Purdue forecast accordingly.	2.20
06/23/20	SKL	Update the Customer Receipt section of the Rhodes forecast using the latest A/R information from SAP.	1.90
06/23/20	SKL	Finalize the Customer Rebate and summary sections of the Purdue and Rhodes forecasts and began updating the deck accordingly.	2.10
06/23/20	SKL	Create accounts payable release file.	0.70
06/23/20	SKL	Prepare for and participate in discussion with the Prime Clerk team re: claim image inquiries and claim summary review.	0.80
06/24/20	SKL	Create accounts payable release file.	1.00
06/24/20	SKL	Finalize updates to the IAC and Restructuring/Retained Professional piece of the Purdue and Rhodes forecast and updated the deck accordingly.	2.40
06/24/20	SKL	Review and reconciled the week ended 06/19 East West report and prepared categorizing information accordingly.	1.80
06/24/20	SKL	Finalize review of the latest Paysource report re: week ended 06/19 weekly cash report and updated the report accordingly.	1.90
06/24/20	SKL	Review the latest updates provided for the week ended 06/12 weekly cash report and updated the Purdue and Rhodes cash summaries accordingly.	2.20
06/24/20	JD	Review and provide comments on latest draft 13 week cash flow forecast.	0.80
06/25/20	JD	Review and provide comments on latest 13 week cash	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		flow draft.	
06/25/20	SKL	Review and reconciled the latest Restructuring/Retained professional holdback tracker provided by C. MacDonald and ensured the latest cash forecast was updated accordingly.	1.70
06/25/20	SKL	Review and reconciled the latest cash information provided by R. Brown (Purdue) and E. Nowakowski (Purdue) and updated the summaries and IAC sections of the cash report accordingly.	2.40
06/25/20	SKL	Prepare for and participate in discussion with J. Liceaga (TXP) re: cash forecast interest rates and updated the forecast with the latest information provided.	1.10
06/25/20	SKL	Create accounts payable release file.	0.90
06/26/20	SKL	Finalize updates to the week ended 06/12 cash report and began putting together the forecast-to-variance slides.	1.70
06/26/20	SKL	Finalize updates to the week ended 06/19 cash report and prepared list of open items for E. Nowakowski and R. Brown (both Purdue) accordingly.	1.80
06/26/20	SKL	Create accounts payable release file.	0.80
06/29/20	SKL	Create accounts payable release file.	0.90
06/29/20	SKL	Continue to follow-up and finalized the IAC transactions and IAC summaries of the latest weekly cash report.	1.50
06/29/20	SKL	Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and continued to finalize the Rhodes and Purdue summaries slides re: week ended 06/12 cash actuals.	1.60
06/29/20	SKL	Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and prepared and finalized the forecast-to-actuals piece of the week ended 06/12 weekly cash report.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
06/29/20	SKL	Review the latest feedback provided by E. Nowakowski (Purdue) and R. Brown (Purdue) and prepared and finalized the forecast-to-actuals piece of the week ended 06/19 weekly cash report.	2.10
06/29/20	HSB	Review weekly cash reports prepared by S. Lemack (AlixPartners) for weeks ended 6/12 and 06/19.	0.80
06/30/20	SKL	Finalize updates to the Purdue and Rhodes IAC summary slides of the week ended 06/19 cash report.	1.20
06/30/20	SKL	Review the April Financial Board Deck provided by E. Nowakowski (Purdue) and prepared the updated non-PEO version of the April Flash report accordingly.	2.70
06/30/20	SKL	Review latest feedback provided on the non-PEO version of the April Flash report and updated accordingly.	2.10
06/30/20	SKL	Review and reconciled latest feedback provided on the week ended 06/12 and 06/19 weekly cash report and revised and recirculated the reports accordingly.	2.50
06/30/20	SKL	Create accounts payable release file.	0.80
06/30/20	JD	Review and provide comments on 6/12 and 6/19 cash forecast to actual reports.	0.80
07/01/20	SKL	Meeting with HS Bhattal and S. Lemack (both AlixPartners) to discuss cash reporting process and procedures.	0.90
07/01/20	SKL	Create accounts payable release file.	0.80
07/01/20	SKL	Review the latest EastWest cash transaction report and categorized for the week ended 06/26 cash report.	2.00
07/01/20	SKL	Review the latest Paysource cash transaction report and categorized for the week ended 06/26 cash report.	1.60
07/01/20	SKL	Prepare the Purdue and Rhodes IAC summaries and prepared updated to the deck accordingly.	1.50
07/01/20	SKL	Finalize updates to the Purdue and Rhodes cash	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		summaries and prepared list of open items.	
07/01/20	HSB	Meeting with HS Bhattal and S. Lemack (both AlixPartners) to discuss cash reporting process and procedures.	0.90
07/02/20	JD	Correspondence with HS Bhattal and S. Lemack (both AlixPartners) re: last 2 weekly forecast to actual cash reports with review of the latest reports.	0.70
07/02/20	SKL	Create accounts payable release file.	0.80
07/02/20	SKL	Review updates provided by E. Nowakowski (Purdue) and J. Liceaga (TXP) and finalized updates to the Purdue and Rhodes cash summaries accordingly.	1.40
07/02/20	SKL	Update the latest Purdue forecast with this past week's cash actuals and prepared the Purdue forecast to actual analysis.	1.90
07/02/20	SKL	Update the latest Rhodes forecast with this past week's cash actuals and prepared the Rhodes forecast to actual analysis.	1.50
07/02/20	SKL	Prepare and finalize updates to the weekly cash report deck and circulated for final sign-off.	1.90
07/06/20	SKL	Prepare the latest Monthly Flash reports and provided to R. Aleali (Purdue) per her request.	0.40
07/06/20	SKL	Finalize the Purdue and Rhodes Medicaid piece of the March Customer Programs report.	2.10
07/06/20	SKL	Finalize the Purdue and Rhodes Commercial rebate piece of the March Customer Programs report.	2.70
07/06/20	SKL	Prepare breakdown of June prepetition payments per J. Lowne (Purdue) request.	0.80
07/06/20	SKL	Update the Medicaid by state breakout for the Customer Programs report.	1.30
07/06/20	SKL	Finalize updates to the rebate summary section of the	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		March Customer Programs report and circulated for final sign-off.	
07/06/20	SKL	Create accounts payable release file.	0.90
07/07/20	SKL	Prepare operational disbursements through 2020 and began preparing the updated analysis re: min cash balance.	2.30
07/07/20	SKL	Finalize updates to the Medicaid piece of the March Customer Programs report based on the feedback provided by E. Nowakowski (Purdue) and circulated for final sign-off.	1.80
07/07/20	SKL	Prepare analysis of the latest retained professional payments and circulated inquiry to H. Benson (TXP) to help provide additional info.	0.70
07/07/20	SKL	Finalize updates to the week ended 06/26 cash report and circulated to the DPW team to begin the production process.	1.30
07/07/20	SKL	Finalize updates to the Min. Cash Analysis based on the feedback provided by J. DelConte (AlixPartners) and circulated update to the AlixPartners team.	2.20
07/07/20	SKL	Create accounts payable release file.	0.80
07/08/20	SKL	Create accounts payable release file.	0.70
07/09/20	SKL	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/09/20	SKL	Create accounts payable release file.	0.90
07/09/20	SKL	Review the latest EastWest cash transaction report and categorized for the week ended 07/03 cash report.	2.00
07/09/20	SKL	Review the latest Paysource cash transaction report and categorized for the week ended 07/03 cash report.	1.90
07/09/20	SKL	Review and reconcile the latest investment activity files provided by J. Liceaga (TXP) and updated the investment	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		section of the week ended 07/03 weekly cash report accordingly.	
07/09/20	SKL	Review and reconcile the latest IAC cash activity provided by J. Liceaga (TXP) and circulated list of open-items to E. Nowakowski (Purdue).	1.40
07/09/20	JD	Review latest cash flow forecasts, cash actual reporting and business plan cash forecasts to respond to outstanding questions from the AHC on year end cash forecast.	1.20
07/09/20	JD	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/09/20	HSB	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/10/20	SKL	Finalize reconciliation of the IAC feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) and updated the weekly cash report accordingly.	1.40
07/10/20	SKL	Update the latest Rhodes forecast with this past week's cash actuals and prepared the Rhodes forecast to actual analysis.	1.60
07/10/20	SKL	Update the latest Purdue forecast with this past week's cash actuals and prepared the Purdue forecast to actual analysis.	1.60
07/10/20	SKL	Create accounts payable release file.	0.80
07/13/20	SKL	Create accounts payable release file.	0.80
07/13/20	SKL	Review and reconcile the latest feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) re: week ended 07/03 cash report and updated the report accordingly.	2.30
07/13/20	SKL	Finalize updates to the week ended 07/03 weekly cash report deck and circulated internally for final sign-off.	1.90
07/13/20	SKL	Review latest batch of Indemnatee invoices provided by C.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		MacDonald (Purdue) and included in today's AP release files.	
07/13/20	SKL	Review the latest Purdue investment activity and prepared the updated Purdue account balances for the June Monthly Operating Report.	2.20
07/13/20	SKL	Finalize updates to the May PEO Flash report and sent to Chris Robertson (Davis Polk) to begin the production process.	0.50
07/13/20	HSB	Review weekly cash actuals report for the week of 7/03 prepared by S. Lemack (AlixPartners).	0.80
07/13/20	HSB	Review underlying excel document for the weekly cash report.	0.20
07/13/20	JD	Review and provide comments on the latest cash report.	0.50
07/14/20	JD	Review minimum cash analysis put together by S. Lemack (AlixPartners).	0.50
07/14/20	SKL	Continue to finalize updates to the Min. Cash Analysis based on the inquiry from FTI.	1.80
07/14/20	SKL	Review and reconcile professional payments made in June and prepared the professional payment section of the Monthly Operating Report accordingly.	2.10
07/14/20	SKL	Finalize review of the cash receipts and disbursements from the month of June and prepared the updated cash activity section the Monthly Operating Report.	2.60
07/14/20	SKL	Create accounts payable release file.	0.60
07/15/20	SKL	Create accounts payable release file.	0.70
07/15/20	SKL	Review updates provided by C. Ostrowski (Purdue) re: Customer Programs and finalized updates to the report.	1.80
07/15/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/10 cash report.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/15/20	SKL	Review the latest PaySource cash transaction report and categorized for the week ended 07/10 cash report.	1.80
07/15/20	SKL	Review and reconcile the latest IAC transactions, prepared the updated IAC summaries and prepared list of open IAC inquiries for J. Liceaga (TXP) and E. Nowakowski (Purdue) to review.	1.50
07/15/20	SKL	Review and reconcile the latest Purdue investment activity and updated the weekly cash report accordingly.	0.90
07/15/20	HSB	Review underlying excel file with financial statements for May reporting.	1.20
07/15/20	HSB	Analyze actual ytd financial results per the May flash report and compared against business plan forecasts.	0.60
07/16/20	SKL	Review and reconcile the latest Rhodes Medicaid and Commercial rebate info provided by the Rhodes Pharma team and updated the April Customer Programs report accordingly.	1.70
07/16/20	SKL	Review and reconcile the latest Purdue Medicaid and Commercial rebate info provided by the E. Nowakowski (Purdue) and updated the April Customer Programs report accordingly.	2.20
07/16/20	SKL	Finalize updates to the remaining sections of the April Customer Programs report, Customer Programs deck, and circulated update to C. Ostrowski (Purdue) for final sign-off.	2.60
07/16/20	SKL	Review the latest feedback provided by C. Ostrowski (Purdue) re: April's Customer Programs report, updated the report accordingly, and began preparing a redacted version of the final deck.	1.60
07/16/20	SKL	Create accounts payable release file.	0.80
07/17/20	SKL	Create accounts payable release file.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/17/20	SKL	Finalize review of the latest weekly cash report feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) and updated the Purdue and Rhodes cash summaries accordingly.	1.30
07/17/20	SKL	Prepare the updated Purdue forecast-to-actuals section of the weekly cash report and prepared and finalized the Purdue slides of the report.	1.30
07/17/20	SKL	Prepare the updated Rhodes forecast-to-actuals section of the weekly cash report and prepared and finalized the Rhodes slides of the report.	1.30
07/17/20	SKL	Finalize Min. Cash Analysis and prepared updated response to the AHC open question list.	0.80
07/17/20	SKL	Review and reconcile prepetition invoices paid in June and prepared updated analysis for J. Lowne (Purdue) review.	0.60
07/17/20	SKL	Review the docket for the latest fee applications filed by Restructuring and Retained Professionals to update our professional tracker accordingly.	1.30
07/17/20	JD	Review and provide comments on the latest cash forecast to actual.	0.50
07/17/20	HSB	Review weekly cash report prepared by S. Lemack (AlixPartners).	0.70
07/20/20	HSB	Review updated weekly cash report (week ended 7/10) prepared by S. Lemack (AlixPartners).	0.20
07/20/20	JD	Review and provide comments on latest draft forecast to actual cash report.	0.60
07/20/20	SKL	Create accounts payable release file.	1.00
07/20/20	SKL	Finalize remaining updates to the week ended 07/10 cash report and circulated for final sign-off.	0.80
07/20/20	SKL	Review the latest OCP payment inquiry and prepared updated OCP breakdown.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/20/20	SKL	Finalize remaining updates to the March and April Customer Program's reports and circulated for final sign-off.	2.10
07/20/20	SKL	Prepare for and participate in OCP discussion with C. MacDonald (Purdue).	0.50
07/20/20	SKL	Begin reconciliation of the latest fee applications filed by retained professionals re: 13-week forecast.	1.40
07/20/20	SKL	Continue reconciliation of the latest fee applications filed by restructuring professionals re: 13-week forecast.	2.00
07/21/20	SKL	Refresh the week ended 07/10 cash report with the latest IAC feedback provided by J. Liceaga (TXP) and recirculated final version of the deck.	1.50
07/21/20	SKL	Review latest feedback and reconciliation of customer deposits re: 13-week cash forecast.	0.50
07/21/20	SKL	Create accounts payable release file.	0.80
07/21/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/17 cash report.	2.00
07/21/20	SKL	Review the latest Paysource transaction report and categorized for the week ended 07/17 cash report.	1.80
07/21/20	SKL	Review and reconcile the latest Purdue rebate tracker provided by D. Krishnan (Purdue) and updated the week ended 07/17 cash report accordingly.	1.30
07/21/20	SKL	Review and reconcile the latest IAC transactions for Purdue and Rhodes and prepared the updated IAC summaries for the week ended 07/17 cash report accordingly.	1.20
07/22/20	SKL	Finalize updates to the Purdue section of the week ended 07/17 cash report, prepared the forecast-to-actuals analysis and updated the cash report accordingly.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/22/20	SKL	Finalize updates to the Rhodes section of the week ended 07/17 cash report, prepared the forecast-to-actuals analysis and updated the cash report accordingly.	1.30
07/22/20	SKL	Review and reconcile the latest Purdue weekly sales info provided by E. Nowakowski (Purdue) and prepared the updated Purdue weekly sales report accordingly.	1.20
07/22/20	SKL	Review and reconcile the latest Rhodes weekly sales info provided by P. Phouthasone (Rhodes) and prepared the updated Rhodes weekly sales report accordingly.	1.00
07/22/20	SKL	Create accounts payable release file.	0.80
07/22/20	SKL	Prepare for Liquidation analysis meeting.	0.60
07/22/20	SKL	Review and reconcile non-recurring legal fees based on the May 2020 financials provided by the company.	2.10
07/22/20	SKL	Begin preparing updated Liquidation Analysis based on May financials.	1.30
07/22/20	JD	Review and provide comments on latest cash forecast to actual report.	0.30
07/22/20	HSB	Review weekly cash report (week ending 07/17) prepared by S. Lemack (AlixPartners).	0.40
07/23/20	SKL	Finalize updates to the week ended 07/17 weekly cash report based on the feedback provided by J. Liceaga (TXP) and circulated for final sign-off.	1.40
07/23/20	SKL	Finalize review and reconciliation of non-recurring legal fees.	1.40
07/23/20	SKL	Continue to finalize review and reconciliation of the latest fee applications filed by retained professionals re: 13-week forecast.	2.30
07/23/20	SKL	Continue to finalize review and reconciliation of the latest fee applications filed by restructuring professionals re: 13-week forecast.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/23/20	SKL	Create accounts payable release file.	1.20
07/24/20	SKL	Create accounts payable release file.	0.80
07/24/20	SKL	Finalize review of the retained professional fee applications, update the retained professional tracker, and circulate list of open inquiries to C. MacDonald (Purdue).	1.20
07/24/20	SKL	Continue to create a refreshed liquidation analysis based on May financials, and began reviewing the underlying assumptions for the high, mid and low case.	2.70
07/24/20	SKL	Finalize review of the restructuring professional fee applications, updated the restructuring professional tracker, and circulated list of open inquiries to C. MacDonald (Purdue).	1.80
07/24/20	SKL	Begin updating the latest Purdue 13-week forecast summary and bringing in the latest A/P and A/R source information.	1.80
07/27/20	SKL	Create accounts payable release file.	0.70
07/27/20	SKL	Review and reconcile the latest receipt forecast and update the Purdue cash forecast accordingly.	2.40
07/27/20	SKL	Pull the latest Purdue A/R detail from SAP and begin updating the receipt section of the Purdue forecast accordingly.	1.50
07/27/20	SKL	Pull the latest Purdue A/P detail from SAP and begin updating the operating expense section of the Purdue forecast accordingly.	1.80
07/27/20	SKL	Review and reconcile the latest Purdue customer rebate forecast and update the Purdue cash forecast accordingly.	2.60
07/28/20	SKL	Finalize review and reconciliation of latest retained professional fee applications filed and update the Purdue cash forecast accordingly.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/28/20	SKL	Finalize review and reconciliation of latest restructuring professional fee applications filed and update the Purdue cash forecast accordingly.	1.80
07/28/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/24 cash report.	1.80
07/28/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 07/24 cash report.	2.40
07/28/20	SKL	Review and reconcile latest finance report slides from C. George (Purdue) and redact and recirculate deck to begin the production process.	1.10
07/28/20	SKL	Create accounts payable release file.	0.60
07/29/20	SKL	Create accounts payable release file.	0.80
07/29/20	SKL	Prepare for and participate in discussions with C. MacDonald (Purdue) re: OCP fees/expenses incurred.	1.10
07/29/20	SKL	Review and reconcile latest OCP fee/expense detailed provided by C. MacDonald (Purdue) and updated the OCP report accordingly.	1.60
07/29/20	SKL	Prepare final list of updates for the June OCP report and circulated final report for DPW review.	2.10
07/29/20	SKL	Review and reconcile the latest IAC transactions for Purdue and Rhodes and prepared the updated IAC summaries for the week ended 07/24 cash report accordingly.	1.10
07/29/20	SKL	Review latest feedback provided re: Rhodes customer rebates and update the Rhodes cash forecast accordingly.	2.60
07/30/20	SKL	Pull the latest Rhodes A/P detail from SAP and begin updating the operating expense section of the Rhodes forecast accordingly.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/30/20	SKL	Pull the latest Purdue A/R detail from SAP and begin updating the receipt section of the Purdue forecast accordingly.	1.20
07/30/20	SKL	Finalize updates to the customer receipt section of the Rhodes cash forecast.	2.10
07/30/20	SKL	Finalize updates to the operating expense section of the Rhodes cash forecast.	2.40
07/30/20	SKL	Finalize updates to the IAC receipts section of the Rhodes cash forecast.	1.70
07/30/20	SKL	Create accounts payable release file.	0.60
07/31/20	SKL	Create accounts payable release file.	0.90
07/31/20	SKL	Finalize updates to the IAC disbursements section of the Rhodes cash forecast.	1.20
07/31/20	SKL	Prepare updated Rhodes forecast-to-actual slides for the week ended 07/24 cash forecast.	0.60
07/31/20	SKL	Prepare updated Purdue forecast-to-actual slides for the week ended 07/24 cash forecast.	0.60
07/31/20	SKL	Finalize updates to the Purdue cash forecast and update the Purdue slides of the latest cash forecast deck accordingly.	2.40
07/31/20	SKL	Finalize updates to the Rhodes cash forecast and update the Rhodes slides of the latest cash forecast deck accordingly.	2.10
07/31/20	SKL	Update the cash forecast with the latest feedback provided and recirculate for final sign-off.	0.70
07/31/20	HSB	Review Cash Forecast report prepared by S. Lemack (AlixPartners).	0.70
08/01/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
08/03/20	JD	Review and provide comments on the latest cash	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		forecast.	
08/03/20	SKL	Create accounts payable release files.	1.10
08/03/20	SKL	Review, reconcile and provide response to the latest Critical Vendor inquiry provided by R. Johansen (Purdue).	0.80
08/03/20	SKL	Review, reconcile and provide updated on latest prepetition invoice queries provided by C. MacDonald (Purdue).	1.10
08/03/20	SKL	Review latest feedback provided re: professional payment forecast and prepare updates to the latest cash forecast accordingly.	2.40
08/03/20	HSB	Review post-petition invoices submitted for payment.	0.20
08/04/20	JD	Review updated cash forecast per management comments.	0.40
08/04/20	SKL	Prepare updated US Trustee payment calculation and support and prepare update for J. Lowne (Purdue) accordingly.	0.90
08/04/20	SKL	Finalize review of final notes and feedback provided on the latest cash forecast and circulated for production.	0.70
08/04/20	SKL	Review final feedback provided internally re: cash forecast and circulate to the Purdue team for final sign-off.	1.70
08/04/20	SKL	Create accounts payable release files.	0.90
08/05/20	SKL	Create accounts payable release files.	0.60
08/05/20	SKL	Prepare updated Critical Vendor breakdown per C. Robertson (Davis Polk) request.	0.80
08/05/20	SKL	Finalize updates to the week ended 07/24 cash report and circulate internally for final sign-off.	1.80
08/05/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/31 cash report.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/05/20	JD	Review and provide comments on latest cash forecast to actual analysis.	0.50
08/05/20	JD	Review material contract analysis from Davis Polk.	0.70
08/05/20	HSB	Review Cash Report (for week ended 07/24) prepared by S. Lemack (AlixPartners).	0.80
08/05/20	HSB	Review excel file with cash actuals tracking activity (for week ended 07/24) prepared by S. Lemack (AlixPartners).	0.90
08/06/20	HSB	Review supporting excel files for weekly cash report.	0.80
08/06/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 07/31 cash report.	2.20
08/06/20	SKL	Review and reconciled the latest investment activity re: East West cash transactions and updated the weekly cash report accordingly.	1.10
08/06/20	SKL	Review and reconcile the latest IAC cash activity and prepare updated list of open items for E. Nowakowski (Purdue) accordingly.	1.80
08/06/20	SKL	Review and reconcile the latest restructuring and retained professional payments against the latest fee application tracker.	1.10
08/06/20	SKL	Create accounts payable release files.	0.70
08/07/20	SKL	Create accounts payable release files.	0.70
08/07/20	SKL	Review and reconcile latest May-PEO Flash report and prepared non-PEO version.	2.40
08/07/20	SKL	Update the Purdue cash forecast with the latest weekly cash actuals and prepared the updated forecast to actual slide of the weekly cash report accordingly.	1.10
08/07/20	SKL	Update the Rhodes cash forecast with the latest weekly cash actuals and prepared the updated forecast to actual	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		slide of the weekly cash report accordingly.	
08/07/20	SKL	Update the weekly cash report with the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue) and circulated internally for final sign-off.	1.80
08/07/20	HSB	Review list of outstanding government payments in response to query.	0.20
08/10/20	HSB	Review excel file with the PPLP Cash Flow Model	1.10
08/10/20	SKL	Review latest vendor match updates and update the vendor master accordingly.	2.30
08/10/20	SKL	Finalize remaining updates to the 07/31 weekly cash report and circulate for approval.	0.70
08/10/20	SKL	Finalize updates to the non-PEO May Flash report and circulate for final approval.	1.20
08/10/20	SKL	Create accounts payable release files.	0.70
08/10/20	SKL	Review the EastWest cash transactions from July and prepare updated cash activity report for the July MOR.	1.90
08/11/20	SKL	Review and reconcile all July investment activity and prepare updated bank account balances for the July MOR.	1.90
08/11/20	SKL	Review and reconcile professional payments for July and prepare the updated professional payment piece of the July MOR and circulate to C. MacDonald (Purdue) for approval.	2.20
08/11/20	SKL	Review latest feedback provided re: customer deposits and prepare updated list of open items and follow-up questions accordingly.	0.70
08/11/20	SKL	Continue to review the May financial board deck and prepare the non-PEO Flash report accordingly.	2.10
08/11/20	SKL	Finalize updates to the non-PEO Flash report and circulate to J. Lowne (Purdue) and R. Aleali (Purdue) for final approval.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/11/20	SKL	Create accounts payable release files.	0.60
08/12/20	SKL	Prepare for and participate in discussion with C. MacDonald (Purdue) re: OCP firm payments and caps.	0.60
08/12/20	SKL	Reconcile latest OCP firm payments and prepare update for C. MacDonald (Purdue) and DPW team.	0.50
08/12/20	SKL	Create accounts payable release files.	0.90
08/12/20	SKL	Finalize updates to the professional payment piece of the July MOR based on the latest feedback provided by C. MacDonald (Purdue) and circulate accordingly.	1.90
08/12/20	SKL	Prepare final updates to the May non-PEO Flash report based on the latest feedback provided and circulated for final sign-off.	1.10
08/12/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 08/07 cash report.	2.20
08/12/20	SKL	Review and reconcile the latest investment activity re: 08/07 cash report and update the IAC summary schedules accordingly.	1.30
08/12/20	HSB	Review revised version of the non-PEO Flash report for May 2020.	0.30
08/13/20	HSB	Review excel file with financial statements for June 2020, prepared by S. Lemack (AlixPartners).	0.80
08/13/20	HSB	Review Financial Statement (full deck) for June 2020.	1.40
08/13/20	HSB	Review PEO Flash report for June 2020, prepared by S. Lemack (AlixPartners) and provided comments.	1.30
08/13/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 08/07 cash report.	2.20
08/13/20	SKL	Review and reconcile the latest restructuring and retained professional payments against the latest fee application	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		tracker, and update the Restructuring fee schedule accordingly.	
08/13/20	SKL	Review and reconcile the latest IAC cash activity and prepare updated list of open items for A. Green (Purdue) and T. Gabriele (Purdue) accordingly.	1.20
08/13/20	SKL	Finalize updates to the Purdue cash summary and cash detail and compared forecast-to-actuals for the week ended 08/07.	2.10
08/13/20	SKL	Finalize updates to the Rhodes cash summary and cash detail and compared forecast-to-actuals for the week ended 08/07.	1.90
08/13/20	SKL	Create accounts payable release files.	0.30
08/14/20	SKL	Review and reconcile the Purdue weekly sales report provided by E. Nowakowski (Purdue) and formatted accordingly for production purposes.	0.90
08/14/20	SKL	Review and reconcile the Rhodes weekly sales report provided by P. Phouthasone (Purdue) and formatted accordingly for production purposes.	0.90
08/14/20	SKL	Began review of the June financial board deck and began preparing the June PEO Flash report accordingly.	2.30
08/14/20	SKL	Finalize updates to the June PEO Flash report based on the latest feedback provided and circulate to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	2.30
08/14/20	SKL	Prepare final updates to the June PEO Flash report based on the feedback provided by J. Lowne (Purdue) and circulate for final approval.	0.80
08/14/20	SKL	Create accounts payable release files.	0.70
08/14/20	HSB	Review weekly Cash Report prepared by S.Lemack (AlixPartners).	0.70
08/14/20	JD	Review and provide comments on this week's cash	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		forecast to actual report.	
08/17/20	SKL	Review and reconcile the latest Prime Clerk claims report provided and updated the claims database accordingly re: newly filed claims.	2.30
08/17/20	SKL	Create accounts payable release files.	0.80
08/17/20	SKL	Review latest fee applications filed by Restructuring professionals and update the Restructuring professional fee tracker accordingly.	1.30
08/17/20	SKL	Review latest fee applications filed by Retained professionals and update the Retained professional fee tracker accordingly.	1.30
08/18/20	SKL	Finalize remaining updates to the week ended 08/07 cash report and circulate to J. Lowne (Purdue) for final sign-off.	1.10
08/18/20	SKL	Update the latest liquidation analysis with the June financials provided by E. Nowakowski (Purdue).	2.20
08/18/20	SKL	Continue to refresh the latest liquidation analysis with the June financials and prepare updates to the consolidated summary accordingly.	1.10
08/18/20	SKL	Create accounts payable release files.	0.70
08/19/20	SKL	Review and reconcile latest indemnitee fee invoices provided by C. MacDonald (Purdue) and prepare accounts payable release files.	1.60
08/19/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 08/14 cash report.	2.20
08/19/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 08/14 cash report.	1.90
08/19/20	SKL	Review and reconcile latest IAC and investment	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		transactions provided by J. Liceaga (TXP) and provided list of open items and question to E. Nowakowski (Purdue).	
08/19/20	SKL	Review and reconcile the latest Rhodes critical vendor inquiry provided by R. Haberlin (Purdue) and provide updated breakdown and analysis accordingly.	0.90
08/20/20	SKL	Finalize updates to the IAC cash summary based on the feedback provided by E. Nowakowski's (Purdue) team and updated the Purdue and Rhodes cash summaries accordingly.	1.70
08/20/20	SKL	Review and reconcile latest rebate transactions and provide list of open items to C. Hobbick (Purdue) accordingly.	0.80
08/20/20	SKL	Create accounts payable release files.	0.70
08/21/20	SKL	Finalize updates to the Rhodes cash summary and cash detail and compared forecast-to-actuals for the week ended 08/14.	1.70
08/21/20	SKL	Finalize updates to the Purdue cash summary and cash detail and compared forecast-to-actuals for the week ended 08/14.	1.80
08/21/20	SKL	Finalize updates to the week ended 08/14 cash report and circulated for final sign-off.	1.80
08/21/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.50
08/21/20	HSB	Review Weekly Cash Report for week ended 8/14 prepared by S. Lemack (AlixPartners).	0.60
08/24/20	SKL	Create accounts payable release files.	0.60
08/24/20	SKL	Continued to review the latest claims register provided by Prime Clerk and update the claims database accordingly.	2.10
08/24/20	SKL	Review the latest EastWest cash transaction report	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		provided by J. Liceaga (TXP) and categorized for the week ended 08/21 cash report.	
08/25/20	SKL	Create accounts payable release files.	0.70
08/25/20	SKL	Review the latest Paysource transaction report and prepared open list of items for E. Nowakowski (Purdue) to review.	1.90
08/25/20	SKL	Review and reconcile the latest IAC and investment cash transactions and update the IAC summary and investment piece of the cash summary re: weekly cash report.	1.70
08/25/20	SKL	Review and reconcile the latest rebate payments and provide list of open items to C. Hobbick (Purdue) and P. Phouthasone (Purdue).	0.90
08/25/20	SKL	Continue to update the matching between the latest filed proof of claims and the scheduled liabilities.	1.40
08/25/20	SKL	Update the latest Purdue forecast with cash actuals and prepare the latest forecast-to-actuals analysis.	1.80
08/26/20	SKL	Update the latest Rhodes forecast with cash actuals and prepare the latest forecast-to-actuals analysis.	1.60
08/26/20	SKL	Review the latest professional payment info from July and prepare and distribute the OCP report to C. MacDonald (Purdue) for review.	2.40
08/26/20	SKL	Review and reconcile the latest debit balance inquiry provided by H. Benson (Purdue) and prepare updated analysis accordingly.	1.30
08/26/20	SKL	Review the latest information re: cash activity provided by R. Brown (Purdue) and update the week ended 08/21 cash report accordingly.	1.40
08/26/20	SKL	Create accounts payable release files.	0.70
08/27/20	SKL	Create accounts payable release files.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
08/27/20	SKL	Finalize remaining updates to the IAC summary and update the cash summary accordingly.	0.90
08/27/20	SKL	Review and reconcile the latest feedback provided by C. MacDonald (Purdue) and finalized updates to the July OCP report.	2.60
08/27/20	SKL	Continue to review and reconcile the latest claims register provided by Prime Clerk and update the claims database accordingly.	2.40
08/27/20	SKL	Review the latest feedback provided by R. Brown (Purdue) and updated the weekly cash report accordingly.	0.90
08/28/20	SKL	Review the latest Purdue sales report provided by E. Nowakowski (Purdue) and prepare the Purdue sales by product report accordingly.	0.90
08/28/20	SKL	Review the latest Rhodes sales report provided by P. Phouthasone (Purdue) and prepare the Rhodes sales by product report accordingly.	0.80
08/28/20	SKL	Review and reconcile latest critical vendor inquiry provided and prepared updated analysis accordingly.	1.10
08/28/20	SKL	Finalize updates to the weekly cash report and circulate the updated deck for final sign-off.	1.60
08/28/20	SKL	Review the latest fee applications filed on the docket and update the restructuring professional fee tracker accordingly.	1.80
08/28/20	SKL	Review the latest fee applications filed on the docket and update the retained professional fee tracker accordingly.	1.60
08/28/20	HSB	Review Weekly Cash Report for week ended 8/21 prepared by S. Lemack (AlixPartners).	0.60
08/28/20	HSB	Review Weekly Sales Reports for Purdue & Rhodes prepared by S. Lemack (AlixPartners).	0.40
08/28/20	JD	Review and provide comments on weekly cash forecast to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		actual reporting.	
08/31/20	SKL	Finalize remaining updates to cash report and circulate to Davis Polk team for production.	0.40
08/31/20	SKL	Create accounts payable release files.	0.70
08/31/20	SKL	Finalize remaining updates to the latest OCP report and circulate to Davis Polk team.	1.00
08/31/20	SKL	Finalize remaining updates to the restructuring professional fee tracker and brought into the latest cash forecast accordingly.	1.40
08/31/20	SKL	Finalize remaining updates to the retained professional fee tracker and brought into the latest cash forecast accordingly.	1.20
08/31/20	SKL	Pull latest AP information from SAP and create and implement latest analysis into the Purdue and Rhodes cash forecasts accordingly.	1.40
08/31/20	SKL	Pull latest AR information from SAP and create and implement latest analysis into the Purdue and Rhodes cash forecasts accordingly.	1.20
08/31/20	SKL	Carry forward all cash summaries on the latest 13-week cash forecast and begin updating the forecast accordingly.	2.10
09/01/20	SKL	Create accounts payable release files.	0.60
09/01/20	SKL	Prepare and finalize updates to the operating expense section of the latest 13-week cash forecast.	2.10
09/01/20	SKL	Review the latest Purdue rebate tracker and updated the customer rebate section of the Purdue cash forecast accordingly.	2.10
09/01/20	SKL	Prepare and finalize updates to the customer receipt section of the Purdue cash forecast.	1.90
09/01/20	SKL	Review the latest updates to the IAC disbursement	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		section of the Purdue cash forecast and finalize accordingly.	
09/01/20	SKL	Review the latest updates to the IAC receipt section of the Purdue cash forecast and finalize accordingly.	1.40
09/01/20	JD	Review draft of settlement cash flow forecast from PJT. Provide comments re: same.	0.40
09/02/20	SKL	Prepare and finalize updates to the operating expense section of the latest Rhodes cash forecast.	2.20
09/02/20	SKL	Prepare and finalize updates to the customer receipt section of the latest Rhodes cash forecast.	2.00
09/02/20	SKL	Review and finalize updates to the customer rebate section of the latest Rhodes cash forecast.	1.70
09/02/20	SKL	Create accounts payable release files.	0.70
09/02/20	SKL	Finalize remaining updates to the Purdue and Rhodes forecast deck and circulate internally for review and sign-off.	2.30
09/03/20	SKL	Create accounts payable release files.	0.70
09/03/20	SKL	Review and prepare update on the restructuring invoice inquiry per C. MacDonald (Purdue) request.	0.50
09/03/20	JD	Review and provide comments on the latest cash forecast file.	0.70
09/03/20	JD	Review comments from Davis Polk on the settlement cash forecast analysis from PJT.	0.40
09/03/20	HSB	Review 13-week cash forecast (for period beginning with week ended 8/28) prepared by S. Lemack (AlixPartners).	0.80
09/04/20	JD	Review latest version of the cash settlement forecast.	0.30
09/04/20	SKL	Review latest restructuring fee approvals and updated invoices for today's AP release file.	1.50
09/07/20	JD	Correspondence with S. Lemack (AlixPartners) re: cash	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		forecast and KEIP/KERP amounts.	
09/08/20	SKL	Review latest KEIP/KERP motion and updated the cash forecast accordingly.	1.50
09/08/20	SKL	Review the latest Paysource transaction report and updated the week ended 08/28 cash report accordingly.	2.00
09/08/20	SKL	Finalize review of the week ended 08/28 EastWest cash report and updated categorizations accordingly.	2.10
09/08/20	SKL	Finalize updates to the Purdue and Rhodes IAC summaries re: week ended 08/28 weekly cash report.	1.90
09/08/20	SKL	Finalize updates to the Purdue forecast-to-actuals analysis re: week ended 08/28 cash report.	0.60
09/08/20	SKL	Finalize updates to the Rhodes forecast-to-actuals analysis re: week ended 08/28 cash report.	0.40
09/08/20	SKL	Create accounts payable release file.	0.60
09/08/20	JD	Review latest draft cash flow forecast.	0.60
09/09/20	JD	Review final cash forecast prior to sending to the company.	0.50
09/09/20	JD	Review updated cash forecast per management comments.	0.30
09/09/20	JD	Review latest cash forecast to actual reporting.	0.40
09/09/20	JD	Review latest draft illustrative settlement cash flow forecast.	0.40
09/09/20	SKL	Review of week ended 09/04 EastWest transactions report and categorizing transactions.	2.00
09/09/20	SKL	Pull latest Paysource transaction report and began matching to the latest EastWest report accordingly.	1.90
09/09/20	SKL	Finalize updates to the IAC and investment summaries re: week ended 09/04 weekly cash report and prepare list of open items for E. Nowakowski (Purdue) accordingly.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/09/20	SKL	Create accounts payable release file.	0.70
09/09/20	HSB	Review weekly cash report (for week ended 8/28) prepared by S. Lemack (AlixPartners).	0.70
09/10/20	RDS	Review API plant unit economics and resulting cash flow bridge	0.70
09/10/20	SKL	Create accounts payable release file.	0.90
09/11/20	SKL	Prepare updated Purdue forecast-to-actuals analysis re: week ended 09/04 cash report.	0.90
09/11/20	SKL	Prepare updated Rhodes forecast-to-actuals analysis re: week ended 09/04 cash report.	0.80
09/14/20	SKL	Create accounts payable release file.	0.70
09/14/20	SKL	Finalize forecast-to-actuals and prepare and circulate week ended 09/04 cash report.	2.40
09/14/20	SKL	Review and prepare update to the latest critical vendor inquiry provided by R. Haberlin (Purdue).	0.60
09/14/20	GJK	Review Mundipharma new statement of cash flows.	2.50
09/14/20	JD	Review last week's forecast to actual analysis.	0.30
09/14/20	HSB	Review weekly cash report (week ended 9/041) prepared by S. Lemack (AlixPartners).	0.90
09/15/20	GJK	Review Mundipharma updated balance sheet and cash forecast.	3.00
09/15/20	SKL	Create accounts payable release file.	0.70
09/15/20	SKL	Review the latest EastWest transactions report and began categorizing transactions for the week ended 09/11 weekly cash report.	2.20
09/15/20	SKL	Prepare the cash activity, disbursements and credits, section of the August monthly operating report and circulate internally.	2.10
09/15/20	SKL	Review the latest bank account activity for the month of	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/16/20	SKL	August and prepare and circulate the August bank balances for the August monthly operating report.	1.70
09/16/20	SKL	Review the latest Paysource transactions report and incorporate into the latest weekly cash report.	2.40
09/16/20	SKL	Review the latest professional payment information and prepare and circulate the latest professional payment piece of the August Monthly Operating Report.	0.50
09/16/20	SKL	Review the latest feedback provided by C. MacDonald (Purdue) and circulate updated report accordingly.	1.90
09/16/20	SKL	Review the latest IAC cash activity and prepare and circulate list of open cash items for T. Gabriele (Purdue) and R. Brown (Purdue).	0.70
09/16/20	NAS	Create accounts payable release file.	1.00
09/17/20	NAS	Build projections of Mundipharma free cash flow by product category.	0.40
09/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review initial analysis of Mundipharma free cash flow by product category.	2.70
09/17/20	NAS	Finalize analysis of Mundipharma free cash flow by product category across scenarios.	1.30
09/17/20	SKL	Analyze movements in Mundipharma product category free cash flow relative to prior iteration of model.	0.90
09/17/20	SKL	Create accounts payable release file.	1.60
09/17/20	SKL	Reviewed latest cash transaction feedback provided by S. Visciglia (Purdue) and R. Brown (Purdue) and updated the week ended 09/11 cash report accordingly.	1.10
09/17/20	SKL	Update the restructuring professional fee tracker with the latest fee applications files.	0.70
09/17/20	SKL	Review and reconcile latest critical vendor payment inquiry provided by M. Kroese (Purdue) and prepare	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		update accordingly.	
09/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review initial analysis of Mundipharma free cash flow by product category.	0.40
09/17/20	HSB	Review July Flash report (PEO version) prepared by S. Lemack (AlixPartners) and provide feedback.	1.90
09/18/20	HSB	Review July 2020 full board presentation.	2.40
09/18/20	HSB	Review weekly cash report (week ended 9/11) prepared by S. Lemack (AlixPartners).	1.20
09/18/20	HSB	Call with H. Bhattal, S. Canniff, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update.	0.50
09/18/20	JD	Review and provide comments on latest forecast to actual cash reporting.	0.60
09/18/20	SKL	Create accounts payable release file.	0.70
09/18/20	SKL	Finalize updates to the Purdue forecast-to-actuals and update the weekly cash report accordingly.	1.30
09/18/20	SKL	Finalize updates to the Rhodes forecast-to-actuals and update the weekly cash report accordingly.	1.20
09/18/20	SKL	Finalize review of July board presentation and circulate final July Flash report for review	2.30
09/21/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off.	1.80
09/21/20	SKL	Create accounts payable release file.	0.70
09/21/20	NAS	Provide detailed Mundipharma free cash flow projections by product category to PJT.	0.90
09/21/20	JD	Review latest cash forecast to actual report and give final comments.	0.40
09/22/20	SKL	Create accounts payable release files.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/22/20	SKL	Review and reconcile the latest East West cash transactions report and began categorizing for the latest weekly cash report.	2.20
09/22/20	SKL	Review and reconcile the latest Paysource transactions report and began categorizing for the latest weekly cash report.	2.00
09/22/20	JD	Review latest version of the settlement cash flows to be sent to the Board.	0.30
09/22/20	HSB	Review weekly sales product reports for Purdue and Rhodes prepared by S. Lemack (AlixPartners)	0.30
09/23/20	SKL	Prepare the latest IAC cash summaries and circulate list of open items to S. Visciglia (Purdue).	1.50
09/23/20	SKL	Review and reconcile latest rebate activity and circulate list of open questions to C. Hobbick (Purdue).	0.70
09/23/20	SKL	Create accounts payable release files.	0.70
09/23/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) and J. Arsic (PJT) to review Mundipharma free cash flow by product category analysis.	0.40
09/23/20	JD	Review and comment on the draft email to the Board re: illustrative cash settlement forecast.	0.30
09/23/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) and J. Arsic (PJT) to review Mundipharma free cash flow by product category analysis.	0.40
09/23/20	SKL	Review latest critical vendor payment inquiry and next steps.	0.40
09/24/20	LJD	Review board presentation on cash flows	0.60
09/24/20	SKL	Create accounts payable release files.	0.70
09/24/20	SKL	Update the Purdue forecast with the latest format changes made to the Purdue cash actuals and prepare the latest Purdue forecast-to-actuals.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/24/20	SKL	Finalize updates to the Rhodes section of the weekly cash report and updated the formatting to match the latest Rhodes forecast.	1.80
09/24/20	SKL	Finalize updates to the Purdue section of the weekly cash report and updated the formatting to match the latest Purdue forecast.	2.10
09/25/20	SKL	Update the Rhodes forecast with the latest format changes made to the Purdue cash actuals and prepare the latest Rhodes forecast-to-actuals.	1.30
09/25/20	SKL	Create accounts payable release files.	0.70
09/25/20	SKL	Continue review of the latest critical vendor inquiry provided by R. Haberlin (Purdue) and prepare updated breakdown accordingly.	0.80
09/27/20	HSB	Review July 2020 full board presentation and C. Landau (Purdue) presentation in response to request for info for KERP related data.	1.30
09/27/20	HSB	Compile summary of Purdue operating performance statistics, management initiatives & qualitative data in response to request for info for KERP related data.	0.80
09/28/20	HSB	Review weekly cash report (week ended 9/18) prepared by S. Lemack (AlixPartners).	0.90
09/28/20	JD	Review and provide comments on last week's forecast to actual cash report.	0.50
09/28/20	SKL	Finalize remaining updates to the week ended 09.18 weekly cash report and circulate for final sign-off.	2.10
09/28/20	SKL	Finalize updates to the format of the Purdue cash detail in the 09.18 weekly cash report and circulate for sign-off.	1.20
09/28/20	SKL	Create accounts payable release file.	0.90
09/29/20	SKL	Create accounts payable release file.	0.70
09/29/20	SKL	Review latest OCP fee/expense detail provided by C.	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		MacDonald (Purdue) and prepare updated OCP report accordingly.	
09/29/20	SKL	Review latest A/R activity and prepare open item inquiry for E. Nowakowski (Purdue) and team to provide update re: A/R aging.	0.50
09/29/20	SKL	Review and reconcile latest critical vendor inquiry and prepare list of open items and updates accordingly.	0.60
09/29/20	SKL	Review and reconcile latest East West cash transactions report and began categorizing for the week ended 09.25 cash report accordingly.	2.10
09/30/20	SKL	Review and reconcile latest Paysource transactions report and began categorizing and implemented into the week ended 09.25 cash report accordingly.	1.80
09/30/20	SKL	Finalize updates to the August OCP report based on the feedback provided by C. MacDonald (Purdue) and circulate to the Davis Polk team for sign-off and to submit.	1.40
09/30/20	SKL	Update the no-hold vendor list based on the updates provided by C. MacDonald (Purdue).	0.40
09/30/20	SKL	Finalize review of latest cash transactions and circulate list of open items to T. Gabriele, E. Nowakowski, C. Hobbick and S. Visciglia (all Purdue) to provide updates.	1.70
09/30/20	SKL	Review latest investment related activity and update to Purdue cash summary and Purdue cash detailed summary accordingly.	1.30
09/30/20	SKL	Prepare for and participate in discussion with C. MacDonald (Purdue) re: August OCP activity.	0.50
09/30/20	SKL	Create accounts payable release file.	0.60
09/30/20	SKL	Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and procedures.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
09/30/20	HSB	Review monthly OCP report prepared by S. Lemack and provide comments.	0.30
09/30/20	LTN	Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and procedures.	1.20
09/30/20	ADD	Meeting with A. DePalma, L. Nguyen, S. Lemack (all AlixPartners) re: weekly cash reporting processes and procedures.	1.20
Total			677.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	1.20	515.00	618.00
Sam K Lemack	610.00	515.00	314,150.00
Lan T Nguyen	1.20	515.00	618.00
Nate A Simon	6.70	515.00	3,450.50
Ryan D Sublett	0.70	735.00	514.50
Gabe J Koch	6.30	840.00	5,292.00
HS Bhattal	29.40	840.00	24,696.00
Jesse DelConte	20.90	950.00	19,855.00
Lisa Donahue	0.60	1,195.00	717.00
Total Hours & Fees	677.00		369,911.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/01/20	ADD	Compile documentation in support of diligence request and requested approval from the client to produce documents.	1.20
06/01/20	ADD	Review list of third-parties provided by Davis Polk for relationships with third-party confidentiality implications.	2.40
06/01/20	JD	Correspondence with R. Aleali (Purdue), M. Kesselman (Purdue), S. Birnbaum (Dechert), J. Turner (PJT) and A. DePalma (AlixPartners) re: status of side by side presentation data room sharing access.	0.80
06/01/20	JD	Participation in call with M. Kesselman (Purdue), M. Huebner, E. Vonnegut (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), S. Birnbaum (Dechert) and various ad hoc groups re: side by side analysis presentation.	1.40
06/01/20	JD	Correspondence with A. DePalma (AlixPartners) re: redaction process for diligence materials.	0.30
06/01/20	JD	Review materials from PJT re: AHC diligence requests on latest business plan.	0.40
06/02/20	JD	Review draft responses to Duff & Phelps business plan diligence questions. Review draft excel files to be shared during the call.	1.10
06/02/20	JD	Prepare for and attend call with J. Turner, R. Schnitzler, M. Thomas (all PJT), R. Schwartz, A. Chrysostomou, R. Levy (all Duff & Phelps) re: business plan assumptions.	0.90
06/02/20	JD	Prepare for and attend call with J. Turner, R. Schnitzler, M. Thomas (all PJT), J. Lowne, D. Fogel, E. Ruiz, D. Rosen (all Purdue), R. Schwartz, B. Bartell, J. Feltman (all Duff & Phelps) re: business plan diligence.	1.00
06/02/20	ADD	Review materials created in response to diligence requests for third party confidential information prior to processing and production.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/02/20	ADD	Compile wholesaler/distributor agreements for David Polk's review.	2.30
06/02/20	ADD	Review Committee diligence request list for and provided draft responses.	2.20
06/02/20	ADD	Identify and compile categories of information and materials produced in the dataroom for Davis Polk's Review.	1.60
06/04/20	ADD	Identify distribution agreements with Rhodes entities and compile agreements for Davis Polk's diligence team's review.	1.80
06/04/20	ADD	Prepare updated interested parties list and review entities for inclusion.	1.50
06/05/20	ADD	Research material entities for inclusion in third-party entity list requested by Davis Polk.	1.90
06/05/20	ADD	Review list of third-parties provided by Davis Polk for relationships with third-party confidentiality implications.	2.80
06/05/20	JD	Review final AHC April business plan diligence responses.	0.90
06/05/20	JD	Review consolidated model responses from Purdue for AHC questions.	0.40
06/05/20	JD	Review draft question list from FTI for the IACs.	0.30
06/05/20	JD	Call with G. Koch, N. Simon and J. DelConte (all AlixPartners) M. Diaz, B. Bromberg (both FTI), M. Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	0.50
06/05/20	NAS	Call with G. Koch, N. Simon and J. DelConte (all AlixPartners) M. Diaz, B. Bromberg (both FTI), M. Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	0.50
06/05/20	GJK	Call with G. Koch, N. Simon and J. DelConte (all AlixPartners) M. Diaz, B. Bromberg (both FTI), M.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Atkinson (Province), J. Turner (PJT) re: IAC diligence response letter.	
06/05/20	GJK	Plan and prepare for call with Advisor group for Mundipharma diligence re: next steps and process for moving forward	1.00
06/08/20	JD	Review responses from R. Aleali (Purdue) re: documents to post to the data room.	0.20
06/08/20	JD	Review and comment on draft diligence request lists for Mundipharma.	0.50
06/08/20	JD	Review Province diligence questions and status of various reporting work streams.	0.60
06/08/20	JD	Review side by side analysis to prepare non-PEO version of the deck.	0.50
06/08/20	JD	Review draft ad hoc committee diligence responses prior to posting.	0.30
06/08/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.50
06/08/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.30
06/08/20	ADD	Compile and review diligence information provided by client in response to diligence requests.	2.60
06/09/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.90
06/09/20	ADD	Call with Davis Polk to discuss distributor agreements.	0.40
06/09/20	ADD	Research entity relationships for potential third-party confidentiality implications.	3.20
06/09/20	ADD	Upload documents submitted in response to diligence requests to the data room.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/09/20	ADD	Call with PJT, FTI, and HL re: business plan diligence questions.	0.50
06/09/20	ADD	Review and compile information provided by client in response to diligence requests Committees.	2.10
06/09/20	JD	Review files per request from the ad hoc committee to disclose information from certain PEO files to the committee members.	1.40
06/09/20	JD	Review correspondence from K. McCarthy (Purdue) re: Project Catalyst diligence process. Review updated diligence list and categorization.	0.80
06/10/20	ADD	Compile and review diligence information provided by client in response to diligence requests.	2.70
06/10/20	ADD	Review document for potential redactions of third-party information at request of Davis Polk.	0.40
06/10/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.60
06/10/20	ADD	Upload documentation processed by the eDiscovery team for the various creditor groups.	1.30
06/10/20	ADD	Review and redact third-party information from Purdue Pharma LP board materials in preparation for production in response to diligence requests.	2.90
06/11/20	ADD	Review and redact third-party information from Purdue Pharma Inc board materials in preparation for production in response to diligence requests.	2.40
06/11/20	ADD	Upload documentation processed by the eDiscovery team for the various creditor groups.	1.70
06/11/20	ADD	Compile and review agreements in response to diligence request for distributor information.	2.20
06/11/20	ADD	Review materials submitted in response to diligence requests to determine responsiveness to Committee	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		request.	
06/11/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: NCSG diligence request to share certain information.	0.30
06/11/20	JD	Review and provide comments on initial draft April flash report.	1.10
06/12/20	JD	Review overview of settlement proposal to post to the data room.	0.50
06/12/20	ADD	Upload files provided by Davis Polk to the data room.	1.80
06/12/20	ADD	Review history of diligence requests provided by the committees.	1.20
06/15/20	ADD	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review	0.70
06/15/20	ADD	Update third-party confidentiality research materials in preparation for team to conduct additional research.	1.50
06/15/20	ADD	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	JD	Correspondence with R. Aleali (Purdue) and T. Melvin (PJT) re: Monitor diligence requests.	0.90
06/15/20	MBB	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review	0.70
06/15/20	MBB	Conduct third-party confidentiality review of claims.	2.10
06/15/20	BJF	Call with B. Ferguson, S. Betik, A. DePalma (all AlixPartners) re: third-party confidentiality review.	0.70
06/16/20	MBB	Conduct third-party confidentiality review of claims.	1.90
06/16/20	MBB	Review claims database to identify possible duplicate claims.	2.70
06/16/20	BJF	Third party confidentiality research for due diligence request.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/16/20	BJF	Research third party confidentiality for due diligence request.	2.30
06/16/20	JD	Correspondence with AlixPartners team re: audits and transfer pricing.	0.50
06/16/20	JD	Review and provide comments on draft AHC questions and responses.	0.70
06/16/20	ADD	Review documentation submitted in response to diligence requests in preparation for production.	2.70
06/16/20	ADD	Draft correspondence in response to request for files by client.	0.50
06/17/20	JD	Correspondence with PJT and management re: insurance diligence requests from Duff & Phelps.	0.40
06/17/20	JD	Review correspondence from PJT, Davis Polk and management re: updated buyers log.	0.30
06/17/20	BJF	Third party confidentiality research for due diligence request.	1.80
06/17/20	MBB	Review claims database to identify possible duplicate claims.	2.70
06/17/20	MBB	Conduct third-party confidentiality review of claims for matching.	2.80
06/18/20	MBB	Review claims database to identify possible duplicate claims.	2.40
06/18/20	MBB	Review claims database to match with duplicates.	2.80
06/18/20	JD	Review draft AHC diligence questions and responses. Provide comments re: same.	0.40
06/18/20	JD	Correspondence with Davis Polk and PJT re: request from AHC for ability to share certain information with their committee members.	0.30
06/18/20	ADD	Review documentation submitted in response to diligence requests in preparation for production.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/19/20	JD	Review latest severance details file per open AHC diligence requests.	0.40
06/19/20	JD	Correspondence with AlixPartners and Purdue re: Project Catalyst diligence request items.	0.30
06/19/20	JD	Review and provide comments on draft ad hoc committee diligence question responses from management.	0.60
06/19/20	MBB	Conduct third-party confidentiality review of claims.	2.90
06/19/20	MBB	Review claims database to identify possible duplicate claims.	2.60
06/19/20	MBB	Review claims database to match with duplicates.	1.90
06/21/20	JD	Correspondence with PJT and Province re: delayed emergence presentation timing.	0.20
06/22/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/22/20	MBB	Review claims database to match with duplicates.	2.40
06/22/20	ADD	Add new users to existing creditor groups to the data room and manage data room permissions.	0.80
06/22/20	JD	Review claims report summary data in response to AHC due diligence questions.	0.50
06/22/20	JD	Call with Ad Hoc Committee professionals and committee members, Davis Polk (E. Vonnegut, M. Huebner), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman), Dechert (S. Birnbaum) re: updated side by side presentation.	1.10
06/22/20	JD	Correspondence with PJT and Davis Polk re: non-PEO version of the side by side deck to share with various creditor advisors.	0.20
06/23/20	JD	Correspondence with various parties in order to schedule a call with the UCC advisors, Debtor advisors and management.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/23/20	ADD	Review materials provided in response to diligence requests in preparation for production to the data room.	2.90
06/23/20	ADD	Prepare and format response to HR diligence request.	0.80
06/23/20	MBB	Review claims database to match with duplicates.	2.90
06/23/20	MBB	Review claims database to determine duplicate claims and matched.	2.60
06/24/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/24/20	MBB	Review claims database to match with duplicates.	2.40
06/24/20	ADD	Add new creditor group to data room and update access/permissions accordingly.	2.10
06/24/20	ADD	Research and compile information for tax diligence request.	1.50
06/24/20	JD	Review excel diligence files to potentially be shared with the individual victim's group.	0.30
06/24/20	JD	Review and provide comments on various diligence files from Davis Polk that are responsive to outstanding UCC requests.	0.50
06/25/20	ADD	Upload production of diligence files to Intralinks data room for creditor groups.	0.80
06/26/20	ADD	Upload files provided by Davis Polk eDiscovery team for upload to the data room for the creditor committees.	1.30
06/26/20	JD	Prepare for UCC delayed emergence call.	0.30
06/26/20	JD	Participate in a call with J. Lowne, M. Ronning, D. Rosen, R. Aleali, M. Kesselman (all Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), S. Brauner, A. Preis (both Akin Gump), M. Atkinson, S. Morrison (both Province), L. Schlezinger, K. Sheridan (both Jefferies) re: delayed emergence.	1.00
06/26/20	MBB	Review claims database to match with duplicates.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/26/20	MBB	Review claims database to determine duplicate claims and matched.	2.10
06/27/20	JD	Review UCC diligence request and correspondence from management re: same.	0.70
06/28/20	ADD	Upload documents provided by Davis Polk eDiscovery team to the data room.	1.60
06/29/20	HSB	Attended meeting with J.Turner, R.Schnitzler, T.Melvin (All PJT), M.Atkinson, S.Morrison (both Province), S.Morrison, L.Szlezinger, K. Sheridan (all Jefferies), M.Diaz, B.Bromberg (both FTI), G.Coutts, H.Schenk (both HL), H. Bhattal, J.DelConte, K.McCafferty (all AlixPartners). Discussed Rhodes Updates.	0.90
06/29/20	KM	Attended meeting with J.Turner, R.Schnitzler, T.Melvin (All PJT), M.Atkinson, S.Morrison (both Province), S.Morrison, L.Szlezinger, K. Sheridan (all Jefferies), M.Diaz, B.Bromberg (both FTI), G.Coutts, H.Schenk (both HL), H. Bhattal, J.DelConte, K.McCafferty (all AlixPartners). Discussed Rhodes Updates.	0.90
06/29/20	MBB	Review claims database to determine duplicate claims and matched.	2.80
06/29/20	MBB	Matched duplicate claims in claims database.	2.10
06/29/20	MBB	Review and matched duplicate claims in database.	2.40
06/29/20	JD	Attended meeting with J.Turner, R.Schnitzler, T.Melvin (All PJT), M.Atkinson, S.Morrison (both Province), S.Morrison, L.Szlezinger, K. Sheridan (all Jefferies), M.Diaz, B.Bromberg (both FTI), G.Coutts, H.Schenk (both HL), H. Bhattal, J.DelConte, K.McCafferty (all AlixPartners). Discussed Rhodes Updates.	0.90
06/29/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: delayed emergence information sharing with UCC.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
06/30/20	JD	Correspondence with Province re: open diligence items.	0.30
06/30/20	MBB	Review claims database to determine duplicate claims and matched.	2.90
06/30/20	MBB	Matched duplicate claims in claims database.	2.80
06/30/20	ADD	Compile and format third-party confidential disclosure agreements to document confidentiality provisions.	2.90
06/30/20	ADD	Compile licensing and assignment agreements at client's request.	0.90
07/01/20	ADD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	ADD	Call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.50
07/01/20	KM	Call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.50
07/01/20	KM	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update and compilation of diligence responses, and upload materials to the VDR.	2.00
07/01/20	JD	Edit UCC diligence responses and collect and edit various responsive excel files to share. Circulate documents to internal group for approval prior to moving to get	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		processed and uploaded.	
07/01/20	JD	Correspondence with J. Doyle, R. Aleali (both Purdue) and C. Robertson (Davis Polk) re: Prodrug diligence items.	0.30
07/01/20	JD	Review management comments on non-PEO April flash report.	0.20
07/01/20	JD	Correspondence with PJT and management re: Project Catalyst diligence responses.	0.40
07/01/20	JD	Call with W. Curran, C. Robertson, C. Oluwole (all Davis Polk), T. Melvin, J. Turner (both PJT), M. Florence, J. Bragg (both Skadden), J. Bucholtz (both King & Spalding), R. Aleali, M. Kesselman (both Purdue) re: pre-call for Duff & Phelps call.	0.40
07/01/20	JD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	JD	Partial participation in call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.30
07/01/20	BJF	Research third party confidentiality for due diligence request.	1.80
07/02/20	JD	Review UCC motion for additional discovery and examinations.	0.40
07/02/20	JD	Review responses to draft UCC diligence responses and correspondence with production team to push to process documents and responses.	0.50
07/02/20	JD	Provide final responses to open business development diligence questions.	0.30
07/02/20	ADD	Prepare and organize files provide by Davis Polk	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		eDiscovery team for upload to the data room.	
07/02/20	ADD	Upload files provided by David Polk eDiscovery team to the data room.	1.30
07/05/20	JD	Review correspondence from A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: AHC questions on sharing materials.	0.30
07/05/20	JD	Correspondence with Province re: status of open diligence items.	0.30
07/05/20	JD	Correspondence with R. Collura and A. DePalma (both AlixPartners) re: Province diligence question on the chart of accounts.	0.30
07/06/20	ADD	Compile and format materials submitted in response to diligence requests for approval, processing and production.	1.90
07/06/20	JD	Call with R. Aleali (Purdue) re: outstanding UCC diligence request items.	0.40
07/06/20	JD	Correspondence with Purdue and Dechert teams re: monitor requests.	0.50
07/06/20	JD	Review AHC diligence questions and proposed responses.	0.30
07/07/20	SJC	Review and redact board meeting minutes in preparation for processing an upload to data room.	3.00
07/07/20	SJC	Continue to review and redact board meeting minutes in preparation for processing an upload to data room.	1.00
07/07/20	ADD	Review and redact third-party information from board materials submitted in response to diligence requests in preparation for production.	2.20
07/08/20	ADD	Review and redact third-party information from board materials (Rhodes entities) submitted in response to diligence requests in preparation for production.	2.70
07/08/20	KM	Call with R. Schnitzler (PJT), interested party diligence	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/08/20	SJC	team re: environmental response process overview. Review and redact Rhodes' board meeting minutes in preparation for processing an upload to data room.	4.00
07/08/20	JD	Review final financial tables to be uploaded per UCC request.	0.20
07/08/20	JD	Edit final business development diligence materials and send around to the internal group for final approval.	0.50
07/08/20	JD	Correspondence with J. Lowne (Purdue) and PJT re: OxyContin only scenario request from the UCC and AHC.	0.60
07/08/20	JD	Call with M. Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both Houlihan), J. Turner, R. Schnitzler (both PJT), J. Lowne, M. Ronning, D. Rosen (all Purdue) re: delayed bankruptcy emergence scenario.	1.00
07/09/20	JD	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/09/20	JD	Review Project Catalyst proposed diligence responses from D. Fogel (Purdue).	0.30
07/09/20	SJC	Review and redact Rhodes' board meeting minutes in preparation for processing an upload to data room.	3.00
07/09/20	SKL	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/09/20	HSB	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/09/20	ADD	Review and redact third-party information from files submitted in response to diligence requests in preparation	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		for production.	
07/10/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.50
07/13/20	SJC	Review and redact board meeting minutes in preparation for processing an upload to data room.	2.00
07/13/20	ADD	Compile and upload files provided in response to diligence request for processing and upload to the data room.	1.60
07/13/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, E. Ruiz (both Purdue), M. Atkinson, S. Morrison (both Province), L. Szlenzinger (Jefferies), M. Diaz, B. Bromberg, C. Kim (all FTI), G. Coutts (Houlihan) re: OxyContin only scenario.	1.50
07/13/20	JD	Correspondence with management re: FTI diligence request on IMS data.	0.30
07/14/20	JD	Call with M. Diaz (FTI), M. Atkinson (Province), L. Szlenzinger (Jefferies), G. Coutts (Houlihan), J. Lowne (Purdue), J. Turner, T. Melvin (PJT) re: business scenarios.	0.50
07/14/20	JD	Correspondence with R. Aleali (Purdue) re: UCC managed care diligence questions.	0.40
07/14/20	ADD	Research employee with insider titles and aggregate data for processing and upload to the dataroom.	2.40
07/14/20	SJC	Review and redact Rhodes board meeting minutes in preparation for processing an upload to data room.	1.50
07/15/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	1.00
07/15/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	3.00
07/15/20	ADD	Research employee with insider titles and aggregate data	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		for processing and upload to the dataroom.	
07/15/20	ADD	Compile and upload files provided in response to diligence request for processing and upload to the data room.	1.80
07/15/20	ADD	Upload diligence production provided by Davis Polk's eDiscovery team to the virtual data room.	2.10
07/15/20	ADD	Prepare files processed by Davis Polk's eDiscovery team for upload to the data room.	1.30
07/15/20	JD	Review latest IMS data to be uploaded for creditor advisors.	0.30
07/16/20	JD	Review questions and proposed responses to FTI diligence questions for the distributable value report.	1.20
07/16/20	JD	Review and comment on follow up responses from the company to certain AHC and UCC follow diligence questions.	0.50
07/16/20	JD	Call with J. Lowne, E. Ruiz (both Purdue), J. Turner, T. Melvin (both PJT), M. Atkinson, S. Morrison (both Province), L. Szlenzinger (Jefferies), M. Diaz, B. Bromberg (FTI), G. Coutts (Houlihan) re: distributable value analysis.	1.00
07/16/20	KM	Advisors meeting with R. Schnitzler (PJT), M. Gibson (Skadden), and interested party Diligence Team re: Project Catalyst.	0.60
07/16/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to data room.	1.00
07/16/20	ADD	Identify documents produced in the data room at the request of Davis Polk.	0.80
07/16/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/16/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/17/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	3.50
07/17/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to data room.	2.40
07/20/20	ADD	Review outstanding diligence requests and compile responses for review.	2.40
07/20/20	ADD	Draft approval requests to produce to the Creditor Committees items compiled in response to diligence requests.	1.10
07/20/20	KM	Advisors meeting with R. Schnitzler (PJT), M. Gibson (Skadden), and interested party Diligence Team re: Project Catalyst.	0.50
07/20/20	JD	Provide responses to various questions from the AHC and the UCC on the distributable value deck.	0.50
07/20/20	JD	Review responses from management on various questions from the AHC and UCC.	0.30
07/20/20	JD	Correspondence with management and PJT re: scheduling the UCC and management meeting.	0.50
07/21/20	JD	Review latest distributable value presentation from the UCC/AHC. Provide comments to management on ability to share with specific creditors.	0.90
07/21/20	JD	Correspondence with management, PJT and Davis Polk re: ability to share UCC/AHC with specific creditors.	0.70
07/21/20	JD	Review IAC diligence presentation in advance of board meeting.	0.50
07/21/20	JD	Review open AHC questions on items to disclose to their committee members.	0.80
07/21/20	ADD	Compile list of agreements to create list of third-parties for review of items for production.	2.40
07/21/20	ADD	Review and draft responses to committee diligence	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		requests.	
07/21/20	ADD	Research prior documents production to determine if specific materials were provided.	1.50
07/22/20	ADD	Review data room for materials requested by creditor committee in response to diligence request.	1.70
07/22/20	ADD	Prepare and upload documents provided by Davis Polk's eDiscovery team to the data room for the UCC.	2.30
07/22/20	JD	Participate in the UCC/AHC distributable value presentation to creditors.	1.40
07/22/20	JD	Correspondence with management, Davis Polk and PJT re: sharing the distributable value presentation.	0.40
07/23/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/23/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/23/20	ADD	Research VDR access error at request of committees members.	0.80
07/24/20	ADD	Draft correspondence to request approval to produce diligence request.	0.80
07/24/20	ADD	Review and compile materials submitted in response to diligence request for upload to the data room.	1.90
07/27/20	ADD	Research and document Purdue's tax distribution process for diligence request.	1.90
07/27/20	HSB	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	HSB	Partial participation in a call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/27/20	JD	(Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	1.70
07/27/20	GJK	Partial participation in a call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	2.00
07/27/20	LJD	Call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	2.30
07/28/20	ADD	Prepare for and attend UCC call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	0.70
07/28/20	ADD	Research and locate historical Purdue contract to review terms.	1.10
07/28/20	ADD	Call with R. Shamblen, A. Soma (both Purdue), R. Schnitzler (PJT), K. McCafferty (AlixPartners), and	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		interested party diligence team re: Ramboll EHS diligence interview for Catalyst.	
07/28/20	KM	Call with interested party re: project Catalyst site visit plan.	0.50
07/28/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson (Skadden), interested party diligence team re: Catalyst term sheet feedback.	0.50
07/28/20	KM	Call with R. Shamblen, A. Soma (both Purdue), R. Schnitzler (PJT), A. DePalma (AlixPartners), and interested party diligence team re: Ramboll EHS diligence interview for Catalyst.	1.10
07/29/20	ADD	Research former Purdue employee's role at the room using SAP data.	1.10
07/30/20	ADD	Review and redact Rhodes entities board minutes and resolutions for confidential third party information in preparation for production to the creditor committees.	3.40
07/30/20	JD	Call with J. Turner (PJT), M. Atkinson (Province), M. Diaz (FTI), G. Coutts (Houlihan), L. Szlezinger (Jefferies) re: business development deal.	0.30
07/31/20	JD	Call with J. Turner, T. Melvin (both PJT), M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Rosen, M. Ronning, and K. Gadski (all Purdue) re: opioid scenarios.	0.70
07/31/20	ADD	Review outstanding diligence requests and compile responsive materials for production.	1.10
08/03/20	MBB	Review claims detail to determine duplicate claims.	2.90
08/03/20	MBB	Review claims detail and assigned match numbers	1.90
08/03/20	JD	Call with J. Feltman, R. Levy, M. Vitti (all Duff & Phelps), J. Turner, R. Schnitzler, T. Melvin (all PJT), W. Curran (Davis Polk) re: organization structure diligence update.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/03/20	JD	Review UCC diligence requests re: professional fee payments.	0.30
08/04/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. Oluwole (Davis Polk) and T. Melvin (PJT) re: UCC professional fee diligence requests.	0.50
08/04/20	JD	Call with M. Atkinson (Province) and J. Turner (PJT) re: adcom.	0.40
08/04/20	JD	Call with J. Turner (PJT) re: next steps on adcom diligence.	0.20
08/04/20	JD	Correspondence with FTI re: diligence questions on Adhansia.	0.40
08/04/20	JD	Review responses to various FTI diligence requests.	0.50
08/04/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. Oluwole (Davis Polk) and T. Melvin (PJT) re: UCC professional fee diligence requests.	0.50
08/05/20	JD	Review second diligence list re: Project Catalyst.	0.30
08/06/20	ADD	Research and locate contracts / agreement for a counter party at the request of Davis Polk.	0.80
08/06/20	JD	Call with M. Huebner, E. Vonnegut, B. Kaminetsky (all Davis Polk) re: UCC pre-call.	0.30
08/06/20	JD	Call with M. Huebner, E. Vonnegut, B. Kaminetzky (all Davis Polk), A. Preis, M. Hurley (both Akin Gump), M. Atkinson (Province) re: claims process.	1.00
08/06/20	JD	Review materials created by PJT in response to request from Shareholders for business plan bridges.	0.30
08/07/20	MBB	Review claims detail to determine duplicate claims.	2.80
08/09/20	ADD	Prepare UCC diligence production provided by Davis Polk eDiscovery team for upload to the data room.	2.70
08/09/20	ADD	Upload UCC diligence production provided by Davis Polk eDiscovery team for upload to the data room.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/09/20	JD	Call with M. Atkinson (Province) re: suboxone.	0.30
08/10/20	JD	Review data room for historical sales details per FTI diligence request.	0.70
08/10/20	JD	Call with M. Diaz, B. Bromberg (both FTI) and T. Melvin (PJT) re: future insurance costs.	0.50
08/10/20	JD	Review and provide comments on draft email to Mundipharma re: open diligence requests. Correspondence re: same.	0.30
08/10/20	JD	Review correspondence and input from Purdue and Dechert re: FTI insurance questions.	0.30
08/10/20	ADD	Review and research diligence questions submitted by the FTI, compiling necessary information.	1.60
08/10/20	ADD	Research insurance file production history at the request of Davis Polk.	1.30
08/10/20	ADD	Review and compile documentation submitted in response to diligence requests in preparation for upload to the data room.	2.20
08/11/20	ADD	Research diligence questions submitted by the FTI, compiling necessary information.	2.40
08/11/20	ADD	Research Purdue purchase orders issued under RT agreements and identify potential data elements in SAP to complete the analysis.	2.60
08/11/20	JD	Call with M. Atkinson (Province), A. Preis, S. Brauner (both Akin Gump), J. Turner (PJT), P. Strassburger, R. Silbert (both Purdue) and P. Mathers (Kleinfeld) re: AdCom meeting.	0.70
08/12/20	ADD	Upload approved materials to the data room and update permissions.	1.50
08/12/20	ADD	Review outstanding UCC diligence requests and follow up with outstanding item.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
08/13/20	MBB	Review claims detail to determine duplicate claims.	2.40
08/13/20	JD	Review various IAC agreements to be shared with creditor advisors.	0.30
08/14/20	JD	Call with M. Diaz, B. Bromberg (FTI), S. Birnbaum (Dechert), A. Kramer (Reed Smith), C. Ricarte, R. Aleali (Purdue), T. Melvin (PJT) re: Insurance Proceeds.	0.40
08/14/20	JD	Review IAC licensing agreements currently uploaded to the data room per an AHC request.	0.50
08/17/20	JD	Review and comment on draft responses to AHC OxyContin diligence questions.	0.40
08/17/20	ADD	Compile and transfer files provided in response to diligence requests in preparation for review, processing and production to the creditor committees.	1.90
08/18/20	ADD	Research employment history to document debtor employment at the request of Davis Polk.	0.50
08/18/20	ADD	Update insider titles employment diligence request and submit for approval and production in response to creditor diligence request.	1.40
08/18/20	JD	Call with M. Atkinson (Province) re: UCC AdCom discussion follow up.	0.20
08/18/20	JD	Correspondence with Province and PJT re: distributable value.	0.20
08/18/20	JD	Correspondence with Province re: Collegium conversations.	0.20
08/18/20	JD	Review and provide comments on latest draft email to Mundipharma for diligence. Review latest iterations.	0.30
08/18/20	JD	Review updated responses with management revisions to AHC OxyContin diligence questions.	0.30
08/19/20	JD	Call with M. Atkinson (Province) re: PBGC.	0.20
08/19/20	JD	Call with E. Suric, M. Diaz, B. Bromberg (all FTI), M.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Atkinson (Province), L. Sczlezinger, K. Sheridan (both Jefferies), J. Turner, T. Melvin, G. Sim (all PJT), A. DePalma, J. DelConte (both AlixPartners), J. Lowne, M. Ronning, D. Rosen, K. Gadski (all Purdue) re: OxyContin scenarios.	
08/19/20	ADD	Prepare production of diligence materials provide by Davis Polk's eDiscovery team for upload to the data room	2.30
08/19/20	ADD	Upload files to upload to the data room and provide access to the creditor committees.	1.80
08/19/20	ADD	Call with E. Suric, M. Diaz, B. Bromberg (all FTI), M. Atkinson (Province), L. Sczlezinger, K. Sheridan (both Jefferies), J. Turner, T. Melvin, G. Sim (all PJT), A. DePalma, J. DelConte (both AlixPartners), J. Lowne, M. Ronning, D. Rosen, K. Gadski (all Purdue) re: OxyContin scenarios.	1.00
08/19/20	HSB	Review letter from UCC to Mediation parties.	0.40
08/19/20	HSB	Review net distributable value analysis from UCC to mediation parties.	0.40
08/20/20	JD	Review latest draft Mundipharma email per comments from AHC.	0.20
08/23/20	JD	Correspondence with Province and management re: E&Y scope expansion.	0.30
08/23/20	ADD	Prepare and upload materials requested by the creditor committees and processed by the Davis Polk eDiscovery team to the data room.	1.50
08/27/20	ADD	Prepare UCC and Consenting/Non-consenting states productions for upload to the data room and upload files to data room.	1.10
08/28/20	ADD	Compile items in response to creditor diligence requests for approval and production to the data room.	1.20
08/30/20	ADD	Prepare UCC and Consenting/Non-consenting states	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		productions for upload to the data room and upload files to data room.	
08/31/20	ADD	Prepare UCC and Consenting/Non-consenting states productions for upload to the data room and upload files to data room.	2.20
08/31/20	JD	Call with M. Atkinson (Province) re: initial feedback on KEIP/KERP motion.	0.20
09/02/20	JD	Correspondence with Province and Akin Gump re: responses to open UCC diligence questions on the KEIP/KERP motion.	0.40
09/02/20	JD	Review questions from M. Atkinson (Province) re: KEIP/KERP diligence information. Prepare response re: same.	1.50
09/03/20	JD	Correspondence with Davis Polk and Willis Towers Watson re: questions from Akin Gump on the KEIP/KERP.	0.70
09/03/20	JD	Review responses to AHC diligence requests.	0.30
09/04/20	JD	Correspondence with M. Atkinson (Province) re: KEIP/KERP diligence questions.	0.70
09/05/20	ADD	Prepare and upload documents processed by Davis Polk's eDiscovery team for upload to the data room.	2.80
09/08/20	JD	Call with B. Bromberg, C. Kim (both FTI) re: KEIP/KERP.	0.70
09/08/20	JD	Review open KEIP/KERP questions from the AHC prior to our call.	0.50
09/08/20	JD	Draft responses to additional questions from FTI re: KEIP/KERP calculations and comparisons.	1.10
09/08/20	JD	Draft and send correspondence to FTI with preliminary KEIP/KERP diligence responses.	0.50
09/10/20	JD	Prepare responses to requests from FTI re: KEIP / KERP and correspondence re: same.	1.20
09/10/20	JD	Finalize schedule of Prime Clerk invoices to provide to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		creditor advisors.	
09/12/20	JD	Correspondence with Purdue and Davis Polk re: AG settlement contracts.	0.30
09/14/20	JD	Review diligence question responses to AHC business plan questions.	0.40
09/14/20	JD	Correspondence with Purdue re: HRT follow up questions from the UCC.	0.70
09/14/20	JD	Correspondence with Davis Polk and Purdue re: UCC questions on AG settlements and Project Catalyst.	0.50
09/15/20	JD	Prepare draft set of responses to AHC diligence questions on the KEIP/KERP.	0.70
09/15/20	JD	Prepare responses to Province re: Project Catalyst, HRT and KEIP/KERP. Correspondence with Purdue, Davis Polk and Willis Tower Watson re: same.	2.60
09/16/20	ADD	Upload files provided by Davis Polk's eDiscovery team to the data room for creditor committee review.	1.30
09/16/20	JD	Correspondence with C. DeStefano (Purdue) re: bonus clawbacks from employee resignations.	0.30
09/16/20	JD	Meeting with B. Bromberg, C. Kim (both FTI) re: KEIP/KERP analysis.	0.60
09/16/20	JD	Finalize analysis and draft final responses to FTI re: open KEIP/KERP diligence questions.	2.10
09/17/20	ADD	Draft correspondences to request materials responsive to committee diligence requests.	0.40
09/18/20	JD	Correspondence with Purdue and Davis Polk re: AHC request to share certain KEIP/KERP information.	0.50
09/18/20	JD	Correspondence with Purdue re: diligence request from Province on AG settlements.	0.70
09/18/20	JD	Call with M. Atkinson (Province) re: KEIP/KERP response.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
09/21/20	ADD	Prepare and upload documents provide by Davis Polk's eDiscovery team for upload to the data room.	1.20
09/21/20	JD	Follow up email with FTI re: outstanding diligence questions.	0.30
09/21/20	JD	Correspondence with Davis Polk re: FTI discussion with Bates White.	0.20
09/21/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman (Purdue), J. O'Connell, J. Turner (both PJT) and third party re: business plans.	0.80
09/21/20	JD	Call with M. Kesselman (Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT) re: communications with the non-consenting state group.	1.00
09/21/20	JD	Call with M. Kesselman (Purdue), M. Huebner and E. Vonnegut (both Davis Polk) re: KEIP/KERP responses.	0.40
09/22/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to the data room.	2.00
09/22/20	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.40
09/22/20	JD	Correspondence with Davis Polk re: additional AHC requests.	0.30
09/22/20	JD	Review KEIP/KERP objections from the UST and another ad hoc committee.	0.60
09/23/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to the data room.	1.60
09/23/20	ADD	Prepare and upload documents provide by Davis Polk's eDiscovery team for upload to the data room.	1.40
09/24/20	ADD	Research inquiry from vendor re: outstanding prepetition balance.	1.70
09/24/20	ADD	Compile list of third-party entities for AlixPartners eDiscovery team to redact from board presentation	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		materials.	
09/24/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to the data room.	2.20
09/25/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to the data room.	1.60
09/28/20	ADD	Review board material redactions in preparation for upload to the data room for creditor review.	1.70
09/28/20	JD	Correspondence with Davis Polk and management re: KEIP/KERP objection responses.	0.40
09/29/20	JD	Review final non-PEO business plan refresh file to share with management.	0.70
09/29/20	HSB	Meeting with H. Bhattal, S. Lemack (both AlixPartners) re: latest PBGC inquiry and updates.	0.40
09/29/20	SKL	Meeting with H. Bhattal, S. Lemack (both AlixPartners) re: latest PBGC inquiry and updates.	0.40
09/30/20	ADD	Upload files provided by Davis Polk's eDiscovery team to the data room for creditor committee review.	0.70
09/30/20	JD	Correspondence with PJT and Davis Polk re: AHC request to share information.	0.20
Total			<u>422.10</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	69.10	315.00	21,766.50
Barbara J Ferguson	9.30	315.00	2,929.50
Andrew D DePalma	196.10	515.00	100,991.50
Sam K Lemack	1.10	515.00	566.50
Nate A Simon	0.50	515.00	257.50
Sam J Canniff	37.50	645.00	24,187.50
HS Bhattal	5.50	840.00	4,620.00
Gabe J Koch	3.50	840.00	2,940.00
Jesse DelConte	88.30	950.00	83,885.00
Kevin M McCafferty	8.90	950.00	8,455.00
Lisa Donahue	2.30	1,195.00	2,748.50
Total Hours & Fees	422.10		253,347.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
06/01/20	JD	Review ordinary course professionals summary materials and correspondence with S. Lemack (AlixPartners) re: same.	0.70
06/01/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: and begin preparing the May OCP report.	0.60
06/01/20	MH	Initiate OCP tracking report.	2.40
06/01/20	SKL	Review the latest OCP activity and information provided by C. MacDonald (Purdue) and prepared the updated OCP report accordingly.	2.70
06/01/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: and begin preparing the May OCP report.	0.60
06/02/20	JD	Correspondence with M. Atkinson, C. Cabello (both Province) and S. Lemack (AlixPartners) re: OCP diligence questions.	0.40
06/03/20	ESK	Review of final versions of the AlixPartners' application and Schedule 1.	0.40
06/03/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest OCP report and updates to the OCP tracker.	0.70
06/03/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest OCP report and updates to the OCP tracker.	0.70
06/04/20	SKL	Review and reconcile the latest OCP updates and prepared updates to the OCP tracker for next month's report.	2.00
06/08/20	SKL	Finalize OCP reconciliation and prepared and finalized updated OCP fee tracker.	2.70
06/08/20	JD	Review details of the ordinary course professional report per Province diligence questions.	0.50
06/10/20	NAS	Submit data requests for insider payments section of May MOR.	0.70
06/11/20	NAS	Review data sources for insider payments section of May	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		2020 MOR.	
06/11/20	ESK	Review email re: fee application deadlines and procedures.	0.20
06/15/20	NAS	Review data provided for insider payments section of May 2020 MOR.	0.60
06/16/20	NAS	Prepare insider payments section of May MOR.	0.50
06/18/20	NAS	Draft insider payments section of May 2020 MOR.	2.00
06/18/20	NAS	Check insider payments section of May 2020 MOR for accuracy and completeness.	0.40
06/18/20	JD	Review draft May financials for the monthly operating report.	0.40
06/19/20	JD	Review and provide comments on monthly operating report before sending it to the company to sign.	0.70
06/19/20	NAS	Correspondence with J. Lauriat (Purdue) re: insider T&E reimbursements for May MOR.	0.20
06/24/20	ADD	Update Parties in Interest list at request of Davis Polk.	2.10
06/24/20	HSB	Review monthly OCP report prepared by S. Lemack (AlixPartners) and review underlying OCP order.	0.30
06/25/20	SKL	Review and reconciled the latest OCP information provided by C. MacDonald (Purdue) and began preparing the May OCP report accordingly.	1.30
06/25/20	SKL	Finalize updates to the May OCP report and circulated to the team for final sign-off.	1.90
06/26/20	SKL	Review the latest feedback provided on the May OCP report and prepared and circulated updated report accordingly.	1.30
06/26/20	JD	Review and provide comments on monthly ordinary course professional report.	0.40
06/29/20	SKL	Review latest updates provided by D. Consla (DPW) and	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		revised and circulated updated OCP report accordingly.	
07/10/20	SKL	Call A. DePalma and S. Lemack (both AlixPartners) re: MOR quarterly fee calculation discussion.	0.50
07/10/20	NAS	Send data requests to Purdue/TXP for insider payments section of June 2020 MOR.	0.70
07/10/20	ADD	Call A. DePalma and S. Lemack (both AlixPartners) re: MOR quarterly fee calculation discussion.	0.50
07/13/20	ADD	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/13/20	NAS	Analyze indemnification payments for insider payments section of June 2020 MOR.	1.70
07/13/20	NAS	Call with M. Hartley, N. Simon (both AlixPartners) to review Purdue indemnification payment reporting for June 2020 MOR.	0.40
07/13/20	NAS	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/13/20	NAS	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30
07/13/20	SKL	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/13/20	SKL	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30
07/13/20	MH	Call with M. Hartley, N. Simon (both AlixPartners) to review Purdue indemnification payment reporting for June 2020 MOR.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
07/13/20	MH	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30
07/14/20	SKL	Review and reconcile Indemnitee firm payments for the June MOR.	0.90
07/14/20	HSB	Review MOR files prepared by S. Lemack (AlixPartners).	0.80
07/15/20	ADD	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/15/20	SKL	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/15/20	NAS	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/15/20	NAS	Review insider payments section of June 2020 MOR for accuracy.	0.60
07/15/20	NAS	Consolidate all data sources into insider payments section of June 2020 MOR.	0.90
07/16/20	JD	Review draft June financials for the MOR.	0.20
07/17/20	ADD	Compile MOR sections and Prepare June MOR for signature.	2.30
07/17/20	JD	Review and sign off on draft MOR.	0.40
07/20/20	JD	Review final signed MOR.	0.20
07/30/20	JD	Review and provide comments on OCP reporting package to be filed with the court.	0.30
08/04/20	JD	Review US Trustee payment schedule against MORs filed to date.	0.30
08/10/20	JD	Correspondence with the US Trustee's Office, Davis Polk and S. Lemack (AlixPartners) re: latest quarterly fee	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		payment.	
08/12/20	NAS	Request data sources for insider payments section of July MOR and analyze data received.	1.40
08/13/20	NAS	Review and analyze data provided for insider payments section of July 2020 MOR.	0.80
08/14/20	NAS	Analyze data for insider payments section of July 2020 MOR.	0.50
08/17/20	NAS	Finalize insider payments section of July MOR and review for accuracy.	1.50
08/20/20	JD	Review and provide comments on July MOR prior to finalizing and filing.	0.40
09/09/20	NAS	Request insider payments information from Purdue for purposes of August 2020 Monthly Operating Report.	0.60
09/10/20	NAS	Coordinate with Purdue/TXP employees re: MOR insider payments data requests.	0.20
09/15/20	NAS	Analyze and consolidate all data received for insider payments section of August 2020 MOR.	1.20
09/16/20	NAS	Finalize insider payments section of August 2020 MOR and review for accuracy.	0.60
09/17/20	ADD	Compile and prepare August MOR for CFO review and signature.	2.40
09/18/20	JD	Review draft MOR prior to sending to the company for signature.	0.40
09/21/20	ADD	Update MOR per review comments in preparation to send to Davis Polk for upload.	1.40
09/21/20	JD	Correspondence with Purdue and Davis Polk re: MOR updates.	0.30
Total			55.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	9.50	515.00	4,892.50
Sam K Lemack	16.80	515.00	8,652.00
Nate A Simon	16.90	515.00	8,703.50
Elizabeth S Kardos	0.60	710.00	426.00
Michael Hartley	4.40	840.00	3,696.00
HS Bhattal	1.10	840.00	924.00
Jesse DelConte	5.90	950.00	5,605.00
Total Hours & Fees	55.20		32,899.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/01/20	NAS	Review preliminary Mundipharma valuation analysis from PJT.	2.00
06/01/20	NAS	Call with J. Turner, R. Schnitzler, J. Arsic (all PJT), G, Koch, N. Simon (both AlixPartners) re: initial valuation slides for Mundipharma.	0.80
06/01/20	NAS	Consolidate and provide follow-up items related to PJT preliminary Mundipharma valuation discussion.	0.70
06/01/20	NAS	Call with J. Arsic (PJT) re: initial draft of Mundipharma valuation slides.	0.60
06/01/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: initial impressions from preliminary PJT Mundipharma valuation analysis.	0.60
06/01/20	NAS	Draft potential upside slides for Mundipharma diligence presentation.	1.60
06/01/20	IA	Update LTRP 2021 and 2022 estimated payments analysis to include adjusted scenarios requested by WTW and Davis Polk.	2.40
06/01/20	GJK	Call with J. Turner, R. Schnitzler, J. Arsic (all PJT), G, Koch, N. Simon (both AlixPartners) re: initial valuation slides for Mundipharma.	0.80
06/01/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: Mundipharma valuation.	0.60
06/01/20	GJK	Review and prepare comments for Mundipharma initial valuation report.	2.50
06/01/20	GJK	Assess potential updates to Mundipharma key findings based on initial valuation deck from PJT.	2.00
06/01/20	GJK	Planning re: Mundipharma interim report draft revisions.	2.00
06/01/20	ADD	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		timeline and VDR index.	
06/01/20	ADD	Update business plan team contact list.	0.40
06/01/20	ADD	Review Rhodes critical vendor analysis to identify material counter parties.	2.30
06/01/20	KM	Next phase planning for Rhodes business planning and org structure initiatives.	0.40
06/01/20	KM	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	1.20
06/01/20	KM	Meeting with V. Mancinelli (Purdue) re: RP employee mapping.	0.70
06/01/20	KM	Reconcile and augment Rhodes Pharma employee mapping.	1.80
06/01/20	KM	Detailed quality org structure mapping and reconciliation.	1.90
06/01/20	KM	Document and communicate consolidated org changes to D. Lundie (Purdue).	1.30
06/01/20	RDS	Finalize headcount and organizational charts for Rhodes headcount exercise.	1.40
06/01/20	RDS	Review and make changes to October BoD presentation for Catalyst usage.	0.40
06/01/20	RDS	Review Catalyst VDR request list.	1.10
06/01/20	RDS	Update presentation materials for phase 1 project catalyst.	0.90
06/01/20	RDS	Meeting with A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Shamblen, D. Fogel (both Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	1.20
06/01/20	RDS	Review final V. Mancinelli (Purdue) headcount selections.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/01/20	RDS	Correspondence with Catalyst advisors re: process timeline and VDR approval process.	1.40
06/01/20	RDS	Update presentation materials for phase 1 project catalyst.	0.90
06/01/20	JD	Review updated side by side analysis prior to call with various ad hoc groups.	0.50
06/01/20	JD	Review correspondence re: Project Catalyst timeline.	0.60
06/01/20	JD	Review and comment on draft Project Catalyst working group list.	0.20
06/02/20	JD	Review Rhodes transformation presentation.	0.70
06/02/20	JD	Prepare for and attend call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.80
06/02/20	JD	Review previous business development board presentations.	0.50
06/02/20	JD	Update latest professional fee tracker in response to questions from Davis Polk. Correspondence with S. Lemack (AlixPartners) re: same.	0.80
06/02/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst status update.	0.50
06/02/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst status update.	0.30
06/02/20	JD	Review side-by-side deck to share with ad hoc committees on PEO and non-PEO basis.	0.70
06/02/20	JD	Correspondence with S. Daniel and R. Aleali (both Purdue) re: outstanding vendor payment.	0.30
06/02/20	RDS	Review VDR uploads for project catalyst.	1.00
06/02/20	RDS	Assemble and refine materials to back up proposed organizational structure and re-engineered processes at RALP.	3.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/02/20	RDS	Call with D. Fogel (Purdue) re: headcount reconciliation.	0.20
06/02/20	RDS	Call with R. Shamblen (Purdue) re: Project Catalyst data requests.	0.20
06/02/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst status update.	0.30
06/02/20	RDS	Call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.70
06/02/20	RDS	Amendments to presentation for Rhodes.	1.00
06/02/20	RDS	Assemble updated next steps for operational restructuring of Rhodes.	1.10
06/02/20	KM	Next phase planning for Rhodes org structure initiatives.	0.20
06/02/20	KM	Analysis re: Rhodes diligence question response to HR.	0.50
06/02/20	KM	Analysis re: aggressive Rhodes restructuring opportunities.	1.60
06/02/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes diligence question response to HR.	0.50
06/02/20	KM	Rhodes organizational restructuring review presentation edits and augmentation.	1.00
06/02/20	KM	Analysis re: value creation via Rhodes restructuring.	0.70
06/02/20	KM	Call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.70
06/02/20	KM	Assemble updated next steps for operational restructuring.	1.30
06/02/20	ADD	Review Purdue Pharma LP board minutes from 1999 - 2002 for third-party confidential information.	2.60
06/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: current draft of Mundipharma presentation.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma cash position.	0.40
06/02/20	GJK	Plan for next steps in Mundipharma interim diligence process.	1.80
06/02/20	GJK	Analysis of key missing items from diligence request list for Mundipharma.	2.30
06/02/20	GJK	Review inputs for upside and downside case analysis for Mundipharma valuation scenario a.	1.90
06/02/20	LJD	Prepare for and attend call with R. Sublett, K. McCafferty, L. Donahue and J. DelConte (all AlixPartners) re: Rhodes transformation plan.	0.80
06/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma cash position.	0.40
06/02/20	NAS	Provide Mundipharma diligence items requested by PJT and draft overview slides on KPMG tax analysis.	1.80
06/02/20	NAS	Review prior materials provided related to net debt and cash items and summarize findings for G. Koch (AlixPartners).	2.90
06/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: current draft of Mundipharma presentation.	0.70
06/03/20	NAS	Review draft of Mundipharma diligence report from PJT and supporting materials.	1.10
06/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of PJT Mundipharma diligence report.	0.80
06/03/20	NAS	Prepare for and attend call with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	1.10
06/03/20	NAS	Research industry precedents for second adjusted case in Mundipharma business plan model.	1.80
06/03/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: revised draft of valuation section of Mundipharma	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence report from PJT.	
06/03/20	NAS	Review letter from UCC to Judge re: IAC and other diligence requests.	0.40
06/03/20	NAS	Add second adjusted case to Mundipharma business plan model.	0.80
06/03/20	GJK	Calls with I. McClatchey (Norton Rose) re: Mundipharma diligence process.	0.90
06/03/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) and J. Turner (PJT) re: Mundipharma diligence planning.	0.80
06/03/20	GJK	Plan and analysis for Mundipharma diligence process, including follow up email with Advisors and review of process since March.	2.00
06/03/20	GJK	Review and planning re: UCC letter to the Court re: IACs.	1.50
06/03/20	GJK	Review valuation draft update for Mundipharma interim diligence and planning for incorporation with key findings.	2.50
06/03/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: revised draft of valuation section of Mundipharma diligence report from PJT.	0.70
06/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of PJT Mundipharma diligence report.	0.80
06/03/20	ADD	Update liabilities subject to compromise calculation for May financial statements.	2.80
06/03/20	ADD	Download and compile data from Client's SAP system to update liabilities subject to compromise calculation for May.	1.40
06/03/20	ADD	Review Purdue Pharma LP board minutes from 2002 - 2005 for third-party confidential information.	2.80
06/03/20	KM	Create phase 1 offer tracker.	0.70
06/03/20	KM	Meeting with D. Fogel (Purdue), K Laurel (Purdue) and K. McCafferty, R. Sublett (AlixPartners) re: Rhodes planning.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/03/20	KM	Call with K. Laurel, D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: headcount analysis.	0.50
06/03/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Tech fixed asset review.	0.50
06/03/20	KM	Project Catalyst offer tracking process.	0.60
06/03/20	KM	Analysis re: Project Catalyst tracking approach.	0.70
06/03/20	KM	Analysis re: Project Catalyst payroll tracking.	0.30
06/03/20	KM	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: data collection for Project Catalyst.	0.60
06/03/20	KM	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R. Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst update.	1.50
06/03/20	RDS	Coordinate diligence requests on Project Catalyst.	2.10
06/03/20	RDS	Review Project Catalyst scoring methodology and prepare recommendations.	1.90
06/03/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: data collection for Project Catalyst.	0.60
06/03/20	RDS	Call with K. Laurel, D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: headcount analysis.	0.50
06/03/20	RDS	Meeting with W. DiNicola, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Tech fixed asset review.	0.50
06/03/20	RDS	Assemble and refine materials to back up proposed organizational structure and re-engineered processes at RALP.	0.80
06/03/20	RDS	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst update.	
06/03/20	RDS	Meeting with D. Fogel (Purdue), K. Laurel (Purdue) and K. McCafferty, R. Sublett (AlixPartners) re: Rhodes planning.	0.50
06/03/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: individual victim's document requests.	0.20
06/03/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) and J. Turner (PJT) re: Mundipharma diligence planning.	0.80
06/03/20	JD	Meeting with D. Lundie, J. Lowne, R. Aleali, D. Fogel, R. Shamblen, J. Doyle (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (all AlixPartners), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst update.	1.50
06/03/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: individual victim's document requests.	0.20
06/03/20	JD	Review draft materials to provide to the ad hoc individual victims' group.	0.70
06/03/20	JD	Prepare draft business development creditor presentation.	2.20
06/03/20	JD	Review Project Catalyst timeline and index comments from management.	0.60
06/04/20	JD	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	JD	Correspondence with PJT and Davis Polk re: business development creditor presentation.	0.50
06/04/20	JD	Review UCC letter to Judge Drain re: Sackler discovery efforts.	0.60
06/04/20	JD	Review creditor presentation comments from PJT and Davis Polk. Revise presentation and send around to	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management for review and approval.	
06/04/20	JD	Call with J. Turner (PJT), C. Oluwole, C. Robertson (both Davis Polk), G. Koch and J. DelConte (both AlixPartners) re: UCC letter.	0.40
06/04/20	JD	Review draft presentation to be updated for sharing per AHC diligence questions.	0.40
06/04/20	JD	Review and provide comments on Rhodes transformation presentation.	1.00
06/04/20	JD	Review IAC diligence summary from G. Koch (AlixPartners).	0.20
06/04/20	JD	Review correspondence from PJT and Purdue re: AHC diligence responses.	0.30
06/04/20	JD	Review draft governmental abatement plan term sheet.	1.60
06/04/20	ADD	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	0.50
06/04/20	RDS	Coordinate diligence requests on Project Catalyst.	2.50
06/04/20	RDS	Review Project Catalyst Scorecard / tracker.	1.50
06/04/20	RDS	Finalize AlixPartners assessment of ongoing organizational restructuring.	0.40
06/04/20	RDS	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) and R. Schnitzler, J. Wang (both PJT) re: Catalyst VDR Index.	0.50
06/04/20	RDS	Meeting with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst phase 1 tracker.	0.50
06/04/20	RDS	Review Intralinks data structure and prepare correspondence with Rhodes/Purdue team to address	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		deficiencies.	
06/04/20	RDS	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	RDS	Review Catalyst Scorecard with D. Lundie, A. Oliveria (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.80
06/04/20	RDS	Refine Catalyst scorecard.	1.00
06/04/20	KM	Update round 1 tracker re: Project Catalyst.	0.30
06/04/20	KM	Map offer details re: Project Catalyst.	1.10
06/04/20	KM	Analysis re: Project Catalyst phase 1 tracker.	1.40
06/04/20	KM	Meeting with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst phase 1 tracker.	0.50
06/04/20	KM	Discussion with R. Sublett, K. McCafferty and J. DelConte (all AlixPartners) re: Rhodes transformation.	0.30
06/04/20	KM	Data review and compilation re: Project Catalyst.	0.90
06/04/20	KM	Analysis re: Rhodes Project Catalyst roster and compensation.	0.90
06/04/20	KM	Meeting with D. Fogel (Purdue) re: Project Catalyst roster and compensation.	0.20
06/04/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes planning.	0.30
06/04/20	KM	Meeting with R. Shamblen, D. Fogel, K. McCarthy (all Purdue), A DePalma, K. McCafferty, R. Sublett (all AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT) re: Project Catalyst timeline and VDR index.	0.50
06/04/20	KM	Review Rhodes next steps for operational restructuring.	0.20
06/04/20	KM	Review Catalyst Scorecard with D. Lundie, A. Oliveria (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.80
06/04/20	ADD	Review Purdue Pharma LP board minutes from 2006 - 2007 for third-party confidential information.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/04/20	ADD	Review third-party entity list for business relationships with Purdue/Rhodes to document potential confidentiality issues.	2.50
06/04/20	GJK	Call with J. Turner (PJT), C. Oluwole, C. Robertson (both Davis Polk), G. Koch and J. DelConte (both AlixPartners) re: UCC letter.	0.40
06/04/20	GJK	Prepare notes and talking point for weekly planning meeting re: UCC letter to the Court.	0.30
06/04/20	GJK	Continue to develop plan for incorporation of valuation information to Mundipharma interim diligence repeat.	2.00
06/04/20	GJK	Plan for advisor diligence coordination and next steps with focus on meeting information requirements for all advisors.	1.80
06/04/20	GJK	Call with I. McClatchey (Norton Rose) and follow up planning re: Mundipharma diligence.	1.50
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: findings from China pharmaceutical pricing research.	0.40
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence process and second adjusted case.	0.50
06/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to debrief on UCC letter after speaking with counsel.	0.30
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence process and second adjusted case.	0.50
06/04/20	NAS	Finalize second adjusted case in Mundipharma business plan/FCF model.	1.90
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to debrief on UCC letter after speaking with counsel.	0.30
06/04/20	NAS	Finish review of letter from UCC to Judge re: IAC and	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		other diligence requests.	
06/04/20	NAS	Research historical precedents for pharmaceutical pricing in China.	1.00
06/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: findings from China pharmaceutical pricing research.	0.40
06/04/20	NAS	Draft adjusted case 2 slides for Mundipharma diligence report.	1.60
06/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Advisor Group call and next steps.	0.40
06/05/20	NAS	Prepare subsequent draft of Mundipharma Adjusted Case 2 slides.	0.50
06/05/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma Adjusted Case 2 slides and discuss structure of Executive Summary.	0.40
06/05/20	NAS	Review current draft of Mundipharma diligence report to determine what information should be included in Executive Summary.	1.40
06/05/20	NAS	Draft Mundipharma Executive Summary slides.	2.80
06/05/20	IA	Create LTRP 2021 estimated payments summary by employee to be shared with Purdue HR team.	1.30
06/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma Adjusted Case 2 slides and discuss structure of Executive Summary.	0.40
06/05/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Advisor Group call and next steps.	0.40
06/05/20	GJK	Review updates to draft diligence report and direction on process.	2.00
06/05/20	GJK	Walkthrough of Mundipharma open items including review of FTI discussion topics for call with A. Breabout (Purdue).	2.20
06/05/20	ADD	Review materials submitted in response to diligence list	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for upload to the data room.	
06/05/20	ADD	Compile and upload document to the virtual data room and manage access for interested parties.	1.50
06/05/20	KM	Develop Rhodes org and re-engineering implementation program.	1.90
06/05/20	KM	Review Rhodes Tech data re: Project Catalyst.	0.60
06/05/20	KM	Review Rhodes Tech org charts and employee information re: Project Catalyst.	0.70
06/05/20	KM	Call with J. Lowne, D. Lundie, J. Doyle, K. ,D. Fogel, R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners), R. Schnitzler (PJT) re: Project Catalyst scorecard and board-level discussion points.	1.00
06/05/20	KM	Summarize Rhodes org and re-engineering.	0.30
06/05/20	KM	Review Rhodes Tech org charts and employee information re: Project Catalyst.	1.20
06/05/20	RDS	Correspondence with management related to Project Catalyst tracker.	1.10
06/05/20	RDS	Manage accounting data uploads to VDR for Project Catalyst.	0.10
06/05/20	RDS	Call with J. Lowne, D. Lundie, J. Doyle, K. ,D. Fogel, R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners), R. Schnitzler (PJT) re: Project Catalyst scorecard and board-level discussion points.	1.00
06/05/20	RDS	Prepare and review updated Org charts for Rhodes Tech.	0.60
06/06/20	KM	Reconciliation of Legal review re: Project Catalyst.	0.60
06/06/20	GJK	Draft email to Mundipharma executives, incorporate feedback from J. Turner (PJT).	2.30
06/07/20	GJK	Finalize draft Mundipharma executives email and send to advisor group for review and edits, follow up email to DPW, follow up response to M. Atkinson (Province)	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/07/20	NAS	Review initial draft of letter to be sent to Mundipharma management.	0.30
06/07/20	RDS	Review Project Catalyst tracker and recent uploads, provide commentary to company-side team.	1.30
06/08/20	RDS	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	RDS	Review of register for Project Catalyst and prepare analysis.	2.10
06/08/20	ADD	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	ADD	Call with J. DelConte and A. DePalma (AlixPartners) re: diligence process and go forward planning.	0.60
06/08/20	KM	Project planning with D. Lundie (Purdue) re: Rhodes.	0.60
06/08/20	KM	Call with K. McCarthy (Purdue), J. Wang (PJT), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.10
06/08/20	JD	Call with J. DelConte and A. DePalma (AlixPartners) re: diligence process and go forward planning.	0.60
06/08/20	JD	Review commentary on open diligence items from Province.	0.30
06/08/20	JD	Research historical liquidation analyses in advance of preparing PPLP liquidation analysis.	0.90
06/08/20	NAS	Review drafts of letter to Mundipharma management and correspondence with other advisors.	1.00
06/08/20	NAS	Review draft list of questions for meeting with A. Breabout (Mundipharma) and other diligence requests.	0.50
06/08/20	NAS	Review revised PJT slides for Mundipharma diligence report.	0.30
06/08/20	IA	Participate in call with C. DeStefano (Purdue), S. Lemack and I Arana (both AlixPartners) re: LTRP sensitivities requested by WTW.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/08/20	SKL	Participate in call with C. DeStefano (Purdue), S. Lemack and I Arana (both AlixPartners) re: LTRP sensitivities requested by WTW.	0.80
06/09/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) re: Mundipharma report slides from PJT.	0.80
06/09/20	NAS	Review revised Mundipharma report slides provided by PJT.	1.80
06/09/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) re: Mundipharma report slides from PJT.	0.80
06/09/20	NAS	Correspondence with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.40
06/09/20	NAS	Review Mundipharma third party debt to determine treatment in report.	1.30
06/09/20	JD	Review March flash report and comment on non-PEO version edits.	0.70
06/09/20	JD	Review net sales and IMS data from Rhodes per open AHC diligence requests.	0.30
06/09/20	JD	Review final AHC diligence request responses.	0.30
06/09/20	KM	Call with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.50
06/09/20	KM	D. Fogel, R. Shamblen, K. McCarthy (Purdue), K. McCafferty, R. Sublett (both AlixPartners), J. Wang (PJT) re: VDR.	0.50
06/09/20	KM	Review Rhodes org structure document.	0.80
06/09/20	KM	Review Rhodes R&D restructuring recommendations.	0.90
06/09/20	KM	Rhodes project review with K. McCafferty, R. Sublett (both AlixPartners).	0.60
06/09/20	RDS	Rhodes project review with K. McCafferty, R. Sublett (both AlixPartners).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/09/20	RDS	Assemble slides for next steps on org structure of Rhodes.	1.60
06/09/20	RDS	D. Fogel, R. Shamblen, K. McCarthy (Purdue), K. McCafferty, R. Sublett (both AlixPartners), J. Wang (PJT) re: VDR.	0.50
06/09/20	RDS	VDR data uploads and management for Project Catalyst.	1.60
06/09/20	RDS	Review Project Catalyst timeline.	0.80
06/09/20	RDS	Call with D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners).	0.50
06/09/20	RDS	Correspondence with Catalyst team re: VDR status.	0.40
06/09/20	RDS	Review VDR and legal comment to items.	1.70
06/09/20	RDS	Review Catalyst VDR structure changes.	0.80
06/10/20	RDS	Review material agreements Project Catalyst.	1.40
06/10/20	RDS	Review and edit Project Catalyst Background Presentation.	0.60
06/10/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Project Catalyst.	0.30
06/10/20	RDS	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/10/20	ADD	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/10/20	KM	Prepare Rhodes re-organization R&D recommendations and proposed structure.	2.50
06/10/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re:	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Project Catalyst VDR check-in.	
06/10/20	KM	Review offer analysis re: Project Catalyst.	0.50
06/10/20	KM	Planning for Rhodes initiatives.	0.50
06/10/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Project Catalyst.	0.30
06/10/20	JD	Review response from Mundipharma re: diligence requests.	0.20
06/10/20	JD	Create draft agenda for the professional's and company catch up call tomorrow.	0.50
06/10/20	JD	Correspondence with M. Huebner (Davis Polk) and J. Lowne (Purdue) re: business plan sensitivities.	0.50
06/10/20	JD	Review draft Avrio dashboard.	0.70
06/10/20	JD	Review diligence materials posted to date in the data room.	0.80
06/10/20	JD	Review summary files provided to date to Willis Towers Watson.	1.00
06/10/20	JD	Review latest professional fee estimates from Purdue.	0.30
06/10/20	JD	Review files to be provided in response to open AHC questions.	0.40
06/10/20	IA	Update LTRP scenarios model to reflect updates requested by WTW.	1.60
06/10/20	IA	Review July retention payments as requested by C. DeStefano (Purdue).	0.80
06/10/20	NAS	Correspondence with Mundipharma management re: diligence process.	0.80
06/10/20	NAS	Revise consolidated Mundipharma diligence report in anticipation of new slides from PJT.	2.40
06/10/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma management response to letter sent by	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence advisors.	
06/10/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to review draft of consolidated Mundipharma diligence report.	0.60
06/10/20	NAS	Analyze Mundipharma third party debt balances.	0.80
06/10/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to review draft of consolidated Mundipharma diligence report.	0.60
06/10/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma management response to letter sent by diligence advisors.	0.70
06/11/20	NAS	Revise latest draft of Mundipharma diligence report.	2.30
06/11/20	NAS	Correspondence with Mundipharma diligence advisors re: response to letter from management.	1.00
06/11/20	KM	Document identification and request re: Project Catalyst liens and encumbrances.	0.20
06/11/20	KM	Document control process and communication re: Project Catalyst.	1.80
06/11/20	KM	Review IP diligence requirements and communication re: Project Catalyst.	0.80
06/11/20	KM	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	KM	Analysis re: Project Catalyst legal review and identification of mismatched external opinions.	1.40
06/11/20	KM	Rhodes overview for Project Catalyst.	1.30
06/11/20	KM	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	KM	Analysis and distribution re: Project Catalyst review tracker for legal review of initial documents.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/11/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/11/20	KM	Analysis re: Project Catalyst VDR tracker for legal approval.	0.60
06/11/20	KM	Development of VDR tacking process re: Project Catalyst.	0.80
06/11/20	KM	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	KM	Organize Intralinks setup.	0.50
06/11/20	JD	Correspondence with R. Aleali and K. McCarthy (both Purdue) re: data room uploads.	0.40
06/11/20	JD	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	JD	Call with R. Aleali (Purdue) re: data room process.	0.30
06/11/20	JD	Review historical business plan sensitivities re: opioid low cases.	0.70
06/11/20	ADD	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	ADD	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	ADD	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/11/20	RDS	Call with K. McCafferty, A. DePalma, R. Sublett (all AlixPartners) re: Project Catalyst VDR data tracking and progress.	0.70
06/11/20	RDS	VDR review for Project Catalyst with D. Fogel, K. McCarthy, R. Shamblen (all Purdue), K. McCafferty, A. DePalma, R. Sublett (all AlixPartners).	0.60
06/11/20	RDS	Call with J. DelConte, A. DePalma, R. Sublett, K. McCafferty (all AlixPartners), M. Boyce (Arnold & Porter), A. Gallogly (Skadden) and K. McCarthy (Purdue) re: data room setup.	0.40
06/11/20	RDS	Update to Project Catalyst timeline and process.	0.30
06/11/20	ADD	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.50
06/12/20	RDS	Review correspondence with advisors on investors, gov fundraising efforts and operational cost reduction categories.	1.10
06/12/20	RDS	Continue monthly review of Rhodes dashboard.	0.30
06/12/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: catalyst catch up.	0.50
06/12/20	RDS	Meeting with N. Davis, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: April dashboard.	0.30
06/12/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst VDR and timing.	0.70
06/12/20	JD	Review latest Project Catalyst diligence tracker.	0.40
06/12/20	JD	Correspondence with PJT and M. Kesselman (Purdue) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence materials re: Rhodes Pharma net sales.	
06/12/20	JD	Review data uploaded to the data room detailing Rhodes Pharma net sales by product.	1.70
06/12/20	JD	Review outstanding Purdue press releases for product level details per request from Purdue legal.	0.80
06/12/20	JD	Review weekly sales reports to be posted to the data room.	0.40
06/12/20	JD	Draft and send responses to diligence requests from Province.	0.70
06/12/20	JD	Correspondence with R. Aleali (Purdue) re: operating reports for the Monitor.	0.30
06/12/20	KM	Review of IT software list for VDR.	0.50
06/12/20	KM	Review of Project Catalyst EE compensation materials.	0.70
06/12/20	KM	VDR document permissioning re: Project Catalyst.	0.20
06/12/20	KM	Meeting with R. Shamblen (Purdue) re: RT overview presentation edits for VDR inclusion.	0.60
06/12/20	KM	RT overview document re: Project Catalyst.	1.70
06/12/20	KM	Meeting with D. Lundie (Purdue) re: Project Catalyst VDR launch timing and needs.	0.20
06/12/20	KM	Meeting with H. Ghnaimeh, D. Fogel (both Purdue) re: IT infrastructure and support for Rhodes Tech.	0.60
06/12/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: catalyst catch up.	0.50
06/12/20	KM	Meeting with N. Davis, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: April dashboard.	0.30
06/12/20	KM	Reconciliation of Legal review re: Project Catalyst.	0.60
06/12/20	KM	Update Legal review for PPLP Legal team re: Project	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst.	
06/12/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst VDR and timing.	0.70
06/12/20	KM	Rhodes project planning and communication -- organization restructuring and Project Catalyst.	1.30
06/12/20	KM	Review and edit Rhodes April dashboard.	0.70
06/12/20	NAS	Draft list of questions in advance of call with A. Breabout (Mundipharma).	0.80
06/12/20	NAS	Research and respond to vendor inquiry sent by E. Ruiz (Purdue).	0.50
06/12/20	NAS	Correspondence with Mundipharma management re: diligence process.	0.60
06/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), KPMG, and other Mundipharma diligence advisors to review latest draft of KPMG tax analysis.	1.00
06/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from 6/12 meetings and next steps.	0.60
06/12/20	IA	Call with D. Sims (WTW) re: benefit program requests.	0.50
06/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from 6/12 meetings and next steps.	0.60
06/13/20	IA	Update base salary, AIP and LTRP statistics summary as requested by WTW.	1.20
06/14/20	NAS	Review revised Mundipharma valuation slides provided by PJT.	0.50
06/15/20	NAS	Revise latest draft of consolidated Mundipharma diligence report.	1.90
06/15/20	NAS	Review new Mundipharma diligence files including management responses to questions and modified budget.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to walkthrough revisions to Mundipharma interim diligence report exec summary and next steps.	0.70
06/15/20	NAS	Call with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.30
06/15/20	IA	Call with I. Arana, S. Lemack (both AlixPartners) re: PPLP rebates in forecast.	0.50
06/15/20	IA	Review employee rosters and AIP and LTRP calculations to provide summary data requested by WTW.	2.20
06/15/20	IA	Update Avrio dashboard for May market share and consumption data.	0.60
06/15/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: edits to interim report for distribution to working group.	0.20
06/15/20	GJK	Edit revised Mundipharma interim diligence report exec summary based on latest valuation slides from PJT.	1.00
06/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to walkthrough revisions to Mundipharma interim diligence report exec summary and next steps.	0.70
06/15/20	GJK	Review of revised interim report sent to working group for review.	0.50
06/15/20	GJK	Assess 2019 actuals performance in product format as provided by Huron.	2.00
06/15/20	GJK	Walkthrough of revised Malta model.	3.00
06/15/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: edits to interim report for distribution to working group.	0.20
06/15/20	GJK	Review of 2015 to 2017 decisions re: European transformation.	1.50
06/15/20	JD	Correspondence with J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.30
06/15/20	JD	Call with C. Oluwole (Davis Polk), J. Turner (PJT), R.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/15/20	JD	Aleali, C. George (both Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Monitor data requests.	1.80
06/15/20	JD	Review data room files for diligence materials re: suboxone sales. Correspondence with PJT and M. Kesselman (Purdue) re: same.	0.50
06/15/20	JD	Correspondence with PJT re: Project Catalyst process letter.	0.30
06/15/20	JD	Review and send April flash report to R. Aleali (Purdue) re: Monitor request.	0.50
06/15/20	JD	Review PBC value comparison update from PJT.	1.00
06/15/20	JD	Review latest Project Catalyst documents.	0.30
06/15/20	RDS	Review Purdue correspondence re: Project Catalyst.	0.30
06/15/20	ADD	Review project catalyst tracker and answer questions.	0.40
06/15/20	ADD	Call with C. Oluwole (Davis Polk), J. Turner (PJT), R. Aleali, C. George (both Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Monitor data requests.	0.70
06/15/20	ADD	Meeting with D. Fogel, D. Lundie, K. McCarthy (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR launch decision.	0.50
06/15/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	1.20
06/15/20	KM	Analysis and updated re: Project Catalyst VDR tracker.	0.50
06/15/20	KM	Meeting with D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR check-in.	0.60
06/15/20	KM	Update and analysis re: Project Catalyst VDR update process and approach for next phase approval and	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		uploading.	
06/15/20	KM	Update and refine re: Project Catalyst VDR tracker.	0.70
06/15/20	KM	Review and manage VDR access list re: Project Catalyst.	0.70
06/15/20	KM	Meeting with D. Fogel, D. Lundie, K. McCarthy (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Project Catalyst VDR launch decision.	0.70
06/15/20	KM	Review Rhodes IT document for Project Catalyst.	0.60
06/15/20	KM	Manage Rhodes and Purdue approvals re: Catalyst VDR launch to external interested parties.	0.90
06/15/20	KM	Review Rhodes environmental document re: Project Catalyst.	1.40
06/15/20	KM	Create document tracker for external review of next wave of documents re: Project Catalyst.	0.90
06/16/20	KM	Call with D. Lundie (Purdue) re: communication process and VDR open issues.	0.20
06/16/20	KM	Track and report re: Project Catalyst next priority of documents for VDR.	0.50
06/16/20	KM	Refine and update Rhodes overview re: Project Catalyst.	0.80
06/16/20	KM	Prepare supporting materials re: diligence submission process for Project Catalyst.	0.70
06/16/20	KM	Create diligence request tracker re: Project Catalyst.	1.30
06/16/20	KM	Review and edit VDR file names re: Project Catalyst.	0.80
06/16/20	KM	Review documents handling and access re: Project Catalyst VDR.	1.30
06/16/20	KM	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40
06/16/20	KM	Modify and edit diligence process re: Project Catalyst.	1.00
06/16/20	KM	Pre-call with K. McCafferty and J. DelConte (both	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: VDR status.	
06/16/20	ADD	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40
06/16/20	ADD	Update project catalyst VDR access list.	0.80
06/16/20	ADD	Call with K. McCarthy, D. Lundi, J. Doyle (all Purdue) and J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: VDR status.	0.40
06/16/20	JD	Call with Purdue (K. McCarthy, D. Lundi, J. Doyle) and AlixPartners (J. DelConte, A. DePalma, K. McCafferty) re: VDR status.	0.40
06/16/20	JD	Pre-call with K. McCafferty and J. DelConte (both AlixPartners) re: VDR status.	0.20
06/16/20	JD	Call with R. Schnitzler, J. Turner (both PJT) , J. DelConte, K. McCafferty, A. DePalma (all and AlixPartners) re: VDR rules, access and diligence tracker.	0.40
06/16/20	JD	Update professional fee tracker.	1.10
06/16/20	JD	Create updated professional fee forecast.	2.30
06/16/20	JD	Correspondence with Purdue re: Project Catalyst timeline.	0.60
06/16/20	JD	Review Duff & Phelps diligence questions re: insurance. Correspondence with PJT re: same.	0.40
06/16/20	KM	Call with K. McCarthy, D. Lundi, J. Doyle (all Purdue) and J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: VDR status.	0.40
06/16/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim diligence report and next steps.	0.70
06/16/20	GJK	Review of PJT edits and updates to Valuation section of Mundipharma interim report.	1.50
06/16/20	GJK	Plan and coordinate next phase of Mundipharma diligence based on meetings noted in exchanges with B. Lea	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(Mundipharma) and potential transition of AlixPartners business plan model.	
06/16/20	GJK	Identify and note potential edits/rewrites to Mundipharma interim report for finalization.	3.00
06/16/20	IA	Update Avrio dashboard for May consumption and market share.	1.00
06/16/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim diligence report and next steps.	0.70
06/16/20	NAS	Review and revise Executive Summary portion of draft Mundipharma diligence report.	1.90
06/16/20	NAS	Review and revise Overview of Diligence Process section of draft Mundipharma diligence report.	1.30
06/16/20	NAS	Review and revise Business Plan Overview portion of draft Mundipharma diligence report.	1.10
06/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim report.	0.40
06/17/20	NAS	Review comments from PJT re: draft of Mundipharma diligence report.	0.70
06/17/20	NAS	Revise draft of Mundipharma diligence report following comments from PJT.	0.40
06/17/20	GJK	Prepare for Mundipharma SEA regional manager call by reviewing market financials and open questions.	3.00
06/17/20	GJK	Review open topics and discussion items for call with A Breabout (Mundipharma).	2.00
06/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma interim report.	0.40
06/17/20	GJK	Plan and coordinate Mundipharma diligence process re: interim report version control and update process.	1.00
06/17/20	JD	Review Project Catalyst process letter.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/17/20	JD	Review previous four weeks of net sales reports. Review against forecasts.	0.50
06/17/20	JD	Begin drafting delayed bankruptcy emergence presentation per UCC requests.	2.70
06/17/20	JD	Call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence (both Skadden), J. Turner, R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	0.90
06/17/20	JD	Revise professional fee tracker for management review. Correspondence with M. Kesselman (Purdue) and Davis Polk re: same.	0.80
06/17/20	JD	Correspondence with PJT and management re: mid-year professional fee forecast and actuals tracker.	2.20
06/17/20	JD	Review draft patent settlement term sheet.	0.30
06/17/20	ADD	Partial participation in a call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence (both Skadden), J. Turner, R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	0.30
06/17/20	KM	Communicate and prepare supporting materials re: Project Catalyst DD tracking.	1.40
06/17/20	KM	Discussion with D. Lundie (Purdue) re: Project Catalyst negotiations process.	0.10
06/17/20	KM	Email K. McCarthy (Purdue) re: VDR round 2 of documents.	0.10
06/17/20	KM	Call with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners), C. Robertson, E. Vonnegut (both Davis Polk), M. Gibson, M. Florence (both Skadden), J. Turner,	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		R. Schnitzler (both PJT), K. McCarthy, D. Lundie, J. Doyle, J. Lowne, R. Aleali (all Purdue), re: Project Catalyst process.	
06/17/20	KM	Review re: Catalyst process timeline.	0.50
06/17/20	KM	Aggregate feedback and create tracking summary re: Project Catalyst VDR documents.	1.00
06/17/20	KM	Next phase planning re: Rhodes business planning and initiatives.	0.50
06/18/20	KM	Slide creation and deck edits re: presentation to the BOD for D. Lundie (Purdue).	0.90
06/18/20	KM	Analysis re: Project Catalyst.	1.30
06/18/20	KM	Create slide re: Coventry Site and Facilities aerial map for VDR.	0.60
06/18/20	KM	Create support slide re: Project Catalyst process timeline for presentation to the BOD for D. Lundie (Purdue).	1.10
06/18/20	KM	Design approval process re: Project Catalyst process timeline for presentation to the BOD for D. Lundie (Purdue).	0.10
06/18/20	KM	Create summary slide of bidder evaluation process re: presentation to the BOD for D. Lundie (Purdue).	0.70
06/18/20	KM	Analysis and slide creation re: re: presentation to the BOD for D. Lundie (Purdue).	1.20
06/18/20	KM	Call with A. DePalma, K. McCafferty (AlixPartners), D. Fogel, R. Shamblen, J. Doyle (Purdue), K. McCarthy (Purdue) re: Project Catalyst data room.	0.50
06/18/20	KM	Meeting with D. Fogel, A. Oliveira (both Purdue) re: presentation to the BOD for D. Lundie (Purdue).	0.50
06/18/20	KM	Analysis and review re: Project Catalyst VDR access list and file views.	0.70
06/18/20	ADD	Call with A. DePalma, K. McCafferty (AlixPartners), D.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Fogel, R. Shamblen, J. Doyle (Purdue), K. McCarthy (Purdue) re: Project Catalyst data room.	
06/18/20	KM	Review documents re: Project Catalyst VDR content for external legal review.	0.30
06/18/20	JD	Review latest business development presentation and recirculate it to the group for final sign off.	0.40
06/18/20	JD	Review and provide diligence materials to M. Kesselman (Purdue) re: Suboxone net sales forecasts.	0.60
06/18/20	JD	Correspondence with Davis Polk, PJT, Skadden and K. McCafferty (AlixPartners) re: Project Catalyst timeline.	0.30
06/18/20	JD	Review initial Project Catalyst teasers and correspondence with various parties. Correspondence with R. Aleali (Purdue) re: same.	0.70
06/18/20	GJK	Review and comment on N. Simon (AlixPartners) potential edits to Mundipharma interim report executive summary section.	1.20
06/18/20	GJK	Walkthrough of Malta model and Mundipharma schedule of releases of Balance Sheet and Cash Forecast, EY reports and LEK report.	2.50
06/18/20	GJK	Call with M. Kesselman, R. Aleali, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: weekly update and planning call.	1.00
06/18/20	GJK	Review and check of financials being presented in draft Mundipharma interim report for finalization.	3.00
06/18/20	NAS	Revise draft of Mundipharma diligence report.	0.30
06/18/20	JD	Review draft Rhodes board presentation slides.	0.30
06/18/20	JD	Finalize first draft of presentation on the potential negative consequences of a delayed bankruptcy	3.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		emergence.	
06/18/20	JD	Review updated Project Catalyst process letter.	0.20
06/18/20	JD	Review draft non-PEO version of the side by side deck to be shared with creditors.	0.50
06/19/20	JD	Create updated summary of professional fee actuals per client request.	0.90
06/19/20	JD	Review comments from commercial and market access teams on presentation on the costs of delayed emergence from bankruptcy. Update presentation to reflect these comments.	1.00
06/19/20	JD	Review updated Project Catalyst diligence request tracker.	0.20
06/19/20	IA	Review and send calculated 2020 severance numbers requested by J. Lowne (Purdue).	0.80
06/19/20	IA	Update cash flow model output tabs to refresh and roll forecast forward as actuals are loaded.	2.20
06/19/20	IA	Update cash flow model to include latest changes on assumption and comments from AlixPartners team.	1.90
06/19/20	GJK	Finalize draft Mundipharma interim diligence report executive summary and valuation sections.	3.00
06/19/20	GJK	Finalize Mundipharma interim report key findings and diligence process sections.	3.00
06/19/20	GJK	Finalize Mundipharma interim report appendix section.	1.00
06/19/20	GJK	Final review and send out of Mundipharma interim report to L Donahue and J. DelConte (both AlixPartners).	1.10
06/19/20	KM	Document management re: Project Catalyst.	0.30
06/19/20	KM	Manage VDR approval and access re: Project Catalyst.	0.30
06/19/20	KM	Discussion with D. Fogel (Purdue) re: historical quarterly financial files for Project Catalyst.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/19/20	KM	Document tracking and new document planning re: Project Catalyst.	0.40
06/19/20	KM	Analysis re: Project Catalyst VDR access.	0.30
06/19/20	KM	Document management re: Project Catalyst.	1.20
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and external party re: Project Catalyst due diligence process.	0.50
06/19/20	KM	Create process and documentation re: Project Catalyst due diligence request and communication process.	0.80
06/19/20	KM	Document management re: Project Catalyst.	0.70
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and external party re: Project Catalyst due diligence process.	0.50
06/19/20	KM	Analysis re: external party VDR access summary for calls.	0.50
06/19/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT), and third party re: Project Catalyst due diligence process.	0.50
06/19/20	KM	Analysis re: third party VDR access summary for bidder calls.	0.70
06/20/20	JD	Review updated delayed emergence presentation and circulate to the broader group for comment.	0.80
06/20/20	JD	Review updated business development deal presentation.	0.30
06/22/20	NAS	Review updates to Mundipharma diligence process provided by advisors.	0.30
06/22/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: diligence process and upcoming interviews.	0.30
06/22/20	GJK	Update planning and coordination for Mundipharma diligence, including new calls/meetings scheduled and new information.	2.00
06/22/20	GJK	Review diligence responses for China market provided by Huron/Mundipharma and open items.	1.20
06/22/20	GJK	Assess Mundipharma business plan model drivers for	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		updates based on upcoming calls and proposed information releases.	
06/22/20	GJK	Review and note key items from EY QOE/VDD reports as potential discussion points for EY call.	2.50
06/22/20	GJK	Call with I. McClatchey (Norton Rose) re: current diligence status, follow up email to working group.	0.60
06/22/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: diligence process and upcoming interviews.	0.30
06/22/20	KM	Update and refine re: Project Catalyst VDR tracker.	0.40
06/22/20	KM	Call with J. Northington (Purdue) re: quality reports and org restructuring.	0.30
06/22/20	KM	Manage VDR document flow and approval re: Project Catalyst.	0.60
06/22/20	KM	Review and edit documentation re: Project Catalyst inspections and APR requests.	1.10
06/22/20	KM	Call with R. Shamblen (Purdue) re: inspections and APR requests.	0.30
06/22/20	KM	Review and edit documentation re: Project Catalyst inspections and APR requests.	0.30
06/22/20	JD	Review pdf version of long term plan model output to be shared with the committee advisors.	0.30
06/22/20	JD	Review updated side by side presentation in advance of AHC meeting.	0.40
06/22/20	JD	Review final business development presentation before uploading for creditor advisors.	0.50
06/22/20	JD	Review and edit latest delayed bankruptcy emergence presentation.	0.40
06/22/20	JD	Correspondence with PJT, Davis Polk and Purdue management re: open questions and comments on delayed bankruptcy emergence presentation.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/22/20	JD	Correspondence with Davis Polk and PJT re: tax basis analysis.	0.30
06/22/20	JD	Update delayed bankruptcy presentation per comments from Davis Polk and management.	0.80
06/22/20	JD	Review correspondence re: Project Catalyst data room access.	0.20
06/23/20	JD	Review latest attrition numbers and voluntary resignation data.	0.40
06/23/20	JD	Review draft Mundipharma diligence report from G. Koch, N. Simon (both AlixPartners) and PJT.	2.20
06/23/20	JD	Review and incorporate comments from management into the delayed emergence presentation. Finalize report for production to creditors.	0.80
06/23/20	JD	Correspondence with management re: payment of prepetition amounts owed on behalf of an assumed lease.	0.30
06/23/20	JD	Call with J. Lowne (Purdue) re: delayed emergence scenarios.	0.20
06/23/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.20
06/23/20	JD	Review and provide HR SAP information to management.	0.30
06/23/20	JD	Review draft market access question responses in advance of call with the UCC.	0.50
06/23/20	KM	Create and document re: Project Catalyst VDR tracking process and cadence for Purdue and Rhodes team.	0.40
06/23/20	KM	Review VDR process flow with K. McCafferty, R. Sublett (both AlixPartners).	0.30
06/23/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.30
06/23/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst diligence document tracking and sharing.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/23/20	KM	Meeting with D. Lundie (Purdue), R. Schnitzler (PJT) re: data room access for Project Catalyst.	0.70
06/23/20	KM	Review document re: Project Catalyst financial information.	0.40
06/23/20	KM	Call with R. Shamblen, W. DiNicola (both Purdue) re: operations and finance diligence document requests.	0.60
06/23/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.00
06/23/20	KM	Update due diligence document tracker re: third party inquiries and questions.	1.20
06/23/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.00
06/23/20	RDS	Review VDR process flow with K. McCafferty (AlixPartners).	0.30
06/23/20	GJK	Call with EY and other advisors re: EY progress on Mundipharma audit and related matters.	0.50
06/23/20	GJK	Call with B. Bromberg (FTI) re: EY progress.	0.20
06/23/20	GJK	Update notes for Mundipharma diligence report phase two.	1.50
06/23/20	GJK	Reassessment and prioritization of open items for Mundipharma diligence finalization.	3.00
06/23/20	GJK	Prepare for call with EY re: Mundipharma.	0.60
06/24/20	GJK	Analysis of 2020 open spend based on Mundipharma spend to date guidance.	2.00
06/24/20	GJK	Update notes and analysis for Mundipharma key findings report based on information provided by A Breabout	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(Mundipharma).	
06/24/20	GJK	Call with A Breabout (Mundipharma) re: business plan, 2019 performance and transaction.	1.70
06/24/20	GJK	Call with I. McClatchey (Norton Rose) re: call with Mundipharma CFO and potential next steps based on call.	0.40
06/24/20	GJK	Prepare for call with A Breabout (Mundipharma).	1.00
06/24/20	IA	Update LTRP analysis for edits requested by WTW.	0.80
06/24/20	KM	Call with R. Shamblen (Purdue) re: RT diligence data for capacity utilization and throughput.	0.80
06/24/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.60
06/24/20	KM	Meeting with D. Lundie, K. McCarthy (both Purdue), R. Schnitzler (PJT) re: Project Catalyst diligence request management.	1.00
06/24/20	KM	Update due diligence document tracker re: third party inquiries and questions.	1.00
06/24/20	KM	Analysis re: Project Catalyst.	1.50
06/24/20	KM	Document and user management re: Project Catalyst.	1.30
06/24/20	JD	Review PPI Board meeting agenda and pre-read materials.	1.50
06/24/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
06/24/20	JD	Correspondence with management and J. Turner (PJT) re: professional fees in a sale scenario.	0.50
06/24/20	JD	Finalize and process delayed emergence presentation to be uploaded to the data room.	0.60
06/25/20	JD	Participate in PPI Board meeting.	3.50
06/25/20	JD	Call with C. Robertson (Davis Polk) re: board meeting follow up.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/25/20	JD	Update HR roster for schedule with only VPs and above.	0.30
06/25/20	KM	Call with R. Shamblen (Purdue) re: document approval process.	0.60
06/25/20	KM	Call with K. McCarthy, R. Aleali, J. Doyle, D. Fogel (all Purdue), R. Schnitzler (PJT), Skadden, and Arnold & Porter re: supply contracts for Project Catalyst.	1.00
06/25/20	KM	Manage VDR document flow and approval re: Project Catalyst.	2.00
06/25/20	KM	Document creation re: Project Catalyst.	0.70
06/25/20	KM	Inventory analysis re: Project Catalyst.	0.80
06/25/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.60
06/25/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle (all Purdue) re: Project Catalyst diligence response generation and review.	1.00
06/25/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.40
06/25/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel (Purdue) re: financial information for Project Catalyst.	0.40
06/25/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.30
06/25/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola, R. Shamblen, J. Doyle (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR Check-In meeting.	1.40
06/25/20	ADD	Review business development agreements to compile the list of entities with active confidentiality provisions.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/25/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), D. Fogel (Purdue) re: financial information for Project Catalyst.	0.40
06/25/20	GJK	Call with Mundipharma Latam management re: Latam performance.	1.00
06/25/20	GJK	Prepare for Mundipharma Latam call.	0.30
06/25/20	GJK	Reevaluate Mundipharma Latam projections based on Latam call.	1.80
06/25/20	GJK	Analysis of Mundipharma projections and findings based on new diligence calls.	3.00
06/26/20	GJK	Plan and coordinate for Mundipharma diligence calls and updated information requests.	2.50
06/26/20	GJK	Call with Mundipharma SEA region GM re: SEA business performance and planning.	1.00
06/26/20	GJK	Prepare for call with Mundipharma SEA region GM re: SEA business performance and planning.	0.80
06/26/20	GJK	Walkthrough and assessment of new Mundipharma material uploaded to data room.	3.00
06/26/20	IA	Prepare 2021 LTRP payment detail by employee for non-insiders requested by WTW.	0.70
06/26/20	ADD	Meeting with D. Fogel, R. Shamblen, W. DiNicola, D. Lundie (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: approval of financial information for VDR.	0.50
06/26/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance Documents for VDR.	1.00
06/26/20	KM	Communicate VDR document flow and approval re: Project Catalyst.	0.40
06/26/20	KM	Manage VDR document approval re: Project Catalyst.	0.20
06/26/20	KM	Continue review of regulatory documents re: Project	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst.	
06/26/20	KM	Call with R. Schnitzler (PJT) re: VDR communication process to Bidders.	0.30
06/26/20	KM	Manage VDR document flow and approval re: Project Catalyst.	1.00
06/26/20	KM	Meeting with D. Fogel, R. Shamblen, W. DiNicola, D. Lundie (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: approval of financial information for VDR.	0.50
06/26/20	KM	Review of financial diligence documents re: Project Catalyst.	0.30
06/26/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance Documents for VDR.	1.00
06/26/20	KM	Review of regulatory documents re: Project Catalyst.	0.50
06/26/20	JD	Correspondence with K. Gadski and M. Ronning (both Purdue) re: opioid scenarios.	1.10
06/26/20	JD	Correspondence with PJT re: UCC call diligence follow ups.	0.70
06/26/20	JD	Review certain market access materials per UCC diligence requests.	0.50
06/26/20	JD	Call with J. Turner (PJT) re: post-UCC meeting follow ups.	0.30
06/26/20	JD	Call with J. Lowne (Purdue) re: downside sensitivity scenario assumptions.	0.50
06/27/20	GJK	Call with M. Atkinson (Province) re: Mundipharma transaction plans.	0.30
06/27/20	GJK	Review and add to proposed questions to send in advance to Huron for call with A Martinez (Mundipharma).	1.00
06/28/20	JD	Correspondence with Province, PJT and Purdue re: providing certain materials to UCC members under the protective order.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/29/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, K. McCarthy (all Purdue), R. Schnitzler (PJT) re: interview preparation and process.	1.00
06/29/20	KM	Analysis and diligence management re: Project Catalyst diligence process.	0.80
06/29/20	KM	Interview scheduling and coordination re: Project Catalyst interviews.	1.20
06/29/20	KM	Call with D. Fogel (Purdue) re: financial diligence request details and interview expectations.	0.60
06/29/20	KM	Update due diligence document tracker re: new due diligence inquiries and questions.	0.20
06/29/20	KM	Manage and schedule interviews re: Project Catalyst updates.	0.70
06/29/20	KM	Call with D. McGuire (Purdue) re: supply chain org restructuring.	0.30
06/29/20	KM	Call with A. DePalma and K. McCafferty (AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.00
06/29/20	ADD	Review business development agreements from 2010 through 2013 to document parties and confidentiality provisions.	2.80
06/29/20	ADD	Review business development agreements from 2014 through 2016 to document parties and confidentiality provisions.	3.10
06/29/20	ADD	Call with A. DePalma and K. McCafferty (AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.00
06/29/20	GJK	Plan for Mundipharma diligence meetings and next steps	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		in process.	
06/29/20	GJK	Email to/from J. Arsic (PJT) and J. DelConte (AlixPartners) re: interim report draft.	0.50
06/29/20	GJK	Review of Mundipharma draft for edits based on feedback.	1.50
06/29/20	GJK	Analysis of Europe product information and potential model changes for Mundipharma business plan model.	2.00
06/29/20	JD	Review consolidated responses to open UCC delayed emergence diligence questions.	0.80
06/29/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.30
06/29/20	JD	Correspondence with J. Doyle and R. Aleali (both Purdue) re: business development deal next steps.	0.40
06/29/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: definition of market participants under the protective order.	0.50
06/29/20	JD	Review draft responses and materials provided in response to open UCC questions on the delayed emergence presentation.	1.00
06/29/20	JD	Review voluntary attrition details and attrition calculations.	0.70
06/29/20	JD	Correspondence with Davis Polk re: Project Catalyst process.	0.30
06/29/20	JD	Call with J. Lowne (Purdue) re: delayed emergence diligence questions.	0.20
06/30/20	JD	Correspondence with Purdue re: attrition numbers and details on exit interviews.	0.40
06/30/20	JD	Review latest IAC diligence report.	1.50
06/30/20	JD	Correspondence with Davis Polk and management re: responding to UCC diligence requests.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/30/20	JD	Review various 2018 tax returns.	0.40
06/30/20	JD	Create analysis of attrition rates in response to UCC diligence questions.	1.00
06/30/20	JD	Review latest information posted to the Project Catalyst data room.	0.50
06/30/20	JD	Call with J. Lowne (Purdue) re: open diligence items.	0.20
06/30/20	JD	Call with R. Aleali (Purdue) re: open diligence items and sharing information with certain parties.	0.50
06/30/20	JD	Review and provide comments on April non-PEO monthly flash report.	0.60
06/30/20	JD	Correspondence with J. Lowne (Purdue) and J. Turner, R. Schnitzler (PJT) re: business plan refresh.	0.70
06/30/20	JD	Review and provide comments on updated non-PEO April draft flash report.	0.30
06/30/20	GJK	Call with A Martinez (Mundipharma) re: Europe region performance.	1.20
06/30/20	GJK	Prepare for call with A Martinez (Mundipharma).	0.50
06/30/20	GJK	Calls with I. McClatchey (Norton Rose) re: Mundipharma diligence process.	1.00
06/30/20	GJK	Review of product level Europe market assumptions based on call with A. Martinez (Mundipharma).	3.00
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Wang, E. Schnitzler (both PJT), D.Fogel, W. DiNicola, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR Check-In meeting.	0.70
06/30/20	HSB	Review monthly PEO and non PEO versions of April Flash report prepared by S. Lemack (AlixPartners).	0.60
06/30/20	KM	Coordinate questions and interview process re: Project Catalyst.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
06/30/20	KM	Virtual working session with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update and compilation of diligence responses.	1.80
06/30/20	KM	Update, edit and circulate due diligence interview guide to internal team re: Project Catalyst.	1.20
06/30/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, K. McCarthy (all Purdue), R. Schnitzler (PJT) re: interview preparation and process.	1.00
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), J. Wang, E. Schnitzler (both PJT), D. Fogel, W. DiNicola, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR Check-In meeting.	0.70
06/30/20	KM	Manage VDR document flow and communications re: Project Catalyst.	1.10
07/01/20	KM	Coordinate and manage expedited legal document review with Skadden and A&P re: Project Catalyst.	0.60
07/01/20	KM	Update interested parties diligence teams re: Project Catalyst interviews.	0.60
07/01/20	KM	Manage VDR document flow and communications re: Project Catalyst.	1.30
07/01/20	KM	Call with W. DiNicola (Purdue) re: finance documents for VDR.	0.50
07/01/20	KM	Log interview inquiries, update diligence tracker and circulate to team re: Project Catalyst.	1.10
07/01/20	KM	Log interview inquiries to DD tracker re: Project Catalyst.	0.20
07/01/20	KM	Update DD tracker to reflect new uploads re: Project Catalyst.	0.50
07/01/20	KM	Call with R. Schnitzler (PJT) re: interview process and	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management.	
07/01/20	KM	Update DD tracker to reflect new uploads re: Project Catalyst.	0.20
07/01/20	KM	Interview prep call with D. Fogel, W. DiNicola (both Purdue) re: Project Catalyst.	0.50
07/01/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.80
07/01/20	JD	Review correspondence from management and Davis Polk re: payment of prepetition monies owed versus set-off.	0.30
07/01/20	JD	Review PBC value comparison to be shared with Duff & Phelps.	0.20
07/01/20	JD	Review timeline and items necessary for business plan refresh from J. Lowne. Provide comments re: same.	0.30
07/01/20	JD	Call with J. Lowne (Purdue), R. Schnitzler and J. Turner (both PJT) re: business plan refresh.	0.50
07/01/20	JD	Call with J. Turner, J. O'Connell, T. Coleman (all PJT), L. Donahue and J. DelConte (both AlixPartners) re: pre-board meeting discussion.	0.80
07/01/20	JD	Call with J. Turner (PJT) re: timeline and decision tree deliverable.	0.40
07/01/20	JD	Finalize draft attrition analysis in response to UCC diligence questions. Correspondence with J. Lowne (Purdue) re: same.	0.60
07/01/20	JD	Update latest professional fee tracker and forecast for 2020.	0.50
07/01/20	GJK	Edits to Mundipharma executive summary based on PJT feedback.	1.20
07/01/20	GJK	Review of new Mundipharma presentations and potential impact on business model projections.	2.00
07/01/20	GJK	Follow up related to FTI question re: potential progress on	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transaction process.	
07/01/20	GJK	Review of Mundipharma Business Plan model and potential updates to working capital.	1.50
07/01/20	GJK	Plan and coordination for July Mundipharma diligence.	1.50
07/01/20	LJD	Call with J. Turner, J. O'Connell, T. Coleman (all PJT), L. Donahue and J. DelConte (both AlixPartners) re: pre-board meeting discussion.	0.80
07/02/20	LJD	Call with L. Donahue, J. DelConte (all AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman (Purdue) re: planning for call with the Board.	1.20
07/02/20	GJK	Call with R. Schnitzler, J. Turner, J. Arsic (all PJT) G. Koch, and J. DelConte (both AlixPartners) re: IAC diligence report.	0.50
07/02/20	GJK	Finalize draft report edits and share with L Donahue and J DelConte (both AlixPartners).	0.30
07/02/20	GJK	Preparation for Mundipharma diligence including review of HL questions for Deutsche Bank and review of updates presentations.	1.80
07/02/20	GJK	Call with B. Kudlek (Mundipharma Tech Ops) to discuss Mundipharma Tech Ops.	1.00
07/02/20	GJK	Prepare and follow up for Tech Ops call, including review of COGs and Malta business plan.	2.20
07/02/20	GJK	Call with PJT to discuss edits to draft Mundipharma report.	0.60
07/02/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: follow up on IAC diligence call.	0.20
07/02/20	JD	Call with R. Schnitzler, J. Turner, J. Arsic (all PJT) G. Koch, and J. DelConte (both AlixPartners) re: IAC diligence report.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/02/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: follow up on IAC diligence call.	0.20
07/02/20	JD	Call with L. Donahue, J. DelConte (all AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman (Purdue) re: planning for call with the Board.	1.20
07/02/20	JD	Call with R. Aleali (Purdue) re: outstanding diligence requests.	0.20
07/02/20	JD	Call with E. Vonnegut (Davis Polk) re: board pre-call follow up.	0.20
07/02/20	JD	Correspondence with Davis Polk and PJT re: setting up a call to discuss upcoming board meeting.	0.60
07/02/20	JD	Review draft business development licensing agreement.	0.50
07/02/20	JD	Correspondence with FTI and PJT re: delayed bankruptcy emergence scenario presentation.	0.40
07/02/20	JD	Correspondence with J. Lowne (Purdue) re: 2021 budget process.	0.20
07/02/20	KM	VDR updating and review re: Project Catalyst.	0.60
07/02/20	KM	Analysis and response proposal in collaboration with R. Shamblen (Purdue) re: Project Catalyst environmental inquiry by Ramboll.	1.30
07/02/20	KM	Analysis in collaboration with R. Shamblen (Purdue) re: procurement commitments for VDR.	1.10
07/02/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, and W. DiNicola (both Purdue) re: Review new finance due diligence questions and compilation of responsive materials.	1.00
07/02/20	KM	VDR response management re: Project Catalyst.	0.50
07/02/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence process.	
07/02/20	KM	Communicate VDR tracker and progress to Bidders re: Project Catalyst.	0.40
07/02/20	KM	Create and track VDR changes and responses re: Project Catalyst VDR tracking tool.	1.50
07/02/20	KM	Analysis re: financial responses and edits for Project Catalyst.	0.90
07/02/20	KM	Analysis re: employee tenure tracking for Project Catalyst.	1.00
07/02/20	KM	Update DD tracker to reflect document changes re: Project Catalyst.	0.80
07/02/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, and W. DiNicola (both Purdue) re: Review new finance due diligence questions and compilation of responsive materials.	1.00
07/02/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.10
07/03/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) and Purdue board members re: go forward case progress.	1.70
07/03/20	JD	Review materials in advance of Board meeting.	0.40
07/03/20	JD	Call with R. Aleali (Purdue) re: post-call follow ups.	0.20
07/03/20	JD	Review and provide comments on updated IAC diligence report.	1.80
07/03/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue (both AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/06/20	GJK	Davis Polk), M. Kesselman, R. Aleali (both Purdue) and Purdue board members re: go forward case progress.	1.20
07/06/20	GJK	Mundipharma LAM diligence call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	0.50
07/06/20	GJK	Prep for R. Singh (Mundipharma) call re: LAM region.	1.00
07/06/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss recent Mundipharma diligence developments and upcoming meetings.	1.30
07/06/20	GJK	Email and follow up with Huron re: Deutsch Bank, ManRev and LEK, including review of prior question lists provided to Huron, review HL proposed DB questions.	3.00
07/06/20	NAS	Review recent posted material and prep for discussion of updates to Mundipharma model with N. Simon (AlixPartners).	1.00
07/06/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss recent Mundipharma diligence developments and upcoming meetings.	2.50
07/06/20	NAS	Review Mundipharma diligence materials provided by Huron for meetings during weeks of 6/22 and 6/29.	0.40
07/06/20	JD	Review revised Executive Summary section of Mundipharma diligence report.	0.80
07/06/20	JD	Review proposed questions and responses for Board discussion from PJT. Provide comments and additions re: same.	0.40
07/06/20	JD	Review executed One Stamford Realty documents.	0.60
07/06/20	JD	Review memo from K. Buckfire (Board Member).	0.50
07/06/20	JD	Review side-by-side per diligence sharing request. Correspondence with PJT and Davis Polk re: same.	0.40
07/06/20	JD	Correspondence with R. Aleali and C. George (both	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue) re: monitor requests.	
07/06/20	JD	Create a diligence tracker for the latest monitor requests.	0.70
07/06/20	JD	Review materials provided by the managed care team in response to requests from the monitor.	3.10
07/06/20	JD	Prepare written responses to business plan diligence questions from Secretary Vilsack.	0.60
07/06/20	JD	Correspondence with J. Turner, R. Schnitzler (both PJT), J. Lowne and E. Ruiz (both Purdue) re: monitor diligence requests.	0.30
07/06/20	IA	Update Avrio dashboard for June results.	1.50
07/06/20	NAS	Mundipharma LAM diligence call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	1.20
07/06/20	NAS	Correspondence with other advisors involved in Mundipharma diligence re: upcoming meetings.	0.90
07/06/20	KM	Summarize regulatory documents for R. Shamblen (Purdue) re: response to Ramboll inquiries.	2.20
07/06/20	KM	Summarize EHS documents for R. Shamblen (Purdue) re: response to Ramboll inquiries.	0.50
07/06/20	KM	Analysis and document review re: Project Catalyst environmental.	1.60
07/06/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	0.60
07/06/20	KM	Manage VDR documents and plan/book team communications re: Project Catalyst.	0.40
07/06/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: response approach for open diligence questions.	0.60
07/06/20	KM	Compile raw materials required response re: due diligence inquiry.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/06/20	KM	Call with R. Schnitzler (PJT) re: responses.	0.30
07/06/20	KM	Compile raw materials required response re: third party diligence inquiry.	0.20
07/06/20	KM	Prepare and research responses re: Project Catalyst diligence inquiries.	0.90
07/06/20	ADD	Update liabilities subject to compromise calculation model for June.	2.80
07/06/20	ADD	Review June liabilities subject to compromise spreadsheet for errors.	1.40
07/07/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen re: Project Catalyst Supply Chain Requests.	1.50
07/07/20	KM	Build API growth support materials re: partnership opportunity.	1.20
07/07/20	KM	Review of documents re: Project Catalyst.	0.60
07/07/20	KM	Coordinate and manage diligence inquires and team analysis re: Project Catalyst.	1.30
07/07/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Project Catalyst Supply Chain Requests	1.50
07/07/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
07/07/20	JD	Prepare for and participate in special committee board meeting with J. DelConte and L. Donahue (both AlixPartners).	1.10
07/07/20	JD	Call with R. Aleali (Purdue) re: board follow up.	0.30
07/07/20	JD	Call with J. Feltman, R. Levy (both Duff & Phelps), W. Curran, C. Robertson (both Davis Polk), J. Turner, T. Melvin (both PJT), J. Bucholtz (King & Spalding), M. Florence (Skadden) re: post-emergence org structure.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/07/20	JD	Review draft response edits to monitor business plan diligence questions.	0.70
07/07/20	JD	Provide updated professional fee estimates to management for June month end estimates.	0.40
07/07/20	JD	Correspondence with C. George (Purdue) and D. Gentin Stock (Dechert) re: Secretary Vilsack diligence requests.	0.40
07/07/20	JD	Review updated materials from managed care team re: Secretary Vilsack diligence requests.	2.30
07/07/20	JD	Edit, prepare and send response to Purdue and Dechert re: monitor diligence requests.	1.40
07/07/20	JD	Prepare final documents for production for monitor requests.	0.60
07/07/20	JD	Prepare final set of diligence materials for potential business development deal.	0.40
07/07/20	JD	Correspondence with S. Lemack and HS Bhattal (both AlixPartners) re: min cash.	0.30
07/07/20	NAS	Correspondence with Mundipharma diligence advisors re: upcoming meetings and question lists.	0.70
07/07/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: Mundipharma diligence status and priorities for day.	0.60
07/07/20	NAS	Transform Mundipharma Europe product profitability data provided by company and match P&L format across different reports.	1.60
07/07/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review comparison of Mundipharma product profitability projections vs. current draft of model.	0.70
07/07/20	NAS	Transform Mundipharma LAM product profitability data provided by company.	0.40
07/07/20	NAS	Review differences in Mundipharma Europe product-level projections for specific P&L items and document findings.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/07/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: Mundipharma diligence status and priorities for day.	0.60
07/07/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to review comparison of Mundipharma product profitability projections vs. current draft of model.	0.70
07/07/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
07/07/20	GJK	Review and edits for group emails and questions to Mundipharama from Financial Advisor group.	1.50
07/07/20	GJK	Plan and coordinate next steps in diligence process based on revised timeline and meeting schedules from Mundipharma.	2.80
07/07/20	GJK	Identify next phase model upgrades for Mundipharma business plan model and provide example.	1.80
07/07/20	LJD	Participate in special committee board meeting with J. DelConte and L. Donahue (both AlixPartners).	0.70
07/08/20	GJK	Begin outline for revised/final Mundipharma report based on new data and diligence.	3.00
07/08/20	GJK	Draft and send email to Huron re: LEK participation in diligence process.	1.20
07/08/20	GJK	Review provided material for potential impact on cash and working capital.	1.50
07/08/20	GJK	Update diligence planning and potential next steps for monetizing IACs and timing.	1.30
07/08/20	GJK	Review of LAM region market by product profitably compared to original budget.	1.00
07/08/20	SKL	Review and reconcile the May financial presentation and began formatting accordingly for the May PEO Flash report.	2.30
07/08/20	SKL	Finalize review of the May financial presentation as well	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		as updates to the May PEO Flash report and circulated internally for final sign-off.	
07/08/20	SKL	Review and reconcile the Purdue weekly sales report provided by E. Nowakowski (Purdue) and formatted accordingly for production purposes.	0.80
07/08/20	SKL	Review and reconcile the Rhodes weekly sales report provided by P. Phouthasone (Purdue) and formatted accordingly for production purposes.	0.80
07/08/20	SKL	Finalize updates to the April non-PEO Flash report based on the feedback provided and circulated to R. Aleali (Purdue) for final sign-off.	1.30
07/08/20	NAS	Review comments to latest draft of Mundipharma diligence report.	1.20
07/08/20	NAS	Transform Mundipharma LAM product profitability data provided by company.	2.40
07/08/20	NAS	Detail takeaways from analysis of Mundipharma LAM product profitability data.	1.60
07/08/20	NAS	Revise latest draft of Mundipharma diligence report following comments from J. DelConte (AlixPartners).	1.20
07/08/20	JD	Review Project Catalyst analysis in advance of call.	0.30
07/08/20	JD	Review the Butrans only scenario in preparing the OxyContin only scenario.	0.40
07/08/20	JD	Review strategic questions to be answered in advance of future board meetings.	0.50
07/08/20	JD	Review correspondence re: Project Catalyst contract provisions.	0.30
07/08/20	JD	Call with J. Turner (PJT) re: open diligence items.	0.20
07/08/20	JD	Call with J. Lowne (Purdue) re: AlixPartners professional fee discussion.	0.40
07/08/20	JD	Call with R. Schnitzler, J. Turner (both PJT), J. Doyle, D.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Lundie, D. Fogel, K. McCarthy, R. Shamblen (all Purdue) J. DelConte and K. McCafferty (both AlixPartners) re: Project Catalyst.	
07/08/20	JD	Call with R. Aleali (Purdue) re: board discussion follow ups.	0.60
07/08/20	JD	Review and provide comments and edits to draft IAC diligence report.	2.80
07/08/20	KM	Update DD tracker for PPLP review and round 2 planning re: Project Catalyst.	0.70
07/08/20	KM	Call with R. Schnitzler, J. Turner (both PJT), J. Doyle, D. Lundie, D. Fogel, K. McCarthy, R. Shamblen (all Purdue) J. DelConte and K. McCafferty (both AlixPartners) re: Project Catalyst.	0.90
07/08/20	KM	Coordinate and manage expedited legal document review with Skadden and A&P re: Project Catalyst.	0.40
07/08/20	KM	Update and refine re: Project Catalyst VDR tracker.	1.00
07/08/20	KM	Review of regulatory documents re: Project Catalyst.	0.90
07/08/20	KM	Analysis re: finance diligence requests.	1.00
07/08/20	KM	Diligence tracker updates and team communications re: Project Catalyst.	1.60
07/08/20	KM	Analysis and slide creation re: prep for partnership growth opportunity discussion points.	0.80
07/08/20	KM	Analysis re: Project Catalyst environmental history and impact for RT.	0.80
07/09/20	KM	Coordinate and process diligence requests re: Project Catalyst.	0.90
07/09/20	KM	Analysis for quota and productivity data re: inquiry for Catalyst.	1.20
07/09/20	KM	Call with D. Fogel (Purdue) re: finance analyses for Catalyst.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/09/20	KM	Call with R. Schnitzler (PJT) and interested party re: Project Catalyst clarifications and bid process.	0.50
07/09/20	KM	Create and circulate trackers to various parties re: Project Catalyst.	0.50
07/09/20	KM	Update tracker and responses re: Project Catalyst.	1.00
07/09/20	KM	Create documents re: procurement commitments for Project Catalyst.	1.00
07/09/20	KM	Prep materials for VDR internal working team meeting re: Project Catalyst.	0.40
07/09/20	KM	Analysis and document generation re: raw materials inquiries for Project Catalyst.	0.80
07/09/20	KM	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	1.50
07/09/20	KM	Analysis re: procurement commitments through 2021.	0.10
07/09/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Shamblen, and A. Nadeau (both Purdue) re: Project Catalyst NRM Supply discussion.	0.90
07/09/20	KM	Analysis re: Catalyst supply chain responses.	0.40
07/09/20	KM	Create response for Rhodes review re: remediation effort summary for Project Catalyst.	0.30
07/09/20	ADD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	1.50
07/09/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Shamblen, and A. Nadeau (both Purdue) re: Project Catalyst NRM Supply discussion.	0.90
07/09/20	JD	Call with J. DelConte, A. DePalma, K. McCafferty (all	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	
07/09/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, E. Ruiz (all Purdue) re: OxyContin only scenario.	0.70
07/09/20	JD	Review post-emergence governance structure presentations.	0.50
07/09/20	JD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. DelConte and L. Donahue (both AlixPartners) re: case status and strategy go forward.	1.40
07/09/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence report.	0.20
07/09/20	JD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), K. Buckfire, J. Dubel (both Purdue Board members), L. Donahue and J. DelConte (both AlixPartners) re: case progress and plan to get to emergence.	1.00
07/09/20	JD	Prepare summary of severance per employee by different Purdue operating company.	0.50
07/09/20	JD	Draft response to Monitor question on business plan presentation to send to C. George (Purdue).	0.40
07/09/20	NAS	Diligence call with L. Reber (Mundipharma Compliance), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	0.50
07/09/20	NAS	Prepare for diligence call with L. Reber (Mundipharma Compliance).	0.30
07/09/20	NAS	Discussions with G. Koch and N. Simon (both AlixPartners) re: takeaways from Mundipharma Compliance call and cases presented in latest draft of report.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/09/20	NAS	Review downside case included in Mundipharma business plan model.	0.40
07/09/20	NAS	Revise latest draft of Mundipharma diligence report following comments from J. DelConte (AlixPartners).	3.50
07/09/20	NAS	Calls with G. Koch and N. Simon (both AlixPartners) to review latest draft of Mundipharma report and strategize best way to incorporate new information to next iteration of model.	0.50
07/09/20	NAS	Call with J. Arsic (PJT) to discuss current draft of Mundipharma diligence report.	0.30
07/09/20	NAS	Review materials provided on Mundipharma licensing agreements.	0.60
07/09/20	GJK	Plan out model revisions based on new market/product level data for Mundipharma model.	2.00
07/09/20	GJK	Continue outlining final draft Mundipharma report based on new data and diligence calls.	1.80
07/09/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence report.	0.20
07/09/20	GJK	Follow up and coordinate on updates to Mundipharma draft report.	1.20
07/09/20	GJK	Review Celltrion summary provided by Mundipharma.	0.50
07/09/20	GJK	Discussions with G. Koch and N. Simon (both AlixPartners) re: takeaways from Mundipharma Compliance call and cases presented in latest draft of report.	1.40
07/09/20	GJK	Calls with G. Koch and N. Simon (both AlixPartners) to review latest draft of Mundipharma report and strategize best way to incorporate new information to next iteration of model.	0.50
07/09/20	GJK	Diligence call with L. Reber (Mundipharma Compliance),	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/09/20	LJD	G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors. Prepare for and participate in call with T. Coleman, J. O'Connell, J. Turner (all PJT), K. Buckfire, J. Dubel (both Purdue Board members), L. Donahue and J. DelConte (both AlixPartners) re: case progress and plan to get to emergence.	1.10
07/09/20	LJD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. DelConte and L. Donahue (both AlixPartners) re: case status and strategy go forward.	1.40
07/10/20	LJD	Participate in informal board discussion on post-emergence governance structure including J. DelConte and L. Donahue (both AlixPartners).	1.40
07/10/20	GJK	Revise Mundipharma draft interim report based on edits from J DelConte (AlixPartners). Review final edits before document released back to PJT.	1.70
07/10/20	GJK	Plan and coordinate for upcoming Mundipharma advisor calls.	2.00
07/10/20	GJK	Review of newly posted Mundipharma materials.	3.00
07/10/20	SKL	Finalize remaining updates to the May PEO-Flash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.40
07/10/20	JD	Continue review of draft IAC diligence report. Edit and provide comments to same.	2.30
07/10/20	JD	Correspondence with Purdue re: Project Catalyst contract analysis.	0.30
07/10/20	JD	Review draft analysis created by J. Lowne and E. Ruiz (both Purdue) re: OxyContin only scenario. Correspondence with management re: same.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/10/20	JD	Participate in informal board discussion on post-emergence governance structure including J. DelConte and L. Donahue (both AlixPartners).	1.40
07/10/20	JD	Prepare agenda for internal AlixPartners weekly update call.	0.30
07/10/20	NAS	Analyze and transform revised product-level raw data provided by Mundipharma for next iteration of model.	2.30
07/10/20	NAS	Revise draft of Mundipharma diligence report following subsequent comments from J. DelConte (AlixPartners).	1.70
07/10/20	ADD	Call with J. Doyle (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract analysis.	0.50
07/10/20	KM	Call with D. Lundie, D. Fogel, R. Shamblen (Purdue), R. Schnitzler (PJT) re: diligence inquiries.	1.70
07/10/20	KM	Team prep and analysis re: diligence inquiries and data links.	1.00
07/10/20	KM	VDR tracker management re: Project Catalyst.	1.00
07/10/20	KM	Create and circulate trackers re: Project Catalyst.	0.30
07/10/20	KM	VDR tracker management re: Project Catalyst.	0.20
07/10/20	KM	Call with R. Shamblen (Purdue) re: manufacturing campaign for Catalyst.	0.10
07/10/20	KM	Analysis re: manufacturing campaign for Catalyst.	1.20
07/10/20	KM	Call with R. Shamblen (Purdue) re: manufacturing campaign for Catalyst.	0.20
07/10/20	KM	Update tracker and responses re: Project Catalyst.	0.50
07/10/20	KM	Call with J. Doyle (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract analysis.	0.50
07/10/20	KM	Analysis re: Oct 2020 inventory position for Project Catalyst	0.30
07/13/20	KM	Update and circulate VDR tracker re: Project Catalyst.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/13/20	KM	Analysis of Rhodes stand-alone financial model re: Project Catalyst.	1.60
07/13/20	KM	Continue financial analysis re: diligence inquiries.	0.90
07/13/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue), R. Schnitzler (PJT) and A. DePalma (AlixPartners) re: Repatriate finance inquiries.	0.60
07/13/20	KM	Call with W. DiNicola, D. Fogel (both Purdue), and A. DePalma (AlixPartners) re: prep for Repatriate discussion.	0.70
07/13/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	0.40
07/13/20	KM	Financial analysis re: diligence inquiries.	1.40
07/13/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	0.70
07/13/20	JD	Review responses provided to previous strategic planning questions.	0.60
07/13/20	JD	Review materials provided re: political memberships and dues.	0.40
07/13/20	JD	Review final OxyContin only scenarios and pre-reads for the UCC.	1.70
07/13/20	JD	Review draft May monthly flash report.	0.70
07/13/20	JD	Review draft Nalmafene report to be shared with creditor advisors.	0.20
07/13/20	JD	Review data on betadine in kind donations.	0.30
07/13/20	JD	Call with C. Robertson (Davis Polk) re: political contribution motion.	0.20
07/13/20	JD	Call with J. Lowne (Purdue) re: business sensitivity scenario.	0.20
07/13/20	JD	Correspondence with Purdue team re: post-petition	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/13/20	JD	donation information and reviewing files produced.	0.80
07/13/20	JD	Edit files to be responsive to UCC managed care diligence questions. Circulate for review and sign off.	0.40
07/13/20	ADD	Correspondence with Davis Polk re: UCC political contribution response information.	0.70
07/13/20	ADD	Call with W. DiNicola, D. Fogel (both Purdue), and K. McCafferty (AlixPartners) re: prep for Repatriate discussion.	0.40
07/13/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	0.60
07/13/20	NAS	Meeting with W. DiNicola, D. Fogel (both Purdue), R. Schnitzler (PJT) and K. McCafferty (AlixPartners) re: Repatriate finance inquiries.	3.70
07/13/20	NAS	Analyze and transform revised Europe product-level raw data provided by Mundipharma for next iteration of model.	1.30
07/13/20	GJK	Review new Mundipharma diligence materials provided by Huron.	2.00
07/13/20	GJK	Prepare for business development and Deutsch Bank calls for Mundipharma diligence calls, including review of Biosimilar and Specialty products.	2.50
07/13/20	GJK	Plan and coordinate Mundipharma diligence updates related to draft report revisions.	2.80
07/13/20	GJK	Analyze cost of goods comparison between business plan updates.	1.10
07/14/20	GJK	Calls with G. Koch and N. Simon (both AlixPartners) to discuss current status of case and review takeaways from calls with M. Cerato (Mundipharma) and Deutsche Bank.	0.50
07/14/20	GJK	Call with I McClatchey (Norton Rose) re: Deutsch Bank	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence call.	
07/14/20	GJK	Coordinate and follow up for Mundipharma diligence including calls/emails with financial advisors.	0.60
07/14/20	GJK	Outline potential upside overall based on call with M Certo and Deutsch Bank on business development opportunities.	2.20
07/14/20	GJK	Call with Deutsche Bank, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss current status of sale process.	1.30
07/14/20	GJK	Diligence call with M. Cerato (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors to review Mundipharma business development initiatives.	1.00
07/14/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
07/14/20	NAS	Check transformed Mundipharma Europe data for accuracy.	1.00
07/14/20	NAS	Calls with G. Koch and N. Simon (both AlixPartners) to discuss current status of case and review takeaways from calls with M. Cerato (Mundipharma) and Deutsche Bank.	1.10
07/14/20	NAS	Diligence call with M. Cerato (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors to review Mundipharma business development initiatives.	1.00
07/14/20	NAS	Call with Deutsche Bank, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss current status of sale process.	1.30
07/14/20	NAS	Analyze and transform revised LAM product-level raw data provided by Mundipharma for next iteration of model.	3.00
07/14/20	HSB	Review Purdue P&L forecasts by segment.	0.50
07/14/20	JD	Call with J. Lowne, E. Ruiz (both Purdue), J. Turner and	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/14/20	JD	R. Schnitzler (both PJT) re: business scenario modeling.	0.20
07/14/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	1.50
07/14/20	JD	Review various proposals re: Project Catalyst.	0.60
07/14/20	JD	Review and correspondence with PJT re: restricted cash roll off schedules.	0.30
07/14/20	JD	Review memo re: insurance recoveries.	2.30
07/14/20	JD	Review distributable value presentation put together by the ACH and UCC.	0.70
07/14/20	JD	Call with J. Turner, T. Melvin, R. Schnitzler (all PJT) re: distributable value analysis.	0.70
07/14/20	JD	Review attrition data and calculate as of 6/30.	0.10
07/14/20	KM	Correspondence with C. DiStefano (Purdue) re: same.	0.30
07/14/20	KM	Circulate revised volume re: Project Catalyst.	0.40
07/14/20	KM	Call with D. Fogel and W. DiNicola (both Purdue) re: volume detail through 2024.	1.00
07/14/20	KM	Review and edit re: Rhodes dashboard for Board review.	1.50
07/14/20	KM	Call with D. Fogel (Purdue) re: CPP analysis and pricing strategy.	0.40
07/14/20	KM	Review and coordinate re: RT supply agreements for Catalyst.	1.50
07/14/20	KM	Analysis re: Project Catalyst inquiries.	1.50
07/14/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	0.80
07/15/20	KM	Summarize and communicate findings re: Catalyst analysis.	2.70
07/15/20	KM	Analysis re: API pricing analysis by Bidder for Project Catalyst 2021-2024.	0.30
07/15/20	KM	Update and circulate VDR tracker re: Project Catalyst.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/15/20	KM	Meeting with R. Sublett (AlixPartners) re: CPP analysis for ClarusONE Oxy-IR product pricing.	0.40
07/15/20	KM	Call with J. DelConte (AlixPartners) re: Project Catalyst bid process.	0.30
07/15/20	KM	Analysis re: Project Catalyst offers.	1.40
07/15/20	KM	Call with D. Fogel (Purdue) re: Catalyst volume scenarios.	0.80
07/15/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst bid analysis.	0.30
07/15/20	KM	Analysis re: API supply agreement offers.	1.10
07/15/20	JD	Review additional materials re: Project Catalyst.	0.50
07/15/20	JD	Call with K. McCafferty (AlixPartners) re: Project Catalyst bid process.	0.30
07/15/20	JD	Call with J. Turner, T. Melvin (both PJT), J. Lowne and E. Ruiz (both Purdue) re: business scenarios.	0.20
07/15/20	JD	Call with AHC advisors, UCC advisors, J. Lowne, E. Ruiz (both Purdue), J. Turner, T. Melvin, R. Schnitzler (all PJT) re: distributable value presentation.	1.50
07/15/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.20
07/15/20	JD	Call with R. Schnitzler (PJT) re: Project Catalyst.	0.20
07/15/20	JD	Review updated business scenarios from management for the distributable value presentation.	2.80
07/15/20	JD	Review updated change in working capital calculation for the updated business scenarios.	0.50
07/15/20	JD	Create initial list of post-petition donations to send around to the team for review.	1.30
07/15/20	JD	Review draft outline for the business plan refresh presentation.	0.60
07/15/20	JD	Review Rhodes Tech analysis per open diligence questions.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/15/20	RDS	Meeting with K. McCafferty (AlixPartners) re: CPP analysis for ClarusONE Oxy-IR product pricing.	0.40
07/15/20	NAS	Analyze and transform revised LAM-META product-level raw data provided by Mundipharma for next iteration of model.	2.40
07/15/20	NAS	Check transformed all Mundipharma LAM data relative to source provided by company.	1.30
07/15/20	NAS	Analyze and transform revised LAM-Asia product-level raw data provided by Mundipharma for next iteration of model.	2.50
07/15/20	IA	Review and confirm projected 2022 payment for LTRP amounts based on scenarios requested by WTW.	0.70
07/15/20	GJK	Review Mundipharma diligence responses and develop next steps.	2.00
07/16/20	GJK	Update Mundipharma diligence planning and next steps.	2.00
07/16/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss priorities for day and plan for revised Mundipharma model.	0.40
07/16/20	GJK	Review of update Malta model with revised product by market data.	1.50
07/16/20	NAS	Analyze and transform revised Canada product-level and Central Function raw data provided by Mundipharma for next iteration of model.	2.60
07/16/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss priorities for day and plan for revised Mundipharma model.	0.40
07/16/20	NAS	Check transformed data against raw sources for accuracy and resolve discrepancies.	1.40
07/16/20	NAS	Build second iteration of Mundipharma business plan model based on revised materials provided by	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		management.	
07/16/20	NAS	Compare versions of Mundipharma business plan model provided by management and investigate changes.	0.60
07/16/20	NAS	Respond to question from J. Arsic (PJT) about price/volume analysis provided by management.	0.50
07/16/20	ADD	Review list of material contracts and cross reference with contract work previously conducted by outside counsel.	2.50
07/16/20	JD	Call with D. Fogel (Purdue) re: recent attrition rates.	0.20
07/16/20	JD	Call with R. Aleali (Purdue) re: distributable value presentation.	0.30
07/16/20	JD	Call with J. Turner (PJT) re: distributable value analysis.	0.30
07/16/20	JD	Review Akin fee statement and correspondence with Davis Polk re: same.	0.30
07/16/20	JD	Review Gilbert insurance presentation and correspondence with C. Ricarte (Purdue) re: same.	0.50
07/16/20	JD	Finalize draft strategic question response draft and circulate to DPW and PJT for comments.	2.30
07/16/20	JD	Review and provide comments on draft business plan refresh presentation.	0.80
07/16/20	JD	Review and edit AHC due diligence responses re: minimum cash.	0.70
07/16/20	JD	Review Project Catalyst proposal analyses.	0.40
07/16/20	KM	Update and circulate VDR tracker re: Project Catalyst.	1.10
07/16/20	KM	Analysis re: prioritization of supply agreements for Project Catalyst VDR.	1.20
07/16/20	KM	Call with D. Fogel (Purdue) re: June 2020 dashboard.	0.30
07/16/20	KM	Analysis re: Rhodes Board dashboard.	0.80
07/16/20	KM	Analysis and communication re: Vendor contracts for RT.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/16/20	KM	Bid offer analysis and summary re: Project Catalyst.	2.10
07/16/20	KM	Meeting with R. Shamblen (Purdue) re: vendor contract prioritization.	0.50
07/17/20	KM	Analysis re: Project Catalyst summary.	1.30
07/17/20	KM	Advisors call with R. Aleaxi, K. McCarthy (both Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.80
07/17/20	KM	Refine prioritized list re: Project Catalyst supply agreements review.	0.60
07/17/20	KM	Final prioritization and review prep re: Project Catalyst supply contract review.	0.70
07/17/20	KM	Manage VDR changes re: Project Catalyst.	0.10
07/17/20	KM	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne, R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	1.40
07/17/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst summaries.	0.10
07/17/20	KM	Coordinate operations team activities re: Project Catalyst diligence.	0.40
07/17/20	KM	Call with J. Turner, R. Schnitzler (both PJT), M. Gibson, R. Schlossberg (both Skadden), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.60
07/17/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.20
07/17/20	KM	Analysis re: Project Catalyst supply contract review.	0.70
07/17/20	ADD	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne,	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	
07/17/20	ADD	Review Rhodes contracts in preparation for Project Catalyst diligence requests.	0.20
07/17/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	1.20
07/17/20	JD	Update latest professional fee tracker to provide to Davis Polk.	0.80
07/17/20	JD	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne, R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	1.40
07/17/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.20
07/17/20	JD	Call with J. Turner, R. Schnitzler (both PJT), M. Gibson, R. Schlossberg (both Skadden), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.60
07/17/20	JD	Review updated responses to minimum cash diligence questions.	0.30
07/17/20	JD	Review updated joint distributable value presentation from the AHC and UCC.	1.10
07/17/20	JD	Correspondence with Davis Polk re: production materials.	0.40
07/17/20	NAS	Review new Mundipharma diligence materials provided by management/Huron.	1.10
07/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review new version of Mundipharma business plan model.	0.70
07/17/20	NAS	Revisions to new version of Mundipharma model based on discussion with G. Koch (AlixPartners).	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/17/20	GJK	Review updates Mundipharma diligence responses from S. Jamieson (Management Revisions).	0.60
07/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review new version of Mundipharma business plan model.	0.70
07/17/20	GJK	Review revised Invokana documents provided by Mundipharma.	2.50
07/18/20	JD	Prepare and send around updated donations diligence response.	0.60
07/18/20	JD	Review and provide comments on diligence questions from AHC and UCC.	0.50
07/19/20	JD	Phone call and correspondence with J. McClammy (Davis Polk) and D. Levy and R. Aleali (both Purdue) re: donations.	0.50
07/20/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.20
07/20/20	JD	Call with R. Aleali (Purdue) re: upcoming creditor presentation.	0.40
07/20/20	JD	Review comments from management re: donation info in order to update the diligence schedule.	1.10
07/20/20	JD	Review and edit responses to strategic review questions.	0.70
07/20/20	JD	Review initial draft of the management business update presentation for the UCC meeting on Monday.	1.80
07/20/20	JD	Review draft customer program reports to be posted to the data room.	0.40
07/20/20	JD	Update strategic issues responses memo for comments from Davis Polk and send it around for final review.	0.90
07/20/20	JD	Review latest draft distributable value presentation from the UCC and AHC.	0.60
07/20/20	NAS	Review new Mundipharma diligence materials provided by management.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/20/20	NAS	Add product/market/region-level analyses to second iteration of Mundipharma business plan model.	2.90
07/20/20	NAS	Review LEK non-reliance letter and correspondence with internal Legal team.	0.70
07/20/20	NAS	Review prior price/volume data and Diabetes segment projections relative to latest Mundipharma model provided.	1.20
07/20/20	NAS	Add product-level benchmarking analyses to new iteration of Mundipharma business plan model.	1.70
07/20/20	GJK	Plan and coordinate for final diligence "push" in August including outline of key outstanding items and next steps.	2.00
07/20/20	GJK	Prep for Special Committee call re Settlement related items.	1.00
07/20/20	GJK	Review and coordinate with Legal re: the review of LEK non-reliance letter.	0.70
07/20/20	GJK	Review and create question list for Mundiapharma business model including revised management case data.	0.80
07/20/20	GJK	Review Mundipharma documents/answers provided to Advisors.	1.50
07/20/20	LJD	Review and comment on draft answers to board strategic questions.	0.90
07/20/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/20/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.00
07/20/20	KM	Call with D. Fogel and W. Dinicola (both Purdue) re:	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/20/20	KM	inventory planning reporting requirements and process. Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/20/20	KM	Planning re: project Catalyst VDR needs and inquiries.	0.80
07/20/20	KM	Analysis re: API month-end inventory.	0.50
07/20/20	KM	Coordinate responses re: project Catalyst.	0.20
07/20/20	KM	Analysis re: RT reports for VDR.	1.10
07/20/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.00
07/20/20	KM	Call with R. Schnitzler (PJT) re: term sheet response review.	0.20
07/20/20	KM	Manage VDR and inquires re: Project Catalyst round 2.	0.70
07/20/20	KM	Analysis and documentation re: project Catalyst.	1.30
07/21/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
07/21/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: project Catalyst messaging prep.	0.50
07/21/20	KM	Analysis and inquiry tracking re: RT environmental questions.	1.00
07/21/20	KM	Create report re: RT org structure for VDR.	1.20
07/21/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne, K. McCarthy, R. Aleali (all Purdue), Skadden re: Catalyst APA Discussion.	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/21/20	KM	Analysis re: supply chain and inventory analysis.	1.10
07/21/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: call debrief.	0.30
07/21/20	KM	Call with D. Lundie (Purdue), R. Schnitzler (PJT), diligence team re: term sheet feedback.	0.60
07/21/20	KM	Analysis re: Project Catalyst proposal.	0.40
07/21/20	KM	Meeting with R. Schnitzler (PJT) re: term sheet feedback.	0.60
07/21/20	KM	Continue analysis re: Project Catalyst proposal.	0.50
07/21/20	KM	Meeting with R. Schnitzler (PJT) re: term sheet feedback.	0.70
07/21/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst due diligence status update.	0.30
07/21/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/21/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
07/21/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst due diligence status update.	0.30
07/21/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/21/20	LJD	Prepare for and attend special committee call (partial participation).	1.10
07/21/20	LJD	Review and discuss status deck for board meeting re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		settlement progress.	
07/21/20	GJK	Outline analysis for bridge/walk between Mundipharma business cases based on Mundipharma 2.0 model.	2.50
07/21/20	GJK	Plan follow up activity based on Special Committee and Advisor call including streamline version of draft interim report.	1.50
07/21/20	GJK	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60
07/21/20	GJK	Call with Special Committee of Purdue Board to discuss Settlement related items.	1.20
07/21/20	GJK	Call with I McClatchey (Norton Rose) to discuss diligence process.	0.30
07/21/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss developments in Mundipharma diligence process and current priorities.	0.50
07/21/20	GJK	Review question list to Mundipharma Treasurer and emails with N. Simon (AlixPartners) for follow up.	0.70
07/21/20	GJK	Walkthrough updates Mundi Model 2.0 from N Simon (AlixPartners).	1.00
07/21/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC discussion with the special committee.	0.20
07/21/20	NAS	Add benchmarking analyses for Gross Margin, Selling & Promotion, and Medical Affairs to Mundipharma model.	3.20
07/21/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss developments in Mundipharma diligence process and current priorities.	0.50
07/21/20	NAS	Review and comment on agendas for upcoming diligence meetings.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/21/20	NAS	Analyze unallocated costs for each P&L line in latest Mundipharma business plan.	2.40
07/21/20	JD	Review final AHC/UCC distributable value presentation.	0.70
07/21/20	JD	Review response from management on open AHC distributable value questions.	0.40
07/21/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC discussion with the special committee.	0.20
07/21/20	JD	Prepare for and participate in the special committee board meeting.	1.40
07/21/20	JD	Call with C. Landau, J. Lowne, M. Kesselman, M. Ronning, K. Gadski (all Purdue), J. Turner (PJT) re: OxyContin scenarios.	0.60
07/21/20	JD	Call with R. Aleali, S. Robertson (both Purdue) and J. Turner (PJT) re: Rebranding.	0.40
07/21/20	JD	Call with J. Turner (PJT) re: AHC/UCC presentation.	0.30
07/21/20	JD	Prepare updates professional fee payments to date slide for UCC presentation.	0.70
07/21/20	JD	Prepare responses to open Monitor diligence questions on the latest business plan presentation.	1.20
07/22/20	JD	Call with J. Lowne (Purdue) re: latest UCC deck.	0.20
07/22/20	JD	Participate in Purdue board meeting.	1.30
07/22/20	JD	Call with R. Aleali (Purdue) re: post board meeting follow ups.	0.20
07/22/20	JD	Review and provide comments on Purdue rebranding memo from S. Robertson (Purdue).	0.70
07/22/20	JD	Correspondence with PJT and management re: UCC call and prep scheduling.	0.50
07/22/20	JD	Correspondence with Davis Polk and management re: reporter inquiry on the MOR.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/22/20	JD	Review MOR professional fees and investigate difference in cash versus accrual amounts.	0.50
07/22/20	JD	Call with M. Sharp (Purdue) re: reporter inquiry.	0.20
07/22/20	JD	Review and provide comments on draft memo re: creditor negotiations.	0.60
07/22/20	NAS	Review Purdue business plan update provided to UCC.	0.70
07/22/20	NAS	Analyze non-commercial region product financials in latest budget provided by Mundipharma management.	1.10
07/22/20	NAS	Review new Mundipharma diligence responses from S. Jamieson (Management Revisions) and note additional questions for 7/24 call.	0.60
07/22/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review latest iteration of Mundipharma business plan model.	1.50
07/22/20	NAS	Review comments to Mundipharma diligence report provided by Counsel (DPW) and note follow-ups.	1.00
07/22/20	NAS	Build new Net Sales overview page in Mundipharma business plan model.	0.60
07/22/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to review latest iteration of Mundipharma business plan model.	1.50
07/22/20	GJK	Review comments from DPW on Mundipharma interim report.	0.60
07/22/20	GJK	Review and assessment of LAM region in light of executive departures (ongoing).	2.00
07/22/20	GJK	Walkthrough UCC deck update draft to prepare for UCC-Purdue meeting on Monday.	2.50
07/22/20	LJD	Prepare for and attend board call (partial participation).	1.10
07/22/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma, and K. McCafferty (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Catalyst operations and supply chain diligence.	
07/22/20	KM	Coordinate environmental diligence responses re: project Catalyst.	1.40
07/22/20	KM	Analysis re: RT crewing and capacity for Catalyst.	1.30
07/22/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst process.	0.40
07/22/20	KM	Review and coordinate action items re: project Catalyst VDR.	0.60
07/22/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/22/20	KM	Call with R. Shamblen (Purdue) re: interview prep for Catalyst.	0.50
07/22/20	KM	Analysis re. value creation opportunities.	1.60
07/23/20	KM	Document edits and reporting re: RT org structure for Catalyst VDR.	0.70
07/23/20	KM	VDR management re: project Catalyst.	0.50
07/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.70
07/23/20	KM	Analysis re: inventory transition re: project Catalyst.	0.50
07/23/20	KM	Coordination of diligence visit re: project Catalyst.	0.80
07/23/20	KM	Analysis re: environmental diligence for Catalyst.	1.20
07/23/20	KM	Attend Advisors call with D. Lundie, R. Aleali, K. McCarthy (all Purdue), R. Schnitzler (PJT), K. McCafferty, J. DelConte (both AlixPartners), M. Gibson, and A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/23/20	KM	Analysis re: excluded liabilities in transaction for project Catalyst.	0.10
07/23/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.90
07/23/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, W. DiNicola, D. Fogel (all Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/23/20	KM	Analysis re: RT org structure for Catalyst VDR.	0.30
07/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR activity.	0.70
07/23/20	KM	Update VDR tracking re: project Catalyst.	1.10
07/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR activity.	0.70
07/23/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.70
07/23/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.90
07/23/20	LJD	Prepare for and attend board call (partial participation).	1.10
07/23/20	GJK	Call with J Turner (PJT) to discuss diligence report next steps.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/23/20	GJK	Project management including reviewing and responding to G&A questions in model, responses from Huron, prep for call with Mundipharma CEO.	1.50
07/23/20	GJK	Review S Jamieson (Management Revisions) responses to open questions on financials.	1.20
07/23/20	GJK	Review and assessment of LAM region in light of executive departures (ongoing).	2.50
07/23/20	GJK	Review of growth product data provided by Huron.	1.20
07/23/20	NAS	Review new Mundipharma diligence responses from S. Jamieson (Management Revisions).	1.70
07/23/20	NAS	Revise Mundipharma business plan model to include new product, category, market, and region-level metrics.	2.90
07/23/20	NAS	Map different product classifications used by Mundipharma across data sources to have common methodology.	1.60
07/23/20	NAS	Update methodology notes and assumptions used in Mundipharma business plan model.	0.90
07/23/20	JD	Participate in Purdue board meeting.	1.60
07/23/20	JD	Call with M. Huebner (Davis Polk) re: reporter inquiry.	0.20
07/23/20	JD	Create analysis of professional fees to send to Davis Polk and management re: reporter inquiry.	0.70
07/23/20	JD	Attend Advisors call with D. Lundie, R. Aleali, K. McCarthy (all Purdue), R. Schnitzler (PJT), K. McCafferty, J. DelConte (both AlixPartners), M. Gibson, and A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.50
07/23/20	JD	Call with M. Kesselman (Purdue) re: meeting schedules.	0.20
07/23/20	JD	Call with R. Aleali (Purdue) re: court follow up.	0.20
07/23/20	JD	Review analysis of professional fees post-petition from the company.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/23/20	JD	Update latest strategic questions memo and send out update to Purdue management.	0.80
07/23/20	JD	Review and edit latest UCC presentation and send around to internal group for review prior to prep call tomorrow.	0.70
07/24/20	JD	Call with C. Landau, M. Kesselman, J. Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner (both PJT) re: UCC meeting prep.	1.30
07/24/20	JD	Prepare for and attend call with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.60
07/24/20	JD	Correspondence with PJT and management re: insurance liability post-petition per UCC diligence request.	0.80
07/24/20	JD	Correspondence with PJT and management re: strategic issues memo.	0.30
07/24/20	NAS	Call with M. Princen (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors re: Mundipharma diligence.	0.90
07/24/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with Mundipharma CEO and discuss next steps.	0.60
07/24/20	NAS	Update notes and assumptions pages in revised Mundipharma business plan model.	0.90
07/24/20	NAS	Review new Invokana/Vokanamet market sizing model provided by Mundipharma.	0.90
07/24/20	NAS	Refine product classifications in Mundipharma business plan model and request further detail from company.	0.60
07/24/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/24/20	SJC	Continue to review and redact documents from P drive in	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/24/20	GJK	preparation for processing an upload to data room. Review of Europe business plan based on discussion with Mundipharma CEO including potential refocusing of product categories.	2.00
07/24/20	GJK	Call with M. Princen (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors re: Mundipharma diligence.	0.90
07/24/20	GJK	Plan and coordinate Mundipharma diligence re: report and model updates, including emails from Huron on timing.	2.50
07/24/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) to share takeaways from call with Mundipharma CEO and discuss next steps.	0.60
07/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR updates.	0.30
07/24/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/24/20	KM	Communicate virtual site visit plan re: project Catalyst.	0.40
07/24/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/24/20	KM	Prepare guidelines for virtual site visit re: project Catalyst.	1.40
07/24/20	KM	Design virtual site visit proposal re: project Catalyst.	0.60
07/24/20	KM	Planning re: project Catalyst.	0.20
07/24/20	KM	Update VDR tracker re: project Catalyst.	0.80
07/24/20	KM	Meeting with D. Lundie, J. Lowne, K. McCarthy, R. Aleaxi (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly,	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		R. Schlossberg (all Skadden) re: project Catalyst catch-up.	
07/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR updates.	0.30
07/24/20	KM	Call with R. Schnitzler (PJT) re: edits to project Catalyst presentation to the Board.	0.20
07/24/20	KM	Call with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.50
07/24/20	KM	Meeting with R. Shamblen (Purdue), diligence team re: diligence interview.	1.00
07/24/20	KM	Meeting with D. Lundie, J. Lowne, K. McCarthy, R. Aleai (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden) re: project Catalyst catch-up.	1.00
07/24/20	KM	Analysis re: revised volume forecast.	0.70
07/25/20	LJD	Review and comment on UCC deck.	1.10
07/25/20	JD	Correspondence with management, PJT and Davis Polk re: edits to the UCC deck for Monday.	0.70
07/25/20	JD	Correspondence with management, PJT and Davis Polk re: ability to share the UCC deck with all committee members.	0.50
07/27/20	JD	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	NAS	Review new Mundipharma diligence materials provided by management/Huron.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/27/20	NAS	Further research into Mundipharma income statement items to ensure all appropriate lines are incorporated in model.	2.90
07/27/20	NAS	Correspondence with other Mundipharma diligence advisors re: latest requests for company.	0.50
07/27/20	NAS	Call with G. Koch (AlixPartners) re: findings from research into Mundipharma P&L structure.	1.00
07/27/20	LJD	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	LJD	Prepare for and attend call with M. Kesselman and M Heubner (both Purdue) re: board questions and issues	0.40
07/27/20	GJK	Call with N. Simon (AlixPartners) re: findings from research into Mundipharma P&L structure.	1.00
07/27/20	GJK	Working capital analysis and prep for call with Mundipharma Treasurer.	2.50
07/27/20	GJK	Review of updates Mundipharma Malta 2.0 model.	0.80
07/27/20	GJK	Comparison and analysis of updates to Malta Model 2.0 and original EY VDD.	2.20
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review outstanding diligence request redact documents in response to diligence request for Project Catalyst.	1.10
07/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne, D. McGuire, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst supply agreement discussion.	1.60
07/27/20	KM	Coordinate interested party diligence visits re: project	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst.	
07/27/20	KM	Structure response re: project Catalyst diligence questions.	0.40
07/27/20	KM	Review and establish virtual site visit guidelines re: project Catalyst.	0.90
07/27/20	KM	Design virtual site visit platform re: project Catalyst.	1.50
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APR redactions.	0.80
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.30
07/27/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.80
07/27/20	KM	Update VDR re: project Catalyst.	0.10
07/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
07/27/20	KM	Create and circulate trackers to all bidders re: project Catalyst.	0.80
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.80
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.30
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review outstanding	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence request redact documents in response to diligence request for Project Catalyst.	
07/27/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.80
07/27/20	ADD	Compile bank statements provided by Purdue's accounting service provider TXP for Purdue's accounting team review.	1.50
07/28/20	ADD	Compile additional historical bank statements provided by Purdue's accounting service provider TXP for Purdue's accounting team review and transfer files to file transfer program.	1.40
07/28/20	ADD	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), K. McCafferty, and A. DePalma (both AlixPartners) re: project Catalyst VDR.	0.50
07/28/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.20
07/28/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
07/28/20	KM	Analysis re: site visit strategy for Catalyst.	1.00
07/28/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.50
07/28/20	KM	Call with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update.	0.20
07/28/20	KM	Call with D. Lundie (Purdue) re: project Catalyst legal	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		progress.	
07/28/20	KM	Analysis and VDR updates re: project Catalyst.	1.10
07/28/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), and A. DePalma (AlixPartners) re: project Catalyst VDR.	0.50
07/28/20	KM	Prepare for and attend meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), and A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
07/28/20	KM	Review Supply agreement re: project Catalyst.	0.70
07/28/20	KM	Analysis and preparation re: EHS and diligence site visits for project Catalyst.	1.80
07/28/20	KM	Meeting with R. Schnitzler (PJT) diligence team re: Catalyst offer feedback.	0.30
07/28/20	KM	VDR updates re: project Catalyst.	0.40
07/28/20	GJK	Review and walkthrough of updates to Malta 2.0 model and inclusions into EBITDA including EY VDD, work ok tie into potential cash flows.	2.00
07/28/20	GJK	Review of transaction perimeter and settlement framework language as it relates to Mundipharma joint ventures.	0.80
07/28/20	GJK	Coordinate work stream activities, including exchanges with Province and FTI on state of diligence and next steps/priority open items.	2.60
07/28/20	GJK	Calls with N. Simon (AlixPartners) to discuss takeaways from D. Jefferies (Mundipharma) meeting and review current draft of business plan model.	1.00
07/28/20	GJK	Call with J Turner (PJT) re: call with Province and FTI on current state of Mundipharma diligence responses.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/28/20	NAS	Prepare for diligence call with D. Jefferies (Mundipharma Treasurer).	0.30
07/28/20	NAS	Calls with G. Koch (AlixPartners) to discuss takeaways from D. Jefferies (Mundipharma) meeting and review current draft of business plan model.	1.00
07/28/20	NAS	Arrange source data in Mundipharma business plan model to run more efficiently.	1.90
07/28/20	NAS	Build product category standalone P&Ls in revised Mundipharma business plan model.	2.80
07/29/20	NAS	Call with G. Koch (AlixPartners) to discuss current version of Mundipharma business plan model and next steps.	0.40
07/29/20	NAS	Build business line-level standalone scenario in Mundipharma business plan model.	1.20
07/29/20	NAS	Refine allocation methodology in Mundipharma business plan model for standalone scenarios.	2.10
07/29/20	NAS	Revise Mundipharma business plan model to include category and business line-level standalone scenarios.	2.20
07/29/20	NAS	Build check function for category standalone scenarios in Mundipharma business plan model.	1.10
07/29/20	JD	Follow up correspondence with management, PJT and Davis Polk RE: business development deal.	0.50
07/29/20	GJK	Prepare for call with Management Revisions and walkthrough of open items to be addressed by S. Jamieson (Management Revisions).	2.00
07/29/20	GJK	Call with N. Simon (AlixPartners) to discuss current version of Mundipharma business plan model and next steps.	0.40
07/29/20	GJK	Review of VDD relative to Malta 2.0 model categories.	2.60
07/29/20	GJK	Review of Consumer Health VDD to compare against implied Consumer Health categorization in Malta model.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/29/20	LJD	Call with M. Kesselman (Purdue) re: Board Meeting.	0.30
07/29/20	LJD	Call with K Buckfire (board member) and M. Kesselman (Purdue) re: board meeting and outstanding issues.	0.30
07/29/20	LJD	Review draft board deck and comment.	0.70
07/29/20	KM	Analysis and review of site surveys re: project Catalyst.	0.70
07/29/20	KM	Call with D. Lundie (Purdue), R. Schnitzler (PJT) re: response for project Catalyst.	0.30
07/29/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst Supply Agreement.	1.00
07/29/20	KM	Update virtual site documentation re: interested party specific requests.	0.40
07/29/20	KM	Update diligence requests and tracker re: project Catalyst.	0.30
07/29/20	KM	Upload and edit site visit documents re: project Catalyst.	2.30
07/29/20	KM	Create site visit documents re: project Catalyst.	1.50
07/29/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Rhodes), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
07/29/20	KM	Prepare response re: proposal.	0.50
07/29/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	1.00
07/29/20	KM	Review long form documents re: project Catalyst.	0.80
07/29/20	ADD	Prepare and upload documentation to AlixPartners eDiscovery team for upload to Relativity.	0.80
07/29/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/30/20	ADD	Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.80
07/30/20	ADD	Meeting with A. Nadeau, (Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and virtual site visit preparations.	0.50
07/30/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.50
07/30/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, and A. Gallogly (both Skadden) re: project Catalyst Supply Agreement.	0.60
07/30/20	KM	Update diligence progress re: project Catalyst.	0.60
07/30/20	KM	Coordinate and communicate re: project Catalyst diligence.	0.10
07/30/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst coordination for interested party diligence.	0.70
07/30/20	KM	Review of additional site visit photos re: project Catalyst.	1.10
07/30/20	KM	Call with A. Nadeau (Purdue) re: virtual site visit for project Catalyst.	0.50
07/30/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.90
07/30/20	KM	Update environmental diligence requests re: project Catalyst.	0.80
07/30/20	KM	Create virtual visit overview and tour route map re: project Catalyst.	1.80
07/30/20	KM	Meeting with A. Nadeau (Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and virtual site visit preparations.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/30/20	KM	Participate in Purdue BOD meeting (partial participation).	0.40
07/30/20	JD	Call with M. Huebner (Davis Polk) RE: UCC meeting recap.	0.10
07/30/20	JD	Review board material pre-reads in advance of board call.	0.80
07/30/20	LJD	Prepare for and attend Purdue board meeting (partial participation).	3.50
07/30/20	LJD	Review and comment on chart for board strategic questions.	0.40
07/30/20	GJK	Walkthrough of updates to Malta 2.0 model and outline comparative approaches to bridging to previous base case.	2.00
07/30/20	GJK	Review of revised standalone cases in Mundipharma business plan model with N. Simon (AlixPartners).	0.60
07/30/20	GJK	Plan and coordinate next steps in diligence process based on week's calls and proposed timeline for release of new information.	2.40
07/30/20	GJK	Call with N. Simon (AlixPartners) to review takeaways from diligence meeting with S. Jamieson (Management Revisions).	0.50
07/30/20	JD	Participate in PPI Board meeting.	4.70
07/30/20	JD	Participate in final session of PPI Board meeting.	1.00
07/30/20	JD	Correspondence with management RE: business development deal follow ups.	0.20
07/30/20	JD	Review final board strategic issues draft from PJT.	0.70
07/30/20	NAS	Review of revised standalone cases in Mundipharma business plan model with G. Koch (AlixPartners).	0.60
07/30/20	NAS	Consolidate and review notes/follow-ups from meetings with S. Jamieson (Management Revisions) and other Mundipharma diligence advisors (FTI, Province).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/30/20	NAS	Compare EY Consumer Health VDD report to latest model and revise allocation methodologies as appropriate.	2.90
07/30/20	NAS	Call with G. Koch (AlixPartners) to review takeaways from diligence meeting with S. Jamieson (Management Revisions).	0.50
07/31/20	JD	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	NAS	Coordination with other Mundipharma diligence advisors re: current status of diligence process.	0.50
07/31/20	NAS	Call with G. Koch (AlixPartners) to review Consumer Health figures in latest Mundipharma business plan model relative to EY VDD.	0.40
07/31/20	NAS	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	NAS	Compare latest draft of Mundipharma business plan model to version used in prior iteration of report.	0.50
07/31/20	GJK	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	GJK	Call with N. Simon (AlixPartners) to review Consumer Health figures in latest Mundipharma business plan model relative to EY VDD.	0.40
07/31/20	GJK	Plan for updates to Mundipharma review deck.	1.50
07/31/20	GJK	Review of interim Mundipharma report and back up detail related to other Financial Advisor challenges with developing reports.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/31/20	LJD	Call with M Kesselman (Purdue) re: board meeting.	0.40
07/31/20	JD	Review docket for recently filed fee apps to update latest professional fee tracker for Davis Polk.	0.60
07/31/20	JD	Review materials created and provided to the UCC RE: opioid scenarios.	1.20
07/31/20	KM	Editing re: project Catalyst site tour agenda and plan.	0.50
07/31/20	KM	Create presentation documents re: virtual site visit for project Catalyst.	1.40
07/31/20	KM	Coordinate VDR updates with Rhodes Operations and Finance re: project Catalyst.	0.80
07/31/20	KM	Call with A. Soma (Purdue) and A. DePalma (AlixPartners) re: manufacturing presentation materials for virtual site tour.	0.70
07/31/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), and A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
07/31/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, and A. Gallogly (both Skadden) re: project Catalyst daily updates.	1.00
07/31/20	KM	Analysis and presentation prep re: virtual site visit for project Catalyst.	1.80
07/31/20	ADD	Call with A. Soma (Purdue) and K. McCafferty (AlixPartners) re: manufacturing presentation materials for virtual site tour.	0.70
08/03/20	KM	Create and populate site visit folder re: virtual site visits.	0.90
08/03/20	KM	Coordinate retained liabilities analysis re: diligence request.	0.10
08/03/20	KM	Edit and augment Building 5 and 7 site visit materials re: project Catalyst.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	KM	Call with A. Nadeau (Purdue) re: project Catalyst virtual tour of warehousing and upper mill.	1.00
08/03/20	KM	Analysis and presentation creation re: Upper Mill site tour for project Catalyst.	0.80
08/03/20	KM	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst assigned contracts plan.	0.70
08/03/20	KM	Analysis re: project Catalyst supply contracts.	0.50
08/03/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
08/03/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: contract review and process.	0.10
08/03/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
08/03/20	KM	Coordinate VDR updates with Rhodes Operations and Finance re: project Catalyst.	0.40
08/03/20	KM	Prepare presentation documents re: virtual site visit for project Catalyst.	2.40
08/03/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: contract review and process.	0.10
08/03/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
08/03/20	ADD	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden), A. DePalma, K. McCafferty (both	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: project Catalyst assigned contracts plan.	
08/03/20	JD	Update and check latest attrition data.	0.50
08/03/20	LJD	Review staffing and work on transition plan	0.70
08/03/20	LJD	Call with M. Kesselman (Purdue) re: case status update.	0.30
08/03/20	LJD	Call with K. Buckfire - board member RE: update on case progress.	0.50
08/03/20	GJK	Prepare for walkthrough of Mundipharma report and adjustments, including outlining outstanding information needs.	1.50
08/03/20	GJK	Coordinate and follow up on Mundipharma diligence.	1.50
08/03/20	GJK	Prep for PJT, DPW call.	0.30
08/03/20	GJK	Review Mundipharma report re: potential walkthrough of process with other advisors.	1.50
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: current Mundipharma diligence priorities.	0.30
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to determine necessary updates within first four sections of Mundipharma diligence report.	2.10
08/03/20	GJK	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review takeaways from discussion with PJT and DPW and discuss implications for Mundipharma diligence process.	0.40
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: current Mundipharma diligence priorities.	0.30
08/03/20	NAS	Review notes and follow up items from prior discussions with other Mundipharma diligence advisors.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to determine necessary updates within first four sections of Mundipharma diligence report.	2.10
08/03/20	NAS	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review takeaways from discussion with PJT and DPW and discuss implications for Mundipharma diligence process.	0.40
08/03/20	NAS	Review raw data provided by Mundipharma to ensure that all product/market pairs have cost information.	1.50
08/03/20	JD	Review weekly IMS data prior to posting.	0.40
08/03/20	JD	Review opioid sensitivity case back up data. Review commentary from PJT re: same.	0.60
08/03/20	JD	Review final files that are responsive to UCC opioid case diligence questions.	0.70
08/03/20	JD	Call with P. Strassburger (Purdue) re: upcoming advisory committee meeting.	0.30
08/03/20	JD	Call with E. Vonnegut (Davis Polk) re: claims process.	0.20
08/03/20	JD	Call with J. Turner, J. Arsic (both PJT), G. Koch, N. Simon, J. DelConte (all AlixPartners), C. Robertson, C. Oluwole, A. Lutchen (Davis Polk) re: Mundipharma diligence update.	0.60
08/03/20	JD	Correspondence with management re: professional fee payments.	0.30
08/03/20	JD	Review and mark-up distributable value presentation so that it can be shared with market participants from the UCC.	1.20
08/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		necessary revisions to prior draft of Mundipharma diligence report.	
08/04/20	NAS	Analyze product/market-level variances between latest Mundipharma sales forecast and prior price/volume data.	2.10
08/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review necessary revisions to prior draft of Mundipharma diligence report.	1.60
08/04/20	GJK	Review documents and outstanding country level items and Canada projections and outstanding questions.	2.30
08/04/20	GJK	Analyze working capital and excess cash needs at Mundipharma.	1.80
08/04/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: post weekly professionals call planning.	0.50
08/04/20	JD	Review updated bridges for the various OxyContin scenarios.	0.70
08/04/20	JD	Call with P. Strassburger, R. Fanelli (both Purdue) and P. Mathers (Kleinfield Kaplan) re: adcom.	0.50
08/04/20	JD	Correspondence with M. Kesselman (Purdue) re: responses to UCC questions on the AdCom.	0.60
08/04/20	JD	Review presentation presented to the shareholders in order to prepare a bridge to the latest business plan.	1.20
08/04/20	ADD	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden) and A. DePalma, K. McCarthy (both AlixPartners) re: project Catalyst assigned contracts plan.	0.80
08/04/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCarthy (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/04/20	ADD	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (both PJT), A. DePalma, K. McCafferty (both	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: project Catalyst VDR.	
08/04/20	KM	Review, edit and upload VDR documents re: project Catalyst.	0.40
08/04/20	KM	Analysis re: payroll, benefits and taxes in support of Catalyst.	0.60
08/04/20	KM	Call with R. Schnitzler (PJT) re: diligence process and management.	0.20
08/04/20	KM	Create virtual site visit tour materials re: RTC and grounds and Building 9.	1.10
08/04/20	KM	Create virtual site visit tour materials re: RTC and grounds.	2.20
08/04/20	KM	Review and analysis re: supply agreement diligence for Catalyst.	1.10
08/04/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (both PJT), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst VDR.	0.50
08/04/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCarthy (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/04/20	KM	Coordinate site visits re: project Catalyst.	0.10
08/04/20	KM	Meeting with J. Doyle, K. McCarthy (both Purdue), M. Gibson (Skadden) and A. DePalma, K. McCarthy (both AlixPartners) re: project Catalyst assigned contracts plan.	0.80
08/04/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.60
08/04/20	KM	Create Grounds overview presentation re: virtual site visit.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/04/20	KM	Analysis re: supply agreements for diligence.	1.10
08/05/20	KM	Analysis re: projected inventory coverage for Catalyst.	0.60
08/05/20	KM	Meeting with D. Lundie, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: review of project Catalyst bidders questions.	1.00
08/05/20	KM	Analysis and editing re: virtual site tour for project Catalyst.	1.50
08/05/20	KM	Review, edit and upload VDR documents re: project Catalyst.	1.00
08/05/20	KM	Call with D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: compensation, payroll and benefits re: project Catalyst.	0.60
08/05/20	KM	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	1.00
08/05/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
08/05/20	KM	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	KM	Call with D. Lundie (Purdue) re: project Catalyst.	0.30
08/05/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.70
08/05/20	KM	Coordinate supply agreement review re: diligence in support of project Catalyst.	0.60
08/05/20	KM	Virtual site visit document editing re: project Catalyst.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/05/20	ADD	Research Purdue client repositories and prior efforts to compile material contracts.	1.40
08/05/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
08/05/20	ADD	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	1.00
08/05/20	ADD	Call with D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: compensation, payroll and benefits re: project Catalyst.	0.60
08/05/20	ADD	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	ADD	Call with K. McCarthy, B. Miller (both Purdue), A. Lele, W. Taylor, E. Diggs, C. Robertson (all Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: material contracts.	0.60
08/05/20	JD	Catch up call with R. Aleali (Purdue) re: open diligence items.	0.30
08/05/20	JD	Catch up call with J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.20
08/05/20	JD	Call with K. McCarthy, B. Miller (both Purdue), A. Lele, W. Taylor, E. Diggs, C. Robertson (all Davis Polk), J. DelConte and A. DePalma (both AlixPartners) re: material contracts.	0.60
08/05/20	JD	Meeting with J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: cure costs.	0.50
08/05/20	JD	Review materials to produce to the UCC re: AdCom. Correspondence with Davis Polk re: same.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/05/20	JD	Draft biweekly agenda for the professionals call tomorrow.	0.40
08/05/20	JD	Review list of critical vendors per request from Davis Polk.	0.50
08/05/20	JD	Review Project Catalyst diligence request questions.	0.40
08/05/20	JD	Review list of material contracts to provide to Davis Polk.	1.50
08/05/20	JD	Review final details re: UCC insurance diligence response.	0.30
08/05/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: latest developments in Purdue case and current status of Mundipharma diligence.	0.90
08/05/20	GJK	Catch up call with J. DelConte and G. Koch (both AlixPartners) re: Mundipharma diligence.	0.20
08/05/20	GJK	Call with I. McClatchey (Norton Rose) re: Mundipharma diligence.	1.10
08/05/20	GJK	Follow up planning on diligence based on Norton Rose discussion.	0.80
08/05/20	GJK	Analyze major movements in cost structure between COGS and review previous Tech Ops presentation and VDD comments.	2.50
08/05/20	GJK	Identify potential cost reduction impact areas from reducing footprint.	1.20
08/05/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: latest developments in Purdue case and current status of Mundipharma diligence.	0.90
08/05/20	NAS	Review press coverage about new reported DOJ Purdue charges.	0.50
08/05/20	NAS	Finalize revised sales forecast vs. price/volume comparison and provide summary to G. Koch (AlixPartners).	0.80
08/06/20	JD	Call with K. McCafferty, J. DelConte (both AlixPartners), R. Schnitzler, J. Wang (both PJT), M. Gibson, R.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/06/20	JD	Schlossberg, A. Gallogly (all Skadden), D. Lundie, K. McCarthy (both Purdue) re: Project Catalyst.	0.50
08/06/20	JD	Call with P. Strassburger, R. Fanelli (both Purdue) and P. Mathers (Kleinfield) re: AdCom presentation.	1.20
08/06/20	JD	Review and provide comments on latest draft KEIP/KERP motion.	2.70
08/06/20	JD	Review latest draft KEIP/KERP LTRP analysis. Update analysis from last year for 2021 and 2022.	0.80
08/06/20	JD	Finalize initial list of material contracts to provide to Davis Polk to review.	0.60
08/06/20	JD	Correspondence with M. Kesselman (Purdue) and M. Huebner (Davis Polk) re: questions from the UCC on Suboxone.	0.50
08/06/20	JD	Review updated materials from the company re: AdCom.	0.40
08/06/20	JD	Review AdCom executive summary to potentially share with the UCC.	1.20
08/06/20	IA	Call with J. Tran (Avrio) re: process for updating monthly dashboard and pushing through July results.	2.00
08/06/20	GJK	Draft updates to Key Finding slides for Mundipharma report based on CEO transformation initiatives.	2.50
08/06/20	GJK	Outline revisions to Mundipharma report potential risk adjustments.	2.00
08/06/20	GJK	Outline new sections for updated Mundipharma report.	0.50
08/06/20	GJK	Review Mundipharma PV data variance analysis.	0.30
08/06/20	LJD	Prepare for and attend coordination call with Prime Clerk	0.20
08/06/20	LJD	Prepare for and attend call with team re: claims reconciliation process and staffing	0.60
08/06/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: virtual site	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		visit practice and tech check.	
08/06/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: cure costs for term sheets.	0.50
08/06/20	ADD	Meeting with R. Shamblen, A. Soma, R. Deady, A. Nadeau (all Purdue), K. McCafferty, A. DePalma (both AlixPartners), Ramboll diligence team re: Catalyst Phase I site interview.	2.50
08/06/20	ADD	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	0.80
08/06/20	ADD	Call with W. DiNicola (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: payroll-benefits-pension-taxes diligence inquiry.	0.50
08/06/20	KM	Review, edit and upload VDR documents re: project Catalyst.	0.30
08/06/20	KM	Communication with third party re: virtual site tour.	0.30
08/06/20	KM	Call with W. DiNicola (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: payroll-benefits-pension-taxes diligence inquiry.	0.50
08/06/20	KM	Prepare support materials re: molecules of interest on virtual visit.	0.20
08/06/20	KM	Call with J. Doyle, K. McCarthy (both Purdue), M. Gibson, A. Gallogly (both Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: assigned contracts workplan and activities.	0.80
08/06/20	KM	Meeting with D. Lundie, D. Fogel, K. McCarthy (all Purdue), R. Schnitzler (PJT), third party diligence team re: business diligence inquiries.	0.50
08/06/20	KM	Meeting with D. Lundie, D. Fogel, K. McCarthy (all	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue), R. Schnitzler (PJT) re: preparation for third party business diligence call.	
08/06/20	KM	Meeting with R. Shamblen, A. Soma, R. Deady, A. Nadeau (all Purdue), K. McCafferty, A. DePalma (both AlixPartners), Ramboll diligence team re: Catalyst Phase I site interview.	2.50
08/06/20	KM	Prepare presentation re: Phase I diligence meeting.	0.40
08/06/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: cure costs for term sheets.	0.50
08/06/20	KM	Update documents re: virtual site visit for Catalyst.	0.30
08/06/20	KM	Call with K. McCafferty, J. DelConte (both AlixPartners), R. Schnitzler, J. Wang (both PJT), M. Gibson, R. Schlossberg, A. Gallogly (all Skadden), D. Lundie, K. McCarthy (both Purdue) re: Project Catalyst.	0.70
08/06/20	KM	Call with R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden), diligence team re: project Catalyst transaction documents.	0.80
08/06/20	KM	Call with R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden), diligence team re: project Catalyst transaction documents.	0.50
08/06/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
08/06/20	KM	Analysis re: cure costs for project Catalyst.	0.40
08/06/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (AlixPartners) re: virtual site visit practice and tech check.	0.60
08/06/20	KM	Analysis and editing re: virtual site tour for project Catalyst.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/07/20	KM	Analysis re: materials agreements for project Catalyst.	0.70
08/07/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.30
08/07/20	KM	Call with R. Shamblen (Purdue) re: project Catalyst site visit debrief.	0.10
08/07/20	KM	Continue virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	0.30
08/07/20	KM	Meeting with K. McCarthy (Purdue), PJT, M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.20
08/07/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), K. McCafferty, A. DePalma (both AlixPartners) re: project Catalyst APA schedules.	0.80
08/07/20	KM	Call with J. Lieberman (SK Capital), R. Schnitzler (PJT), A. DePalma, K. McCafferty (both AlixPartners) re: diligence follow up.	0.50
08/07/20	KM	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/07/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue) re: virtual site visit afternoon session prep.	0.50
08/07/20	KM	Call with D. Lundie (Purdue) re: approach for virtual site visit.	0.20
08/07/20	KM	Document edits and corrections re: project Catalyst virtual site visit.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/07/20	KM	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte (all AlixPartners), bidder diligence team re: Rhodes Technologies plant tour part 1.	2.40
08/07/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.50
08/07/20	KM	Edits and final document preparation re: Catalyst virtual site visit.	0.90
08/07/20	ADD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte (all AlixPartners), bidder diligence team re: Rhodes Technologies plant tour part 1.	2.40
08/07/20	ADD	Meeting with K. McCarthy (Purdue), PJT, M. Gibson (Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.20
08/07/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	1.30
08/07/20	ADD	Continue virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: project Catalyst material agreements schedules.	0.30
08/07/20	ADD	Call with J. Lieberman (SK Capital), R. Schnitzler (PJT), A. DePalma, K. McCafferty (both AlixPartners) re: diligence follow up.	0.50
08/07/20	ADD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), K. McCafferty, A. DePalma (both	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/07/20	ADD	AlixPartners) re: project Catalyst APA schedules. Update July liability subject to compromise calculation for Purdue accounting team used for monthly financial statement close process.	2.80
08/07/20	ADD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/07/20	JD	Call with E. Vonnegut, D. Consla, S. Brecher (Davis Polk), S. Hinden, D. Sims, J. Gartrell (all Wilis Towers Watson) re: KEIP/KERP.	0.90
08/07/20	JD	Review estimates for month end professional accruals.	0.40
08/07/20	JD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), K. McCafferty, A. DePalma, J. DelConte (all AlixPartners), bidder diligence team re: Rhodes Technologies plant tour part 1.	2.40
08/07/20	JD	Virtual Site Visit with D. Lundie, D. Fogel, R. Shamblen, A. Soma, A. Nadeau, W. DiNicola (all Purdue), R. Schnitzler (PJT), A. DePalma, K. McCafferty, J. DelConte (all AlixPartners), Bidder diligence team re: Rhodes Technologies plant tour part 2.	1.50
08/07/20	GJK	Plan and coordinate for follow up with other financial advisors re: Mundipharma next steps and information needs.	2.30
08/07/20	GJK	Assess data source files in preparation for call with G. Koch, N. Simon (both AlixPartners).	0.60
08/07/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) re: data source completeness testing, price/volume vs. revised forecast, and priorities moving forward.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/07/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) re: data source completeness testing, price/volume vs. revised forecast, and priorities moving forward.	1.10
08/07/20	NAS	Correspondence with Province and FTI re: Mundipharma diligence process.	0.20
08/07/20	NAS	Compare cost structure in first and second iteration of Mundipharma business plan models.	1.60
08/07/20	NAS	Test Mundipharma business plan source data to ensure completeness.	1.50
08/07/20	NAS	Analyze source data variances for product/market pairs in price/volume and revised forecast files.	0.70
08/07/20	NAS	Compare product/market benchmarking data across first and second iteration of Mundipharma business plan model.	0.80
08/09/20	JD	Correspondence with M. Huebner, J. McClammy, C. Robertson (all Davis Polk) and P. Strassburger, R. Fanelli, R. Silbert, M. Kesselman (all Purdue) re: committee suboxone response.	0.60
08/09/20	JD	Correspondence with M. Huebner, C. Robertson (Davis Polk) and J. Turner (PJT) re: conversation with Province.	0.30
08/09/20	KM	Analysis re: compensation benefits details for project Catalyst.	2.50
08/10/20	KM	Upload and review re: schedules and exhibits for project Catalyst.	0.10
08/10/20	KM	Analysis re: R&D portfolio for project Catalyst diligence.	0.80
08/10/20	KM	Review, edit and upload VDR documents re: project Catalyst.	2.20
08/10/20	KM	Call with R. Schnitzler (PJT), diligence team re: project Catalyst diligence and submission timing.	0.70
08/10/20	KM	Benefits analysis re: project Catalyst.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/10/20	KM	Analysis and tracking re: open diligence requests.	1.70
08/10/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
08/10/20	KM	Analysis re: employee compensation.	0.30
08/10/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst offer process.	0.20
08/10/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	0.60
08/10/20	KM	Review APA disclosure schedules re: project Catalyst.	0.80
08/10/20	JD	Call with J. Turner (PJT), C. Robertson and M. Huebner (Davis Polk) re: UCC Suboxone discussions.	0.30
08/10/20	JD	Call with J. Lowne (Purdue) re: suboxone discussions with UCC and next steps.	0.30
08/10/20	JD	Call with P. Strassburger, R. Silbert (Purdue), C. Robertson (Davis Polk) and P. Mathers (Kleinfeld) re: UCC AdCom discussion.	0.50
08/10/20	JD	Correspondence with D. Fogel (Purdue) re: Suboxone historical and financial details.	0.40
08/10/20	JD	Edit memo on Suboxone historical and forecast financial details.	0.60
08/10/20	JD	Review latest UCC AdCom materials. Edit and prepare for production.	0.70
08/10/20	JD	Review materials collected re: insurance costs in the forecast in advance of the call with FTI.	0.60
08/10/20	JD	Review May non-PEO monthly flash report to provide to creditors.	0.70
08/10/20	JD	Review weekly IMS details to provide to creditor advisors.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/10/20	JD	Review updated AdCom slides from R. Silbert (Purdue) for UCC call.	0.30
08/10/20	JD	Review diligence questions from FTI re: OxyContin only scenario.	0.40
08/10/20	JD	Review draft responses to FTI diligence questions re: OxyContin only scenarios.	0.50
08/10/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
08/10/20	ADD	Review and compile material contracts and submit contracts to Purdue for review.	2.30
08/10/20	NAS	Review new diligence files uploaded to Purdue data room.	0.50
08/10/20	NAS	Call with Province, FTI professionals and G. Koch, N. Simon (both AlixPartners) re: outstanding Mundipharma diligence items.	0.50
08/10/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to prepare for and discuss call with Province and FTI professionals.	0.50
08/10/20	NAS	Build comparison of product/market-level cost structure in first and second iterations of Mundipharma management forecast.	3.50
08/10/20	NAS	Review Mundipharma diligence request letter drafted by G. Koch (AlixPartners) and provide comments.	0.60
08/10/20	NAS	Prepare for Mundi diligence process strategy call with FTI and Province.	0.30
08/10/20	GJK	Correspondence with J. DelConte (AlixPartners) re: Mundipharma diligence.	0.20
08/10/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to prepare for and discuss call with Province and FTI professionals.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/10/20	GJK	Call with Province, FTI professionals and G. Koch, N. Simon (both AlixPartners) re: outstanding Mundipharma diligence items.	0.50
08/10/20	GJK	Draft Mundipharma email and notes from Province and FTI.	2.50
08/10/20	GJK	Update analysis framework for Malta model review.	2.00
08/10/20	GJK	Plan and coordinate Mundipharma diligence.	1.50
08/11/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to walk through changes in product/market pair cost structures between versions of Mundipharma management's forecasts.	1.00
08/11/20	GJK	Assess diligence information provided for support for Mundipharma projected cost improvements.	2.50
08/11/20	GJK	Review open LAM Region items and available diligence information (including VDD).	2.40
08/11/20	LJD	Review and comment on OTC combination analysis	0.80
08/11/20	NAS	Finalize comparison of product/market pair cost structures between iterations of Mundipharma management forecast.	1.60
08/11/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to walk through changes in product/market pair cost structures between versions of Mundipharma management's forecasts.	1.00
08/11/20	ADD	Compile system access instructions for new users and provided information to Davis Polk team members.	1.20
08/11/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
08/11/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (both PJT), D. Fogel,	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/11/20	ADD	R. Shamblen, J. Doyle, W. DiNicola (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/11/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	0.70
08/11/20	JD	Call with E. Diggs, D. Lojac, W. Taylor, J. Schwartz (all Davis Polk), R. Aleali, K. McCarthy, B. Miller (Purdue), J. Bragg, M. Florence (both Skadden), T. Melvin (PJT), J. DelConte and A. DePalma (both AlixPartners) re: Trust Transfer process.	0.70
08/11/20	JD	Call with E. Diggs, D. Lojac, W. Taylor, J. Schwartz (all Davis Polk), R. Aleali, K. McCarthy, B. Miller (Purdue), J. Bragg, M. Florence (both Skadden), T. Melvin (PJT), J. DelConte and A. DePalma (both AlixPartners) re: Trust Transfer process.	0.30
08/11/20	JD	Correspondence with M. Ronning and B. Shank (both Purdue) re: managed care updates.	0.40
08/11/20	JD	Review materials and prepare for AdCom meeting.	0.50
08/11/20	JD	Correspondence with PJT and Davis Polk re: Suboxone next steps.	0.30
08/11/20	JD	Correspondence with D. Fogel (Purdue) and update memo on historical and forecasted Suboxone financials.	0.80
08/11/20	JD	Review request from the Ad Hoc Committee to share various PEO materials with their committee members.	1.80
08/11/20	KM	Analysis re: inventory scenarios for project Catalyst.	1.60
08/11/20	KM	Review and document management re: benefits diligence for project Catalyst.	0.50
08/11/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/11/20	KM	Analysis re: transition services for project Catalyst.	0.30
08/11/20	KM	Meeting with D. Fogel, W. DiNicola, J. Lowne (all Purdue), R. Schnitzler (PJT) re: transitions services analysis for Catalyst.	0.80
08/11/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (both PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/11/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
08/11/20	KM	Analysis and documentation re: R&D portfolio for project Catalyst diligence.	0.40
08/11/20	KM	Analysis and update diligence tracker and open items re: project Catalyst.	2.20
08/12/20	KM	Diligence updates to VDR re: project Catalyst.	1.30
08/12/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Review approved documents and upload materials to Project Catalyst VDR	1.20
08/12/20	KM	Coordination of diligence tracking re: project Catalyst.	0.30
08/12/20	KM	Call with D. Fogel (Purdue) re: project Catalyst.	0.30
08/12/20	KM	Detailed compensation analysis re: project Catalyst VDR.	1.60
08/12/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/12/20	KM	Analysis and document management re: environmental due diligence.	1.30
08/12/20	KM	Analysis and coordination re: benefits policies for VDR.	1.50
08/12/20	JD	Review and provide comments on PJT OTC analysis.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/12/20	JD	Review updated PJT materials pulled together in response to open shareholder diligence requests.	0.70
08/12/20	JD	Review draft updated Adhansia forecast presentation materials.	0.80
08/12/20	JD	Review management comments to draft Adhansia slides.	0.30
08/12/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.20
08/12/20	JD	Call with R. Aleali (Purdue) re: open diligence items and trust transfer process.	0.40
08/12/20	JD	Meeting with J. Lowne, K. Gadski, D. Rosen, M. Ronning (all Purdue), R. Schnitzler, T. Melvin, J. Turner (PJT) re: Adhansia business plan.	0.70
08/12/20	JD	Call with J. Turner (PJT) re: Adhansia business plan.	0.30
08/12/20	JD	Call with J. Lowne (Purdue) re: Adhansia business plan.	0.20
08/12/20	JD	Review and process Nalmafene report.	0.30
08/12/20	JD	Review and update the latest Suboxone draft memo.	0.40
08/12/20	ADD	Compile material contracts for review by Purdue and Davis Polk.	1.30
08/12/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Review approved documents and upload materials to Project Catalyst VDR	1.20
08/12/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.50
08/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to walk through changes in market/product level financials across management forecasts.	2.40
08/12/20	NAS	Correspondence with FTI and Province re: current state of Mundipharma diligence process.	0.60
08/12/20	GJK	Analyze and assess market comparisons compared to	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		prior management and base case and potential upside scenario.	
08/12/20	GJK	Coordinate follow up activities for Mundipharma diligence including letter from counsel.	1.00
08/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to walk through changes in market/product level financials across management forecasts.	2.40
08/13/20	GJK	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	0.90
08/13/20	GJK	Review Mundipharma June diligence files for support of cost of sales and S&P revisions.	2.20
08/13/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments detailed on advisor group call.	0.30
08/13/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to complete review of changes from current and prior iterations of Mundipharma management business plan.	1.50
08/13/20	LJD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, T. Melvin, G. Sim (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and planning call.	0.90
08/13/20	NAS	Call with G. Koch (AlixPartners) re: latest case developments detailed on advisor group call.	0.30
08/13/20	NAS	Review mark-up to Mundi diligence letter provided by UCC.	0.30
08/13/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to complete review of changes from current and prior iterations of Mundipharma management business plan.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/13/20	NAS	Draft product/market diligence question list and supporting exhibits for Huron/Mundipharma.	1.90
08/13/20	JD	Correspondence with J. Lowne and D. Fogel (both Purdue) re: Suboxone fact sheet.	0.50
08/13/20	JD	Update Suboxone memo in advance of discussion with the UCC.	0.60
08/13/20	JD	Review correspondence from PJT and management re: costs of liability insurance post-emergence.	0.40
08/13/20	JD	Review comments from management re: latest distributor agreements.	0.30
08/13/20	JD	Review monthly IMS data to be shared with creditors.	0.40
08/13/20	JD	Review and provide comments on June draft monthly flash report.	0.70
08/13/20	JD	Update professional fee actual amounts and 2020 forecast.	0.80
08/13/20	ADD	Meeting with A. Nadeau, A. Soma, D. Lundie, R. Shamblen (Purdue), A. DePalma. K. McCafferty (AlixPartners) re: RT R&D Discussion.	1.30
08/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) A. Gallogly K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/13/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	0.90
08/13/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/13/20	KM	Virtual working session with A. DePalma and K.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners) re: diligence tracking and VDR updates.	
08/13/20	KM	Analysis re: transition planning for project Catalyst.	0.70
08/13/20	KM	Meeting with A. Nadeau, A. Soma, D. Lundie, R. Shamblen (Purdue), A. DePalma. K. McCafferty (AlixPartners) re: RT R&D Discussion.	1.30
08/13/20	KM	Analysis re: working capital and inventory scenarios for project Catalyst.	1.30
08/13/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) A. Gallogly K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	0.50
08/13/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/13/20	KM	Analysis re: R&D portfolio planning for Catalyst.	0.30
08/13/20	KM	Call with D. Lundie (Purdue) re: project Catalyst.	0.60
08/13/20	KM	Call with W. DiNicola, D. Fogel (Purdue) re: cost center detail schedules for Catalyst.	0.60
08/13/20	KM	Update VDR tracking and analyses re: project Catalyst.	0.90
08/13/20	KM	Analysis and response re: inquires to recently posted diligence documents.	1.60
08/14/20	KM	Call with third party re: project Catalyst diligence.	0.30
08/14/20	KM	Analysis re: key agreements and terms and impact on Catalyst options.	0.60
08/14/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: diligence and negotiation next steps.	1.00
08/14/20	KM	Coordinate RM/WIP/FG inventory analysis re: project Catalyst diligence.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/14/20	KM	Analysis and document management re: environmental diligence for project Catalyst.	1.90
08/14/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.30
08/14/20	KM	Document approval and management re: benefits programs for project Catalyst.	0.70
08/14/20	KM	Analysis re: product mapping for tech transfer requirements.	0.80
08/14/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst bi-weekly update.	0.70
08/14/20	KM	Analysis re: transition planning for project Catalyst.	0.90
08/14/20	JD	Review opioid forecasts and WAC details for OxyContin, Butrans and Hysingla per diligence request from Province. Correspondence with Province re: same.	0.80
08/14/20	JD	Review and provide comments on weekly cash by product reports for Purdue and Rhodes prior to sharing with creditor advisors.	0.40
08/14/20	JD	Review list of active insurance policies re: AHC request.	0.20
08/14/20	JD	Review special committee presentation re: OSR shared services agreement.	0.40
08/14/20	JD	Call with E. Diggs, D. Lojac (both Davis Polk), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.40
08/14/20	JD	Review and sort through list of material contracts in advance of material contract review call with Davis Polk.	1.40
08/14/20	JD	Call with M. Huebner, C. Robertson (Davis Polk), S. Birnbaum, D. Gentin Stock (both Dechert), J. Bragg (Skadden), J. Bucholtz (King & Spalding), J. O'Connell, T. Melvin (PJT), L. Donahue and J. DelConte (AlixPartners)	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: next Monitor report.	
08/14/20	JD	Call with R. Aleali (Purdue) re: Monitor report.	0.30
08/14/20	JD	Correspondence with Davis Polk re: Subutex.	0.30
08/14/20	ADD	Research and compile active, material contracts and submit materials to Purdue contact for review.	2.20
08/14/20	ADD	Research sources of material contracts and identify potential documents for review.	2.50
08/14/20	ADD	Call with E. Diggs, D. Lojac (both Davis Polk), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.40
08/14/20	HSB	Review OxyContin sales forecasts prepared in response to UCC advisors' request for OxyContin only scenario data.	0.40
08/14/20	HSB	Review OxyContin sales forecasts prepared in response to UCC advisors' request for OxyContin only scenario data (continued).	0.40
08/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments and priorities moving forward.	0.30
08/14/20	NAS	Build new cost structure adjustments for latest iteration of Mundipharma business plan model.	2.20
08/14/20	NAS	Draft follow-up market product-level questions for Mundipharma and send to Huron.	0.40
08/14/20	LJD	Prepare for and attend call with M. Huebner, C. Robertson (Davis Polk), S. Birnbaum, D. Gentin Stock (both Dechert), J. Bragg (Skadden), J. Bucholtz (King & Spalding), J. O'Connell, T. Melvin (PJT), L. Donahue and J. DelConte (AlixPartners) re: next Monitor report.	0.60
08/14/20	GJK	Follow up and planning for outstanding diligence items and next steps for Mundipharma diligence.	2.00
08/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest case developments and priorities moving forward.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/14/20	GJK	Outline outstanding key items and potential impact on diligence findings, brain storm potential walkthrough with groups.	1.50
08/17/20	GJK	Plan and coordination for Mundipharma diligence.	2.00
08/17/20	NAS	Finalize upload from first iteration of Mundipharma business plan model for base case cost structure.	1.80
08/17/20	NAS	Build Other Europe and Other LAM cost structure for markets outside of top 15 provided by Mundipharma.	2.40
08/17/20	NAS	Conform Management Revisions product terminology across January and June files provided.	0.80
08/17/20	NAS	Check initial draft of Mundipharma business plan base case and resolve discrepancies.	2.10
08/17/20	NAS	Build preliminary Mundipharma business plan 2.0 P&L using certain cost data from 1.0 model.	0.90
08/17/20	HSB	Call with T. Matlock, A. Hendin (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte and H. Bhattal (both AlixPartners) re: tax analysis.	0.50
08/17/20	ADD	Review and compile agreements for contract materiality analysis.	2.60
08/17/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR	0.70
08/17/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/17/20	KM	Meeting with D. Lundie, K. McCarthy (both Purdue), R. Schnitzler (PJT) and third party re: project Catalyst inquiries.	1.00
08/17/20	KM	Review supply agreements re: project Catalyst.	0.80
08/17/20	KM	Review supply agreements re: project Catalyst.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/17/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR	0.70
08/17/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	1.00
08/17/20	KM	Manage VDR document re: material agreements.	0.50
08/17/20	KM	Call with R. Schnitzler (PJT) re: diligence follow up.	0.30
08/17/20	KM	Meeting with D. Fogel (Purdue) re: tech transfers for project Catalyst.	0.40
08/17/20	KM	Analysis re: product and API mapping for Catalyst.	1.10
08/17/20	KM	Call with D. Fogel (Purdue) re: tech transfers for project Catalyst.	0.40
08/17/20	KM	Product and API mapping re: project Catalyst.	0.80
08/17/20	KM	VDR and diligence tracking updates re: project Catalyst.	1.20
08/17/20	JD	Finalize LTRP analysis file to send across to Purdue HR team to double check numbers.	0.70
08/17/20	JD	Call with S. Hinden (Willis Towers Watson), S. Brecher, E. Vonnegut (both Davis Polk), R. Aleali, C. DiStefano, K. Laurel (all Purdue) re: KEIP/KERP plans.	0.70
08/17/20	JD	Call with T. Matlock, A. Hendin (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte and H. Bhattal (both AlixPartners) re: tax analysis.	0.50
08/17/20	JD	Call with M. Huebner (Davis Polk) re: Suboxone discussion with UCC.	0.20
08/17/20	JD	Review updated draft Adhansia board slides in advance of call.	0.60
08/17/20	JD	Meeting with J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner, R. Schnitzler (both PJT) re: updated	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/17/20	JD	Adhansia projections. Review AHC advisor diligence questions re: updated OxyContin forecast. Review potential responses from UCC presentation.	0.60
08/17/20	JD	Review correspondence between Davis Polk and R. Aleali (Purdue) re: material contract review.	0.40
08/17/20	JD	Review listing of active insurance policies and correspondence with Purdue re: same.	0.30
08/17/20	JD	Correspondence with Purdue re: professional fee payments.	0.20
08/17/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/18/20	JD	Call with C. DeStefano (Purdue) re: KEIP / KERP calculations.	0.50
08/18/20	JD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	0.80
08/18/20	JD	Review forecasts to provide to Davis Polk for tax modeling purposes. Review audited financials re: same.	0.80
08/18/20	JD	Review distributable value analysis and interim OxyContin updated business case.	0.60
08/18/20	JD	Review Monitor's second report.	0.70
08/18/20	JD	Review existing materials re: state by state sales information and managed care contract timing per Davis Polk request.	1.00
08/18/20	JD	Call with E. Vonnegut (Davis Polk) re: upcoming case progress.	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/18/20	JD	Call with M. Huebner (Davis Polk) re: distributable value calculations.	0.20
08/18/20	JD	Call with J. Lowne (Purdue) re: business plan refresh.	0.40
08/18/20	JD	Call with D. Lojac, C. Robertson, E. Diggs (all Davis Polk), K. McCarthy, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.80
08/18/20	KM	Analysis and response re: additional diligence requests.	0.40
08/18/20	KM	Edit ACP map diligence document re: project Catalyst.	0.60
08/18/20	KM	Refine, edit and circulate ACP map re: project Catalyst.	1.30
08/18/20	KM	Call with D. Fogel (Purdue) re: API volume mapping and prioritization for Catalyst.	0.40
08/18/20	KM	Analysis re: API-customer-Product mapping for Catalyst.	0.40
08/18/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, K. Kolar, T. Delahant, D. McGuire, G. Sparta (all Purdue) re: API-Customer-Product mapping for Catalyst.	1.10
08/18/20	KM	Analysis and response re: due diligence inquiries.	2.10
08/18/20	KM	Coordinate diligence and VDR requirements re: environmental inquiries for Catalyst.	0.80
08/18/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.30
08/18/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/18/20	KM	VDR and diligence tracking updates re: project Catalyst.	1.20
08/18/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst APA schedules.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/18/20	KM	Planning for urgent diligence needs re: project Catalyst.	0.70
08/18/20	ADD	Call with D. Lojac, C. Robertson, E. Diggs (all Davis Polk), K. McCarthy, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), A. DePalma and J. DelConte (both AlixPartners) re: material contract review.	0.80
08/18/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.30
08/18/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re:Catalyst operations and supply chain diligence.	0.30
08/18/20	ADD	Review liquidation analysis and draft assumption for various accounts.	1.70
08/18/20	NAS	Build roll-up tabs for 2.0 Mundipharma base case.	0.90
08/18/20	NAS	Incorporate adjustments to original Management Revisions data in Mundipharma business plan model.	1.30
08/18/20	NAS	Compare product/market-level COGS figures across Base and Management cases in Mundipharma business plan model.	1.80
08/18/20	NAS	Calls with G. Koch, N. Simon (both AlixPartners) to review initial draft of new Mundipharma Base Case.	0.90
08/18/20	NAS	Compare product/market-level S&P figures across Base and Management cases in Mundipharma business plan model.	2.40
08/18/20	NAS	Finalize revised cost structure for inclusion in Mundipharma Base Case.	0.80
08/18/20	GJK	Calls with G. Koch, N. Simon (both AlixPartners) to review initial draft of new Mundipharma Base Case.	0.90
08/18/20	GJK	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: weekly update and go forward planning call.	
08/18/20	GJK	Review open diligence items and Mundipharma responses, plan for business review updates based on revised timetable from Mundipharma.	2.50
08/18/20	GJK	Walkthrough of model revisions and open items for slide updates.	2.00
08/18/20	GJK	Review non-top 15 market product breakouts from Mundipharma.	2.00
08/18/20	LJD	Call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. DelConte, L. Donahue, H. Bhattal, G. Koch (all AlixPartners) re: weekly update and go forward planning call.	0.80
08/19/20	LJD	Review correspondence between debtors counsel and committee counsel	0.50
08/19/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review latest drafts of Mundipharma 2.0 Base Case.	1.10
08/19/20	GJK	Review and assess variances between Mundipharma models and potential next steps.	2.50
08/19/20	NAS	Apply adjustments from Mundipharma 1.0 model to base case in 2.0 model.	1.10
08/19/20	NAS	Investigate variances between management and base cases from Mundipharma 1.0 and 2.0 models.	1.70
08/19/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review latest drafts of Mundipharma 2.0 Base Case.	1.10
08/19/20	NAS	Analyze large journal entries included in Mundipharma source data.	1.30
08/19/20	NAS	Implement risk adjustments to Base Case in Mundipharma 2.0 model.	3.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/19/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	0.40
08/19/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners), re: date room and pending approvals.	0.50
08/19/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne, P. Strassburger, B. Koch (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, (both Skadden) re: project Catalyst MSA review.	2.00
08/19/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: date room and pending approvals.	0.50
08/19/20	KM	VDR and diligence tracking updates re: project Catalyst.	0.60
08/19/20	KM	Call with J. Doyle (Purdue) re: legal changes to support ACP document for Catalyst.	0.60
08/19/20	KM	Planning for urgent diligence needs re: project Catalyst.	0.30
08/19/20	KM	Analysis re: ACP anonymity for project Catalyst API and FD suppliers.	1.20
08/19/20	JD	Review and provide comments to management on the draft Board slides re: Adhansia and Opioid update.	2.20
08/19/20	JD	Review PJT edits and comments to draft Board slides.	0.30
08/19/20	JD	Review and check LTRP performance and pro forma calculations from J. Lowne and C. DiStefano (both Purdue).	0.80
08/19/20	JD	Review final responses to AHC OxyContin diligence questions prior to the call.	0.30
08/19/20	JD	Review Xtampza IMS data to be provided to the committee.	0.40
08/19/20	JD	Correspondence with R. Aleali (Purdue) and Skadden re: sales by state and managed care renewals.	0.40
08/19/20	JD	Review letter from the UCC to mediation parties and the	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		corresponding distributable value calculations.	
08/19/20	JD	Bridge UCC distributable value calculations back to updated business plan materials provided to date.	0.70
08/19/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.40
08/19/20	KM	Analysis and ACP map diligence document re: project Catalyst.	0.80
08/19/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst weekly status updates.	0.70
08/19/20	KM	Analysis and coordination re: outstanding diligence requests.	1.10
08/20/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.30
08/20/20	KM	Update and manage VDR tracker and Intralinks re: project Catalyst.	0.60
08/20/20	KM	Call with D. Fogel (Purdue) re: APA issues.	0.10
08/20/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners), re: diligence status update.	0.20
08/20/20	KM	Analysis for third party mapping re: project Catalyst.	0.70
08/20/20	KM	Analysis and response re: ACP mapping for Catalyst.	1.10
08/20/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review cont'd.	2.00
08/20/20	KM	Update and refresh diligence tracking and management re: project Catalyst.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/20/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: MSA review.	1.10
08/20/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review.	1.50
08/20/20	KM	Analysis re: proposed changes to terms in MSA from bidders.	0.60
08/20/20	JD	Review LTRP and AIP details from Purdue HR for purposes of KEIP/KERP calculations.	1.60
08/20/20	JD	Review correspondence from PJT and management re: bridge of April business plan to latest business plan refresh with respect to total distributable value.	0.50
08/20/20	JD	Review insurance recovery presentation from Gilbert.	0.80
08/20/20	JD	Update latest professional fee tracker and forecast for 2020	0.30
08/20/20	JD	Review revised draft Board slides prior to finalizing and sending them out as prereads.	0.60
08/20/20	JD	Review potential materials to provide to shareholder's re: updated business plan. Correspondence re: same.	0.70
08/20/20	JD	Correspondence with management and PJT re: OxyContin AG modeling in Rhodes forecast.	0.40
08/20/20	JD	Call with J. Lowne (Purdue) re: business plan refresh and Project Catalyst.	0.30
08/20/20	JD	Call with J. Turner, T. Melvin (both PJT), H. Bhattal, J. DelConte (both AlixPartners) re: Adhansia planning.	0.40
08/20/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.30
08/20/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners),	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: diligence status update.	
08/20/20	HSB	Call with J. Turner, T. Melvin (both PJT), H. Bhattal, J. DelConte (both AlixPartners) re: Adhansia planning.	0.40
08/20/20	NAS	Build roll-up and check functionality for standalone cases in Mundipharma business plan model and review takeaways.	1.70
08/20/20	NAS	Send follow-up diligence question re: Mundipharma budget journal entries to Huron/Mundipharma.	0.30
08/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: priorities for revisions to Mundipharma business plan model and diligence report.	0.50
08/20/20	NAS	Incorporate revised allocations to build product category standalone P&Ls in Mundipharma business plan model.	2.70
08/20/20	NAS	Analyze line item detail underlying revised Mundipharma business plan model variances.	2.40
08/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: priorities for revisions to Mundipharma business plan model and diligence report.	0.50
08/20/20	GJK	Assess risk adjustment impact on base case.	2.50
08/20/20	GJK	Review prior Mundipharma working capital information for potential changes to revised model.	2.40
08/20/20	GJK	Review corporate/non-commercial entity charges and variances to previous model.	2.00
08/20/20	LJD	Call with Ken Buckfire RE: case update.	0.40
08/21/20	LJD	Review and comment on response to fee examiner	0.50
08/21/20	LJD	Review and comment on response letter for mediation parties	0.30
08/21/20	GJK	Review updates to model product category projections.	2.00
08/21/20	GJK	Plan for report revisions based on current diligence status	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and model updates.	
08/21/20	NAS	Build check functionality for Base/Adjusted cases of Mundipharma business plan model.	2.40
08/21/20	NAS	Compare new Mundipharma Base/Adjusted standalone cases with prior iteration of model and note takeaways.	0.80
08/21/20	ADD	Call with M. Florence, J. Bragg (both Skadden), T. Melvin, G. Sim (both PJT), J. DelConte, A. DePalma (both AlixPartners), W. Shank, R. Aleali, M. Kesselman (all Purdue) re: managed care contracts.	0.80
08/21/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/21/20	JD	Correspondence with management and Davis Polk re: suboxone donations.	0.60
08/21/20	JD	Review initial Betadine Gargle store list and sales date.	0.30
08/21/20	JD	Review final mediation letter sent to all parties in response to the UCC letter.	0.30
08/21/20	JD	Call with M. Florence, J. Bragg (both Skadden), T. Melvin, G. Sim (both PJT), J. DelConte, A. DePalma (both AlixPartners), W. Shank, R. Aleali, M. Kesselman (all Purdue) re: managed care contracts.	0.80
08/21/20	JD	Call with C. DeStefano (Purdue) re: KEIP/KERP calculations.	0.50
08/21/20	JD	Review draft mark-ups re: Project Catalyst materials.	1.20
08/21/20	JD	Review correspondence from PJT and Davis Polk re: distributable value bridge.	0.70
08/21/20	KM	Analysis of shared services and intercompany transactions re: project Catalyst.	1.40
08/21/20	KM	Analysis of supply agreements and payables re: project Catalyst.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/21/20	KM	Analysis and review of shared services re: project Catalyst.	0.90
08/21/20	KM	Analysis and responses re: environmental diligence inquiries.	0.60
08/21/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/21/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), diligence team re: APA/MSA submission review.	1.50
08/21/20	KM	Prepare for APA/MSA submission review.	0.20
08/21/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA review.	0.80
08/21/20	KM	Analysis and coordination re: outstanding diligence requests.	0.70
08/22/20	JD	Correspondence with PJT re: Opioid only scenario wind down costs.	0.40
08/23/20	JD	Call with E. Vonnegut (Davis Polk) re: Suboxone donations.	0.20
08/23/20	JD	Correspondence with PJT re: Avrio business plan.	0.20
08/24/20	JD	Call with R. Aleali (Purdue) re: donations.	0.40
08/24/20	JD	Correspondence with management re: analysis of potential donations. Review cost benefit analysis of donation and underlying reasoning.	0.60
08/24/20	JD	Correspondence with team re: pension assumptions.	0.30
08/24/20	JD	Correspondence with Province re: E&Y expansion of services.	0.20
08/24/20	JD	Correspondence with J. Lowne and M. Kesselman (both	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue) re: Nalmafene reporting.	
08/24/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	1.50
08/24/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.40
08/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: analysis of supply contracts.	1.10
08/24/20	ADD	Meeting with D. Fogel (Purdue), A. DePalma K. McCafferty (AlixPartners) re: PO-SOW-Contracts for RT used by RP or PPLP.	1.60
08/24/20	KM	Meeting with D. Fogel (Purdue), A. DePalma K. McCafferty (AlixPartners) re: PO-SOW-Contracts for RT used by RP or PPLP.	1.60
08/24/20	KM	Analysis re: procurement spend for TTM, 2018 and 2019 for project Catalyst.	2.40
08/24/20	KM	Analysis re: consolidation of all RT agreements and match to SAP spend analysis.	1.60
08/24/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	0.40
08/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: analysis of supply contracts.	1.10
08/24/20	KM	Analysis re: supply content tracking for project Catalyst.	0.20
08/24/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Meeting	
08/24/20	KM	Analysis re: top suppliers and customers for 2018/2019 re: project Catalyst schedule and reps requirements.	2.10
08/24/20	NAS	Review new Purdue diligence files uploaded to data room.	0.50
08/24/20	NAS	Review new standalone P&Ls for Base Case with Risk Adjustments.	0.80
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review new Mundipharma Base Case with Risk Adjustments.	0.80
08/24/20	NAS	Review changes to consolidated P&L between first and second iterations of Mundipharma business plan model and identify drivers.	2.60
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review changes in consolidated Mundipharma P&L from first to second iteration of business plan model.	0.80
08/24/20	NAS	Analyze product-level changes between first and second iteration of Mundipharma business plan model and identify drivers.	2.10
08/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review changes in Mundipharma Analgesics standalone P&L from first to second iteration of business plan model.	0.60
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review new Mundipharma Base Case with Risk Adjustments.	0.80
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review changes in consolidated Mundipharma P&L from first to second iteration of business plan model.	0.80
08/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review changes in Mundipharma Analgesics standalone P&L from first to second iteration of business plan model.	0.60
08/24/20	GJK	Review of Malta 2.0 variances with direct allocations.	2.00
08/24/20	GJK	Review Mundipharma model updates.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/24/20	GJK	Plan and coordinate for Mundipharma diligence.	1.00
08/25/20	GJK	Assess Mundipharma product category P&Ls.	2.00
08/25/20	GJK	Review variances in product categories based on Mundipharma June model.	2.50
08/25/20	GJK	Discussions with G. Koch, N. Simon (both AlixPartners) to review detailed reconciliations across first and second iterations of Mundipharma management forecasts.	2.30
08/25/20	LJD	Review and comment on Oxy and adhansia slides for board presentation	0.70
08/25/20	NAS	Compare and conform allocation methodology across first and second iterations of Mundipharma business plan model.	1.30
08/25/20	NAS	Discussions with G. Koch, N. Simon (both AlixPartners) to review detailed reconciliations across first and second iterations of Mundipharma management forecasts.	2.30
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Net Sales line.	1.20
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Cost of Sales line.	1.80
08/25/20	NAS	Build detailed bridge from first and second iterations of Mundipharma management forecasts for Other Revenue and Royalties Receivable lines.	0.80
08/25/20	KM	Meeting with D. Fogel, R. Shamblen, D. Lundie, J. Lowne (all Purdue), R. Schnitzler (PJT) re: inventory plans and impact on credit for Catalyst.	0.50
08/25/20	KM	Analysis re: RT inventory valuation by type for project Catalyst.	0.20
08/25/20	KM	Call with R. Shamblen (Purdue) re: technology transfer requirements for product portfolio.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/25/20	KM	Analysis re: API-product qualification mapping and planning for project Catalyst.	0.60
08/25/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.20
08/25/20	KM	Analysis re: RT inventory valuation by type for project Catalyst.	0.20
08/25/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: Catalyst proposals review.	3.00
08/25/20	KM	Update diligence tracking and analyses re: project Catalyst.	0.40
08/25/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.10
08/25/20	KM	Analysis re: Rhodes Tech agreements for Catalyst.	0.30
08/25/20	KM	Call with D. Fogel (Purdue), J. Carlisle (Purdue) re: Wilson purchasing per Rhodes Technologies agreements.	0.70
08/25/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg, M. Sumner (all Skadden) re: Catalyst supply agreement.	0.50
08/25/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting	1.00
08/25/20	KM	Review and gap analysis re: environmental diligence requests for project Catalyst.	0.90
08/25/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/25/20	ADD	Call A. DePalma, J. DelConte (both AlixPartners), R. Aleali, B. Miller (both Purdue), C. Robertson (Davis Polk), and Skadden team re: Purdue Material contract analysis.	1.00
08/25/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting	1.00
08/25/20	JD	Review pre-read slides in advance of Board meeting on Thursday.	1.00
08/25/20	JD	Call A. DePalma, J. DelConte (both AlixPartners), R. Aleali, B. Miller (both Purdue), C. Robertson (Davis Polk), and Skadden team re: Purdue Material contract analysis.	1.00
08/26/20	JD	Call with R. Aleali (Purdue) re: material contracts.	0.30
08/26/20	JD	Call with J. Lowne, R. Aleali (both Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, C. Robertson, S. Brecher, J. Crandall (all Davis Polk) re: pension plan assumptions and status.	0.40
08/26/20	JD	Prepare and provide draft responses to various questions from the monitor on the June flash report.	1.80
08/26/20	JD	Correspondence with Davis Polk re: questions from Province on the KEIP/KERP proposal.	0.50
08/26/20	JD	Correspondence with management and Davis Polk re: old license agreement diligence questions.	0.40
08/26/20	JD	Review Intellipharmaceutics IPD Analytics report prior to sharing with creditors.	0.30
08/26/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/26/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		contract analysis.	
08/26/20	KM	Analysis of Rhodes Tech MSA re: contracts sharing between PPLP entities.	0.40
08/26/20	KM	Call with third party re: shared services diligence inquiries.	0.40
08/26/20	KM	Meeting with T. Delehant, D. Fogel (both Purdue) re: Rhodes Pharma tech transfer requirements for project Catalyst.	0.80
08/26/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: APA/MSA review.	1.50
08/26/20	KM	Call with D. Fogel (Purdue) , J. Lowne (Purdue), R. Schnitzler (PJT) re: project Catalyst proposal savings review for PPLP Board meeting.	0.50
08/26/20	KM	Analysis re: transition services for project Catalyst.	1.00
08/26/20	KM	Call with R. Schnitzler (PJT) and third party re: APA and MSA feedback for project Catalyst.	0.50
08/26/20	KM	Analysis re: inventory transition planning for project Catalyst.	0.40
08/26/20	KM	Call with D. Fogel (Purdue) re: inventory valuation for APA.	0.60
08/26/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
08/26/20	KM	Analysis re: environmental due diligence inquiries.	0.60
08/26/20	KM	Analysis, documentation and review re: APA rep Section 3.21 for project Catalyst.	1.70
08/26/20	KM	Analysis re: quality agreements currently in place.	0.50
08/26/20	KM	Virtual working session with A. DePalma and K.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners), re: Project Catalyst contract analysis.	
08/26/20	NAS	Build detailed reconciliations across Mundipharma management forecasts for Deductions line items.	1.50
08/26/20	NAS	Build detailed reconciliations across Mundipharma management forecasts for Selling & Promotion, Medical Affairs, and General & Administrative line items.	1.70
08/26/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review detailed management forecast variance for Analgesics segment.	0.40
08/26/20	NAS	Review new diligence files uploaded to Purdue data room.	0.40
08/26/20	NAS	Finalize detailed reconciliation file covering different versions of Mundipharma management forecasts.	1.10
08/26/20	NAS	Add toggle functionality for Journal entries to Mundipharma business plan model.	1.30
08/26/20	NAS	Build summary variances between versions of Mundipharma management forecasts for all individual product categories.	1.10
08/26/20	GJK	Review product category variances and bridge to Malta 1.0 and May Management Case.	2.00
08/26/20	GJK	Review Management Revisions responses to diligence questions.	1.00
08/26/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review detailed management forecast variance for Analgesics segment.	0.40
08/26/20	GJK	Review Mundipharma variances and open questions, planning for report update.	2.00
08/27/20	GJK	Review Mundipharma variances and potential adjustments to base cases.	2.00
08/27/20	GJK	Discussions with G. Koch, N. Simon (both AlixPartners) to	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		review Mundipharma management forecast product category variances and note takeaways.	
08/27/20	GJK	Assess risk adjustment shifts based on product category variances.	2.50
08/27/20	LJD	Review agenda and board materials	0.30
08/27/20	LJD	Partial participation in PPI board meeting.	4.20
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for Cost of Sales line item.	1.30
08/27/20	NAS	Discussions with G. Koch, N. Simon (both AlixPartners) to review Mundipharma management forecast product category variances and note takeaways.	1.60
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for Selling & Promotion line item.	0.90
08/27/20	NAS	Build product category and region-level breakdowns of variance between Mundipharma management forecasts for General & Administrative line item.	1.40
08/27/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status.	0.20
08/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst supply agreement discussion.	1.70
08/27/20	KM	Analysis and document summary re: environmental due diligence requests and reporting for Catalyst.	1.50
08/27/20	KM	Participation in PPLP Board Meeting re: project Catalyst update.	1.00
08/27/20	KM	Analysis and document creation re: APA Schedule A amendments.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/27/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/27/20	KM	Call with D. Fogel (Purdue) re: PPLP and Rhodes Pharma tech transfer planning for Catalyst transition.	0.30
08/27/20	KM	Analysis re: environmental due diligence inquiries.	0.20
08/27/20	KM	Analysis re: PPLP and Rhodes Pharma tech transfer planning for Catalyst transition.	1.10
08/27/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.30
08/27/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status.	0.20
08/27/20	ADD	Analyze material Purdue agreements and create a tracker for client review.	2.50
08/27/20	JD	Participate in PPI Board meeting.	5.00
08/27/20	JD	Review Board pre-reads prior to Board meeting.	0.50
08/27/20	JD	Call with R. Schnitzler (PJT) re: Project Catalyst.	0.30
08/27/20	JD	Correspondence with Davis Polk re: UCC KEIP/KERP requests.	0.40
08/27/20	JD	Review validation files from D. Warren (Purdue) re: compensation arrangement information.	0.30
08/27/20	JD	Review initial draft list of material contracts from A. DePalma (AlixPartners). Make edits and provide comments re: same.	0.60
08/27/20	JD	Review updated bridge analyses from management for the fully updated business plan refresh.	1.00
08/28/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/28/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP declaration.	0.40
08/28/20	JD	Call with J. O'Connell, J. Turner, R. Schnitzler (all PJT) and M. Cola (Board member) re: business plan refresh follow ups.	0.60
08/28/20	JD	Begin work on pulling together a summary wage file that includes all historical wage information as well as future AIP/LTRP/Retention payments by employee per UCC request.	2.80
08/28/20	JD	Finalize pulling together initial draft comprehensive wage tracker in response to UCC request.	1.90
08/28/20	JD	Correspondence with Davis Polk and PJT re: request for updated financial projection information from the NCSG. Review materials posted to the data room to be responsive.	0.60
08/28/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/28/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: material agreements.	0.20
08/28/20	ADD	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	3.10
08/28/20	KM	Analysis edits and review re: MSA and APA for third party negotiations.	0.90
08/28/20	KM	Analysis re: materials agreements for project Catalyst.	1.10
08/28/20	KM	Call M. Gibson, A. Gallogly (both Skadden), J. Doyle, E. Ruta, K. McCarthy (all Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Catalyst contracts Schedule Meeting	3.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/28/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: material agreements.	0.20
08/28/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.30
08/28/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
08/28/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst update.	1.00
08/28/20	NAS	Revise Mundipharma model to incorporate Foundation product terminology to product/region/market metrics.	1.30
08/28/20	LJD	Debrief call with Ken Buckfire (board member) following PPI board meeting.	0.40
08/28/20	GJK	Review Mundipharma responses to country diligence questions.	0.30
08/28/20	GJK	Review open diligence questions.	1.00
08/28/20	GJK	Walkthrough of latest Mundipharma updated model.	2.00
08/28/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
08/29/20	KM	Analysis re: API pricing schedules for APA.	0.30
08/29/20	KM	Debrief session with D. Lundie, J. Lowne, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), and third party diligence team re: project Catalyst discussion.	1.50
08/29/20	KM	Call with D. Lundie (Purdue), J. Lowne, K. McCarthy (Purdue), R. Schnitzler (PJT), M. Gibson (Skadden), and third party re: project Catalyst APA and MSA negotiations.	1.00
08/29/20	KM	Analysis re: API pricing schedules for APA.	0.10
08/29/20	KM	Call with D. Lundie (Purdue), J. Lowne, K. McCarthy	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(Purdue), R. Schnitzler (PJT), M. Gibson (Skadden) re: project Catalyst prep call for third party discussion.	
08/29/20	ADD	Review and update project Catalyst contract materiality analysis in preparation for client review.	1.60
08/30/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis review.	0.80
08/30/20	JD	Review and eddit draft employee wage tracker given comments from management.	0.70
08/30/20	JD	Correspondence with management re: open KEIP / KERP items.	0.50
08/30/20	KM	Analysis re: API pricing schedules for APA.	0.40
08/30/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract analysis review.	0.80
08/31/20	KM	Analysis and coordination re: outstanding diligence requests.	0.50
08/31/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: Catalyst document review.	1.40
08/31/20	KM	Analysis re: MSA pricing.	0.60
08/31/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
08/31/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies agreements.	1.70
08/31/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting.	
08/31/20	KM	Analysis re: supply agreements for project Catalyst.	0.90
08/31/20	KM	Review details of project Catalyst materials contracts.	0.90
08/31/20	KM	Analysis re: transition services and transfer costs for project Catalyst.	1.10
08/31/20	KM	Analysis re: quota and inventory management and scenarios re: project Catalyst.	0.70
08/31/20	KM	Call with R. Schnitzler (PJT) re: transition services net costs for project Catalyst.	0.30
08/31/20	KM	Analysis re: WIP inventory valuation for transfer to third party.	0.40
08/31/20	KM	Analysis re: employee retention for project Catalyst proposal.	0.90
08/31/20	KM	Analysis re: proposed retention by third party by role.	0.40
08/31/20	JD	Review and edit latest wage tracker for latest information. Send around to internal group for review.	0.60
08/31/20	JD	Prepare attrition analysis for J. Lowne (Purdue).	1.10
08/31/20	JD	Review updated compensation validation files from D. Warren (Purdue).	0.70
08/31/20	JD	Update source files and wage tracker for comments from C. DeStefano (Purdue). Correspondence with C. DeStefano (Purdue) re: same.	1.70
08/31/20	JD	Review and edit final material contract analysis from A. DePalma (AlixPartners). Send around to internal Purdue group for review and discussion.	0.60
08/31/20	JD	Review analysis of historical termed employees from Purdue from 2017 to present. Cross reference against existing analyses and review for omissions. Correspondence with Purdue HR team re: same.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
08/31/20	JD	Correspondence with D. Consla (Davis Polk) re: KEIP/KERP motion and outstanding diligence items.	0.40
08/31/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
08/31/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: Catalyst contracts Schedule Meeting.	0.60
08/31/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies agreements.	1.70
08/31/20	HSB	Reviewed UCC letter to Judge Drain regarding discovery undertaken by the UCC.	0.30
08/31/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) to review variances between Base Cases in different versions of Mundipharma model and key drivers.	2.40
08/31/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) to review changes in projected Mundipharma Selling & Promotion expense and underlying methodology.	2.80
08/31/20	GJK	Review of Mundipharma Sales and Promotion drivers.	1.80
08/31/20	GJK	Update commentary for Mundipharma consolidated bridge.	0.50
08/31/20	GJK	Review of updates EBITDA drivers in Mundipharma model.	1.00
08/31/20	NAS	Review new Mundipharma diligence responses provided by Huron.	0.40
08/31/20	NAS	Build consolidated Base Case to Base Case variance across first and second iteration of Mundipharma models.	0.60
08/31/20	NAS	Draft guide to drivers of Base Case to Base Case	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		variances between versions of Mundipharma models.	
08/31/20	NAS	Revise S&P in Mundipharma Base Case to project based on variable methodology (as opposed to fixed).	0.90
08/31/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to review variances between Base Cases in different versions of Mundipharma model and key drivers.	2.40
08/31/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to review changes in projected Mundipharma Selling & Promotion expense and underlying methodology.	2.80
09/01/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: projected Selling & Promotion expense in Mundipharma Base Case.	1.30
09/01/20	NAS	Analyze region- and product-level drivers behind Marketing expense change across Mundipharma forecasts.	1.30
09/01/20	NAS	Review new diligence responses provided by Huron/Mundipharma.	0.50
09/01/20	NAS	Review revised Mundipharma business plan model for accuracy and completeness.	1.00
09/01/20	NAS	Build P&L variance analysis for Mundipharma Risk-Adjusted Base Cases.	0.80
09/01/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: proposed risk adjustments to Mundipharma Base Case.	1.00
09/01/20	NAS	Revise Mundipharma business plan risk adjustments to align with latest findings and updated forecasts.	3.30
09/01/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: proposed risk adjustments to Mundipharma Base Case.	1.00
09/01/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: projected Selling & Promotion expense in Mundipharma Base Case.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/01/20	GJK	Review Mundipharma model variances and adjustments.	2.00
09/01/20	GJK	Review Mundipharma diligence responses to support model adjustments.	2.50
09/01/20	ADD	Call with E. Vonnegut, W. Taylor, A. Lele, C. Robertson (Davis Polk) R. Aleali, K. McCarthy, B. Miller (Purdue), T. Melvin (PJT), A. DePalma, J. DelConte (both AlixPartners) re: trust transfer process.	1.20
09/01/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
09/01/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status.	0.70
09/01/20	JD	Call with J. Lowne (Purdue) re: attrition rates.	0.10
09/01/20	JD	Call with J. Lowne, R. Aleali, C. DeStefano, K. Laurel (all Purdue), E. Vonnegut, D. Consola, S. Brecher (all Davis Polk), D. Sims, S. Hinden (both Willis Towers Watson) re: KEIP/KERP.	0.50
09/01/20	JD	Call with E. Vonnegut, W. Taylor, A. Lele, C. Robertson (Davis Polk) R. Aleali, K. McCarthy, B. Miller (Purdue), T. Melvin (PJT), A. DePalma, J. DelConte (both AlixPartners) re: trust transfer process.	1.20
09/01/20	JD	Review updated employee roster and resignation and terminations information. Prepare analysis to create historical employee rosters.	1.80
09/01/20	JD	Review and edit draft KEIP / KERP motion.	0.80
09/01/20	JD	Finalize initial draft Wage Summary analysis. Tie back historical AIP and LTRP information against source files. Review analysis for employees who have left the company.	3.10
09/01/20	JD	Prepare analysis of LTRP reductions to share with the	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		various creditor advisors.	
09/01/20	JD	Review updated attrition calculations from J. Lowne (Purdue)	0.30
09/01/20	JD	Review status of LTS invoices and correspondence with R. Aleali (Purdue) re: same.	0.50
09/01/20	JD	Correspondence with PJT re: scheduling a call re: Catalyst.	0.20
09/01/20	KM	Analysis re: supply agreements for project Catalyst.	2.10
09/01/20	KM	Analysis and document management re: environmental diligence for Catalyst.	0.80
09/01/20	KM	Analysis re: APA schedules for project Catalyst.	2.50
09/01/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status	0.70
09/01/20	KM	Analysis re: IT agreements and approvals for project Catalyst.	1.70
09/01/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst.	0.40
09/01/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.20
09/01/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Catalyst document review.	0.90
09/01/20	KM	Update diligence requests re: project Catalyst.	0.70
09/02/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies post-petition supply agreements.	1.80
09/02/20	KM	Analysis and document management re: schedules for Catalyst.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/02/20	KM	Analysis re: material supply agreements and spend for project Catalyst.	0.50
09/02/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies IT agreements for assignment.	0.40
09/02/20	KM	Continue analysis re: material supply agreements and spend for project Catalyst.	0.40
09/02/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Catalyst document review.	2.30
09/02/20	KM	Call with D. Fogel (Purdue) re: material IT agreements transfer status for project Catalyst.	0.40
09/02/20	KM	Analysis re: material IT agreements transfer status for project Catalyst.	0.60
09/02/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: APA review.	1.50
09/02/20	KM	Manage and post materials agreements re: project catalyst.	1.10
09/02/20	JD	Review updated termed employee files from D. Warren (Purdue).	0.50
09/02/20	JD	Review and update employee wage summary file for latest information from the company.	1.70
09/02/20	JD	Call with R. Schnitzler, J. Turner (both PJT) and third party re: go forward planning.	0.80
09/02/20	JD	Call with J. Turner and R. Schnitzler (both PJT) re: follow up to third party call.	0.30
09/02/20	JD	Correspondence with PJT, Province, FTI, Jefferies and Houlihan re: scheduling a Catalyst call	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/02/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
09/02/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies IT agreements for assignment.	0.40
09/02/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Rhodes Technologies post-petition supply agreements.	1.80
09/02/20	GJK	Review and assess Mundipharma model comparisons.	2.50
09/02/20	GJK	Review S&P adjustments between Mundipharma models.	2.00
09/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustments made to Mundipharma Base Case.	1.00
09/02/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma business plan update materials to be provided to PJT	0.30
09/02/20	LJD	Update call with J. Dubel (Board Member)	0.40
09/02/20	NAS	Review Mundipharma risk-adjusted case for accuracy and comprehensiveness.	1.70
09/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustments made to Mundipharma Base Case.	1.00
09/02/20	NAS	Review new diligence documents provided by Huron/Mundipharma.	0.40
09/02/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma business plan update materials to be provided to PJT	0.30
09/02/20	NAS	Build annotated variances between Base and Risk-Adjusted Cases for first and second iteration of Mundipharma business plan model to share with PJT.	1.80
09/02/20	IA	Review KEIP/KERP analysis and payments by employee detailed file.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/03/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: prep for call with J Turner (PJT).	0.20
09/03/20	NAS	Finalize Mundipharma Risk-Adjusted Case variance analysis to share with PJT.	1.20
09/03/20	NAS	Draft list of key Mundipharma information provided since first iteration of diligence report.	0.30
09/03/20	GJK	Review updated variances by product category in revised Mundipharma model.	1.00
09/03/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: prep for call with J Turner (PJT).	0.20
09/03/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
09/03/20	ADD	Compile SAP data and update liabilities subject to compromise report for August.	1.10
09/03/20	ADD	Call J. DelConte, K. McCafferty, A. DePalma (AlixPartners), R. Schnitzler (PJT) and Creditor Committee members re: Project Catalyst.	0.50
09/03/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: materials agreements and excluded contracts for schedules.	0.20
09/03/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: RT/RP agreements.	2.50
09/03/20	HSB	Review KEIP/KERP motion.	0.40
09/03/20	JD	Call with J. Lowne (Purdue) re: team call follow-up.	0.50
09/03/20	JD	Call with J. Lowne, E. Ruiz, S. Danil (all Purdue) re: contract analysis.	0.50
09/03/20	JD	Call with R. Schnitzler, J. Turner, T. Melvin (all PJT), M. Atkinson (Province), M. Diaz, B. Bromberg (both FTI), L.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Szlenzinger (Jefferies), G. Coutts, H. Schenk (Houlihan), J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Catalyst update.	
09/03/20	JD	Review draft professional fees for August accruals.	0.40
09/03/20	KM	Analyze and edit APA and MSA schedule re: Catalyst.	1.90
09/03/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: RT/RP agreements.	2.50
09/03/20	KM	Updates and analysis re: project Catalyst APA and MSA supporting documents.	2.60
09/03/20	KM	Call with D. Fogel (Purdue) re: RT employee retention.	0.30
09/03/20	KM	Analysis and document creation re: Catalyst agreement schedules.	1.90
09/03/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta (Purdue), K. McCarthy (Purdue), K. McCafferty, A. DePalma (AlixPartners) re: materials agreements and excluded contracts for schedules.	0.20
09/03/20	KM	Analysis re: RT/RP agreements.	0.10
09/03/20	KM	Advisors call with J. DelConte (AlixPartners), R. Schnitzler (PJT), Jeffries, FTI, HL re: project Catalyst.	0.50
09/03/20	KM	Analysis re: RT/RP agreements.	0.40
09/03/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
09/03/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) re: supply agreements schedules review.	0.10
09/03/20	KM	Analysis re: employee retention costs.	0.60
09/03/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: document and negotiations review.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/03/20	KM	Call with D. Fogel (Purdue) re: analysis of offered employees.	0.30
09/04/20	KM	Analysis re: COVID pay premium for RT employees.	0.40
09/04/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review.	1.60
09/04/20	KM	Analysis re: COVID pay premium for RT employees.	1.10
09/04/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status.	0.20
09/04/20	KM	Analysis and updates re: project Catalyst schedules and exhibits.	1.70
09/04/20	KM	Meeting with D. Lundie, K. McCarthy, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst call debrief.	0.80
09/04/20	KM	Call with R. Aleali (Purdue) re: compensation schedules and VDR files for Catalyst.	0.30
09/04/20	KM	Analysis re: supply agreements for Catalyst.	0.50
09/04/20	KM	Call with R. Shamblen (Purdue) and A. Gallogly (Skadden) re: APA schedules for project Catalyst.	0.50
09/04/20	KM	Call with J. Lowne (Purdue) and R. Schnitzler (PJT) re: COVID pay premium programmed.	0.20
09/04/20	KM	Respond and update schedules re: project Catalyst.	1.10
09/04/20	KM	Analysis re: cure costs and RT purchases for project Catalyst.	2.40
09/04/20	KM	Manage and edit schedules and file for VDR re: project Catalyst.	1.20
09/04/20	KM	Call with R. Schnitzler (PJT), Project Catalyst diligence team re: COVID pay premium and other updates.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/04/20	JD	Update professional fee accruals for June and July.	0.40
09/04/20	JD	Review and provide comments to the latest Lowne declaration re: KEIP.	0.80
09/04/20	JD	Calculate pre-2018 performance amounts for Insiders.	0.60
09/04/20	JD	Discussion with D. Sims (Willis Towers) re: KEIP/KERP motion.	0.90
09/04/20	JD	Discussion with J. Lowne (Purdue) re: KEIP/KERP reductions.	0.30
09/04/20	JD	Correspondence with Davis Polk re: comments on the latest KEIP/KERP motions and declaration.	0.80
09/04/20	JD	Update the wage summary analysis to capture additional LTRP participants. Correspondence with Province re: same.	1.30
09/04/20	JD	Correspondence with K. Laurel (Purdue) re: remote working. Review employee roster re: same.	0.40
09/04/20	JD	Correspondence with J. Lowne (Purdue) re: LTRP reduction analysis.	0.70
09/04/20	JD	Mark-up of the latest KEIP motion and send out to the group.	0.60
09/04/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence status.	0.20
09/04/20	ADD	Compile SAP data and update liabilities subject to compromise report for August.	2.60
09/04/20	GJK	Call with J Turner (PJT) re: Mundipharma model updates, include prep time.	0.50
09/05/20	JD	Correspondence with C. DeStefano (Purdue) and D. Consla (Davis Polk) re: KEIP/KERP questions.	0.30
09/06/20	JD	Correspondence with R. Aleali (Purdue) re: material contract review.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/06/20	JD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules.	0.60
09/06/20	JD	Mark-up of the latest version of the Lowne declaration re: KEIP.	0.70
09/06/20	JD	Discussion with M. Huebner (Davis Polk) re: KEIP motion.	0.10
09/06/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules.	0.60
09/07/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules.	1.30
09/07/20	ADD	Meeting with K. McCafferty, A. DePalma (both AlixPartners), D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review.	0.50
09/07/20	ADD	Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: prorated expenses and cure costs for Catalyst.	0.50
09/07/20	KM	Analysis re: RT 2020 purchases and agreements for project Catalyst.	1.60
09/07/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APA and MSA schedules.	1.30
09/07/20	KM	Meeting with K. McCafferty, A. DePalma (both AlixPartners), D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: Project Catalyst document and negotiations review.	0.50
09/07/20	KM	Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		K. McCafferty (AlixPartners) re: prorated expenses and cure costs for Catalyst.	
09/07/20	KM	Analysis re: APA prorated expenses.	0.30
09/07/20	KM	Call with R. Schnitzler (PJT) re: employee compensation for project Catalyst.	0.10
09/07/20	KM	Analysis re: open RT POs.	1.80
09/07/20	KM	Coordinate and update VDR and supplier contracts re: project Catalyst.	2.00
09/07/20	JD	Analyze break down of compensation agreements by company.	1.10
09/07/20	JD	Correspondence with M. Atkinson (Province) re: KEIP/KERP diligence questions.	0.40
09/07/20	JD	Correspondence with Davis Polk and Purdue re: Project Catalyst.	0.50
09/07/20	JD	Correspondence with Davis Polk and Willis Towers Watson re: open diligence questions from FTI and Province.	0.60
09/07/20	LJD	Review prereads for board meeting	1.20
09/08/20	LJD	Participate in PPI Board meeting including L. Donahue and J. DelConte (both AlixPartners) in attendance.	1.10
09/08/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma business plan model and plan priorities for week.	0.80
09/08/20	GJK	Plan and coordinate for updating Mundipharma final report.	2.50
09/08/20	GJK	Review Mundipharma model variances and potential updates to report.	2.80
09/08/20	GJK	Review strong opioids across markets.	2.00
09/08/20	NAS	Add downside case to Mundipharma business plan model.	1.20
09/08/20	NAS	Draft cover note for Mundipharma business plan model	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and share materials with PJT.	
09/08/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review latest draft of Mundipharma business plan model and plan priorities for week.	0.80
09/08/20	NAS	Implement final revisions to Mundipharma business plan model prior to sharing with PJT.	2.00
09/08/20	JD	Participate in PPI Board meeting including L. Donahue and J. DelConte (both AlixPartners) in attendance.	1.10
09/08/20	JD	Call with J. Lowne (Purdue) re: Project Catalyst.	0.30
09/08/20	JD	Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst.	0.50
09/08/20	JD	Correspondence with Davis Polk and PJT re: long term bonuses and Project Catalyst.	0.30
09/08/20	JD	Review latest draft of the APA and Supply Agreement for Project Catalyst.	1.00
09/08/20	JD	Review latest draft Project Catalyst sale order.	0.60
09/08/20	JD	Correspondence with Davis Polk, Willis Towers Watson and Province re: open KEIP/KERP questions.	0.80
09/08/20	JD	Correspondence with Davis Polk re: getting Project Catalyst and KEIP/KERP documents uploaded to the dataroom.	0.40
09/08/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence questions review.	0.20
09/08/20	KM	Call with D. Fogel (Purdue) re: Project Catalyst deal analysis and bridge to April 2020 business plan.	1.10
09/08/20	KM	Analysis re: volume and pricing impact of Catalyst offer versus April 2020 budget.	0.90
09/08/20	KM	Meeting with J. Doyle, D. Fogel, E. Ruta, K. McCarthy (all Purdue), A. Gallogly, M. Gibson, M. Sumner, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both AlixPartners) re: Catalyst schedules.	
09/08/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: vendor activities associated with cure costs.	0.70
09/08/20	KM	Analysis re: project Catalyst savings.	0.50
09/08/20	KM	Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Cure Costs Discussion.	0.40
09/08/20	KM	Review re: outstanding purchases and cure costs for project Catalyst.	0.70
09/08/20	KM	Call with J. Lowne (Purdue) re: cure costs for Catalyst.	0.10
09/08/20	KM	Analysis re: outstanding purchases and cure costs for project Catalyst.	1.70
09/08/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
09/08/20	KM	Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst.	0.50
09/08/20	KM	Analysis re: open RT POs.	1.80
09/08/20	ADD	Compile, review and request approval to upload document to the Project Catalyst data room.	2.10
09/08/20	ADD	Meeting with K. McCafferty, J. DelConte and A. DePalma (all AlixPartners) re: cure costs for project Catalyst.	0.50
09/08/20	ADD	Meeting with W. DiNicola, D. Fogel, (Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Cure Costs Discussion.	0.40
09/08/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence questions review.	0.20
09/08/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re:	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/08/20	ADD	Catalyst operations and supply chain diligence.	0.70
09/08/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: vendor activities associated with cure costs.	1.20
09/09/20	ADD	Meeting with J .Doyle, D. Fogel, E. Ruta, K. McCarthy (all Purdue), A. Gallogly, M. Gibson, M. Sumner, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst schedules.	0.90
09/09/20	ADD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst update and document review.	0.40
09/09/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update discussion.	1.40
09/09/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (Purdue), A. DePalma K. McCafferty (AlixPartners) re: re: open POs in SAP and Ariba for Catalyst.	1.90
09/09/20	ADD	Review and compile contracts for external counsel review.	0.40
09/09/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update discussion.	1.20
09/09/20	KM	Analysis and schedule updates re: project Catalyst.	1.30
09/09/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) re: Api pricing versus base case.	0.50
09/09/20	KM	Analysis re: API pricing and volume impact of Catalyst savings.	1.10
09/09/20	KM	Create schedule of critical open RT POs re: project Catalyst.	1.70
09/09/20	KM	Analysis re: open PO data for schedules for Catalyst.	0.60
09/09/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) re: offer	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		versus Base Case analysis for Catalyst.	
09/09/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), A. DePalma (AlixPartners) re: open POs in SAP and Ariba for Catalyst.	1.40
09/09/20	KM	Analysis re: API pricing and volume impact of Catalyst savings.	1.00
09/09/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst update and document review.	0.90
09/09/20	KM	Review of disclosure schedules re: project Catalyst.	0.70
09/09/20	JD	Update employee and compensation trackers in order to capture recent hires.	0.80
09/09/20	JD	Review HRT updates prior to uploading them to the dataroom.	0.80
09/09/20	JD	Meeting with R. Aleali, J. Lowne, E. Ruiz and S. Daniel (all Purdue) re: contract review.	0.60
09/09/20	JD	Call with C. Oluwole (Davis Polk) re: UCC presentation.	0.10
09/09/20	JD	Review Purdue compensation committee presentation.	0.70
09/09/20	JD	Review CTC board resolutions.	0.30
09/09/20	JD	Correspondence with C. DeStefano (Purdue) re: process for updating AIP and LTRP trackers.	0.50
09/09/20	JD	Review list of termed employees and previous bonus payments.	1.00
09/09/20	JD	Review and edit responses from management to various open KEIP/KERP creditor inquiries.	0.50
09/09/20	JD	Review latest WTW declaration to be filed with the KEIP/KERP motion.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/09/20	JD	Review the latest J. Lowne (Purdue) declaration re: KEIP/KERP motion.	0.70
09/09/20	NAS	Respond to diligence question re: Mundipharma Board structure.	0.40
09/09/20	NAS	Prepare for Mundipharma model walk-through with PJT.	0.40
09/09/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner (PJT), and J. Arsic (PJT) to review latest draft of Mundipharma business plan model.	0.70
09/09/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review necessary changes to Key Findings section of draft Mundipharma diligence report.	0.50
09/09/20	NAS	Revise Key Findings section of Mundipharma diligence report per latest model.	1.90
09/09/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review edits to Mundipharma diligence report and note additional changes to be made.	1.30
09/09/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner (PJT), and J. Arsic (PJT) to review latest draft of Mundipharma business plan model.	0.70
09/09/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review necessary changes to Key Findings section of draft Mundipharma diligence report.	0.50
09/09/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review edits to Mundipharma diligence report and note additional changes to be made.	1.30
09/09/20	GJK	Review of Mundipharma slides for updates.	2.50
09/10/20	GJK	Review key findings slides for potential updates.	2.50
09/10/20	GJK	Review prior working capital/cash flows/balance sheet information to plan for updated projections from Mundipharma.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/10/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to walk through risk adjustment slides.	1.20
09/10/20	NAS	Build comparison of Mundipharma 2020 Original Budget to latest forecast for inclusion in diligence report.	1.60
09/10/20	JD	Correspondence with Davis Polk and PJT re: comments on the illustrative settlement cash flow forecast.	0.40
09/10/20	JD	Review presentations presented to the UCC per a Davis Polk request.	0.70
09/10/20	JD	Follow up correspondence with WTW re: open FTI diligence questions on KEIP/KERP.	0.50
09/10/20	JD	Correspondence with PJT re: draft illustrative settlement cash flow forecast.	0.30
09/10/20	JD	Discussion with C. DeStefano (Purdue) re: KERP promo calculation examples.	0.60
09/10/20	JD	Correspondence with PJT and Purdue re: follow-up conversation with M. Burke.	0.30
09/10/20	NAS	Revisions to Mundipharma Business Plan Overview section of diligence report.	2.90
09/10/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to walk through risk adjustment slides.	1.20
09/10/20	NAS	Add individual product P&Ls to latest draft of Mundipharma business plan model.	0.70
09/10/20	KM	Analysis and review re: association of Cure POs to supply agreements for Catalyst.	1.10
09/10/20	KM	Analysis and review re: documentation of supply agreements for schedules.	0.50
09/10/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis.	1.50
09/10/20	KM	Analysis or RT versus RT contracts re: project Catalyst.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/10/20	KM	Meeting with D. Fogel (Purdue) re: Catalyst savings impact over April budget.	0.70
09/10/20	KM	Update savings calculations re: project Catalyst.	0.40
09/10/20	KM	Call with K. McCafferty, R. Sublett (both AlixPartners) re: April Rt closure plan and impact on project Catalyst savings.	0.50
09/10/20	KM	Analysis and savings bridge re: project Catalyst versus April 2020 Budget.	2.30
09/10/20	KM	Call with A. Gallogly (Skadden) re: purchase orders required for project Catalyst.	0.20
09/10/20	KM	Meeting with D. Fogel (Purdue) re: savings bridge from April budget to current catalyst proposal.	0.50
09/10/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel (all Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	1.20
09/10/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (Skadden) re: Catalyst update and document review.	1.00
09/10/20	KM	Analysis API pricing impact re: offer for project Catalyst.	0.90
09/10/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis.	1.50
09/10/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel (all Purdue), A. DePalma K. McCafferty (AlixPartners) re: Catalyst status update meeting.	1.20
09/10/20	RDS	Call with K. McCafferty, R. Sublett (both AlixPartners) re: April Rt closure plan and impact on project Catalyst savings.	0.50
09/11/20	ADD	Virtual working session with A. DePalma and K.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners) re: Project Catalyst diligence production	
09/11/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: open POs in SAP and Ariba for Catalyst.	1.40
09/11/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, E. Ruta, R. Shamblen, A. Soma, A. Nadeau (Purdue), K. McCarthy (Purdue), A. DePalma (AlixPartners) re: Finalization of the contract list.	1.10
09/11/20	ADD	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, K. McCarthy (both Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst - Revised APA (IP Comments) and supply agreements.	0.80
09/11/20	ADD	Research contracts/agreements for potential inclusion in the schedules and release to the bidders as part of diligence.	2.80
09/11/20	ADD	Compile and upload materials in response to diligence requests for upload to the Project Catalyst data room.	2.30
09/11/20	KM	Call M. Gibson, A. Gallogly (Skadden), J. Doyle, K. McCarthy (both Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst - Revised APA (IP Comments) and supply agreements.	0.80
09/11/20	KM	Call with D. Fogel, J. Dolye, R. Shamblen (all Purdue) re: agreements and materiality for project Catalyst.	0.70
09/11/20	KM	Analysis re: project Catalyst material supply agreements.	0.40
09/11/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst financial impact and savings.	0.60
09/11/20	KM	Update schedules re: project Catalyst.	0.30
09/11/20	KM	Call with R. Shamblen, D. Fogel, J. Doyle, A. Nadeau, A. Soma (Purdue), K. McCarthy (Purdue), A. Gallogly (Skadden), and A. DePalma (AlixPartners) re: finalization	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		of schedules for project Catalyst.	
09/11/20	KM	Analysis and research re: RT agreements for project Catalyst.	0.70
09/11/20	KM	Call with D. Fogel, J. Lowne (both Purdue), and R. Schnitzler (PJT) re: Catalyst savings impact review.	0.50
09/11/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: open POs in SAP and Ariba for Catalyst.	1.40
09/11/20	KM	Analysis re: project Catalyst supply schedules.	0.80
09/11/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence production.	1.30
09/11/20	KM	Review and editing re: project Catalyst schedules and exhibits.	1.20
09/11/20	JD	Correspondence with Purdue re: KEIP/KERP calculation questions.	0.40
09/11/20	JD	Call with B. Leuchter, R. Schnitzler, J. Turner (all PJT) and T. McDonnell (BW Health) re: Adhansia.	0.50
09/11/20	JD	Correspondence with Province re: open KEIP/KERP calculation questions.	0.30
09/11/20	JD	Call with S. Hinden (Willis Towers) re: open FTI KEIP/KERP questions.	0.20
09/11/20	JD	Call with R. Aleali (Purdue) re: open KEIP/KERP questions.	0.50
09/11/20	JD	Review draft business plan to present to the creditors per the August business plan refresh.	0.60
09/11/20	JD	Review this month's Nalmafene reporting and correspondence from Purdue re: same.	0.40
09/11/20	JD	Review updated draft Project Catalyst sale motion and declaration.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/11/20	NAS	Analyze key products not assessed in Summary Mundipharma/LEK Commercial Due Diligence Report.	1.00
09/11/20	NAS	Build overview of working capital ratios included in latest Mundipharma management forecast.	0.80
09/11/20	NAS	Review summary Mundipharma/LEK Commercial Due Diligence Report.	2.50
09/11/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to share initial takeaways from review of Summary LEK/Mundipharma Commercial Due Diligence Report.	1.50
09/11/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to share initial takeaways from review of Summary LEK/Mundipharma Commercial Due Diligence Report.	1.50
09/11/20	GJK	Review LEK commercial report for Mundipharma.	3.00
09/11/20	GJK	Review updates Tech Ops cost reduction targets and compare to original Tech Ops plan provided to BoardZ	1.60
09/11/20	GJK	Scan updated Malta model for variances.	2.00
09/12/20	JD	Correspondence with Davis Polk and Purdue re: contract notice parties.	0.30
09/12/20	JD	Review new KEIP/KERP questions from FTI. Draft and send an initial set of responses.	0.80
09/12/20	JD	Prepare responses to certain business questions from the Monitor.	0.50
09/12/20	JD	Correspondence with PJT re: open questions from the UCC on Project Catalyst.	0.20
09/12/20	KM	Analysis re: materials contracts for project Catalyst.	1.30
09/12/20	KM	Analysis re: post-petition POs for Catalyst.	2.20
09/13/20	KM	Analysis re: PO obligations for project Catalyst.	0.70
09/13/20	KM	Analysis re: post-petition POs for Catalyst.	2.40
09/13/20	KM	Analysis re: identifying notice parties.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/14/20	KM	Call with K. McCafferty and J. DelConte (both AlixPartners) re: Project Catalyst PMO.	0.30
09/14/20	KM	Manage supply agreements re: project Catalyst.	1.10
09/14/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis.	0.80
09/14/20	KM	Review of documents and schedules re: project Catalyst.	1.30
09/14/20	KM	Analysis and tracking re: post-petition contracts for Catalyst.	1.70
09/14/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: open POs in SAP and Ariba for Catalyst.	0.40
09/14/20	KM	Analysis and research re: post-petition contracts.	1.10
09/14/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, M. Gibson (all Skadden) re: pre-signing review call.	0.40
09/14/20	KM	Review and edits re: project Catalyst schedules.	1.10
09/14/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract review and analysis.	0.80
09/14/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: open POs in SAP and Ariba for Catalyst.	0.40
09/14/20	JD	Review analysis of API's to be sourced from Project Catalyst per UCC requests.	0.30
09/14/20	JD	Review updated August plan refresh to be shared with the creditor advisors.	0.60
09/14/20	JD	Prepare draft responses to the AHC diligence questions on the KEIP / KERP and correspondence with Davis Polk and	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Willis Towers Watson re: same.	
09/14/20	JD	Prepare analysis of retention participants by subarea and 2020 insider bonus payments.	1.00
09/14/20	JD	Review details on investigation hours per Davis Polk request.	0.50
09/14/20	JD	Review list of contract counterparties and notice addresses for Project Catalyst.	0.30
09/14/20	JD	Call with J. Lowne, C. DeStefano (both Purdue) re: LTRP accounting.	0.40
09/14/20	JD	Call with M. Kesselman, R. Aleali, J. Lowne (both Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte (both AlixPartners) re: follow-up with M. Burke (BTCF Pharma).	0.60
09/14/20	JD	Call with K. McCafferty and J. DelConte (both AlixPartners) re: Project Catalyst PMO.	0.30
09/14/20	JD	Review and provide comments on the August business plan refresh presentation to share with creditors.	0.70
09/14/20	NAS	Review working capital projections in latest Mundipharma Balance Sheet/Cash Flow Statement.	1.40
09/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from initial review of revised Mundipharma working capital projections.	1.10
09/14/20	NAS	Compare Mundipharma working capital projections from latest forecast to prior version provided in March.	1.60
09/14/20	NAS	Draft Mundipharma net working capital overview for PJT.	1.60
09/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: takeaways from initial review of revised Mundipharma working capital projections.	1.10
09/14/20	GJK	Review new Mundipharma balance sheets.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/14/20	GJK	Review Mundipharma model updates.	2.00
09/14/20	LJD	Call with M. Kesselman, R. Aleali, J. Lowne (both Purdue), M. Huebner, C. Robertson (both Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), L. Donahue, J. DelConte (both AlixPartners) re: follow-up with M. Burke (BTC Pharma).	0.60
09/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review net working capital overview to be sent to PJT.	0.60
09/15/20	GJK	Plan and coordinate Mundipharma analysis updates.	2.50
09/15/20	NAS	Draft list of questions for 9/16 call with A. Breabout (Purdue).	0.40
09/15/20	NAS	Draft Mundipharma FCF overview for PJT based on latest management Balance Sheet and Cash Flow Statement.	2.50
09/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review net working capital overview to be sent to PJT.	0.60
09/15/20	JD	Prepare list of employees related to Project Catalyst.	0.70
09/15/20	JD	Call with A. DePalma, J. DelConte and K. McCafferty (all AlixPartners) re: Project Catalyst status discussion	0.50
09/15/20	JD	Correspondence with Province re: Project Catalyst API sourcing questions.	0.40
09/15/20	JD	Correspondence with C. DeStefano (Purdue) re: KEIP/KERP calculations.	0.30
09/15/20	JD	Review go-forward plan from C. DeStefano (Purdue) re: remainder of 2020 LTRP and AIP calculations.	0.60
09/15/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst schedule follow ups.	0.40
09/15/20	ADD	Call with A. DePalma, J. DelConte and K. McCafferty (all AlixPartners) re: Project Catalyst status discussion	0.50
09/15/20	KM	Prepare transition planning workplan re: project Catalyst.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/15/20	KM	Call with A. DePalma, J. DelConte and K. McCafferty (all AlixPartners) re: Project Catalyst status discussion	0.50
09/15/20	KM	Analysis re: project Catalyst post-signing activities.	0.90
09/15/20	KM	Analysis re: final API sourcing outcome and financial impact.	1.50
09/15/20	KM	Update and review operations and supply chain transition activities re: project Catalyst.	1.70
09/15/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst schedule follow ups.	0.40
09/15/20	KM	Develop required action list re: post signing for Rhodes and Purdue.	1.20
09/15/20	ADD	Review accounting data to develop liquidation analysis assumption.	2.10
09/15/20	ADD	Review Rhodes vendor analysis to identify and classify by entity any Rhodes contracts.	3.10
09/15/20	ADD	Download and compile source data for Purdue liquidation analysis model.	1.60
09/16/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst post signing work plan development discussion.	1.20
09/16/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
09/16/20	ADD	Call D. Fogel (Purdue), A. DePalma and K. McCafferty (AlixPartners) re: RT and RP contracts for Chapter 11 emergence.	0.70
09/16/20	ADD	Call with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: project Catalyst transition planning.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/16/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners) re: next steps for Project Catalyst.	0.30
09/16/20	ADD	Call with R. Aleali, K. McCarthy, B. Miller (all Purdue), A. Lele, E. Diggs, E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), M. Florence, J. Bragg (both Skadden), J. Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: contract transfers.	0.60
09/16/20	KM	Call D. Fogel (Purdue), A. DePalma and K. McCafferty (AlixPartners) re: RT and RP contracts for Chapter 11 emergence.	0.70
09/16/20	KM	Analysis and document preparation re: Catalyst transition plan and program management structure.	2.50
09/16/20	KM	Call with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. DelConte, A. DePalma, K. McCafferty (all AlixPartners) re: project Catalyst transition planning.	0.50
09/16/20	KM	Analysis and workplan development re: project Catalyst transition plan.	1.40
09/16/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst post signing work plan development discussion.	1.20
09/16/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.30
09/16/20	KM	Call with K. McCafferty, J. DelConte (both AlixPartners) re: Project Catalyst work plan.	0.40
09/16/20	KM	Creation documents re: Catalyst transition plan.	0.70
09/16/20	KM	Analysis and coordination re: outstanding diligence requests.	1.30
09/16/20	JD	Call with R. Aleali, K. McCarthy, B. Miller (all Purdue), A. Lele, E. Diggs, E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), M. Florence, J. Bragg (both Skadden), J.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/16/20	JD	Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: contract transfers.	0.70
09/16/20	JD	Prepare for and participate in call with J. Lowne, D. Lundie, D. Fogel (all Purdue), K. McCafferty, J. DelConte, A. DePalma (all AlixPartners) re: Project Catalyst transition planning.	0.30
09/16/20	JD	Correspondence with Davis Polk and Purdue re: Nalmafene reporting.	0.70
09/16/20	JD	Review and calculate annual AIP accruals for Purdue, Rhodes Pharma and Rhodes Tech.	0.30
09/16/20	JD	Correspondence with E. Vonnegut (Davis Polk) re: UCC KEIP/KERP feedback.	0.80
09/16/20	JD	Draft list of ongoing company workstreams in advance of potential KEIP/KERP objection reply.	1.00
09/16/20	JD	Analyze differences between current 2020 retention award amounts and amounts provided to creditors last year.	0.40
09/16/20	JD	Update LTRP tracker for 3 additional participants / payments.	0.50
09/16/20	JD	Update latest professional fee tracker for Davis Polk in advance of the preliminary injunction hearing.	0.30
09/16/20	JD	Call with J. Lowne (Purdue) re: KEIP/KERP accounting.	0.30
09/16/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners) re: next steps for Project Catalyst.	0.40
09/16/20	JD	Call with K. McCafferty, J. DelConte (both AlixPartners) re: Project Catalyst work plan.	0.70
09/16/20	NAS	Prepare for meeting with A. Breabout (Purdue).	1.10
09/16/20	NAS	Mundipharma diligence call with A. Breabout (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/16/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, I. Mian (all PJT) to review changes in Mundipharma net working capital implied by latest management forecast.	0.70
09/16/20	NAS	Build variance between latest versions of Mundipharma management forecast and investigate changes.	1.40
09/16/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: variance between latest iterations of Mundipharma management forecast.	0.30
09/16/20	GJK	Prepare for call with A Breabout (Purdue) to recede 2Q 2020 performance.	1.50
09/16/20	GJK	Mundipharma diligence call with A. Breabout (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	1.10
09/16/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic, I. Mian (all PJT) to review changes in Mundipharma net working capital implied by latest management forecast.	0.70
09/16/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: variance between latest iterations of Mundipharma management forecast.	0.30
09/16/20	GJK	Analyze 2H performance trend to Mundipharma business plan.	2.00
09/16/20	GJK	Review product category trends in Mundipharma model and business update.	2.00
09/17/20	GJK	Review Mundipharma diligence documents for product category working capital assumptions.	2.20
09/17/20	GJK	Review Mundipharma FCF assumptions.	2.00
09/17/20	GJK	Compare market level balance sheet and cash flows.	2.50
09/17/20	LJD	Preread materials for special committee call	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/17/20	LJD	Attend special committee call	0.40
09/17/20	NAS	Draft and send follow-up questions re: latest Mundipharma forecast provided by company.	0.60
09/17/20	JD	Call with R. Aleali (Purdue) re: post-call catch up.	0.20
09/17/20	JD	Call led by Debevoise re: Side A Sackler distributions.	0.80
09/17/20	JD	Prepare for and participate in PPI board meeting.	0.60
09/17/20	JD	Update professional fee tracker for M. Huebner (Davis Polk).	0.30
09/17/20	JD	Correspondence with Davis Polk re: additional AIP related to OT and shift differentials for hourly employees.	0.50
09/17/20	JD	Correspondence with C. DeStefano and D. Warren (both Purdue) re: additional AIP for OT and shift differential.	0.60
09/17/20	JD	Correspondence with M. Kesselman (Purdue) re: latest bankruptcy costs.	0.20
09/17/20	JD	Review latest Project Catalyst workplan.	0.30
09/17/20	JD	Correspondence with Purdue re: open critical vendor invoices.	0.30
09/17/20	JD	Review draft July monthly flash report prior to providing to creditors.	0.60
09/17/20	KM	Call with D. Fogel (Purdue) and A. DePalma., K. McCafferty (AlixPartners) re: RP contract analysis results.	0.90
09/17/20	KM	Analysis and tracking re: post-petition contracts for Catalyst.	0.10
09/17/20	KM	Review documents re: project Catalyst transition plan.	1.60
09/17/20	KM	Analysis and workplan development re: project Catalyst transition plan.	2.20
09/17/20	KM	Analysis re: RP active contracts.	2.80
09/17/20	ADD	Review and analyze Rhodes contracts for materiality and relative importance.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/18/20	ADD	Download and compile accounting data for liquidation analysis.	1.70
09/18/20	KM	Create transition kickoff documents re: project Catalyst.	0.60
09/18/20	KM	Edit documents re: Catalyst transition plan.	1.10
09/18/20	KM	Create milestone tracker re: Catalyst transition.	1.60
09/18/20	KM	Analysis re: executory contracts and supply agreements for Catalyst.	1.20
09/18/20	JD	Call with E. Vonnegut (Davis Polk) re: UCC KEIP/KERP response.	0.20
09/18/20	JD	Correspondence with Purdue and Davis Polk re: LTRP for retirees.	0.80
09/18/20	JD	Review draft responses from the creditors on KEIP/KERP. Analyze effects on various employee groups.	1.00
09/18/20	JD	Review latest draft Project Catalyst transition work plan.	0.30
09/18/20	JD	Review Side A distribution detail excels.	0.50
09/18/20	JD	Prepare KEIP/KERP accounting summary for Purdue for J. Lowne (Purdue)	2.60
09/18/20	JD	Prepare KEIP/KERP accounting summary for Rhodes for J. Lowne (Purdue).	1.50
09/18/20	NAS	Review discrepancy in Mundipharma Other Charges P&L line in data provided.	0.70
09/18/20	NAS	Review new files posted to Purdue data room.	0.40
09/18/20	NAS	Review Mundipharma diligence documents for information on inventory by product line.	1.70
09/18/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review Mundipharma net working capital analysis.	0.70
09/18/20	IA	Reviewed Purdue retention information to validate participant payments to be made in October.	1.10
09/18/20	LJD	Update call with J. Dubel (Board Member)	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/18/20	GJK	Plan and coordinate for Mundipharma risk adjustment section of report.	1.90
09/18/20	GJK	Review Mundipharma net working capital trends and supporting historical information.	3.00
09/18/20	GJK	Review key open questions for diligence.	1.50
09/18/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review Mundipharma net working capital analysis.	0.70
09/18/20	SKL	Review July financials presentation and began making updates to the July Flash report accordingly.	2.10
09/20/20	JD	Finalize accounting summary and send it over to Purdue management team for review.	0.80
09/21/20	JD	Call with J. Lowne and C. DeStefano (both Purdue) re: bonus accounting accruals.	0.80
09/21/20	JD	Prepare for call with Purdue management re: bonus accruals.	0.40
09/21/20	JD	Call with J. Turner (PJT) re: call follow up.	0.20
09/21/20	JD	Discussion with A. DePalma and J. DelConte (both AlixPartners) re: open diligence items.	0.20
09/21/20	JD	Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review status.	0.50
09/21/20	JD	Correspondence with Davis Polk and PJT re: cost of delayed bankruptcy emergence materials.	0.50
09/21/20	JD	Update latest professional fee actuals and forecast through Q1 2021.	0.80
09/21/20	JD	Assemble different attrition analyses for KEIP/KERP.	2.60
09/21/20	JD	Follow up correspondence with Purdue re: AG settlements and bonus clawbacks.	0.60
09/21/20	JD	Draft responses to UCC HRT diligence questions.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/21/20	JD	Follow up and edit Nalmafene reporting for the month.	0.30
09/21/20	JD	Finalize Prime Clerk schedule to be posted to the dataroom.	0.20
09/21/20	JD	Update information to provide to the company for immigration.	0.30
09/21/20	JD	Correspondence with Fidelity re: pension termination estimates.	0.20
09/21/20	NAS	Review prior Mundipharma diligence files for additional information on inventory levels.	0.90
09/21/20	NAS	Draft risk adjustment slides and supporting materials related to Mundipharma COGS, S&P, and MA cost structure.	2.40
09/21/20	NAS	Draft risk adjustment slides and supporting materials related to Mundipharma operational risks.	2.20
09/21/20	GJK	Call with I McClatchey (Norton Rose) re: general state of diligence.	0.30
09/21/20	GJK	Plan and coordinate diligence report updates.	2.50
09/21/20	GJK	Review Mundipharma model cases bridges.	1.50
09/21/20	GJK	Review Mundipharma net working capital historical and current model analysis.	2.40
09/21/20	KM	Develop transition team structure and approach re: project Catalyst.	1.90
09/21/20	KM	Edit and update transition plan for steering review re: project Catalyst.	2.50
09/21/20	ADD	Call with J. Lowne, E. Ruiz, S. Daniel (all Purdue), J. DelConte and A. DePalma (both AlixPartners) re: contract review status.	0.50
09/21/20	ADD	Discussion with A. DePalma and J. DelConte (both AlixPartners) re: open diligence items.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/22/20	ADD	Download and organize data for liquidation analysis.	1.80
09/22/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning	0.90
09/22/20	ADD	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, R. Aleali, J. Lowne (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) and Arnold & Porter legal team. re: Transition Planning and Legal Considerations.	1.00
09/22/20	HSB	Review UST objection to KEIP/KERP in preparation for meeting with Davis Polk team.	0.60
09/22/20	HSB	Review AHC memo (KEIP/KERP) in preparation for meeting with Davis Polk team.	0.80
09/22/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning	0.90
09/22/20	KM	Discussion with D. Lundie (Purdue) re: project Catalyst transition.	0.80
09/22/20	KM	Transition tracking process design and smartsheet editing re: project catalyst.	1.60
09/22/20	KM	Call J. Doyle, D. Fogel, and D. Lundie, K. McCarthy, R. Aleali, J. Lowne (all Purdue), A. DePalma, K. McCafferty (both AlixPartners) and Arnold & Porter legal team. re: Transition Planning and Legal Considerations.	1.00
09/22/20	KM	Edit transition planning introduction re: project Catalyst.	0.70
09/22/20	KM	Transition planning and legal considerations re: project Catalyst.	1.10
09/22/20	JD	Call with R. Kreppel (Purdue) re: AG settlements.	0.50
09/22/20	JD	Call with J. Lowne (Purdue), J. Turner, T. Melvin (both PJT) re: business plan sensitivities.	0.50
09/22/20	JD	Review business plan overview deck to create a non-PEO	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		version.	
09/22/20	JD	Correspondence with Davis Polk re: AHC feedback on the KEIP/KERP.	0.40
09/22/20	JD	Correspondence with management and Davis Polk re: AIP calculations.	0.30
09/22/20	JD	Correspondence with R. Aleali (Purdue) and C. Oluwole (Davis Polk) re: AHC request to share certain wage information.	0.60
09/22/20	JD	Create list of employees per UCC proposal for Skadden.	0.70
09/22/20	JD	Correspondence with management and Davis Polk re: Nalmafene reporting.	0.30
09/22/20	JD	Finalize attrition numbers and send around to Davis Polk.	2.00
09/22/20	JD	Review updated term list for latest attrition details.	0.30
09/22/20	JD	Review Side A net asset report.	0.70
09/22/20	JD	Review latest comments to the latest transition plan.	0.30
09/22/20	JD	Review professional fee budget template for 2021 budgeting. Work on preliminary budget estimates.	1.30
09/22/20	GJK	Review key findings slides for report updates.	1.90
09/22/20	GJK	Assess COS and Opex ratios between model cases.	2.50
09/22/20	SKL	Review and reconcile August Business Plan deck and began redaction process for non-PEO report.	2.40
09/22/20	SKL	Finalize redaction of the non-PEO August business plan update.	1.20
09/22/20	NAS	Draft new Mundipharma diligence report slides related to product-level risk adjustments.	2.90
09/22/20	NAS	Correspondence with J. Arsic (PJT) re: analysis of Mundipharma free cash flow by product category.	0.50
09/22/20	NAS	Draft new Mundipharma diligence report slides related to region-level cost reduction adjustments.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/23/20	JD	Review mediators report that was filed.	0.40
09/23/20	JD	Review attrition survey stats from Willis Towers Watson.	0.20
09/23/20	JD	Review detailed Project Catalyst savings file.	0.50
09/23/20	JD	Review notes from Purdue and Davis Polk re: go forward compensation planning.	0.30
09/23/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review draft of Mundipharma risk adjustment slides.	1.20
09/23/20	NAS	Revise Mundipharma risk adjustment slides following comments from G. Koch (AlixPartners).	2.90
09/23/20	NAS	Review latest draft of Mundipharma risk adjustment slides.	1.70
09/23/20	SKL	Prepare for and attend call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call.	0.60
09/23/20	SKL	Finalize latest Purdue weekly sales by product report and circulate for production.	1.20
09/23/20	SKL	Finalize latest Rhodes weekly sales by product report and circulate for production.	1.00
09/23/20	SKL	Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep.	0.30
09/23/20	GJK	Prepare and review for risk adjustment discussion.	1.00
09/23/20	GJK	Review Mundipharma diligence open items including LEK, DB and CFO questions.	2.00
09/23/20	GJK	Develop edits to Mundipharma overview slides.	2.00
09/23/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review draft of Mundipharma risk adjustment slides.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/23/20	JD	Begin preparing analysis of historical LTRP grant amounts by year by level by company.	1.70
09/23/20	JD	Call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call.	0.50
09/23/20	JD	Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep.	0.30
09/23/20	JD	Review latest weekly sales report by product for Rhodes and Purdue. Analyze latest sales trends.	0.60
09/23/20	JD	Review bonus repayment tracker and compare it to the latest wage file.	0.80
09/23/20	JD	Review retention detail sheet and repayment obligations.	0.40
09/23/20	KM	Call E. Ruta (Purdue), K. McCafferty, A. DePalma (AlixPartners) re Post-signing contract management discussion	0.40
09/23/20	KM	Analysis re: contract information and reporting requirements.	0.50
09/23/20	KM	Call J. Giordano (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Post-signing contract management discussion	0.50
09/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning presentation review.	0.80
09/23/20	KM	PMO process management re: project Catalyst needs and requirements.	1.40
09/23/20	KM	Meeting with D. Lundie, R. Shamblen, V. Mancinelli, J. Doyle, D. McGuire, J. Northington, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: business integration planning for Catalyst.	
09/23/20	KM	Follow up with Rhodes Tech re: operations and supply chain analyses for Catalyst.	1.00
09/23/20	KM	Update transition plan for Leadership launch re: project Catalyst.	0.40
09/23/20	HSB	Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep.	0.30
09/23/20	HSB	Call with D. Consla, E. Vonnegut, S. Brecher (all Davis Polk), J. Gartrell, S. Hinden (Willis Towers Watson), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP hearing status call.	0.50
09/23/20	ADD	Call with J. McClammy, C. Oluwole (both Davis Polk), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal, A. DePalma, S. Lemack (all AlixPartners) re: Landau deposition prep.	0.30
09/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst transition planning presentation review.	0.80
09/23/20	ADD	Meeting with D. Lundie, R. Shamblen, V. Mancinelli, J. Doyle, D. McGuire, J. Northington, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: business integration planning for Catalyst.	1.00
09/23/20	ADD	Call E. Ruta (Purdue), K. McCafferty, A. DePalma (AlixPartners) re Post-signing contract management discussion	0.40
09/23/20	ADD	Call J. Giordano (Purdue), K. McCafferty, A. DePalma (both AlixPartners) re: Post-signing contract management	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/24/20	ADD	discussion	
09/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition planning.	0.60
09/24/20	ADD	Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning.	0.60
09/24/20	ADD	Call with C. Oluwole, J. McClammy (both Davis Polk), J. Turner, T. Melvin (both PJT), L. Imes, C. Dysard (both Spears Imes), J. DelConte and A. DePalma (both AlixPartners) re: Landau deposition.	0.40
09/24/20	HSB	Call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses.	0.50
09/24/20	KM	Create preliminary tracking report re: Catalyst implementation.	0.70
09/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst transition planning.	0.60
09/24/20	KM	Analysis and document editing re: transition PMO for Catalyst.	1.70
09/24/20	KM	Create transition team onboarding materials re: project Catalyst transition.	1.50
09/24/20	KM	Meeting with J. Giordano, D. McGuire, J. Northington (Purdue) re: Catalyst transition planning for Wilson NC.	0.40
09/24/20	KM	Analysis re: contracts for Catalyst.	0.90
09/24/20	KM	Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning.	0.60
09/24/20	KM	Create documents for Kickoff re: Catalyst transition	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		planning.	
09/24/20	JD	Call with C. Oluwole, J. McClammy (both Davis Polk), J. Turner, T. Melvin (both PJT), L. Imes, C. Dysard (both Spears Imes), J. DelConte and A. DePalma (both AlixPartners) re: Landau deposition.	0.40
09/24/20	JD	Call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses.	0.50
09/24/20	JD	Correspondence with Purdue re: HRT diligence questions.	0.30
09/24/20	JD	Review presentations sent around for C. Landau (Purdue) deposition prep.	0.50
09/24/20	JD	Correspondence with Davis Polk and management re: response to KEIP/KERP proposals.	0.80
09/24/20	GJK	Frame out new findings pages for Mundipharma report update.	2.50
09/24/20	GJK	Review Mundipharma documents for support for revised key findings.	3.00
09/24/20	SKL	Prepare for and participate in call with D. Consla, E. Vonnegut, S. Brecher (Davis Polk), S. Hinden (Willis Towers Watson), H. Bhattal, J. DelConte, S. Lemack (all AlixPartners) re: KEIP/KERP responses.	0.60
09/24/20	NAS	Review revisions to Mundipharma risk adjustment diligence report slides.	0.20
09/25/20	NAS	Revise risk adjustment section of draft Mundipharma diligence report.	2.90
09/25/20	JD	Participate in PPI Board meeting, J. DelConte, L. Donahue (both AlixPartners) in attendance	3.50
09/25/20	SKL	Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consla, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re:	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		KEIP/KERP responses.	
09/25/20	GJK	Review latest Mundipharma modeling.	2.50
09/25/20	GJK	Plan and coordinate upcoming calls and completion of draft final report.	2.90
09/25/20	LJD	Participate in PPI Board meeting, J. DelConte, L. Donahue (both AlixPartners) in attendance	3.50
09/25/20	JD	Review materials in advance of board meeting.	0.70
09/25/20	JD	Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consla, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP responses.	0.50
09/25/20	JD	Call with S. Hinden and J. Gartrell (both Willis Towers Watson) re: KEIP/KERP reductions.	0.30
09/25/20	JD	Prepare summary schedule of reductions by group in the KEIP/KERP motion.	1.40
09/25/20	JD	Prepare revised version of the summary KEIP/KERP reduction schedule after discussion with Willis Towers Watson.	1.80
09/25/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.20
09/25/20	KM	Call with D. Lundie (Purdue) re: Catalyst transition and Rhodes Pharma going forward.	0.60
09/25/20	KM	Process tracking and development re: project Catalyst.	0.80
09/25/20	KM	Transition milestone update re: project Catalyst.	1.80
09/25/20	KM	Meeting with E. Ruta, K. McCarthy (both Purdue), A. Gallogly, M. Gibson (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst continuing contract review.	0.50
09/25/20	KM	Milestone tracking development re: Catalyst transition planning.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/25/20	HSB	Participate in call with S. Hinden, J. Gartrell (both Willis Towers Watson), D. Consola, S. Brecher (both Davis Polk), J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: KEIP/KERP responses.	0.50
09/25/20	ADD	Meeting with E. Ruta, K. McCarthy (both Purdue), A. Gallogly, M. Gibson (both Skadden) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst continuing contract review.	0.50
09/25/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.20
09/25/20	ADD	Upload materials provided by Davis Polk's eDiscovery team to the Intralinks data room.	2.30
09/26/20	JD	Correspondence with Willis Towers Watson and Davis Polk re: KEIP/KERP reductions.	0.30
09/26/20	JD	Prepare final KEIP/KERP analysis and provide responses to the UCC.	0.80
09/27/20	JD	Correspondence with management and Davis Polk re: proposals from the UCC on the KEIP/KERP.	0.80
09/27/20	JD	Prepare summary response for KEIP/KERP negotiations including analysis of business performance to date and other qualitative reasons for the necessity of the compensation programs.	1.30
09/28/20	JD	Call with J. Lowne, J. Doyle, D. Fogel (all Purdue), J. Turner, T. Melvin (both PJT) re: potential BD deals.	0.30
09/28/20	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: transition planning.	0.50
09/28/20	JD	Correspondence with Davis Polk re: discussions with Bates White.	0.30
09/28/20	JD	Review and provide comments on the draft non-PEO version of the August refresh business plan presentation	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		to share with various creditors.	
09/28/20	JD	Review Rhodes BD deal opportunity presentation.	0.30
09/28/20	JD	Review revised August business plan refresh files to be posted to the data room for the creditor advisors.	0.40
09/28/20	JD	Review and provide comments on the debtor KEIP/KERP objection reply.	0.90
09/28/20	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: transition planning.	0.50
09/28/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.60
09/28/20	KM	Link milestone tracking re: project Catalyst.	0.50
09/28/20	KM	Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta (Purdue), D. McGuire, B. Evans, J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain kickoff.	1.20
09/28/20	KM	Preliminary milestone identification re: Catalyst core supply chain and procurement activities.	1.10
09/28/20	KM	Preliminary milestone identification re: Catalyst tech transfers.	1.30
09/28/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - kick off and orientation - Operations, Tech Transfers, Supply Chain, Quality / Regulatory	0.60
09/28/20	KM	Call with J. Giordano (Purdue) re: Catalyst transition kickoff.	0.30
09/28/20	KM	Workstream edits and improvements re: project Catalyst	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		transition kickoff.	
09/28/20	KM	Prepare documents re: project Catalyst transition kickoff.	2.20
09/28/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Eber, J. Waltz, B. Mayer, K. Kolar, A. Soma, A. Nadeau, J. Doyle, E. Ruta, D. Shell, J. Gibbs, S. Yates, D. McGuire, J. Northington, J. Fox, D. Eades, B. Evans, S. Aschmann, B. Purdon, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - kick off and orientation - Operations, Tech Transfers, Supply Chain, Quality / Regulatory	0.60
09/28/20	ADD	Meeting with V. Mancinelli, R. Shamblen, A. Nadeau, J. Gibbs, E. Ruta (Purdue), D. McGuire, B. Evans, J. Giordano (Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - supply chain kickoff.	1.20
09/28/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.60
09/28/20	SKL	Review the April non-PEO business plan and continue to make updates to the non-PEO August business plan refresh.	2.40
09/28/20	SKL	Continue to finalize redactions to the August business plan refresh and circulate for final sign-off.	1.50
09/28/20	NAS	Revise risk adjustment section of Mundipharma diligence report following comments from G. Koch (AlixPartners).	1.20
09/28/20	NAS	Draft qualitative risk factor slides for Mundipharma diligence report.	1.40
09/28/20	NAS	Draft Downside Case risk adjustment slides for Mundipharma diligence report.	1.20
09/28/20	NAS	Update latest draft of Mundipharma diligence report with latest Base Case.	0.90
09/29/20	NAS	Analyze new product-level support for September Model provided by Huron/Mundipharma.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/29/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustment slides	1.20
09/29/20	NAS	Revisions to latest draft of Mundipharma diligence report following comments from G. Koch (AlixPartners).	3.20
09/29/20	SKL	Review latest inquiry re: PBGC termination claim and prepare updated breakdown accordingly.	0.60
09/29/20	SKL	Finalize remaining redactions to the August business plan refresh based on the feedback provided, and circulated updated deck and list of changes to T. Melvin (PJT) to review and sign-off.	2.30
09/29/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
09/29/20	GJK	Develop Mundipharma diligence final report notes.	2.00
09/29/20	GJK	Assess Mundipharma diligence items - LAM region.	2.10
09/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review risk adjustment slides	1.20
09/29/20	GJK	Review risk adjustment slide updates and prep for call with N Simon (AlixPartners)	0.40
09/29/20	ADD	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - tech transfers and qualifications.	1.10
09/29/20	ADD	Meeting with V. Mancinelli, R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	1.10
09/29/20	ADD	Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/29/20	ADD	Review material Rhodes Pharma relationships to identify material contracts for additional review and analysis.	1.60
09/29/20	KM	Milestone tracking approach and technology management re: project Catalyst transition.	2.10
09/29/20	KM	Transition PMO management re: project Catalyst transition.	2.10
09/29/20	KM	Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings.	0.80
09/29/20	KM	Meeting with V. Mancinelli, R. Shamblen, A. Soma, A. Nadeau, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - Coventry operations.	1.10
09/29/20	KM	Prepare for Coventry operations transition workstream launch meeting re: project Catalyst transition.	0.10
09/29/20	KM	Meeting with V. Mancinelli, R. Shamblen, T. Delehant, D. Ebere, J. Waltz, B. Mayer, K. Kolar, D. McGuire, J. Fox, D. Eades, J. Giordano (all Purdue), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition - tech transfers and qualifications.	1.10
09/29/20	KM	Prepare for transition workstream launch meetings re: project Catalyst transition.	1.40
09/29/20	JD	Call with J. Lowne (Purdue) re: open items.	0.20
09/29/20	JD	Call with A. DePalma, K. McCafferty, J. DelConte (all AlixPartners) and D. Fogel (Purdue) re: material contract analysis and Project Catalyst savings.	0.80
09/29/20	JD	Call with J. Lowne, E. Ruiz and S. Daniel (all Purdue) re: material contract analysis.	0.40
09/29/20	JD	Call with J. Turner (PJT), E. Vonnegut, C. Robertson (Davis Polk) re: BD deals.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
09/29/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
09/29/20	JD	Prepare quick reference sheets for the hearing on the KERP for Davis Polk outlining the top 41 paid employees.	2.20
09/29/20	JD	Correspondence with management re: contract cure costs for a Rhodes Tech vendor.	0.30
09/29/20	JD	Correspondence with Fidelity and with H. Bhattal (AlixPartners) re: pension claim calculations.	0.40
09/29/20	JD	Prepare analysis of the KERP less the 8 employee deferred employees for potential negotiations.	0.50
09/29/20	JD	Review bonus accrual accounting file from management.	0.60
09/30/20	JD	Finalize updated professional fee forecast for the remainder of 2020 and 2021 for DPW and PJT review.	0.80
09/30/20	JD	Prepare update of bonus accrual accounting file re: with management on Friday.	1.80
09/30/20	JD	Call with J. Lowne (Purdue) re: prep for court hearing.	0.20
09/30/20	JD	Call with J. Turner (PJT) re: OxyContin sensitivities.	0.20
09/30/20	KM	Activity tracking and transition planning re: RP and Wilson supply chain.	2.10
09/30/20	KM	Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning.	0.50
09/30/20	KM	Update Coventry operations transition planning re: project Catalyst.	1.20
09/30/20	KM	Update/edit supply chain transition planning re: project Catalyst.	1.30
09/30/20	KM	Edit, update and circulate tech transfer mapping re: project Catalyst transfer requirements.	1.30
09/30/20	ADD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle,	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		K. McCarthy, R. Aleali, J. Lowne, D. McGuire (all Purdue), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst closing checklist.	
09/30/20	ADD	Meeting with J. Giordano (Purdue) and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst transition PMO planning.	0.50
09/30/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, K. McCarthy, R. Aleali, J. Lowne, D. McGuire (all Purdue), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden), and A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst closing checklist.	1.10
09/30/20	KM	Tracking dashboard edits re: project Catalyst.	0.80
09/30/20	GJK	Review Appendix slides for updates.	2.00
09/30/20	GJK	Review overview materials for updates.	2.00
09/30/20	NAS	Review list of Mundipharma diligence questions for 10/12 call with Deutsche Bank.	0.70
Total			<u>2,426.40</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	26.20	515.00	13,493.00
Andrew D DePalma	230.20	515.00	118,553.00
Nate A Simon	371.30	515.00	191,219.50
Sam J Canniff	8.00	645.00	5,160.00
Isabel Arana de Uriarte	25.20	690.00	17,388.00
Ryan D Sublett	56.10	735.00	41,233.50
Gabe J Koch	501.50	840.00	421,260.00
HS Bhattal	6.70	840.00	5,628.00
Jesse DelConte	439.20	950.00	417,240.00
Kevin M McCafferty	718.70	950.00	682,765.00
Lisa Donahue	43.30	1,195.00	51,743.50
Total Hours & Fees	2,426.40		1,965,683.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
07/22/20	JD	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
07/22/20	SKL	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
07/22/20	ADD	Compile materials for liquidation analysis and review representative examples.	2.30
07/22/20	HSB	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
08/17/20	ADD	Virtual working session A. DePalma and S. Lemack (both AlixPartners) to update liquidation analysis spreadsheet with new data	1.00
08/17/20	SKL	Virtual working session A. DePalma and S. Lemack (both AlixPartners) to update liquidation analysis spreadsheet with new data	1.00
08/18/20	SKL	Virtual working session A. DePalma and S. Lemack (AlixPartners) to review liquidation analysis spreadsheet and identify next steps.	1.50
08/18/20	ADD	Virtual working session A. DePalma and S. Lemack (AlixPartners) to review liquidation analysis spreadsheet and identify next steps.	1.50
08/19/20	ADD	Virtual working session with A. DePalma and S. Lemack (both AlixPartners) to review and update liquidation analysis assumptions	1.30
08/19/20	HSB	Review updated excel file with liquidation analysis for all debtor entities.	0.60
08/19/20	SKL	Virtual working session with A. DePalma and S. Lemack (both AlixPartners) to review and update liquidation analysis assumptions	1.30
08/20/20	SKL	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		steps	
08/20/20	SKL	Prepare updated professional fee breakout to the liquidation analysis and update the consolidated summary accordingly.	1.60
08/20/20	SKL	Prepare updated Purdue/Rhodes payroll breakout to the liquidation analysis and update the consolidated summary accordingly.	1.30
08/20/20	SKL	Finalize remaining updates to the latest liquidation analysis and distribute prior to today's liquidation meeting.	1.80
08/20/20	HSB	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps	0.90
08/20/20	ADD	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps.	0.90
08/20/20	JD	Meeting with J. DelConte, HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) re: liquidation analysis and next steps.	0.90
08/21/20	SKL	Continue to update the liquidation analysis based on the latest feedback provided and provided additional notes and detail behind the assumptions.	2.30
08/24/20	SKL	Continue to review and update underlying assumptions in the latest liquidation analysis.	1.40
08/24/20	SKL	Call with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis next steps.	0.40
08/24/20	GJK	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
08/24/20	RC	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/24/20	JD	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/24/20	ADD	Call with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis next steps.	0.40
08/24/20	ADD	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/26/20	HSB	Review excel file with liquidation analysis for Purdue.	0.90
08/28/20	JD	Correspondence with management and Davis Polk re: ongoing settlement discussions.	0.30
09/01/20	HSB	Review PJT's valuation of Purdue and conducted related research for liquidation analysis.	1.30
09/03/20	HSB	Review liquidation analysis comments.	0.40
09/03/20	HSB	Review updated excel file with draft of liquidation analysis.	0.80
09/03/20	HSB	Review disclosure statements for recent pharma b/k filings for liquidation analysis assumptions.	1.70
09/03/20	JD	Review and provide comments on the draft liquidation analysis. Review previous liquidation analyses for context.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
09/03/20	JD	Correspondence with Davis Polk re: plan confirmation issues.	0.30
09/04/20	HSB	Review draft of liquidation analysis and prepared comments for updates.	1.30
09/08/20	HSB	Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis.	0.90
09/08/20	ADD	Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis.	0.90
09/08/20	SKL	Meeting with H. Bhattal, A. DePalma and S. Lemack (all AlixPartners) to review and discuss liquidation analysis.	0.90
09/09/20	SKL	Continue review of latest feedback and comments received re: liquidation analysis and prepared updated assumptions accordingly.	2.10
09/09/20	HSB	Review updated liquidation analysis and prepare comments ahead of working session.	0.70
09/09/20	HSB	Review recent liquidation analysis comps and related issues.	1.20
09/10/20	HSB	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps.	3.20
09/10/20	HSB	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) follow up meeting to review latest updates made to the liquidation analysis and discuss next steps.	1.20
09/10/20	HSB	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps.	1.10
09/10/20	ADD	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps.	3.20
09/10/20	ADD	Meeting with HS Bhattal, A. DePalma and S. Lemack (all	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
09/10/20	ADD	AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps.	1.20
09/10/20	SKL	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) follow up meeting to review latest updates made to the liquidation analysis and discuss next steps.	1.20
09/10/20	SKL	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) initial meeting to review latest updates made to the liquidation analysis and discuss next steps.	1.10
09/10/20	SKL	Meeting with HS Bhattal, A. DePalma and S. Lemack (all AlixPartners) final meeting to review latest updates made to the liquidation analysis and discuss next steps.	3.20
09/10/20	SKL	Continue to work through the latest feedback received on the liquidation analysis and prepare update and breakdown for internal review.	2.50
09/10/20	JD	Review latest liquidation analysis edits and open questions.	0.80
09/14/20	SKL	Update inventory and PPE sections of the liquidation analysis and flow through to the consolidated level.	2.10
09/14/20	SKL	Update liquidation analysis with asset and claim level checks on both the consolidated level and debtor by debtor level.	1.80
09/14/20	SKL	Continue to update the liquidation analysis with the latest postpetition AP detail and begin preparing the administrative claim portion of the analysis.	1.40
09/15/20	SKL	Incorporate the latest accrued rebate detail into the administrative claim component of the liquidation analysis.	1.40
09/15/20	HSB	Review recent pharma bankruptcy disclosure statements	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		and related assumptions for liquidation analysis and prepare excel summary worksheet.	
09/16/20	HSB	Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps.	0.70
09/16/20	HSB	Review APA and assessed impact on liquidation analysis.	1.30
09/16/20	ADD	Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps.	0.70
09/16/20	JD	Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps.	0.70
09/16/20	SKL	Meeting with J. DelConte, HS Bhattal, A. DePalma (all AlixPartners) re: latest liquidation analysis and discuss next steps.	0.70
09/17/20	SKL	Update the consolidated piece of the liquidation analysis with the new assumptions for PPLP, Rhodes and Avrio.	2.10
09/17/20	SKL	Finalize updates to the PPE and accrued rebate section of the latest liquidation analysis.	1.40
09/21/20	SKL	Continue review of latest balance sheet detail provided and begin updating the liquidation analysis accordingly.	2.30
09/21/20	SKL	Review latest feedback provided on the Rhodes balance sheet detail and continue updating the debtor entity and consolidated tabs accordingly.	2.60
09/21/20	SKL	Meeting with A. DePalma and S. Lemack (both AlixPartners) to pull Rhodes balance sheet detail and discuss updates to the liquidation analysis accordingly.	0.70
09/21/20	HSB	Review excel draft of liquidation analysis.	0.40
09/21/20	ADD	Meeting with A. DePalma and S. Lemack (both AlixPartners) to pull Rhodes balance sheet detail and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		discuss updates to the liquidation analysis accordingly.	
09/23/20	ADD	Call with A. DePalma and S. Lemack (AlixPartners) re: liquidation analysis follow up items.	0.30
09/23/20	SKL	Call with A. DePalma and S. Lemack (AlixPartners) re: liquidation analysis follow up items.	0.30
09/23/20	SKL	Continue to update the liquidation analysis with the latest Rhodes balance sheet detail and claims estimates.	2.20
09/28/20	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis and follow-up items.	0.40
09/28/20	ADD	Meeting with A. DePalma, S. Lemack (both AlixPartners) re: liquidation analysis and follow-up items.	0.40
Total			94.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	17.60	515.00	9,064.00
Sam K Lemack	44.40	515.00	22,866.00
Gabe J Koch	1.70	840.00	1,428.00
HS Bhattal	21.20	840.00	17,808.00
Jesse DelConte	7.80	950.00	7,410.00
Richard Collura	1.70	1,090.00	1,853.00
Total Hours & Fees	94.40		60,429.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
08/06/20	JD	Review draft cure costs analysis.	0.20
08/24/20	ADD	Call with J. DelConte and A. DePalma (AlixPartners) re: material contracts.	0.30
08/24/20	JD	Call with J. DelConte and A. DePalma (AlixPartners) re: material contracts.	0.30
Total			0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	0.30	515.00	154.50
Jesse DelConte	0.50	950.00	475.00
Total Hours & Fees	0.80		629.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
06/03/20	ADD	Meeting with A. DePalma, S. Lemack (both AlixPartners) to review the PrimeClerk claims summary report and discuss next steps re: claims management.	1.20
06/03/20	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners) to review the PrimeClerk claims summary report and discuss next steps re: claims management.	1.20
06/18/20	BJF	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	MBB	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	SKL	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/18/20	ADD	Meeting with A. DePalma, S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: claims and matching updates.	0.50
06/19/20	SKL	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/19/20	BJF	Match vendor names for claims reconciliation.	2.80
06/19/20	BJF	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/19/20	MBB	Meeting with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: status of claims and matching project.	0.40
06/22/20	BJF	Third party confidentiality research for due diligence request.	2.80
06/23/20	BJF	Third party confidentiality research for due diligence request.	2.90
06/23/20	BJF	Research third party confidentiality for due diligence request.	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
06/23/20	BJF	Continue third party confidentiality research for due diligence request.	2.10
06/23/20	BJF	Correspond with S. Betik, B. Ferguson, S. Lemack (all AlixPartners) re: matching updates.	0.40
06/25/20	BJF	Third party confidentiality research for due diligence request.	2.40
06/25/20	BJF	Research third party confidentiality for due diligence request.	2.70
06/26/20	BJF	Third party confidentiality research for due diligence request.	2.70
06/26/20	BJF	Research third party confidentiality for due diligence request.	2.40
06/26/20	BJF	Continue third party confidentiality research for due diligence request.	1.80
06/29/20	BJF	Third party confidentiality research for due diligence request.	2.70
06/29/20	BJF	Research third party confidentiality for due diligence request.	1.80
06/30/20	BJF	Third party confidentiality research for due diligence request.	2.90
06/30/20	BJF	Research third party confidentiality for due diligence request.	1.40
07/01/20	BJF	Match vendor names for claims reconciliation.	2.40
07/01/20	BJF	Match vendors for claims resolution.	1.90
07/01/20	MBB	Review claims database to determine duplicate claims and matched.	2.70
07/01/20	MBB	Review claims database and matched duplicate filings.	2.40
07/01/20	SKL	Review and reconcile the claims summary report and continued matching updates accordingly.	0.90
07/02/20	MBB	Review claims database to determine duplicate claims and	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		matched.	
07/02/20	MBB	Search filed claims for duplicate filings.	2.60
07/02/20	BJF	Research third party confidentiality for due diligence request.	1.10
07/06/20	MBB	Review claims database to determine duplicate claims and assigned match numbers to new claims.	2.70
07/06/20	MBB	Review claims database to determine duplicate claims and matched.	2.90
07/06/20	MBB	Search filed claims for duplicate filings.	2.90
07/07/20	MBB	Search filed claims for duplicate filings.	2.20
07/07/20	MBB	Review claims database to determine duplicate claims and assigned match numbers to new claims.	2.90
07/07/20	MBB	Review claims database to determine duplicate claims and matched.	2.70
07/07/20	BJF	Match vendor names for claims reconciliation.	2.60
07/08/20	BJF	Match vendor names for claims reconciliation.	2.90
07/08/20	BJF	Match vendors for claims resolution.	2.80
07/08/20	MBB	Review claims database to determine duplicate claims and assigned match numbers to new claims.	2.90
07/08/20	MBB	Review claims database to determine duplicate claims and matched.	2.60
07/08/20	MBB	Search filed claims for duplicate filings.	2.70
07/09/20	MBB	Search filed claims for duplicate filings.	2.40
07/10/20	BJF	Match vendor names for claims reconciliation.	1.30
07/13/20	BJF	Match vendor names for claims reconciliation.	2.90
07/13/20	BJF	Match vendors for claims resolution.	2.40
07/13/20	BJF	Continue to match vendor names for claims reconciliation.	1.70
07/15/20	JD	Review claims estimation presentation.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
08/03/20	ADD	Call with A. DePalma and S. Lemack (both AlixPartners) re: claims process status and determine next steps	0.40
08/03/20	SKL	Call with A. DePalma and S. Lemack (both AlixPartners) re: claims process status and determine next steps	0.40
08/04/20	SKL	Review and reconcile latest Prime Clerk claims register and prepare list of open items/questions for the Prime Clerk team.	2.20
08/04/20	SKL	Meeting with A. DePalma (AlixPartners) and S. Lemack (AlixPartners) to review and reconcile latest claims register provided by Prime Clerk.	2.20
08/04/20	ADD	Meeting with A. DePalma (AlixPartners) and S. Lemack (AlixPartners) to review and reconcile latest claims register provided by Prime Clerk.	2.20
08/05/20	ADD	Meeting with A. DePalma, S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	2.10
08/05/20	SKL	Meeting with A. DePalma, S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	2.10
08/05/20	SKL	Review and reconcile latest match updates provided and circulate updated match table for review.	2.20
08/06/20	SKL	Continue review and reconciliation of the latest Prime Clerk claims register and provide updates list of open items and questions to the Prime Clerk team.	2.40
08/06/20	BJF	Match vendor names for claims reconciliation.	2.80
08/06/20	BJF	Vendor matching for claims resolution.	2.40
08/06/20	JD	Correspondence with L. Donahue (AlixPartners) re: claims process.	0.20
08/06/20	JD	Call with B. Schrag (Prime Clerk) re: claims reconciliation process.	0.30
08/06/20	JD	Call with C. Robertson (Davis Polk) re: claims	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		reconciliation process.	
08/07/20	BJF	Match vendor names for claims reconciliation.	2.80
08/07/20	BJF	Vendor matching for claims resolution.	1.70
08/07/20	SKL	Finalize import of scheduled liabilities into the claims database.	1.80
08/07/20	JD	Call with C. Robertson (Davis Polk) re: claims process.	0.20
08/10/20	JD	Review latest claims match table re: claims reconciliation process.	0.20
08/10/20	SKL	Review the latest Prime Clerk claims register and prepare updated match table accordingly.	1.70
08/10/20	SKL	Review latest feedback re: payment info for UST and work with the AP team to prepare update for future payments.	0.60
08/11/20	SKL	Call with S. Lemack and J. DelConte (both AlixPartners) re: claims process.	0.20
08/11/20	JD	Call with S. Lemack and J. DelConte (both AlixPartners) re: claims process.	0.20
08/13/20	BJF	Match vendor names for claims reconciliation.	2.80
08/13/20	BJF	Vendor matching for claims resolution.	2.40
08/13/20	BJF	Continue to match vendor names for claims reconciliation.	1.70
08/17/20	SKL	Review latest match updates provided by S. Betik (AlixPartners) and B. Ferguson (AlixPartners) and update the claims database accordingly.	2.00
08/18/20	SKL	Continue to review and reconcile the latest Prime Clerk claims register and update the claims database accordingly.	2.50
08/24/20	SKL	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattachal, A. DePalma, G. Koch, R. Collura, S. Lemack and	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		J. DelConte (all AlixPartners) re: state claim.	
08/24/20	HSB	Participate in a call with AHC and NCSG groups, Brattle Group, M. Huebner, B. Kaminetsky, M. Tobak (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), H. Bhattal, A. DePalma, G. Koch, R. Collura, S. Lemack and J. DelConte (all AlixPartners) re: state claim.	1.70
08/26/20	ADD	Meeting with A. DePalma and S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	1.20
08/26/20	SKL	Meeting with A. DePalma and S. Lemack (both AlixPartners) Update claims database and reconcile latest claims register provided by Prime Clerk.	1.20
08/27/20	SKL	Virtual Working Session with A. DePalma, S. Lemack (both AlixPartners) Update claims database and review new claims.	1.00
08/27/20	ADD	Virtual Working Session with A. DePalma, S. Lemack (both AlixPartners) Update claims database and review new claims.	1.00
09/24/20	SKL	Update claims database with the latest Prime Clerk claims report and circulate Rhodes Tech claims for review.	1.10
Total			151.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	37.30	315.00	11,749.50
Barbara J Ferguson	73.90	315.00	23,278.50
Andrew D DePalma	8.60	515.00	4,429.00
Sam K Lemack	28.30	515.00	14,574.50
HS Bhattal	1.70	840.00	1,428.00
Jesse DelConte	1.80	950.00	1,710.00
Total Hours & Fees	151.60		57,169.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/12/20	KG	Prepare eleventh production for delivery.	2.20
06/15/20	ADD	Review and compile materials for Project Catalyst data room.	2.10
06/15/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.60
06/15/20	ADD	Prepare project catalyst data room for internal and third-parties review.	1.60
06/15/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.60
06/16/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room management.	1.20
06/16/20	ADD	Prepare Project catalyst data room to open outside parties.	2.80
06/16/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room management.	1.20
06/16/20	KG	Load third party production into Relativity. Update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.20
06/17/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.70
06/17/20	ADD	Research and compile agreements in response to diligence requests for approval and production.	1.80
06/17/20	ADD	Research origination of corrupted file provided in response to diligence requests to produce file to the committee.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/17/20	ADD	Review and compile results of third-party entity review for Davis Polk review team.	2.60
06/17/20	ADD	Review and compile materials in response to diligence request for upload to the data room.	2.90
06/17/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.70
06/18/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	0.80
06/18/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.80
06/18/20	ADD	Review and compile materials in response to diligence request for upload to the data room.	2.40
06/19/20	ADD	Compile documentation submitted for project catalyst data room and request necessary approvals.	2.80
06/19/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process and coordination of next steps.	1.50
06/19/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update and discussion of outstanding items.	1.50
06/19/20	KG	Load third party production into Relativity. Update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.80
06/22/20	KG	Create file listing of new documents loaded and send to A. DePalma (AlixPartners).	0.60
06/22/20	ADD	Review and index materials provided in response to	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		diligence tax requests.	
06/22/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst data room, diligence status and review of outstanding items.	1.50
06/22/20	ADD	Review and prepare materials submitted in response to Project Catalyst diligence request for upload to the data room.	2.60
06/22/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.50
06/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.20
06/23/20	ADD	Compile and review Project Catalysts diligence materials diligence materials to request approval by internal and external counsel for upload to the data room.	2.40
06/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	1.20
06/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst review of requests for data room access and outstanding diligence requests.	1.30
06/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst review of requests for data room access and outstanding diligence requests.	1.30
06/24/20	KG	Process data for loading. Perform quality control review of processed data. Export and import into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/25/20	KG	Process data for loading. Export and import into Relativity. Load third party production into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation. Generate document listing.	2.20
06/25/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process status discussion and review of submitted information in response to diligence request.	1.60
06/25/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process status discussion and review of submitted information in response to diligence request.	1.60
06/25/20	ADD	Compile and review materials submitted in response to Project Catalyst diligence requests in preparation for upload to the data room.	2.10
06/26/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status and analyses of new inquiries.	1.80
06/26/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation of responses to diligence questions and compilation responses to questionnaires.	2.70
06/26/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation of responses to diligence questions and compilation responses to questionnaires.	2.70
06/26/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status and analyses of new inquiries.	1.80
06/29/20	ADD	Review and recommend redactions in preparation for	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
06/29/20	ADD	document production and upload to the data room.	2.10
06/29/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola (Purdue) re: Finance due diligence questions review discussion.	0.20
06/29/20	ADD	Call with A. DePalma and K. McCafferty(AlixPartners); re: Project catalyst due diligence question.	2.70
06/29/20	KM	Compile and review responses to Project Catalyst diligence requests and upload files to the data room.	2.10
06/29/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola (Purdue) re: Finance due diligence questions review discussion.	0.20
06/29/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	0.80
06/29/20	KG	Process data for loading. Export and import into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	0.40
06/30/20	KG	Process data for loading. Export and import into Relativity. Image documents, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.50
06/30/20	KM	Call and analysis with W. DiNicola, D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: finance DD interview questions for third parties.	2.00
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola (Purdue) re: Continuation of finance due diligence questions review discussion.	1.50
06/30/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Operations due	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		diligence questions review.	
06/30/20	ADD	Redaction documents submitted in response to diligence requests.	2.20
06/30/20	ADD	Call and analysis with W. DiNicola, D. Fogel (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: finance DD interview questions for third parties.	1.50
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Operations due diligence questions review.	1.50
06/30/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D.Fogel, W. DiNicola (Purdue) re: Continuation of finance due diligence questions review discussion.	2.00
06/30/20	ADD	Virtual working session with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update and compilation of diligence responses.	1.80
07/01/20	ADD	Compile and review responses to Project Catalyst diligence requests and upload files to the data room.	1.90
07/01/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update and compilation of diligence responses, and upload materials to the VDR.	2.00
07/01/20	ADD	Compile materials provided in response to Project Catalyst diligence request and submit materials for legal and business approval,	2.40
07/01/20	KG	Process data for loading including export and import into Relativity.	0.40
07/01/20	KG	Load third party production into Relativity including image documents, update/overlay data and index for search/retrieval.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/01/20	KG	Update SPOT tracking documentation and generate document listing.	0.40
07/06/20	ADD	Compile documents and request approval to upload files to the Project Catalyst VDR.	1.60
07/06/20	ADD	Download accounts payable data to update liabilities subject to compromise calculation.	0.50
07/07/20	ADD	Review and compile materials produced in response to diligence requests for Project Catalyst	2.30
07/07/20	KG	Load image documents and update/overlay data and index for search/retrieval.	0.30
07/07/20	KG	Update SPOT tracking documentation including import third party production and update/overlay data and index for search/retrieval.	0.30
07/07/20	KG	Process data for loading including export and import into Relativity.	0.30
07/08/20	ADD	Compile materials and request approval to upload files to the Project Catalyst data room.	2.60
07/09/20	ADD	Review and compile materials produced in response to diligence requests for debtor entities.	1.80
07/10/20	ADD	Compile materials and request approval to upload files to the Project Catalyst data room.	2.10
07/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst VDR and diligence progress.	0.40
07/13/20	ADD	Review and compile debtor entity employee title history for upload to the data room.	1.90
07/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst VDR and diligence progress.	0.40
07/14/20	ADD	Download and compile Rhodes Tech agreements from the	3.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		contract database with entities (A though L) for review and analysis.	
07/14/20	ADD	Download and compile Rhodes Tech agreements from the contract database with entities (J though Z) for review and analysis.	3.10
07/16/20	ADD	Compile Rhodes contracts in preparation for Project Catalyst diligence requests.	2.60
07/20/20	ADD	Compile and format items submitted in response to diligence requests for upload to the Project Catalyst data room.	2.70
07/21/20	ADD	Compile and upload Project catalyst diligence materials for external legal review.	1.40
07/22/20	ADD	Upload documents submitted in response to diligence requests and request approval from external legal counsel.	1.80
07/23/20	ADD	Compile files submitted in response to diligence requests for Project Catalyst.	1.30
07/23/20	ADD	Request approval to release files to the Project Catalyst data room.	0.90
07/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	0.60
07/24/20	ADD	Request approval to provide documents to interested parties in response to Project Catalyst diligence requests.	0.40
07/24/20	ADD	Compile list of material agreements to request consent to disclose for Project Catalyst.	1.90
07/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	0.60
07/24/20	KG	Export and re-image documents in LAW database	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		including export and email correspondence to replace corrupt images with new ones.	
07/24/20	KG	Stage and load data into Relativity including perform quality control review of loaded data, update/overlay data and index for search/retrieval and create file listing of new documents.	1.20
07/27/20	ADD	Compile list of third-parties to request consent to disclose relationship details including agreements.	1.50
07/27/20	ADD	Review and redact documents in preparation to produce in response to Project Catalyst diligence request.	1.10
07/28/20	ADD	Update with additional data elements the list of third-parties used by Rhodes to request consent to disclose relationship details including agreements.	1.10
07/28/20	ADD	Update Project Catalyst data room, removing users that no longer require access.	0.40
07/29/20	ADD	Prepare files submitted in response to Project Catalyst diligence request and upload files to data room.	2.20
07/29/20	KG	Stage and process data including perform quality control review of processed data.	0.60
07/29/20	KG	Export and import data into Relativity including perform quality control review of loaded data, update/overlay data and index for search/retrieval, and update SPOT tracking documentation.	1.00
07/31/20	ADD	Request approval to upload files compiled in response to diligence request to Project Catalyst data room.	0.70
07/31/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (AlixPartners) re: Catalyst status update meeting.	1.50
07/31/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/31/20	ADD	Review outstanding materials responsive to project catalyst diligence request and prepare documents for upload to data room.	0.30
07/31/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	1.00
08/03/20	ADD	Identity and review Rhodes Tech materials contracts for potential assignment.	2.80
08/03/20	ADD	Research agreements entered and updated since September 2019 for review and analysis.	1.30
08/03/20	ADD	Review outstanding diligence requests and follow up with outstanding items.	1.70
08/03/20	ADD	Review material Rhodes Tech relationships and compile corresponding agreements into a spreadsheet for review by external counsel and client.	2.70
08/04/20	ADD	Review compile corresponding agreements into a spreadsheet for review by external counsel and client and extract relevant data elements necessary for review.	2.70
08/04/20	ADD	Compare contract tracker to clients iContracts database to identify missing agreements.	2.90
08/04/20	ADD	Research and identify Rhodes Tech business development counter parties at request of Davis Polk to determine potential confidentiality issues.	1.80
08/05/20	ADD	Compile materials submitted in response to diligence requests for processing by Davis Polk's eDiscovery team.	2.30
08/06/20	ADD	Calculate Rhodes Tech cure costs for material entities and distribute spreadsheet for review	2.70
08/06/20	KG	Stage and process data. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
08/08/20	ADD	search/retrieval. Update SPOT tracking documentation.	2.80
08/11/20	ADD	Compile contracts for review by external counsel and upload to the Project Catalyst data room	1.40
08/12/20	ADD	Review outstanding Project Catalysts diligence questions and compile status update.	1.40
08/12/20	KG	Review outstanding supply contract and request approval to upload materials.	2.20
08/13/20	ADD	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.90
08/13/20	ADD	Compile and upload approved contracts to data room for review by counter parties.	2.60
08/14/20	ADD	Compile documentation in response to diligence requests in preparation for approval and upload to the data room.	1.70
08/14/20	ADD	Compile material IT contracts for legal review and upload to the data room.	0.20
08/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: diligence status update	0.20
08/14/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: diligence status update	2.30
08/17/20	ADD	Review and compile materials submitted in response to project Catalyst Diligence request.	2.40
08/18/20	ADD	Compile and upload to data room documents submitted in response to Project Catalyst diligence requests.	2.40
08/18/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Load third party production into Relativity.	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
08/19/20	ADD	Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	2.20
08/20/20	ADD	Compile and prepare Project Catalyst diligence materials for approval and release.	3.20
08/20/20	ADD	Identify and compile material contracts for review and upload to the Project Catalyst data room.	2.60
08/20/20	ADD	Continue to identify and compile material contracts for review and upload to the Project Catalyst data room.	1.80
08/20/20	ADD	Compile and upload documents provided in response to Project Catalyst diligence request in preparation for legal review.	1.20
08/20/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	3.00
08/21/20	ADD	Identify and compile material contracts for review and upload to the Project Catalyst data room.	1.40
08/21/20	ADD	Prepare approval trackers and request approval to release files compile to response to diligence request.	2.30
08/21/20	ADD	Compile and upload documents provided in response to Project Catalyst diligence request in preparation for legal review.	2.70
08/23/20	ADD	Identify and review Rhodes tech contracts for review by external legal counsel in preparation for production in the Project Catalyst data room.	2.20
08/24/20	ADD	Compile and upload project Catalyst diligence requests for external legal and client review prior to production.	2.30
08/25/20	ADD	Review and analyze Rhodes Tech contracts to understand	

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		and categorize material agreements.	
08/26/20	ADD	Organize and upload Project Catalyst diligence items to the data room for third-party review	1.80
08/27/20	ADD	Prepare and upload project Catalyst diligence request for upload to the data room for review.	2.60
08/27/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	1.20
08/28/20	ADD	Review and analyze Rhodes Tech contracts to understand and categorize material agreements.	2.60
08/28/20	ADD	Organize and upload Project Catalyst diligence items to the data room for third-party review	2.80
08/29/20	ADD	Review contract schedules Project Catalyst in preparation for submission for legal review.	1.80
08/30/20	ADD	Review and analysis of history of Rhodes Tech agreements by entity for Project Catalyst diligence request.	2.30
08/31/20	ADD	Identify and research missing agreements for Project Catalyst contract schedules.	2.30
08/31/20	ADD	Compile items submitted in response to project Catalyst diligence questions and request approval to post materials.	1.20
09/01/20	ADD	Review Research Purdue IAC agreement list to determine if the list is incomplete.	0.70
09/01/20	ADD	Compile agreements for Project Catalyst's external counsel's review.	1.20
09/01/20	ADD	Compile and upload materials submitted in response	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		diligence requests for upload to the Project Catalyst data room.	
09/01/20	ADD	Review material contracts list and compile newly executed agreements for upload to the Project Catalyst data room.	1.20
09/01/20	ADD	Request approval from external counsel and internal counsel to upload documents to the data room and release to external parties.	0.60
09/01/20	ADD	Redact documents in preparation for upload to the Project Catalyst data room.	1.80
09/01/20	KG	Stage and process data for loading. Perform quality control review of processed data. Export and import data into Relativity. Perform quality control review of loaded data. Generate TIF images, update/overlay data and index for search/retrieval. Update SPOT tracking documentation.	0.80
09/02/20	ADD	Review consent requirements to share agreements with third parties for project catalyst.	0.50
09/02/20	ADD	Research and compile agreements for external legal review.	2.90
09/02/20	ADD	Compile and upload materials submitted in response diligence requests for upload to the Project Catalyst data room.	2.80
09/02/20	ADD	Work with external legal counsel to identify agreements to share in the Project Catalyst data room.	1.20
09/02/20	ADD	Request approval from external counsel and internal counsel to upload documents to the data room and release to external parties.	0.80
09/03/20	ADD	Research and analyze Rhodes Tech contractual relationships to assist external counsel with schedule creation.	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
09/03/20	ADD	Compile and upload documents submitted in response to diligence request for upload to the data room.	2.60
09/03/20	ADD	Request approval from external counsel and internal counsel to upload documents to the data room and release to external parties.	1.20
09/04/20	ADD	Compile and agreements in response to Project Catalyst diligence request and request approval to upload.	2.30
09/06/20	ADD	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCarthy, R. Aleali, J. Lowne (Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (Skadden) re: MSA review.	3.30
09/08/20	ADD	Compile data and update cure cost calculation to determine entities with pre-petition liabilities.	3.10
09/14/20	ADD	Compile and upload documents responsive to diligence request to the Project Catalyst data room.	1.80
09/14/20	ADD	Research possible addresses for noticing purposes for Rhodes Tech counter parties with missing contact information.	0.80
09/14/20	ADD	Review and analysis of Rhodes Tech contracts for project catalyst term sheet schedules.	2.40
09/14/20	ADD	Research and compile noticing addresses to notify Rhodes Tech counter parties re: project catalyst.	3.30
09/15/20	ADD	Research possible addresses for noticing purposes for Rhodes Tech counter parties with missing contact information.	0.50
09/15/20	ADD	Prepare and upload ad hoc committee diligence requests to the data room for review by the committees.	1.90
09/16/20	ADD	Review and analyze Rhodes contracts for materiality and relative importance.	1.00
09/16/20	ADD	Research Rhodes' counter party addresses for noticing	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
		purposes.	
09/17/20	ADD	Call with D. Fogel (Purdue) and A. DePalma., K. McCafferty (AlixPartners) re: RP contract analysis results.	0.90
09/17/20	ADD	Research Rhodes' counter party addresses for noticing purposes.	1.60
09/17/20	ADD	Compile materials submitted in response to diligence requests in preparation for processing and upload to the data room	1.80
09/18/20	ADD	Research Rhodes' counter party addresses for noticing purposes.	0.60
09/18/20	ADD	Draft correspondence to follow up on outstanding diligence requests.	0.50
09/18/20	KG	Coordinate with ETS to reactivate Relativity credentials for S. Canniff (AlixPartners).	0.10
09/21/20	ADD	Research Rhodes' counter party addresses for noticing purposes.	0.70
09/22/20	KG	Stage and import third party productions into Relativity. Troubleshoot load file issues and import errors into Relativity.	3.30
09/23/20	KG	Export and create copies of documents as requested by A. DePalma (AlixPartners). Perform quality control review of new data. Generate TIF images.	1.80
09/25/20	KG	Run Blackout process across requested documents. Batch documents that need review.	1.20
09/25/20	ADD	Review and compile Rhodes agreements to update contract database for Project Catalyst.	1.90
09/27/20	ADD	Review Purdue employment data and prepare information requested by Davis Polk.	2.40
09/30/20	ADD	Review agreements shared with Rhodes Tech bidders and identify additional agreements to be shared via the data	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
09/30/20	ADD	room. Compile and review Rhodes Technologies contracts in preparation for closing.	3.20
Total			308.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	249.80	515.00	128,647.00
Kristina Galbraith	32.70	645.00	21,091.50
Kevin M McCafferty	26.00	950.00	24,700.00
Total Hours & Fees	308.50		174,438.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
06/01/20	ESK	Attend to disclosure matters.	0.40
06/02/20	ESK	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	ESK	Email J. Fee (AlixPartners) re: disclosure matter.	0.30
06/02/20	JD	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: disclosure matters.	0.20
06/02/20	LJD	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/02/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: disclosure matters.	0.20
06/02/20	GJK	Call with L. Donahue, E. Kardos, G. Koch and J. DelConte (all AlixPartners) re: disclosure matters.	1.00
06/03/20	LJD	Prepare for and attend call with M. Huebner (Davis Polk), M. Kesselman (Purdue), L. Donahue and J. DelConte (both AlixPartners) re: disclosure matters.	0.60
06/03/20	LJD	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	JD	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	JD	Call with J. DelConte and E. Kardos (all AlixPartners) re: various disclosure matters.	0.60
06/03/20	ESK	Call with J. DelConte and E. Kardos (all AlixPartners) re: various disclosure matters.	0.60
06/03/20	ESK	Call L. Donahue, J. DelConte and E. Kardos (all AlixPartners) re: addressing possible disclosure matter.	1.00
06/03/20	ESK	Email J. Fee (AlixPartners) re: disclosure matter.	0.30
06/03/20	ESK	Prepare disclosure report.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
06/03/20	ESK	Email to/from T. Antidel (AlixPartners) re: disclosure report.	0.30
06/03/20	JD	Correspondence with Davis Polk re: SOFA/SOAL disclosures.	0.40
06/03/20	JD	Review correspondence re: potential disclosures.	0.30
06/03/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman (Purdue), L. Donahue and J. DelConte (both AlixPartners) re: disclosure matters.	0.50
09/03/20	ESK	Work on the Purdue disclosure matter	0.30
Total			12.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Elizabeth S Kardos	4.50	710.00	3,195.00
Gabe J Koch	1.20	840.00	1,008.00
Jesse DelConte	4.00	950.00	3,800.00
Lisa Donahue	2.60	1,195.00	3,107.00
Total Hours & Fees	12.30		11,110.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/01/20	JD	Begin reviewing draft April fee statement.	1.50
06/01/20	JD	Finalize reviewing and editing draft April fee statement.	2.70
06/01/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.50
06/01/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	1.50
06/02/20	JD	Review final April 2020 professional fees and expenses.	0.30
06/03/20	TB	Prepare eighth monthly fee statement for April 2020 and exhibits.	1.30
06/05/20	JD	Conversation with J. Lowne (Purdue) re: AlixPartners fee statement review.	0.30
06/08/20	JD	Review draft April fee statement and provide comments.	0.40
06/08/20	TB	Update April monthly fee statement and exhibits.	0.40
06/08/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.40
06/09/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.10
06/10/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.70
06/10/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	2.90
06/10/20	MSM	Further preparation of professional fees for May 2020 monthly fee statement.	3.00
06/11/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	3.30
06/11/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	3.10
06/12/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/12/20	ESK	Review eighth monthly fee statement for the period April 1, 2020 through April 30, 2020.	0.30
06/13/20	ESK	Review email from Davis Polk re: fee examiner request and email response internally re: same.	0.10
06/15/20	ESK	Review eighth monthly fee statement for the period of April 1, 2020 through April 30, 2020.	0.30
06/15/20	JD	Correspondence with accounting re: fee examiner requests.	0.20
06/15/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.00
06/16/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.70
06/16/20	MSM	Continue to prepare professional fees for May 2020 monthly fee statement.	2.10
06/16/20	TB	Review professional fees for May 2020 monthly fee statement.	1.20
06/16/20	JD	Review initial fee examiner report and back up materials.	1.30
06/16/20	ESK	Review fee examiner report and began to consider responses.	0.50
06/16/20	ESK	Review emails from M. Pera (Davis Polk) re: objection to AlixPartners' first interim fee application.	0.30
06/16/20	ESK	Call with J. DelConte, E. Kardos (both AlixPartners) re: various Purdue matters, including objection to first interim fee application.	0.40
06/16/20	JD	Call with J. DelConte, E. Kardos (both AlixPartners) re: various Purdue matters, including objection to first interim fee application.	0.40
06/16/20	JD	Correspondence with Davis Polk and AlixPartners legal re: fee examiner.	0.60
06/17/20	ESK	Review and provide comments to Fee Examiners'	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		objection to the first interim fee application.	
06/17/20	JD	Call with B. Filler, E. Kardos and J. DelConte (all AlixPartners) re: fee examiner report.	0.70
06/17/20	JD	Draft responses to the fee examiner initial report.	0.90
06/17/20	ESK	Call J. DelConte and B. Fuller (both AlixPartners) to review fee examiner report and prepare response to same.	0.70
06/17/20	ESK	Internal calls re: various case administration matters.	0.50
06/17/20	BFF	Updates/revisions to draft response to Fee Examiner.	1.90
06/17/20	BFF	Call with E. Kardos and J. DelConte (both AlixPartners) re: preparation of response to Fee Examiner report re: first interim fee application.	0.70
06/17/20	BFF	Prepare draft response to Fee Examiner's report re: first interim fee application.	2.80
06/18/20	BFF	Review air travel receipts in connection with Fee Examiner report re: first interim fee application.	0.60
06/18/20	ESK	Review and revise Response to Fee Examiner objection to first interim fee application.	1.20
06/18/20	JD	Review and edit fee examiner response letter. Review underlying data per fee examiner letter.	0.80
06/19/20	JD	Update fee examiner response. Correspondence with E. Kardos and L. Donahue (both AlixPartners) re: same.	0.90
06/19/20	JD	Call with E. Kardos, B. Filler and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	JD	Check and finalize fee examiner response. Draft correspondence re: same.	0.70
06/19/20	TB	Review professional fees for May 2020 monthly fee statement.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
06/19/20	ESK	Call with E. Kardos, B. Filler and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	ESK	Emails to/from L. Donahue (AlixPartners) re: fee examiner response.	0.30
06/19/20	ESK	Review and revise response to fee examiner report.	0.90
06/19/20	BFF	Call with E. Kardos, B. Filler and J. DelConte (both AlixPartners) re: finalizing response to Fee Examiner report re: first interim fee application.	0.60
06/19/20	BFF	Update response to Fee Examiner report re: first interim fee application.	2.10
06/22/20	BFF	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	ESK	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	ESK	Review and respond to emails re: response to Fee Examiner objection to first interim application.	0.50
06/22/20	ESK	Emails to/from J. DelConte and L. Donahue (both AlixPartners) re: settlement of reduction of fees/expenses.	0.20
06/22/20	JD	Review fee examiner response letter and fee examiner flagged time entries to prepare for call.	0.40
06/22/20	JD	Correspondence with E. Kardos and L. Donahue (both AlixPartners) re: fee examiner response and settlement.	0.40
06/22/20	JD	Call with D. Klauder, T. Bielli (both Bielli & Klauder), J. DelConte, E. Kardos and B. Filler (all AlixPartners) re: response to first fee examiner report.	0.50
06/22/20	TB	Review professional fees for May 2020 monthly fee	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		statement.	
06/24/20	MSM	Prepare professional fees for May 2020 monthly fee statement.	2.50
06/24/20	MSM	Prepare professional fees for June 2020 monthly fee statement.	1.50
06/24/20	JD	Begin reviewing and providing comments to draft May 2020 professional fees and expenses.	2.20
06/25/20	JD	Finalize review of draft May fee application.	1.50
07/01/20	TB	Prepare ninth monthly fee statement May 2020 and exhibits.	1.80
07/02/20	TB	Update ninth monthly fee statement for May 2020.	0.60
07/02/20	JD	Review final version of the May fee statement to be filed with the court.	0.30
07/06/20	LJD	Review and comment on 9th monthly fee statement.	0.40
07/06/20	MSM	Prepare professional fees for June 2020 fee statement.	2.50
07/06/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	3.00
07/07/20	MSM	Prepare professional fees for June 2020 fee statement.	1.50
07/08/20	TB	Prepare workbook for the second interim.	1.90
07/09/20	TB	Prepare second interim fee application and exhibits.	3.20
07/09/20	TB	Continue to prepare second interim fee application and exhibits.	1.40
07/09/20	MSM	Prepare professional fees for June 2020 fee statement.	2.50
07/10/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/10/20	JD	Review and provide comments on the 2nd interim fee application draft.	1.00
07/13/20	MSM	Prepare professional fees for June 2020 fee statement.	1.70
07/13/20	TB	Update fee and expense status chart. Update the second	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		interim fee application.	
07/14/20	JD	Review final second interim fee application.	0.50
07/16/20	MSM	Prepare professional fees for June 2020 fee statement.	3.80
07/17/20	MSM	Prepare professional fees for June 2020 fee statement.	3.50
07/17/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	3.10
07/17/20	MSM	Further preparation of professional fees for June 2020 fee statement.	2.40
07/18/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/19/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/19/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	1.80
07/23/20	MSM	Prepare professional fees for July 2020 fee statement.	2.50
07/24/20	MSM	Prepare professional fees for July 2020 fee statement.	3.40
07/27/20	MSM	Prepare professional fees for July 2020 fee statement.	1.80
07/28/20	MSM	Prepare professional fees for July 2020 fee statement.	2.50
07/31/20	MSM	Prepare professional fees for July 2020 fee statement.	1.50
07/31/20	JD	Begin initial review of June fee statement for filing with the court.	1.80
07/31/20	JD	Finalize review of June fee statement.	2.30
08/01/20	MSM	Prepare professional fees for July 2020 fee statement.	3.10
08/02/20	MSM	Prepare professional fees for July 2020 fee statement.	2.90
08/04/20	AML	Prepare professional fees for July 2020 fee statement.	2.00
08/04/20	TB	Prepare June 2020 monthly fee statement and exhibits.	2.10
08/04/20	JD	Correspondence with J. Lowne (Purdue) re: AlixPartners May invoice.	0.30
08/05/20	ESK	Review June monthly fee statement	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
08/05/20	AML	Prepare professional fees for July 2020 fee statement.	1.50
08/06/20	AML	Prepare professional fees for July 2020 fee statement.	3.50
08/07/20	AML	Email correspondence with J. DelConte (AlixPartners) re: Professional Fees	0.20
08/07/20	JD	Review final fee application to be filed with the court.	0.70
08/08/20	AML	Prepare professional fees for July 2020 fee statement.	3.00
08/13/20	JD	Initial review of second interim fee app review from the Fee Examiner.	0.80
08/13/20	LCV	Review Fee Examiner's Report of AlixPartners' Second Interim Fee Application	0.20
08/13/20	LCV	Draft exhibits and response to Fee Examiner re: AlixPartners' Second Interim Fee Application	2.40
08/14/20	LCV	Correspondence with E. Kardos (AlixPartners) re: response to Fee Examiner's Report of AlixPartners 2nd Interim Fee App	0.30
08/17/20	LCV	Emails with J. DelConte (AlixPartners) re: status of response to fee examiner for AlixPartners 2nd Interim Fee Application	0.10
08/17/20	JD	Edit draft response to the fee examiner's interim report on AlixPartners's 2nd interim fee application.	1.20
08/18/20	JD	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/18/20	JD	Finish review of fee examiner report and finish drafting initial draft response.	1.50
08/18/20	LCV	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/18/20	LCV	Emails with Travel Services and Engagement Accounting re: response to Fee Examiner's Report of AlixPartners 2nd	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		Interim Fee Application	
08/18/20	ESK	Call with J. DelConte, E. Kardos and L. Verry (all AlixPartners) re: response to fee examiners report of AlixPartners 2nd Interim Fee Application	0.50
08/19/20	TB	Analyze expenses noted in the Fee Examiners' objection to second interim fee application.	0.50
08/20/20	ESK	Prepare response to UST objection to interim fee application	1.00
08/20/20	ESK	Provide comments to UST objection to interim fee application	1.30
08/20/20	ESK	Emails to/from J. DelConte (AlixPartners) re: Review UST objection to interim fee application	0.30
08/20/20	LCV	Emails with T. Brewer, C. Mosher, J. DelConte (all AlixPartners) re: to follow up on information for response to Fee Examiner's Report on AlixPartners 2nd Interim Fee Application	0.20
08/20/20	JD	Correspondence with Concur and accounting re: flight details re: fee examiner questions.	0.60
08/21/20	JD	Finalize draft Fee Examiner response and send to L. Donahue (AlixPartners) for final review.	1.60
08/21/20	ESK	Provide comments to UST objection to interim fee application	1.30
08/21/20	ESK	Emails to/from J. DelConte (AlixPartners) re: Review UST objection to interim fee application	0.30
08/24/20	JD	Review final response to the fee examiner and send across to D. Klauder (Bielli & Klauder).	0.40
08/24/20	JD	Review response from the fee examiner. Correspondence with L. Donahue and E. Kardos (both AlixPartners) re: same.	0.40
08/25/20	JD	Begin review of July fee statement.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
08/26/20	ESK	Review proposed interim fee order	0.20
08/28/20	JD	Continue review of July fee application.	1.40
09/01/20	MSM	Prepare professional fees for August 2020 fee statement.	0.80
09/02/20	JD	Finalize review of draft July fee statement to file with the court.	2.60
09/03/20	MSM	Prepare professional fees for August 2020 fee statement.	2.00
09/04/20	TB	Prepare the eleventh monthly fee statement for July 2020 and exhibits.	1.40
09/04/20	JD	Review final mark up and final version of the July fee statement.	0.30
09/08/20	TB	Email to M. Pera, D. Consla, C. Robertson (all David Polk) attaching the eleventh monthly fee statement July 2020 for filing with the court.	0.20
09/08/20	MSM	Prepare professional fees for August 2020 fee statement.	3.80
09/12/20	MSM	Prepare professional fees for August 2020 fee statement.	3.20
09/12/20	MSM	Continue to prepare professional fees for August 2020 fee statement.	2.80
09/13/20	MSM	Prepare professional fees for August 2020 fee statement.	1.20
09/13/20	MSM	Continue to prepare professional fees for August 2020 fee statement.	3.60
09/13/20	MSM	Further preparation of professional fees for August 2020 fee statement.	2.70
09/14/20	MSM	Prepare professional fees for August 2020 fee statement.	3.90
09/15/20	MSM	Prepare professional fees for August 2020 fee statement.	4.00
09/19/20	MSM	Prepare professional fees for September 2020 fee statement.	2.20
09/28/20	TB	Prepare monthly fee statement and exhibits for August 2020.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
09/28/20	JD	Start the initial review of the August fee statement to be filed with the court.	2.20
09/28/20	JD	Finish review of the August fee statement to be provided to the court and provide comments for the next turn of the draft.	2.10
09/29/20	TB	Update of exhibit A on the August monthly fee statement.	0.20
Total			220.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Andrea M LeBar	10.20	375.00	3,825.00
Melanie McCabe	121.40	415.00	50,381.00
Brooke F Filler	9.20	445.00	4,094.00
Tammy Brewer	20.60	450.00	9,270.00
Laurie C Verry	4.10	510.00	2,091.00
Elizabeth S Kardos	13.30	710.00	9,443.00
Jesse DelConte	40.90	950.00	38,855.00
Lisa Donahue	0.40	1,195.00	478.00
Total Hours & Fees	220.10		118,437.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
06/03/20	MFR	Participate in the Court hearing.	2.50
06/03/20	RC	Dial into Purdue court hearing re: bar date.	1.70
06/03/20	JD	Participate telephonically in court hearing on bar date extension.	2.50
06/23/20	JD	Dial in to Purdue hearing on HRT.	1.00
07/23/20	JD	Participate in Purdue court hearing.	3.20
08/26/20	NAS	Partial attendance of telephonic court hearing.	0.50
08/26/20	JD	Participate telephonically in court hearing.	1.60
08/26/20	HSB	Attend telephonic court hearing.	1.60
09/30/20	HSB	Court hearing (dialed in) re: KERP.	1.80
09/30/20	JD	Listen in to telephonic court hearing.	4.00
09/30/20	NAS	Attend 9/30 telephonic hearing (partial).	3.40
Total			23.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	3.90	515.00	2,008.50
HS Bhattal	3.40	840.00	2,856.00
Mark F Rule	2.50	910.00	2,275.00
Jesse DelConte	12.30	950.00	11,685.00
Richard Collura	1.70	1,090.00	1,853.00
Total Hours & Fees	23.80		20,677.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/01/20	SJC	Review of email and files from Haug Partners for 2008 and 2009 Ex-US distributions.	2.50
06/01/20	SJC	Update distribution samples selected by Province new bank statements received from Haug Partners.	3.00
06/01/20	SJC	Continue to update distribution samples selected by Province new bank statements received from Haug Partners.	2.50
06/01/20	RC	Review distribution related documentation gathered in response to requests from the UCC.	1.60
06/01/20	MFR	Review and organization of supporting documents related to Report 1B Intercompany Non-Cash Transfers of Value.	3.10
06/01/20	MFR	Review and analysis of documentation supporting accounts payable analyses.	2.80
06/01/20	MFR	Review and analysis of workpapers supporting Report 1B, Intercompany Non-Cash Transfers of Value.	2.70
06/01/20	ADD	Review UCC tax requests and compared to responses received from TXP to determine outstanding items.	2.60
06/02/20	JDH	Finalization of 2008 distribution documentation.	2.30
06/02/20	RC	Review additional documentation gathered in response to requests from the UCC's advisors.	0.60
06/02/20	SJC	Update distribution samples selected by Province new bank statements received from Haug Partners.	3.00
06/02/20	SJC	Continue to update distribution samples selected by Province new bank statements received from Haug Partners.	2.00
06/02/20	SJC	Update distributions with new bank statements received from Haug Partners (years 2017, 2015, 2013, 2011, and 2009).	3.00
06/03/20	SJC	Review and redact 2017 board meeting minutes in preparation for processing an upload to data room.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/03/20	SJC	Review and redact 2016 board meeting minutes in preparation for processing an upload to data room.	3.00
06/03/20	SJC	Review and redact 2015 board meeting minutes in preparation for processing an upload to data room.	3.00
06/03/20	SJC	Review and redact 2014 board meeting minutes in preparation for processing an upload to data room.	1.00
06/03/20	RC	Review letter from UCC to the court re: discovery issues with the Sacklers.	0.50
06/03/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.50
06/04/20	SJC	Review and redact 2018 board meeting minutes in preparation for processing an upload to data room.	3.00
06/04/20	SJC	Review and redact 2017 board meeting minutes in preparation for processing an upload to data room.	1.00
06/05/20	RC	Review SAP information related to tax and distribution requests.	0.80
06/05/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.80
06/07/20	RC	Review and update comments related to the status of diligence requests.	0.40
06/07/20	RC	Review and prepare comments related to the summary status of diligence requests and communications with TXP.	0.60
06/07/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: comments re: status of diligence requests.	0.50
06/07/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: comments re: status of diligence requests.	0.50
06/08/20	RC	Review documentation gathered in response to the UCC's requests for tax and distribution information.	1.10
06/08/20	SJC	Review and redact Rhodes board materials in preparation for processing an upload to data room.	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/08/20	SJC	Continue review and redaction of Rhodes board materials in preparation for processing an upload to data room.	4.00
06/08/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	3.20
06/09/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.40
06/09/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/09/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/09/20	RC	Review available information gathered in response to additional tax information related requests made by the UCC.	1.40
06/10/20	RC	Review status of information provided by TXP in response to special committee and UCC requests and identify additional follow-up items.	1.30
06/10/20	RC	Review updated TXP diligence request tracker.	0.30
06/10/20	NAS	Research and respond to question from R. Collura (AlixPartners) re: payroll information for admin professionals.	0.40
06/10/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/10/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/10/20	MFR	Review and organization of Report 1B supporting documentation and analyses.	2.70
06/11/20	SJC	Continue review and redaction of Rhodes board materials	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		from the P drive in preparation for processing an upload to data room.	
06/11/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/11/20	RC	Review cash distribution support documentations gathered in response to information requests.	1.30
06/11/20	RC	Outline next steps re: responding to the UCC's requests related to distributions support.	0.40
06/12/20	RC	Review communications from FTI and coordinate with Davis Polk re: next steps and related responses.	0.20
06/12/20	RC	Coordinate with team on responding to requests made by FTI related to the cash and non-cash transfers of value reports.	0.30
06/12/20	RC	Review status of compiling cash distribution support documentation related to requests from the UCC.	0.90
06/12/20	RC	Review information provided by TXP to the UCC.	0.40
06/12/20	RC	Review summary of distribution support documentation gathered in connection with the UCC's requests.	0.50
06/12/20	RC	Review SAP information related to the UCC's requests for tax information.	0.40
06/12/20	RC	Review cash distribution support documentation in response to requests from the UCC.	0.70
06/12/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/12/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.50
06/14/20	RC	Review summary of work performed in connection with gathering the distribution support documentation.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/15/20	RC	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	RC	Review documentation related to cash distributions and other diligence requests from the UCC and provide comments to team.	1.30
06/15/20	RC	Review documentation provided by TXP and provide comments related to the diligence tracker.	0.80
06/15/20	SJC	Meeting with R. Collura, A. DePalma, S. Canniff (all AlixPartners) re: diligence requests.	1.00
06/15/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/15/20	SJC	Review and organization of 2017-2008 distributions.	3.00
06/15/20	FOS	Compose email to M. Rule (AlixPartners) re: information requests relating to Report 1B.	1.50
06/16/20	SJC	Review of 2008, 2010, 2012, 2014, and 2016 distributions.	3.00
06/16/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.00
06/16/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.00
06/16/20	RC	Review distribution related information compiled in response to requests from the UCC.	1.20
06/16/20	RC	Review information related to transactions with the IACs.	0.50
06/17/20	RC	Review summary of supporting information related to requests from the UCC.	1.20
06/17/20	RC	Review additional information provided by TXP to the UCC.	0.60
06/17/20	RC	Review and comment on summary of distribution support	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		documentation.	
06/17/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	4.00
06/17/20	SJC	Review of distribution completeness testing.	4.00
06/17/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: Intercompany and non-cash transfers report information requests.	0.20
06/17/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: Intercompany and non-cash transfers report information requests.	0.20
06/18/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	2.20
06/18/20	FOS	Review documents received re: supply agreements between debtor companies and IACs.	0.20
06/18/20	SJC	Review of distribution completeness testing.	3.50
06/18/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.00
06/18/20	SJC	Continue review and redaction of Rhodes board materials from the P drive in preparation for processing an upload to data room.	1.00
06/18/20	SJC	Working session with S. Canniff, A. DePalma (both AlixPartners) to review TXP/UCC diligence items .	1.00
06/18/20	RC	Review and comment on summary of distribution testing analysis.	0.90
06/18/20	RC	Coordinate and schedule calls with FTI re: the cash and non-cash transfers of value reports.	0.10
06/18/20	RC	Review detail transactions related to distribution completeness testing analysis.	0.80
06/18/20	ADD	Working session with S. Canniff, A. DePalma (both	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners) to review TXP/UCC diligence items .	
06/19/20	ADD	Compile and prepare May MOR for review, signature and upload.	2.90
06/19/20	ADD	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	RC	Review transactions related to distributions completeness testing and provide comments to team.	0.40
06/19/20	RC	Review outline of topics provided by FTI and prepare for upcoming calls re: the transfers of value reports.	0.60
06/19/20	RC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	RC	Review summary of distribution completeness testing and provide comments and next steps.	1.10
06/19/20	RC	Review status update provided by TXP's counsel related to tax returns provided.	0.20
06/19/20	RC	Review support documentation related to the non-cash transfers of value report.	1.00
06/19/20	SJC	Review of distribution completeness testing.	2.00
06/19/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.00
06/19/20	SJC	Continue review of distribution completeness testing.	2.20
06/19/20	SJC	Call with R. Collura, S. Canniff and A. DePalma (all AlixPartners) to review TXP/UCC diligence items and distribution completeness testing.	1.30
06/19/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.10
06/22/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/22/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: completeness testing for Report 1B.	0.30
06/22/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	3.20
06/22/20	FOS	Review SAP data and documents re: preparation for discussion with FTI on report 1B.	3.50
06/22/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: completeness testing for Report 1B.	0.30
06/22/20	FOS	Compose email to R. Collura (AlixPartners) re: completeness testing for Report 1B.	0.20
06/22/20	SJC	Review and discussion of distribution completeness testing.	3.00
06/22/20	SJC	Continue review of distribution completeness testing.	2.60
06/22/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.00
06/22/20	SJC	Call with R. Collura, S. Canniff (both AlixPartners) re: distributions testing.	0.40
06/22/20	RC	Review additional testing analysis related to transactions with IACs.	1.10
06/22/20	RC	Call with R. Collura, S. Canniff (both AlixPartners) re: distributions testing.	0.40
06/22/20	RC	Draft outline and related responses to questions from FTI re: the cash transfers of value report.	1.30
06/22/20	RC	Review and comment on responses to FTI's questions related to the non-cash transfers of value report.	0.60
06/22/20	RC	Review summary of tax returns provided by TXP.	0.10
06/22/20	RC	Prepare additional responses to questions from FTI and provide draft to Davis Polk.	0.70
06/23/20	RC	Call with R. Collura, M. Rule, F. Silva (all AlixPartners) re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		discussion with FTI re: Reports 1A and 1B.	
06/23/20	RC	Review various testing analyses related to the non-cash transfers of value report.	0.30
06/23/20	RC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	RC	Call with R. Collura and J. DelConte (both AlixPartners) re: case status update prior to diligence calls with FTI on the investigative reports.	0.30
06/23/20	RC	Update outline of responses to questions received from FTI re: the cash transfers and intercompany non-cash transfers of value report.	0.70
06/23/20	SJC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	SJC	Continue review and integration of Province samples into distribution sample population.	3.00
06/23/20	SJC	Review and integration of Province samples into distribution sample population.	2.20
06/23/20	SJC	Review of distribution completeness testing.	2.00
06/23/20	FOS	Call with R. Collura, M. Rule, F. Silva (all AlixPartners) re: discussion with FTI re: Reports 1A and 1B.	0.80
06/23/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	MFR	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80
06/23/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.50
06/23/20	MFR	Prepare for and participate in call with R. Collura, M. Rule, F. Silva (all AlixPartners) re: discussion with FTI re: Reports 1A and 1B.	1.20
06/23/20	ADD	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (AlixPartners) re: 1A and 1B reports.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/23/20	JD	Call with R. Collura and J. DelConte (both AlixPartners) re: case status update prior to diligence calls with FTI on the investigative reports.	0.30
06/24/20	ADD	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10
06/24/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: cash transfers of value report and status of diligence requests.	0.20
06/24/20	MFR	Prepare for and participate in call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.50
06/24/20	MFR	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	MFR	Prepare for call with FTI re: Report 1B (Intercompany/Non-Cash Transfers of Value Report).	2.00
06/24/20	FOS	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	FOS	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10
06/24/20	SJC	Review and integration of Province samples into distribution sample population.	3.00
06/24/20	SJC	Continue review and integration of Province samples into distribution sample population.	2.90
06/24/20	SJC	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
06/24/20	RC	Review cash transfers of value report and prepare for call with FTI.	1.20
06/24/20	RC	Conference call with R. Collura, M. Rule, and F. Silva (all AlixPartners) re: FTI requests on Reports 1A and 1B.	0.70
06/24/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: cash transfers of value report and status of diligence requests.	0.20
06/24/20	RC	Call with R. Collura, M. Rule, S. Canniff, F. Silva and A. DePalma (AlixPartners) and FTI (M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso) re: the cash transfers of value report.	1.10
06/25/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: call with FTI re: the intercompany and non-cash transfers of value report.	0.50
06/25/20	RC	Provide update to Davis Polk re: call with FTI re: the special committee reports.	0.10
06/25/20	RC	Review tax information provided byTXP's counsel and identify follow-up work to perform.	0.30
06/25/20	RC	Review intercompany and non-cash transfers of value report in Prepare for call with FTI.	0.60
06/25/20	RC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/25/20	SJC	Continue review and integration of Province samples into distribution sample population.	3.40
06/25/20	SJC	Review and integration of Province samples into distribution sample population.	3.50
06/25/20	SJC	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re:	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Project Windsor - Cash Transfers of Value Report Discussion.	
06/25/20	FOS	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/25/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: call with FTI re: the intercompany and non-cash transfers of value report.	0.50
06/25/20	MFR	Prepare for and participate in call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.50
06/25/20	MFR	Prepare for call with FTI re: Report 1B Intercompany Non-Cash Transfers of Value Report.	1.20
06/25/20	ADD	Attend call with S. Canniff, R. Collura, A. DePalma, M. Rule, F. Silva (all AlixPartners), M. Greenblatt, B. Broomberg, P. Kyviakidis and N. Costalso (all FTI) re: Project Windsor - Cash Transfers of Value Report Discussion.	1.10
06/26/20	ADD	Working session with A. DePalma, S. Canniff (both AlixPartners) to review PPLP distributions and tax returns.	0.80
06/26/20	SJC	Working session with A. DePalma, S. Canniff (both AlixPartners) to review PPLP distributions and tax returns.	0.80
06/26/20	SJC	Pulling support for 2017 and 2016 tax distributions for data room.	3.50
06/26/20	SJC	Analysis of distributions contained within tax filings.	3.50
06/26/20	RC	Review support documentation compiled for tax distributions and provide comments to team.	0.80
06/29/20	RC	Review support documentation for tax distributions and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		provide comments to team.	
06/29/20	SJC	Review of 2016 tax distributions for upload to data room.	0.60
06/29/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	3.00
06/29/20	SJC	Continue to review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	1.00
06/29/20	SJC	Review and integration of Province samples into distribution sample population.	3.50
06/30/20	SJC	Adding distribution support to 2016 tax distribution samples.	1.00
06/30/20	SJC	Review 2017 tax distributions.	2.00
06/30/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	1.60
06/30/20	SJC	Review and analysis of all distributions with supporting documentation.	1.50
06/30/20	SJC	Review of 2016 tax distributions.	2.00
06/30/20	SJC	Call with S. Canniff, R. Collura (both AlixPartners) re: tax distribution support documentation.	0.40
06/30/20	RC	Review tax distribution support gathered in response to requests from the UCC and provide comments to team.	1.30
06/30/20	RC	Call with S. Canniff, R. Collura (both AlixPartners) re: tax distribution support documentation.	0.40
06/30/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: tax distribution support documentation and next steps.	0.20
06/30/20	RC	Review support documentation available in the SAP system related to tax distribution requests from the UCC.	1.20
06/30/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		tax distribution support documentation and next steps.	
06/30/20	ADD	Review tax distribution support compiled in preparation for upload to the data room.	2.20
07/01/20	ADD	Meeting with A. DePalma and S. Canniff (both AlixPartners) re: diligence requests.	0.50
07/01/20	ADD	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/01/20	RC	Call with S. Canniff, R. Collura (both AlixPartners) to review and discuss responses to tax diligence requests.	1.00
07/01/20	RC	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/01/20	RC	Review tax distribution support documentation gathered in response to requests from the UCC.	0.90
07/01/20	RC	Review and respond to requests from Davis Polk about tax distributions.	0.40
07/01/20	SJC	Pulling support for 2014 tax distributions for data room.	2.50
07/01/20	SJC	Pulling support for 2015 tax distributions for data room.	2.00
07/01/20	SJC	Pulling support for 2009 tax distributions for data room.	1.50
07/01/20	SJC	Meeting with A. DePalma and S. Canniff (both AlixPartners) re: diligence requests.	0.50
07/01/20	SJC	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/01/20	SJC	Call with S. Canniff, R. Collura (both AlixPartners) to review and discuss responses to tax diligence requests.	1.00
07/02/20	SJC	Pulling support for 2013 tax distributions for data room.	2.00
07/02/20	SJC	Pulling support for 2011 tax distributions for data room.	1.00
07/02/20	SJC	Review and analysis of 2014 tax distribution.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/02/20	RC	Call with M. Clarens (Davis Polk) to discuss information related to the tax distributions.	0.30
07/02/20	RC	Review and respond to Davis Polk re: information related to tax distribution calculations.	0.40
07/02/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: UCC filings and information requests.	0.20
07/02/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: UCC filings and information requests.	0.20
07/06/20	RC	Review documentation related the tax distributions requested by the UCC.	1.20
07/06/20	SJC	Review and analysis of 2014 tax distribution.	3.00
07/06/20	SJC	Continue review and analysis of 2014 tax distribution.	2.00
07/07/20	SJC	Review and analysis of 2014 tax distribution.	1.00
07/07/20	SJC	Review and analysis of 2012 tax distribution.	3.00
07/07/20	RC	Review and comment on responses to requests from the UCC re: SAP information.	0.20
07/07/20	RC	Review documentation related to tax distributions in response to requests from the UCC.	0.90
07/07/20	RC	Review status of outstanding requests from the UCC.	0.20
07/07/20	FOS	Compose email to A. DePalma (AlixPartners) re: Information request from Province.	0.20
07/08/20	RC	Review documents gathered in response to requests from the UCC.	0.20
07/08/20	RC	Review support documentation gathered in response to the UCC's requests for tax distribution information.	0.80
07/08/20	RC	Review and respond to diligence questions from Davis Polk re: Rhodes information.	0.20
07/08/20	SJC	Review and analysis of 2012 tax distribution.	1.00
07/08/20	SJC	Review and analysis of 2014 tax distribution.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/09/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/09/20	SJC	Continue review and analysis of 2010 tax distribution.	2.00
07/09/20	RC	Review and provide comments re: tax distributions support documentation.	1.40
07/09/20	RC	Review and respond to questions from Davis Polk re: tax information requests.	0.10
07/09/20	RC	Coordinate with team and responding to additional requests made by the UCC's advisors.	0.10
07/10/20	RC	Review tax information gathered in response to requests from the UCC's advisors.	0.60
07/10/20	RC	Review and comment on responses to requests from the UCC's advisors related to tax withholding information.	0.30
07/10/20	RC	Review and comment on tax distribution support documentation.	0.60
07/10/20	SJC	Review and analysis of 2012 tax distribution.	1.00
07/10/20	SJC	Pulling support for 2014 tax distributions for data room.	2.00
07/10/20	SJC	Pulling support for 2012 tax distributions for data room.	1.50
07/10/20	SJC	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/10/20	MH	Finalize report info for creditors	1.00
07/10/20	MH	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/10/20	ADD	Compile investigation support materials in response to creditor diligence requests.	1.90
07/10/20	ADD	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/13/20	ADD	Review of tax materials provided by TXP to identify	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		materials produced in the data room.	
07/13/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/13/20	SJC	Continue review and analysis of 2010 tax distribution.	3.00
07/13/20	RC	Review tax distribution information and respond to requests from Davis Polk.	0.40
07/14/20	RC	Review and comment on tax distribution support documentation.	1.20
07/14/20	SJC	Review and analysis of 2008 tax distribution.	2.50
07/14/20	SJC	Review and analysis of 2010 tax distribution.	4.00
07/15/20	SJC	Review and analysis of 2010 tax distribution.	2.00
07/15/20	SJC	Review and analysis of 2008 tax distribution.	2.00
07/16/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/17/20	SJC	Review and analysis of 2008 tax distribution.	3.00
07/17/20	SJC	Continue Review and analysis of 2008 tax distribution.	1.00
07/19/20	RC	Review and respond to email from FTI re: the intercompany and non-cash transfers of value report.	0.10
07/20/20	RC	Review documentation related to tax distribution support.	0.60
07/20/20	SJC	Pulling support for 2010 tax distributions for data room.	1.50
07/20/20	SJC	Pulling support for 2008 tax distributions for data room.	1.00
07/20/20	SJC	Review and analysis of 2010 tax distribution.	2.50
07/20/20	SJC	Review and analysis of 2008 tax distribution.	2.00
07/20/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-up questions from counsel on Report 1B.	0.70
07/20/20	FOS	Review documents re: Tax equalization payments for D. Lundie (Purdue).	0.30
07/20/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-up questions from counsel on Report 1B.	0.70
07/20/20	MFR	Review of documents and analyses re: follow-up	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		questions from counsel on Report 1B.	
07/21/20	SJC	Pulling support for 2014 ex us distributions.	3.00
07/21/20	SJC	Analyze and review support for 2014 ex us distributions.	1.50
07/22/20	SJC	Pulling support for 2014 ex us distributions.	3.00
07/22/20	SJC	Analyze and review support for 2014 ex us distributions.	3.00
07/22/20	SJC	Continue to analyze and review support for 2014 ex us distributions.	2.00
07/22/20	FOS	Compose email to M. Clarens (Davis Polk) re: D. Lundie (Purdue) secondment agreement.	0.10
07/23/20	RC	Review additional tax distribution support and research questions from the UCC.	1.20
07/23/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), C. Oluwole, T. Matlock and A. Guo (all Davis Polk) re: tax distribution support and questions from the UCC.	0.40
07/23/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: tax diligence status.	0.40
07/23/20	RC	Review T&E information and respond to questions from Davis Polk.	0.30
07/23/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), C. Oluwole, T. Matlock and A. Guo (all Davis Polk) re: tax distribution support and questions from the UCC.	0.40
07/23/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: tax diligence status.	0.40
07/24/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss additional work to perform based on diligence requests from Davis Polk.	0.50
07/24/20	RC	Review information gathered in connection with reports 1a and 1b in preparation for call with Davis Polk.	0.50
07/24/20	RC	Call with K. Wolfgang and E. Kim (both Davis Polk) to discuss additional diligence requests re: reports 1A and	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		1B.	
07/24/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss additional work to perform based on diligence requests from Davis Polk.	0.50
07/27/20	RC	Research information related to additional questions from Davis Polk re: T&E expenses.	1.10
07/27/20	RC	Call with A. DePalma (AlixPartners) re: outstanding diligence requests and research questions from Davis Polk.	1.40
07/27/20	RC	Review and analysis of tax distribution related information in response to diligence requests.	1.30
07/27/20	RC	Review communications from Davis Polk re: tax distributions and bank statements.	0.10
07/27/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and research of questions from Davis Polk.	1.40
07/28/20	ADD	Research historical board materials to understand historical corporate actions.	2.60
07/28/20	RC	Review documents gathered in response to the UCC's diligence requests.	0.60
07/28/20	RC	Review documents related to tax distributions.	0.70
07/28/20	RC	Research information related to diligence related questions from Davis Polk.	1.00
07/28/20	RC	Review support information gathered in response to cash distributions diligence requests.	0.60
07/28/20	RC	Review tax information in response to diligence questions from Davis Polk.	0.50
07/29/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and Purdue/TXP tax distribution procedures.	1.20
07/29/20	RC	Review various partnership agreements related to	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		diligence requests from Davis Polk.	
07/29/20	RC	Draft email to Davis Polk re: responses to IAC diligence requests.	0.50
07/29/20	RC	Perform additional research and prepare email to Davis Polk re: responses to diligence requests related to the family members.	0.60
07/29/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), K. Wolfgang and E. Kim (both Davis Polk) re: responses to family related diligence requests and additional follow-up.	0.50
07/29/20	RC	Review board materials in response to diligence requests from the UCC.	0.80
07/29/20	RC	Review documents related to partnership ownership structure in response to diligence questions.	1.10
07/29/20	RC	Review information related to tax distributions in response to diligence requests.	1.00
07/29/20	NAS	Research and respond to IAC question posed by R. Collura (AlixPartners).	0.80
07/29/20	FOS	Review documents from client re: specific Purdue personnel.	0.20
07/29/20	ADD	Research historical board materials to understand change in directors and offices and other corporate actions.	1.80
07/29/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), K. Wolfgang and E. Kim (both Davis Polk) re: responses to family related diligence requests and additional follow-up.	0.50
07/29/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and Purdue/TXP tax distribution procedures.	1.20
07/30/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and review of AP activity.	0.70
07/30/20	ADD	Document Purdue tax distribution process at request of	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Davis Polk to understand process and changes over time.	
07/30/20	FOS	Call with M. Rule (AlixPartners) re: information requests from Davis Polk.	0.10
07/30/20	MFR	Call with F. Silva (AlixPartners) re: information requests from Davis Polk.	0.10
07/30/20	SJC	Review and redact documents from Finance Folder(s) in preparation for processing an upload to data room.	2.50
07/30/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and review of AP activity.	0.70
07/30/20	RC	Review documents provided Davis Polk and prepare questions re: tax distribution process.	0.50
07/30/20	RC	Review tax related documentation and update questions for Purdue and TXP.	1.30
07/30/20	RC	Review cash transfer of value report in connection with responding to diligence requests.	0.80
07/30/20	RC	Review support documentation related to tax distributions and update questions for Purdue and TXP.	0.60
07/31/20	RC	Review information related to tax calculations in response to requests from the UCC.	1.30
07/31/20	RC	Review additional tax distributions support gathered in response to the UCC's requests.	1.70
07/31/20	RC	Review additional support gathered in response to the UCC's requests related to tax calculations and tax distributions.	1.20
07/31/20	RC	Call with J. DelConte and R. Collura (both AlixPartners) re: status of creditor investigation diligence.	0.20
07/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding diligence requests and review of vendor payment activity.	1.00
07/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		discuss additional outstanding tax information diligence requests.	
07/31/20	JD	Call with J. DelConte and R. Collura (both AlixPartners) re: status of creditor investigation diligence.	0.20
07/31/20	FOS	Prepare responsive documents re: UCC information requests.	0.50
07/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss additional outstanding tax information diligence requests.	0.80
07/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding diligence requests and review of vendor payment activity.	1.00
08/02/20	RC	Review and provide comments related to tax distribution support compiled in response to requests from the UCC.	1.40
08/03/20	RC	Review distribution analysis and respond to questions from Davis Polk.	0.50
08/03/20	RC	Review additional information related to tax distribution support.	1.00
08/03/20	RC	Review documents gathered in responses to the UCC's request for tax related information.	0.70
08/03/20	SJC	Analyze and review support for 2009 tax distributions.	1.00
08/03/20	SJC	Pull support for 2016 Rhodes distributions.	0.50
08/03/20	SJC	Pull support for 2012 ex us distributions.	3.50
08/03/20	SJC	Review support for and analyzing 2012 ex us distributions.	2.50
08/03/20	FOS	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/03/20	FOS	Prepare Report 1B documentation re: UCC information requests.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/03/20	MFR	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/03/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	1.50
08/03/20	ADD	Call with M. Rule, F. Silva, and A. DePalma (all AlixPartners) re: UCC information requests on cash transactions.	0.50
08/04/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	1.80
08/04/20	FOS	Prepare Report 1B documentation re: UCC information requests.	4.00
08/04/20	SJC	Review support for and analyzing 2012 ex us distributions.	1.50
08/04/20	SJC	Pull support for 2012 partner distributions.	3.50
08/04/20	SJC	Review and redact documents from Finance Folder(s) in preparation for processing an upload to data room.	3.00
08/04/20	RC	Review additional years of tax distribution support in response to requests from the UCC.	1.20
08/04/20	RC	Review documentation related to tax information in response to requests from the UCC.	0.90
08/05/20	RC	Review distributions related support documentation.	1.40
08/05/20	SJC	Pull support for 2015 Rhodes distributions.	0.50
08/05/20	SJC	Analyzing support for 2012 Partner Distributions.	2.50
08/05/20	SJC	Pull support for 2010 ex us distributions.	2.00
08/05/20	SJC	Review and redact documents from David Fogel folder in preparation for processing an upload to data room.	1.00
08/05/20	MFR	Review and analysis of supporting data and	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		documentation for Report 1B re: UCC information requests.	
08/06/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	2.00
08/06/20	SJC	2010 ex us distribution analysis.	3.00
08/06/20	SJC	2010 Partner distribution analysis and pulling documentation from SAP.	3.00
08/06/20	SJC	Review and redact documents from Finance Folder(s) in preparation for processing an upload to data room.	2.00
08/06/20	RC	Review support documentation related to tax calculations.	1.00
08/07/20	RC	Review additional documentation related distributions gathered in response to the UCC's request.	0.80
08/07/20	SJC	2012 Partner distribution analysis and pulling documentation from SAP.	1.00
08/07/20	SJC	Review of 2010 ex us distribution analysis.	2.00
08/07/20	SJC	Review 2012 Partner distribution analysis.	1.50
08/07/20	SJC	Review and redact documents from David Fogel folder in preparation for processing an upload to data room.	1.50
08/07/20	MFR	Review and analysis of supporting data and documentation for Report 1B re: UCC information requests.	1.60
08/10/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.70
08/10/20	SJC	Pull and organize support for 2017 non-tax distributions for data room.	3.50
08/10/20	SJC	2008 Partner distribution analysis and pulling documentation from SAP.	1.00
08/10/20	SJC	Final review of 2012 distribution analysis.	0.50
08/10/20	SJC	2010 ex us and partner distribution analysis and review.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/10/20	RC	Review and analysis of documentation related to tax information.	1.20
08/10/20	RC	Review support documentation related to non-tax distributions.	1.40
08/11/20	RC	Review additional tax information in connection with responding to the UCC's requests.	1.20
08/11/20	RC	Review and update status of special committee related tasks.	0.30
08/11/20	SJC	Pull support for 2016 ex us and partner distributions.	2.00
08/11/20	SJC	Update and pulling bank statements for 2016 ex us and partner distributions.	3.50
08/11/20	SJC	Pull and organize support for 2015 non-tax distributions for data room.	2.50
08/11/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.30
08/12/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.50
08/12/20	SJC	Pull support for 2016 ex us and partner distributions.	3.00
08/12/20	SJC	Update and pulling bank statements for 2016 ex us and partner distributions.	3.00
08/12/20	SJC	Pull and organize support for 2016 non-tax distributions for data room.	2.00
08/12/20	RC	Review non-tax distribution support documentation compiled in response to UCC's requests.	1.40
08/12/20	RC	Review documentation gathered in response to the UCC's request for tax related information.	0.40
08/13/20	RC	Review documents compiled in response to the UCC's requests related to distributions.	1.10
08/13/20	SJC	Pull and organize support for 2016 non-tax distributions for data room.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/13/20	SJC	Continue to pull and organize support for 2016 non-tax distributions for data room.	3.00
08/13/20	SJC	Pull and organize support for 2013 non-tax distributions for data room.	2.00
08/13/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.80
08/14/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	3.10
08/14/20	MFR	Review and analysis of agreement between PPLP and Terramar. Correspondence with A. DePalma (AlixPartners) re: the same.	0.70
08/14/20	SJC	Pull and organize support for 2013 non-tax distributions for data room.	3.00
08/14/20	SJC	Pull and organize support for 2014 non-tax distributions for data room.	3.00
08/14/20	SJC	Continue to pull and organize support for 2014 non-tax distributions for data room.	1.50
08/14/20	RC	Review additional information in the BSA's data room and update related financial analyses.	0.70
08/14/20	RC	Review documentation provided by the Raymond Sackler family's counsel.	0.80
08/14/20	RC	Review documentation related to royalty information.	0.20
08/14/20	RC	Review documentation gathered in response to requests related to cash distributions.	0.60
08/14/20	HSB	Review excel file with liquidation analysis template, prepared by S. Lemack (AlixPartners).	0.40
08/17/20	RC	Review documents gathered in response to the UCC's request for support for non-tax distributions.	1.20
08/17/20	RC	Review support documentation related to Ex-US distributions.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/17/20	RC	Review additional documentation related to non-tax distributions in response to the UCC's requests.	1.00
08/17/20	SJC	Pull and organize support for 2014 non-tax distributions for data room.	3.50
08/17/20	SJC	Pull and organize support for 2011 non-tax distributions for data room.	2.50
08/17/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.40
08/18/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.20
08/18/20	SJC	Pull and organize support for 2011 non-tax distributions for data room.	1.50
08/18/20	SJC	Pull and organize support for 2009 non-tax distributions for data room.	3.50
08/18/20	RC	Review and comment on information gathered in response to non-tax distribution related requests.	0.80
08/18/20	RC	Review additional tax-related information provided by TXP.	0.60
08/19/20	RC	Review documents related to the non-tax distribution requests.	1.00
08/19/20	RC	Review additional information provided by TXP's counsel.	0.80
08/19/20	RC	Continue to review non-tax distribution related documentation.	0.90
08/19/20	SJC	2008 Partner distribution analysis and pulling documentation from SAP.	3.50
08/19/20	SJC	Review of 2008 Partner distribution analysis and related supporting documents.	1.50
08/19/20	SJC	Pull and organize support for 2008 non-tax distributions for data room.	1.50
08/19/20	SJC	2010 Partner distribution and ex-us analysis and pulling	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		documentation from SAP.	
08/19/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.70
08/20/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	2.00
08/20/20	SJC	2010 Partner distribution and ex-us analysis and pulling documentation from SAP.	3.00
08/20/20	RC	Review documentation gathered in response to the UCC's request for tax information.	0.80
08/20/20	RC	Review support documentation related to non-tax distributions.	1.30
08/20/20	RC	Review information provided by the Sackler Family related to distributions.	1.20
08/21/20	RC	Review non-tax distribution related support documentation.	1.20
08/21/20	RC	Additional review of support documentation related to non-tax distributions.	1.50
08/21/20	RC	Review additional documentation related to distributions.	0.70
08/21/20	RC	Review documentation related to Ex-US distributions.	1.30
08/21/20	RC	Review support documentation gathered in response to the UCC's request for distribution related information.	1.00
08/21/20	RC	Review documentation from SAP gathered in response to requests from the UCC.	0.70
08/21/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP.	2.00
08/21/20	MFR	Review of source data and work papers related to Report 1B and the UCC's request.	1.80
08/23/20	RC	Review documentation compiled in response to requests from the UCC related to cash transfers of value report.	0.60
08/24/20	RC	Review support documentation related to the Ex-US	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Distributions.	
08/24/20	RC	Review support documentation related to the non-tax distributions and provide comments to review team.	1.30
08/24/20	RC	Additional review of support documentation related to Ex-US distributions.	1.10
08/24/20	RC	Review support documentation gathered in response to non-tax distribution requests from the UCC.	0.90
08/24/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP.	3.00
08/24/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/25/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/25/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
08/26/20	SJC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/26/20	SJC	Prepare for internal meeting re: diligence requests status.	0.70
08/26/20	SJC	Review of 2016 Rhodes distribution analysis and related documentation.	0.60
08/26/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.50
08/26/20	SJC	Continue 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/26/20	RC	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/26/20	RC	Review and comment on non-tax distribution support documentation related to requests from the UCC.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/26/20	RC	Additional review of the non-tax distribution support documentation gathered in response to requests from the UCC.	1.10
08/26/20	ADD	Call with R. Collura, A. DePalma and S. Canniff (all AlixPartners) re: various diligence requests and status update.	0.50
08/27/20	RC	Review support documentation re: distribution requests made by the UCC.	1.30
08/27/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.20
08/28/20	SJC	2013 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/28/20	SJC	2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.00
08/28/20	MFR	Review of source data and work papers related to Report 1B.	1.60
08/28/20	HSB	Review OCP report prepared by S. Lemack (AlixPartners).	0.50
08/31/20	FOS	Correspondence with M. Rule (AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement.	0.30
08/31/20	FOS	Review documentation and SAP records re: 2019 MITS (UK) and PPLP IT Services Agreement.	2.00
08/31/20	FOS	Compose email to R. Collura and M. Rule (all AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement.	0.10
08/31/20	SJC	2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	4.00
08/31/20	SJC	2018 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.50
08/31/20	SJC	2017 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.50
08/31/20	SJC	2009 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
08/31/20	SJC	2008 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.30
08/31/20	RC	Review questions from Province and setup team on additional next steps.	0.20
09/01/20	SJC	2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.40
09/01/20	SJC	2011 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.60
09/01/20	SJC	2010 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.20
09/01/20	SJC	2009 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	2.70
09/02/20	SJC	2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.60
09/02/20	SJC	Organizing support for 2008 Rhodes/Coventry tax distributions for data room.	2.20
09/02/20	SJC	Review of Rhodes/Coventry 2009 Tax Distributions and supporting documentation including funding.	3.00
09/02/20	RC	Review and comment on response to questions received from the UCC re: the non-cash transfers of value report.	0.80
09/02/20	FOS	Compose emails to R. Collura and M. Rule (AlixPartners) re: 2019 MITS (UK) and PPLP IT Services Agreement.	1.00
09/03/20	SJC	Review of Rhodes/Coventry 2010 Tax Distributions and supporting documentation including funding.	0.70
09/03/20	SJC	Review of Rhodes/Coventry 2011 Tax Distributions and supporting documentation including funding.	1.90
09/03/20	SJC	Review of Rhodes/Coventry 2013 Tax Distributions and supporting documentation including funding.	3.10
09/03/20	SJC	Review of Rhodes/Coventry 2012 Tax Distributions and supporting documentation including funding.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/04/20	SJC	2012 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.10
09/04/20	SJC	2017 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.10
09/04/20	SJC	2018 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.60
09/04/20	SJC	2016 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.00
09/04/20	SJC	2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	0.50
09/08/20	SJC	2015 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.90
09/08/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.00
09/08/20	SJC	Continue 2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	3.30
09/08/20	FOS	Compose email to R. Collura and M. Rule (All AlixPartners) re: question from Province re: RSJ assignment and assumption transaction.	1.00
09/08/20	MFR	Review and analysis of documents related to RSJ transfer. Discussion with F. Silva (AlixPartners) re: the same and internal email re: the same.	1.20
09/08/20	REO	Review non cash transfers from PPLP to PRA re: Lucien, New Suffolk and RSJ transfers	1.50
09/09/20	SJC	2014 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	1.70
09/09/20	SJC	2010 Rhodes distribution analysis and pulling documentation from SAP and bank statements.	4.40
09/10/20	RC	Review documentation related to responses to requests from the UCC.	1.30
09/10/20	RC	Review summary of information gathered in response to	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests from the UCC.	
09/11/20	RC	Review and summarize information related to non-cash transfers value of report and respond to requests from Davis Polk.	0.60
09/11/20	RC	Review information related to tax distributions.	0.50
09/11/20	RC	Review support documentation related to non-tax distributions.	1.20
09/11/20	RC	Review information gathered in response to the UCC's requests related to the cash transfers of value report.	1.40
09/11/20	FOS	Compose email to R. Collura (AlixPartners) re: Davis Polk request for documents reviewed for Report 1B and hours billed.	0.70
09/14/20	RC	Review and research information requests received from the UCC re: S. Baker.	1.30
09/14/20	RC	Prepare summary of compensation related requests made by the UCC's advisors.	1.40
09/14/20	SJC	Pull and organize support for 2009 Coventry tax distributions for data room.	1.20
09/14/20	SJC	Review of compensation data in response to request from DPW.	2.30
09/14/20	SJC	Pull and organize support for 2010 Coventry tax distributions for data room.	1.50
09/14/20	SJC	Pull and organize support for 2011 Coventry tax distributions for data room.	2.20
09/15/20	SJC	Pull and organize support for 2012 Coventry tax distributions for data room.	1.00
09/15/20	SJC	Pull and organize support for 2013 Coventry tax distributions for data room.	1.20
09/15/20	SJC	Pull and organize support for 2014 Coventry tax distributions for data room.	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/15/20	SJC	Pull and organize support for 2016 Coventry tax distributions for data room.	1.60
09/15/20	SJC	Pull and organize support for 2017 Coventry tax distributions for data room.	1.00
09/15/20	RC	Review documents gathered in response to the UCC's requests related to the cash transfers of value report.	0.80
09/15/20	RC	Review source documents related to information requests made by the UCC's advisors.	1.00
09/16/20	RC	Review support documentation related to non-tax distributions in response to requests from the UCC.	0.90
09/16/20	RC	Review documentation gathered in response to the UCC's cash distribution requests.	1.20
09/16/20	SJC	Pull and organize support for 2018 Coventry tax distributions for data room.	0.50
09/16/20	SJC	Pull and organize support for 2015 Coventry tax distributions for data room.	3.00
09/16/20	SJC	Continue to pull and organize support for 2015 Coventry tax distributions for data room.	1.20
09/16/20	ADD	Draft correspondences to request materials responsive to committee diligence requests.	0.30
09/16/20	ADD	Prepare distribution support documentation to send to Davis Polk for processing and upload to the data room.	1.10
09/17/20	ADD	Call with A. DePalma, S. Canniff (AlixPartners) re: re: Coventry/Rhodes distributions and Purdue tax support.	1.30
09/17/20	SJC	Call to with S. Canniff, A. DePalma (both AlixPartners) re: Coventry/Rhodes distributions and Purdue tax support.	1.30
09/17/20	RC	Review information gathered in response to the UCC's requests for tax related information.	0.40
09/18/20	RC	Review support documentation gathered in response to requests from Province.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
09/18/20	RC	Review and comment on support documentation gathered in response to distribution related requests.	1.10
09/18/20	RC	Review of information produced by Debevoise re: distributions.	0.50
09/18/20	SJC	Review of tax returns in Relativity.	3.20
09/18/20	ADD	Review and categorize tax materials submitted by TXP counsel.	2.30
09/21/20	ADD	Review outstanding diligence requests and draft request from appropriate client contacts.	2.10
09/21/20	RC	Review and comment on support documentation related US and Ex-US distributions.	1.30
09/21/20	RC	Review information related to distributions provided by the Sackler's counsel.	0.90
09/21/20	RC	Review support documentation gathered in response to request from the UCC's advisors.	1.10
09/22/20	RC	Review support documentation gathered in response to requests from the UCC's advisors.	1.20
09/22/20	RC	Review US distribution support documentation.	0.70
09/22/20	RC	Review Ex-US distribution support documentation.	1.30
09/23/20	RC	Review support documentation related to Ex-US distributions.	0.80
09/23/20	RC	Review support documentation related to non-tax distributions.	0.70
09/23/20	RC	Review and comment on documents gathered in response to the UCC's requests.	1.40
09/23/20	FOS	Organize and prepare supporting documentation re: Report 1B document requests.	1.60
09/23/20	ADD	Review tax materials submitted by TXP Services in response to committee diligence requests.	1.80
09/24/20	ADD	Call with A. DePalma, S. Canniff (both AlixPartners) re:	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Purdue tax support and Purdue tax distributions	
09/24/20	FOS	Organize and prepare supporting documentation re: Report 1B document requests.	3.30
09/24/20	RC	Review support documentation gathered in response to requests from the UCC's advisors.	1.30
09/24/20	RC	Review distribution information provided by the Sackler's counsel.	0.90
09/24/20	SJC	Call with A. DePalma, S. Canniff (both AlixPartners) re: Purdue tax support and Purdue tax distributions.	1.30
09/24/20	SJC	Review of support provided for Ardsley distribution and related SAP review.	2.10
09/25/20	SJC	Review and redaction of September Board Materials.	3.80
09/25/20	RC	Review and comment on documentation gathered in response to the UCC's requests.	1.10
09/25/20	RC	Review distribution information produced by the Sacklers.	1.20
09/25/20	FOS	Organize and prepare supporting documentation re: Report 1B document requests.	3.00
09/28/20	FOS	Organize and prepare supporting documentation re: Report 1B document requests.	1.20
09/28/20	RC	Review documentation gathered in response to requests from the UCC's advisors.	1.20
09/28/20	RC	Perform additional review of the non-tax distribution support documentation	0.80
09/28/20	SJC	Review and redaction of September Board Materials.	3.50
09/28/20	SJC	Continue review and redaction of September Board Materials.	3.50
09/29/20	SJC	Review and redaction of September Board Materials.	3.00
09/29/20	SJC	Continue review and redaction of September Board Materials.	2.00
09/29/20	RC	Review support documentation gathered in response to	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		the UCC's requests for non-tax distributions.	
		Total	791.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	1.50	420.00	630.00
Andrew D DePalma	45.20	515.00	23,278.00
Nate A Simon	1.20	515.00	618.00
Sam J Canniff	461.80	645.00	297,861.00
Fernando O Silva	35.60	645.00	22,962.00
Jon D Hecht	2.30	690.00	1,587.00
HS Bhattal	0.90	840.00	756.00
Michael Hartley	1.50	840.00	1,260.00
Mark F Rule	75.60	910.00	68,796.00
Jesse DelConte	0.50	950.00	475.00
Richard Collura	165.40	1,090.00	180,286.00
Total Hours & Fees	791.50		598,509.00